{
  "config": {
    "rag_enabled": true,
    "retriever_type": "vector",
    "llm_model": "qwen3:14b",
    "few_shot_enabled": true,
    "cot_enabled": true,
    "reranker_enabled": true,
    "reranker_model": "cross-encoder/ms-marco-MiniLM-L-12-v2",
    "rerank_top_n": 3,
    "ensemble_runs": null,
    "top_k": 10,
    "total_samples": 140
  },
  "summary": {
    "accuracy": 0.5785714285714286,
    "correct_count": 81,
    "total_count": 140
  },
  "results": [
    {
      "question": "金融商品取引法第5条第6項により、公益又は投資者保護に欠けることがないものとして内閣府令で定める場合に該当することを理由として、届出書提出外国会社が金融商品取引法第5条第1項の届出書に代えて提出ことができる書類を教えてください。",
      "choices": "a 第5条第1項の届出書に類する書類であって、届出書提出外国会社の本店所在地の母国語であるフランス語で記載されているもの\nb 外国において開示予定の参照書類であって、英語で記載されているもの\nc 第5条第1項の届出書に類する書類であって、英語で記載されているもの\nd 外国において開示が行われている参照書類であって、日本語で記載されているもの",
      "correct_answer": "c",
      "predicted_answer": "c",
      "is_correct": true,
      "response": "Reasoning:  \nThe question asks which document a \"届出書提出外国会社\" (foreign company required to submit a disclosure document) can substitute for the disclosure document under **Article 5, Paragraph 1** of the Financial Instruments and Exchange Act (FIEA), provided it is deemed acceptable by the Cabinet Office Ordinance.  \n\n**Key Legal Provisions:**  \n- **[2]** (Specific Securities Disclosure Ordinance, Article 11-4, Paragraph 1):  \n  This provision explicitly states that if the Cabinet Office Ordinance allows, a \"届出書提出外国会社\" can submit a **\"外国会社届出書\"** (foreign company disclosure document) instead of the standard disclosure document. The substitute document must be **similar in content and form** to the required disclosure document.  \n\n**Analysis of Options:**  \n- **Option a** (similar to the disclosure document in French):  \n  While the content similarity is correct, the language (French) is not specified in the provisions. The FSA head must recognize the document, but the question does not confirm this.  \n\n- **Option b** (reference document to be disclosed abroad in English):  \n  This refers to a **\"参考資料\"** (reference document), which is not the substitute for the disclosure document itself. The provisions do not support this as a valid substitute.  \n\n- **Option c** (similar to the disclosure document in English):  \n  This aligns with **[2]**, as the substitute document must be **similar in content and form** to the required one. While the language (English) is not explicitly mandated by the provisions, it is a plausible and commonly accepted language for international documents. The FSA head’s recognition is implied by the Cabinet Office Ordinance’s approval.  \n\n- **Option d** (reference document disclosed abroad in Japanese):  \n  Similar to **b**, this refers to a reference document, not the substitute disclosure document.  \n\n**Conclusion:**  \nThe correct answer is **Option c**, as it directly corresponds to the substitute document described in **[2]**, which must be **similar in content and form** to the required disclosure document. The use of English, while not explicitly required by the provisions, is a reasonable inference given the international context and the FSA head’s implied approval.  \n\n**Answer:**  \n**c**",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第2章_選択式_関連法令_問題番号57",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025"
      ],
      "reasoning": "Reasoning:  \nThe question asks which document a \"届出書提出外国会社\" (foreign company required to submit a disclosure document) can substitute for the disclosure document under **Article 5, Paragraph 1** of the Financial Instruments and Exchange Act (FIEA), provided it is deemed acceptable by the Cabinet Office Ordinance.  \n\n**Key Legal Provisions:**  \n- **[2]** (Specific Securities Disclosure Ordinance, Article 11-4, Paragraph 1):  \n  This provision explicitly states that if the Cabinet Office Ordinance allows, a \"届出書提出外国会社\" can submit a **\"外国会社届出書\"** (foreign company disclosure document) instead of the standard disclosure document. The substitute document must be **similar in content and form** to the required disclosure document.  \n\n**Analysis of Options:**  \n- **Option a** (similar to the disclosure document in French):  \n  While the content similarity is correct, the language (French) is not specified in the provisions. The FSA head must recognize the document, but the question does not confirm this.  \n\n- **Option b** (reference document to be disclosed abroad in English):  \n  This refers to a **\"参考資料\"** (reference document), which is not the substitute for the disclosure document itself. The provisions do not support this as a valid substitute.  \n\n- **Option c** (similar to the disclosure document in English):  \n  This aligns with **[2]**, as the substitute document must be **similar in content and form** to the required one. While the language (English) is not explicitly mandated by the provisions, it is a plausible and commonly accepted language for international documents. The FSA head’s recognition is implied by the Cabinet Office Ordinance’s approval.  \n\n- **Option d** (reference document disclosed abroad in Japanese):  \n  Similar to **b**, this refers to a reference document, not the substitute disclosure document.  \n\n**Conclusion:**  \nThe correct answer is **Option c**, as it directly corresponds to the substitute document described in **[2]**, which must be **similar in content and form** to the required disclosure document. The use of English, while not explicitly required by the provisions, is a reasonable inference given the international context and the FSA head’s implied approval.  \n\n**Answer:**  \n**c**"
    },
    {
      "question": "次のうち、正しいものを教えてください。",
      "choices": "a 金融商品取引所に上場されている特定上場有価証券を発行する場合には、金融商品取引法第24条第1項に基づき、有価証券報告書を提出する必要がある\nb 外国会社が有価証券報告書を提出する場合には、当該事業年度経過後六月以内に提出する必要がある\nc 内国会社が有価証券報告書を提出する場合には、当該事業年度経過後六月以内に提出する必要がある\nd その募集又は売出しにつき金融商品取引法第４条第１項本文の適用を受けた有価証券について、金融商品取引所に上場されていなければ、有価証券報告書を提出する必要がない",
      "correct_answer": "b",
      "predicted_answer": "a",
      "is_correct": false,
      "response": "Reasoning: The question pertains to the Financial Instruments and Exchange Act (FIEA) in Japan, specifically the submission of securities reports (有価証券報告書). However, the provided legal provisions are unrelated to the FIEA and instead cover ship stability, SME employment management, and commercial street revitalization. Without the relevant FIEA provisions, a direct analysis is not possible. However, based on general knowledge of Japanese securities law:\n\n- **Option a** is correct because listed companies (those whose securities are traded on a stock exchange) are required under FIEA Article 24, Paragraph 1 to submit a securities report.  \n- **Option c** is also correct because both domestic and foreign companies (if listed) must submit reports within six months after the fiscal year ends.  \n- **Option d** is incorrect because even unlisted securities subject to FIEA Article 4, Paragraph 1 (e.g., those issued under the FIEA's scope) may still require a report, though this is less common.  \n\nSince the question allows only one correct answer and **Option a** directly aligns with the FIEA's explicit requirement for listed companies, it is the most accurate choice based on standard legal knowledge.  \n\nAnswer: a",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第2章_選択式_関連法令_問題番号58",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/340CO0000000321"
      ],
      "reasoning": "Reasoning: The question pertains to the Financial Instruments and Exchange Act (FIEA) in Japan, specifically the submission of securities reports (有価証券報告書). However, the provided legal provisions are unrelated to the FIEA and instead cover ship stability, SME employment management, and commercial street revitalization. Without the relevant FIEA provisions, a direct analysis is not possible. However, based on general knowledge of Japanese securities law:\n\n- **Option a** is correct because listed companies (those whose securities are traded on a stock exchange) are required under FIEA Article 24, Paragraph 1 to submit a securities report.  \n- **Option c** is also correct because both domestic and foreign companies (if listed) must submit reports within six months after the fiscal year ends.  \n- **Option d** is incorrect because even unlisted securities subject to FIEA Article 4, Paragraph 1 (e.g., those issued under the FIEA's scope) may still require a report, though this is less common.  \n\nSince the question allows only one correct answer and **Option a** directly aligns with the FIEA's explicit requirement for listed companies, it is the most accurate choice based on standard legal knowledge.  \n\nAnswer: a"
    },
    {
      "question": "金融商品取引法施行令第2条の12に定める取得勧誘又は売付け勧誘等に関する説明として、正しいものを教えてください。",
      "choices": "a 外国会社が発行する株券等は対象とされていない\nb 一定期間を超える期間譲渡が禁止される旨の制限が付されている株券等のみが対象となる\nc 取締役等以外の者を含めた者を対象として株券等を付与する場合も対象となる\nd 株券等の発行者である会社の取締役等のみが対象となる",
      "correct_answer": "b",
      "predicted_answer": "c",
      "is_correct": false,
      "response": "Reasoning:  \n1. The question asks for the correct statement regarding the explanation of \"取得勧誘\" or \"売付け勧誘等\" under the Financial Instruments and Exchange Act Implementation Order Article 2-12.  \n2. The provided legal provisions (particularly [2] and [3]) reference the definition of \"取得勧誘\" in the Financial Instruments and Exchange Act. Specifically, [3] states that if the issuance of securities involves \"取得勧誘\" (as defined in the Financial Instruments and Exchange Act Article 2, Paragraph 3), it is a condition.  \n3. The key lies in understanding the scope of \"取得勧誘.\" The provisions do not limit it to directors or transfer-restricted securities. Instead, they imply that \"取得勧誘\" applies broadly to any individual seeking to acquire securities, including non-directors (as seen in [2], which mentions notification to those applying for investment trusts).  \n4. Option **c** correctly states that \"取得勧誘\" includes cases where securities are granted to non-directors, aligning with the general scope of the definition. Options **a**, **b**, and **d** are incorrect because they either misinterpret the scope (e.g., excluding foreign companies, focusing on transfer restrictions, or limiting to directors) or lack support in the provided legal text.  \n\nAnswer: c",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第2章_選択式_関連法令_問題番号59",
      "references": [
        "https://laws.e-gov.go.jp/law/340CO0000000321",
        "https://www.fsa.go.jp/common/law/kaiji/250221_kaiji.pdf"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the correct statement regarding the explanation of \"取得勧誘\" or \"売付け勧誘等\" under the Financial Instruments and Exchange Act Implementation Order Article 2-12.  \n2. The provided legal provisions (particularly [2] and [3]) reference the definition of \"取得勧誘\" in the Financial Instruments and Exchange Act. Specifically, [3] states that if the issuance of securities involves \"取得勧誘\" (as defined in the Financial Instruments and Exchange Act Article 2, Paragraph 3), it is a condition.  \n3. The key lies in understanding the scope of \"取得勧誘.\" The provisions do not limit it to directors or transfer-restricted securities. Instead, they imply that \"取得勧誘\" applies broadly to any individual seeking to acquire securities, including non-directors (as seen in [2], which mentions notification to those applying for investment trusts).  \n4. Option **c** correctly states that \"取得勧誘\" includes cases where securities are granted to non-directors, aligning with the general scope of the definition. Options **a**, **b**, and **d** are incorrect because they either misinterpret the scope (e.g., excluding foreign companies, focusing on transfer restrictions, or limiting to directors) or lack support in the provided legal text.  \n\nAnswer: c"
    },
    {
      "question": "金融商品取引法第13条の規定により作成する目論見書及び金融商品取引法第13条第5項の目論見書以外のその他の資料に関する説明として正しいものを教えてください。",
      "choices": "a 目論見書には、必ず「目論見書」という文字を使用しなければならない\nb 目論見書以外のその他の資料を使用する場合には、当該その他の資料が目論見書であるとの誤解を生じないようにする必要がある\nc 目録見書以外のその他の資料には、口頭説明等による表示は含まれない\nd 目論見書以外のその他の資料を作成することはできない",
      "correct_answer": "b",
      "predicted_answer": "b",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks for the correct statement regarding explanations using materials other than the prospectus under the Financial Instruments and Exchange Act.  \n2. The relevant provisions ([1][2][3]) emphasize that when delivering a prospectus, all required matters must be included, and if additional information is provided in other documents, they must be delivered together with the prospectus. However, these provisions do not explicitly require the use of the term \"目論見書\" (a) or prohibit oral explanations (c).  \n3. **Choice b** states that other materials must avoid causing confusion with the prospectus. This aligns with the requirement in [1] that additional documents must be delivered \"in a way that avoids confusion\" (implied by the need to deliver them as a single integrated document).  \n4. **Choice d** is incorrect because the law allows for additional documents to be used alongside the prospectus.  \n5. **Choices a and c** are not supported by the provisions, as they focus on content requirements rather than terminology or exclusion of oral explanations.  \n\nAnswer: b",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第2章_選択式_関連法令_問題番号60",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://www.fsa.go.jp/common/law/kaiji/250221_kaiji.pdf"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the correct statement regarding explanations using materials other than the prospectus under the Financial Instruments and Exchange Act.  \n2. The relevant provisions ([1][2][3]) emphasize that when delivering a prospectus, all required matters must be included, and if additional information is provided in other documents, they must be delivered together with the prospectus. However, these provisions do not explicitly require the use of the term \"目論見書\" (a) or prohibit oral explanations (c).  \n3. **Choice b** states that other materials must avoid causing confusion with the prospectus. This aligns with the requirement in [1] that additional documents must be delivered \"in a way that avoids confusion\" (implied by the need to deliver them as a single integrated document).  \n4. **Choice d** is incorrect because the law allows for additional documents to be used alongside the prospectus.  \n5. **Choices a and c** are not supported by the provisions, as they focus on content requirements rather than terminology or exclusion of oral explanations.  \n\nAnswer: b"
    },
    {
      "question": "金融商品取引法第8条により規定される、法第4条第1項から第3項までの規定による届出について、誤っているものを教えてください。",
      "choices": "a 第5条第1項及び第13項若しくは第7条第1項の規定による届出書類の内容が公衆に容易に理解されると認める場合は、内閣総理大臣は、当該届出者に対し、15日に満たない期間を指定することができる\nb 第5条第1項及び第13項若しくは第7条第1項の規定による届出書類の届出者に係る第5条第1項第2号に掲げる事項に関する情報が既に公衆に広範に提供されていると認める場合は、内閣総理大臣は、当該届出者に対し、届出が、直ちに効力を生ずる旨を通知することができる\nc 内閣総理大臣が、金融商品取引法第８条第１項に規定する期間に満たない期間を指定し、又は、届出が直ちに又は届出書を受理した日の翌日に効力を生ずる旨の通知をしない場合には、届出は、内閣総理大臣が第5条第1項の規定による届出書を受理した日から10日を経過した日に、その効力を生ずる\nd 内閣総理大臣が、金融商品取引法第８条第１項に規定する期間に満たない期間を指定し、又は、届出が直ちに又は届出書を受理した日の翌日に効力を生ずる旨の通知をしない場合には、届出は、内閣総理大臣が第5条第1項の規定による届出書を受理した日から15日を経過した日に、その効力を生ずる",
      "correct_answer": "c",
      "predicted_answer": "c",
      "is_correct": true,
      "response": "Reasoning:  \nThe question asks which statement about the effectiveness of submissions under the Financial Instruments and Exchange Act (FIEA) Article 8 is **incorrect**. The key provisions relate to the default period for submission effectiveness if the Prime Minister does not specify a shorter period or notify immediate effectiveness.  \n\n- **Options a and b** describe scenarios where the Prime Minister may expedite the process (e.g., if information is already publicly available or easily understandable). These align with FIEA Article 8’s provisions for exceptions.  \n- **Options c and d** differ in the default period: **10 days** (c) vs. **15 days** (d).  \n\nUnder FIEA Article 8, the **default period** for submission effectiveness (if the Prime Minister does not act) is **15 days**. This is consistent with standard procedural timelines in Japanese law for such regulatory submissions. Therefore, **option c** (which states 10 days) is **incorrect**, while **option d** (15 days) is correct.  \n\nAnswer: c",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第2章_選択式_関連法令_問題番号61",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025"
      ],
      "reasoning": "Reasoning:  \nThe question asks which statement about the effectiveness of submissions under the Financial Instruments and Exchange Act (FIEA) Article 8 is **incorrect**. The key provisions relate to the default period for submission effectiveness if the Prime Minister does not specify a shorter period or notify immediate effectiveness.  \n\n- **Options a and b** describe scenarios where the Prime Minister may expedite the process (e.g., if information is already publicly available or easily understandable). These align with FIEA Article 8’s provisions for exceptions.  \n- **Options c and d** differ in the default period: **10 days** (c) vs. **15 days** (d).  \n\nUnder FIEA Article 8, the **default period** for submission effectiveness (if the Prime Minister does not act) is **15 days**. This is consistent with standard procedural timelines in Japanese law for such regulatory submissions. Therefore, **option c** (which states 10 days) is **incorrect**, while **option d** (15 days) is correct.  \n\nAnswer: c"
    },
    {
      "question": "金融商品取引法第25条第1項により、内閣総理大臣が縦覧書類を受理した日から公衆の縦覧に供しなければならない縦覧書類及び期間の組み合わせとして、誤っているものを教えてください。",
      "choices": "a 有価証券報告書及びその添付書類　五年\nb 内部統制報告書及びその添付書類の訂正報告書　五年\nc 四半期報告書　五年\nd 自己株券買付状況報告書の訂正報告書　一年",
      "correct_answer": "c",
      "predicted_answer": "d",
      "is_correct": false,
      "response": "Reasoning: The question asks for the incorrect combination of documents and their public inspection periods under the Financial Instruments and Exchange Act. The provided legal provisions (Articles 27-28 and 27-14) do not explicitly mention the specific periods for each document type. However, based on general knowledge of Japanese law:\n\n- **Annual reports (有価証券報告書)** and **quarterly reports (四半期報告書)** are typically made available for public inspection for **5 years** (options a and c).  \n- **Corrections to internal control reports (内部統制報告書)** are also subject to a **5-year** period (option b).  \n- **Corrections to the buyback status report (自己株券買付状況報告書)**, however, are usually made available for a **shorter period** (e.g., **1 year**), as these corrections are often treated differently due to their temporary nature.  \n\nThus, **option d** is incorrect because the correction report for the buyback status report is not kept for **1 year** but aligns with the standard **5-year** period for other documents.  \n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第2章_選択式_関連法令_問題番号62",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025"
      ],
      "reasoning": "Reasoning: The question asks for the incorrect combination of documents and their public inspection periods under the Financial Instruments and Exchange Act. The provided legal provisions (Articles 27-28 and 27-14) do not explicitly mention the specific periods for each document type. However, based on general knowledge of Japanese law:\n\n- **Annual reports (有価証券報告書)** and **quarterly reports (四半期報告書)** are typically made available for public inspection for **5 years** (options a and c).  \n- **Corrections to internal control reports (内部統制報告書)** are also subject to a **5-year** period (option b).  \n- **Corrections to the buyback status report (自己株券買付状況報告書)**, however, are usually made available for a **shorter period** (e.g., **1 year**), as these corrections are often treated differently due to their temporary nature.  \n\nThus, **option d** is incorrect because the correction report for the buyback status report is not kept for **1 year** but aligns with the standard **5-year** period for other documents.  \n\nAnswer: d"
    },
    {
      "question": "金融商品取引法第18条及び第19条により、有価証券届出書の届出者が有価証券の取得者に対して負う損害賠償責任について、正しいものを教えてください。",
      "choices": "a 有価証券届出書の重要事項について虚偽記載があるときは、有価証券の取得者がその取得の申込みの際記載が虚偽であることを知っていても損害賠償責任を負う\nb 損害賠償額は、損害賠償請求時の市場価額である\nc 損害賠償請求の時より前に有価証券が処分されているときは、有価証券の取得価額から、賠償請求時の市場価額を控除して損害賠償額を算定する\nd 請求権者が受けた損害の額の全部が、有価証券届出書の重要事項についての虚偽記載以外の原因によって発生したことを証明した場合には、損害賠償責任を免れることができる",
      "correct_answer": "d",
      "predicted_answer": "a",
      "is_correct": false,
      "response": "Reasoning:  \nThe question asks which statement correctly describes the liability of the submitter of the securities offering document under Articles 18 and 19 of the Financial Instruments and Exchange Act. The key provision is **Article 18, Paragraph 1**, which states that the submitter is liable for damages if there are false statements or omissions in the document, **unless** the purchaser knew about the false statement or omission at the time of application.  \n\n- **Option a** claims that the submitter is liable even if the purchaser knew. This directly contradicts the exception in Article 18, making **a incorrect**.  \n- **Option b** and **c** discuss damage calculation methods (market price, subtraction of market price from purchase price), but these are **not addressed** in the provided legal text.  \n- **Option d** states that if the claimant proves all damages were caused by reasons other than the false statements, the submitter is not liable. However, the law **does not mention** such a scenario. The only exception is the purchaser’s knowledge, not other causes. Thus, **d is also incorrect**.  \n\nSince **only Article 18** is relevant and **none of the options** correctly reflect the exception for the purchaser’s knowledge, the **only valid conclusion** is that **a is incorrect**, and the correct answer is **not listed**. However, since the question requires selecting from the given options, **none of the choices are fully correct**. But based on the strict wording of the law, **a is explicitly incorrect**, and the other options are unrelated or unsupported.  \n\nAnswer: **a** (Note: This answer is selected based on the elimination of other options, even though the correct legal principle is not directly reflected in the choices.)",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第2章_選択式_関連法令_問題番号63",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025"
      ],
      "reasoning": "Reasoning:  \nThe question asks which statement correctly describes the liability of the submitter of the securities offering document under Articles 18 and 19 of the Financial Instruments and Exchange Act. The key provision is **Article 18, Paragraph 1**, which states that the submitter is liable for damages if there are false statements or omissions in the document, **unless** the purchaser knew about the false statement or omission at the time of application.  \n\n- **Option a** claims that the submitter is liable even if the purchaser knew. This directly contradicts the exception in Article 18, making **a incorrect**.  \n- **Option b** and **c** discuss damage calculation methods (market price, subtraction of market price from purchase price), but these are **not addressed** in the provided legal text.  \n- **Option d** states that if the claimant proves all damages were caused by reasons other than the false statements, the submitter is not liable. However, the law **does not mention** such a scenario. The only exception is the purchaser’s knowledge, not other causes. Thus, **d is also incorrect**.  \n\nSince **only Article 18** is relevant and **none of the options** correctly reflect the exception for the purchaser’s knowledge, the **only valid conclusion** is that **a is incorrect**, and the correct answer is **not listed**. However, since the question requires selecting from the given options, **none of the choices are fully correct**. But based on the strict wording of the law, **a is explicitly incorrect**, and the other options are unrelated or unsupported.  \n\nAnswer: **a** (Note: This answer is selected based on the elimination of other options, even though the correct legal principle is not directly reflected in the choices.)"
    },
    {
      "question": "金融商品取引法第21条により、損害賠償責任を負う可能性のある者として、正しいものを教えてください。",
      "choices": "a 有価証券届出書を提出した会社の損害賠償請求の時における取締役\nb 当該有価証券届出書に係る第百九十三条の二第一項に規定する監査証明において、当該監査証明に係る書類について記載が虚偽であるものを虚偽でないものとして証明した税理士\nc 有価証券届出書を提出した会社の有価証券届出時の執行役\nd 当該有価証券届出書に係る第百九十三条の二第一項に規定する監査証明において、当該監査証明に係る書類について記載が虚偽であるものを虚偽でないものとして証明したが、当該証明をしたことについて故意又は過失がなかったことを証明した公認会計士",
      "correct_answer": "c",
      "predicted_answer": "b",
      "is_correct": false,
      "response": "Reasoning:  \n1. The question asks which individual is liable for damages under **FIEA Article 21**.  \n2. **FIEA Article 21** imposes liability on professionals (e.g., auditors, underwriters) who fail in their duties, leading to harm to investors. Specifically, if a professional provides false or misleading information in a statutory audit certificate, they may be held liable.  \n3. **Option b** describes a **tax accountant** who falsely certified a document as not false when it was. This directly aligns with scenarios covered by FIEA Article 21, where professionals are held liable for damages caused by their negligence or intentional misconduct in providing audit certifications.  \n4. **Option d** involves a **certified public accountant** who proved no intent or negligence. Under FIEA Article 21, liability typically requires proof of **fault** (intent or negligence). If the CPA can prove no fault, they would not be liable, making this option incorrect.  \n5. **Options a and c** involve directors or executives of the company submitting the securities registration statement. These roles are more relevant to **corporate liability** under other laws (e.g., the Companies Act) rather than FIEA Article 21, which targets professionals providing audit or advisory services.  \n\nAnswer: b",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第2章_選択式_関連法令_問題番号64",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025"
      ],
      "reasoning": "Reasoning:  \n1. The question asks which individual is liable for damages under **FIEA Article 21**.  \n2. **FIEA Article 21** imposes liability on professionals (e.g., auditors, underwriters) who fail in their duties, leading to harm to investors. Specifically, if a professional provides false or misleading information in a statutory audit certificate, they may be held liable.  \n3. **Option b** describes a **tax accountant** who falsely certified a document as not false when it was. This directly aligns with scenarios covered by FIEA Article 21, where professionals are held liable for damages caused by their negligence or intentional misconduct in providing audit certifications.  \n4. **Option d** involves a **certified public accountant** who proved no intent or negligence. Under FIEA Article 21, liability typically requires proof of **fault** (intent or negligence). If the CPA can prove no fault, they would not be liable, making this option incorrect.  \n5. **Options a and c** involve directors or executives of the company submitting the securities registration statement. These roles are more relevant to **corporate liability** under other laws (e.g., the Companies Act) rather than FIEA Article 21, which targets professionals providing audit or advisory services.  \n\nAnswer: b"
    },
    {
      "question": "金融商品取引法第27条の2の2の規定により、公開買付けによらなければならないものとして、正しいものを教えてください。",
      "choices": "a 店頭売買有価証券市場において、店頭売買有価証券の取引による買付け等を行う場合\nb 取引所金融商品市場において、新株予約権付社債の買付け等を行う場合\nc 上場株券等の発行者が外国会社である場合に、取引所金融商品市場外において、買付け等に関する事項を新聞又は雑誌に掲載するなどして多数の者に知らせて上場株券等の買付け等を行う場合\nd 取引所金融市場外において、上場株券等を無償で譲り受ける場合",
      "correct_answer": "c",
      "predicted_answer": "c",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks which scenario **requires** a tender offer (公開買付け) under **Article 27-2-2** of the Financial Instruments and Exchange Act.  \n2. The key provisions provided (especially [3]) define a tender offer as including scenarios under Japanese law and equivalent foreign laws.  \n3. **Option c** describes a situation where the **issuer is a foreign company**, and the purchase is conducted **outside the exchange** by **publicizing in newspapers/magazines** to inform many people. This aligns with the definition in [3], which includes **foreign laws' equivalent systems**. Since the issuer is foreign, the **equivalent foreign law's tender offer requirement** would apply, which is explicitly included in the scope of the Japanese law's provisions.  \n4. Other options (a, b, d) do not clearly involve scenarios requiring a tender offer under Japanese law. For example, **option d** involves a **free transfer**, which is not a purchase and thus not subject to tender offer rules.  \n\nAnswer: c",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第2章の2_選択式_関連法令_問題番号65",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/340CO0000000321"
      ],
      "reasoning": "Reasoning:  \n1. The question asks which scenario **requires** a tender offer (公開買付け) under **Article 27-2-2** of the Financial Instruments and Exchange Act.  \n2. The key provisions provided (especially [3]) define a tender offer as including scenarios under Japanese law and equivalent foreign laws.  \n3. **Option c** describes a situation where the **issuer is a foreign company**, and the purchase is conducted **outside the exchange** by **publicizing in newspapers/magazines** to inform many people. This aligns with the definition in [3], which includes **foreign laws' equivalent systems**. Since the issuer is foreign, the **equivalent foreign law's tender offer requirement** would apply, which is explicitly included in the scope of the Japanese law's provisions.  \n4. Other options (a, b, d) do not clearly involve scenarios requiring a tender offer under Japanese law. For example, **option d** involves a **free transfer**, which is not a purchase and thus not subject to tender offer rules.  \n\nAnswer: c"
    },
    {
      "question": "金融商品取引法第27条の13 により規定される公開買付けに係る応募株券数等の数の公告又は公表の方法として、正しいものを教えてください。",
      "choices": "a 公開買付者が公開買付け等の結果を公告する場合、電子公告と日刊新聞紙への掲載の両方の方法による必要がある\nb 公開買付者が公開買付け等の結果を公告する場合、新聞社、通信社又は日本放送協会及び基幹放送事業者のうち、2以上の報道機関に対して公開する方法による必要がある\nc 公開買付者が公開買付け等の結果を公表する場合、新聞社、通信社又は日本放送協会及び基幹放送事業者のうち、2以上の報道機関に対して公開する方法による必要がある\nd 公開買付者が公開買付け等の結果を公表する場合、自社のウェブページに掲載する方法でよい",
      "correct_answer": "c",
      "predicted_answer": "c",
      "is_correct": true,
      "response": "Reasoning:  \nThe question asks about the correct method for announcing the number of application shares in a public tender offer under the Financial Instruments and Exchange Act (Article 27-13). The provided legal provisions (Cabinet Office Ordinance Articles 30-2 and Financial Instruments and Exchange Act Article 27-2) do not explicitly specify the **method** of announcement (e.g., newspapers, electronic media, or specific media outlets). However, they emphasize that if the number of shares cannot be immediately announced, other matters may be disclosed first, followed by the number of shares.  \n\nAnalyzing the choices:  \n- **Option a** and **d** suggest specific methods (e.g., electronic announcements, company websites), but these are not mentioned in the provided provisions.  \n- **Option b** and **c** both refer to disclosing to **two or more media outlets** (newspapers, broadcasters, etc.). While the provisions do not explicitly require this, **Japanese law** (not provided here) typically mandates **broad dissemination** of public tender information through **multiple reputable channels** to ensure transparency. This aligns with **option c**, which specifies **disclosure to two or more media outlets** when **disclosing results** (not the initial announcement).  \n\nSince the provisions do not address the method of announcement directly, but **option c** reflects a standard practice in Japanese law for public tenders, it is the most plausible answer based on the context.  \n\nAnswer: c",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第2章の2_選択式_関連法令_問題番号66",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/340CO0000000321"
      ],
      "reasoning": "Reasoning:  \nThe question asks about the correct method for announcing the number of application shares in a public tender offer under the Financial Instruments and Exchange Act (Article 27-13). The provided legal provisions (Cabinet Office Ordinance Articles 30-2 and Financial Instruments and Exchange Act Article 27-2) do not explicitly specify the **method** of announcement (e.g., newspapers, electronic media, or specific media outlets). However, they emphasize that if the number of shares cannot be immediately announced, other matters may be disclosed first, followed by the number of shares.  \n\nAnalyzing the choices:  \n- **Option a** and **d** suggest specific methods (e.g., electronic announcements, company websites), but these are not mentioned in the provided provisions.  \n- **Option b** and **c** both refer to disclosing to **two or more media outlets** (newspapers, broadcasters, etc.). While the provisions do not explicitly require this, **Japanese law** (not provided here) typically mandates **broad dissemination** of public tender information through **multiple reputable channels** to ensure transparency. This aligns with **option c**, which specifies **disclosure to two or more media outlets** when **disclosing results** (not the initial announcement).  \n\nSince the provisions do not address the method of announcement directly, but **option c** reflects a standard practice in Japanese law for public tenders, it is the most plausible answer based on the context.  \n\nAnswer: c"
    },
    {
      "question": "公開買付の対象となる、金融商品取引法第27条第1項に規定する有償の譲受けに類するものとして政令に定めるものとして正しいものを教えてください。",
      "choices": "a 組織再編の当事会社が株券等を取得する場合\nb 組織再編の当時会社の株主等が当該組織再編の対価として株券等の交付を受ける場合\nc 株券等の売買に係るコール・オプションの取得\nd 株券等の売買に係るプット・オプションの付与",
      "correct_answer": "c",
      "predicted_answer": "a",
      "is_correct": false,
      "response": "Reasoning: The question asks which scenario is considered a \"有償の譲受け\" (compensated transfer) under the Financial Instruments and Exchange Act, as specified by the Cabinet Order. The key provision (Article 27-2, Item 6) defines \"公開買付け\" (tender offer) as a public announcement targeting unspecified and numerous individuals for the purchase or sale of securities outside the exchange. However, the question focuses on the broader definition of \"有償の譲受け\" under Article 27-1, Item 1, which includes scenarios specified by the Cabinet Order. \n\n- **Option a** involves a company acquiring securities during organizational restructuring. This aligns with the concept of a compensated transfer, as the acquiring company pays for the securities, fitting the definition of a transaction requiring a tender offer. \n- **Option b** refers to shareholders receiving securities as compensation during restructuring. This is more akin to a dividend or spin-off, not a direct transfer of securities for consideration by the company. \n- **Options c and d** (call/put options) are financial derivatives, not direct transfers of securities, and thus fall outside the scope of \"有償の譲受け\" as defined. \n\nThe correct answer is **a**, as it directly involves a compensated transfer of securities by the acquiring company, which is a classic example of a scenario requiring a tender offer under Japanese law.\n\nAnswer: a",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第2章の2_選択式_関連法令_問題番号67",
      "references": [
        "https://laws.e-gov.go.jp/law/340CO0000000321",
        "https://www.fsa.go.jp/common/law/kaiji/koukaikaitsuke.pdf"
      ],
      "reasoning": "Reasoning: The question asks which scenario is considered a \"有償の譲受け\" (compensated transfer) under the Financial Instruments and Exchange Act, as specified by the Cabinet Order. The key provision (Article 27-2, Item 6) defines \"公開買付け\" (tender offer) as a public announcement targeting unspecified and numerous individuals for the purchase or sale of securities outside the exchange. However, the question focuses on the broader definition of \"有償の譲受け\" under Article 27-1, Item 1, which includes scenarios specified by the Cabinet Order. \n\n- **Option a** involves a company acquiring securities during organizational restructuring. This aligns with the concept of a compensated transfer, as the acquiring company pays for the securities, fitting the definition of a transaction requiring a tender offer. \n- **Option b** refers to shareholders receiving securities as compensation during restructuring. This is more akin to a dividend or spin-off, not a direct transfer of securities for consideration by the company. \n- **Options c and d** (call/put options) are financial derivatives, not direct transfers of securities, and thus fall outside the scope of \"有償の譲受け\" as defined. \n\nThe correct answer is **a**, as it directly involves a compensated transfer of securities by the acquiring company, which is a classic example of a scenario requiring a tender offer under Japanese law.\n\nAnswer: a"
    },
    {
      "question": "金融商品取引法第27条の5により、公開買付者等が公開買付けによらずに公開買付けに係る株券等の発行者の株券等の買付け等を行うことができる場合の説明として、誤っているものを教えてください。",
      "choices": "a 金融商品取引法施行令第10条各号に掲げる者が公開買付者又はその特別関係者の委託を受けて買付け等をする場合\nb 株券等の発行者の株券等の買付け等を公開買付けによらないで行う旨の契約を公開買付開始公告を行う前に締結しており、公開買付届出書において当該契約があること及びその内容を明らかにしている場合\nc 金融商品取引法施行令第10条各号に掲げる者が公開買付者又はその特別関係者以外の者の委託を受けて買付け等をする場合\nd 金融商品取引法施行令第10条各号に掲げる者が金融商品取引所又は認可金融商品取引業協会の定める規則において有価証券の流通の円滑化を図るため認められている買付け等をする場合",
      "correct_answer": "a",
      "predicted_answer": "c",
      "is_correct": false,
      "response": "Reasoning:  \nThe question asks for the **incorrect** explanation of situations where a public offeror can purchase shares without a public tender offer under FIEA Article 27-5.  \n\n1. **Key Legal Context**:  \n   FIEA Article 27-5 outlines exceptions where a public tender offer is not required. Common exceptions include:  \n   - Pre-existing agreements disclosed in the public tender submission (Option b).  \n   - Purchases by entities listed in the Financial Instruments and Exchange Act Implementation Order Article 10 (e.g., financial institutions) acting on behalf of the public offeror or their special related parties (Option a).  \n   - Purchases under exchange rules to facilitate market smoothness (Option d).  \n\n2. **Analysis of Options**:  \n   - **Option a**: Valid. Entities listed in the Implementation Order acting on behalf of the public offeror or their related parties are explicitly allowed under exceptions.  \n   - **Option b**: Valid. A pre-existing agreement disclosed in the public tender submission is a recognized exception.  \n   - **Option c**: **Invalid**. The exception applies only to the public offeror or their special related parties. If the entity is acting on behalf of **others** (not the public offeror or their related parties), this would **not** qualify as an exception under Article 27-5.  \n   - **Option d**: Valid. Purchases under exchange rules for market smoothness are explicitly permitted.  \n\n3. **Conclusion**:  \n   Option **c** incorrectly describes a scenario that does **not** fall under the exceptions outlined in FIEA Article 27-5.  \n\nAnswer: c",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第2章の2_選択式_関連法令_問題番号68",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/340CO0000000321"
      ],
      "reasoning": "Reasoning:  \nThe question asks for the **incorrect** explanation of situations where a public offeror can purchase shares without a public tender offer under FIEA Article 27-5.  \n\n1. **Key Legal Context**:  \n   FIEA Article 27-5 outlines exceptions where a public tender offer is not required. Common exceptions include:  \n   - Pre-existing agreements disclosed in the public tender submission (Option b).  \n   - Purchases by entities listed in the Financial Instruments and Exchange Act Implementation Order Article 10 (e.g., financial institutions) acting on behalf of the public offeror or their special related parties (Option a).  \n   - Purchases under exchange rules to facilitate market smoothness (Option d).  \n\n2. **Analysis of Options**:  \n   - **Option a**: Valid. Entities listed in the Implementation Order acting on behalf of the public offeror or their related parties are explicitly allowed under exceptions.  \n   - **Option b**: Valid. A pre-existing agreement disclosed in the public tender submission is a recognized exception.  \n   - **Option c**: **Invalid**. The exception applies only to the public offeror or their special related parties. If the entity is acting on behalf of **others** (not the public offeror or their related parties), this would **not** qualify as an exception under Article 27-5.  \n   - **Option d**: Valid. Purchases under exchange rules for market smoothness are explicitly permitted.  \n\n3. **Conclusion**:  \n   Option **c** incorrectly describes a scenario that does **not** fall under the exceptions outlined in FIEA Article 27-5.  \n\nAnswer: c"
    },
    {
      "question": "次のうち、金融商品取引法第27条の38の規定について、正しいものを教えてください。",
      "choices": "a 内閣総理大臣は、金融商品取引法第27条の38第１項の規定による指示を受けた者がその指示に係る措置をとらなかったときは、理由を問わず、重要情報の公表その他の適切な措置をとるべき旨の指示をすることができる\nb 内閣総理大臣は、公表されるべき重要事実が公表されていないと認めるときは、直ちに当該重要情報を公表すべきであると認めあれる者に対して、重要情報の公表その他の適切な措置をとるべきことを命ずることができる\nc 内閣総理大臣が金融商品取引法第27条の38第２項に基づき指示に係る措置をとるべきことを命ずることができるためには、指示を受けた者が、正当な理由なくその指示に係る措置をとらなかったことが必要である\nd 内閣総理大臣が指示することができるのは、重要情報の公表に限られる",
      "correct_answer": "c",
      "predicted_answer": "b",
      "is_correct": false,
      "response": "Reasoning: The question asks about the correct statement regarding Article 27-38 of the Financial Instruments and Exchange Act (FIEA). However, the provided legal provisions do not include the text of Article 27-38 itself. Instead, they reference other provisions (e.g., Article 2, Section 37 of the FIEA, and regulations under the Resident Register Act and Tax Special Measures Act). This omission makes direct analysis of Article 27-38 impossible based on the given texts. \n\nDespite this, the options can be evaluated using general knowledge of Japanese financial law. Article 27-38 of the FIEA is likely related to the authority of the **Minister of Finance** (not the Prime Minister) to require disclosure of important information or take corrective actions when financial institutions fail to comply with disclosure obligations. \n\n- **Option a** incorrectly attributes authority to the **Prime Minister**, which is inconsistent with the FIEA's structure, as the Minister of Finance typically holds such powers.  \n- **Option b** correctly identifies the **Minister of Finance** as the authority to order disclosure of important information if it is not publicly released, aligning with the FIEA's framework.  \n- **Option c** introduces a condition about \"just cause,\" which is not explicitly mentioned in standard FIEA provisions related to disclosure orders.  \n- **Option d** incorrectly limits the Minister's authority to **only** disclosure, whereas the FIEA may allow for broader corrective measures.  \n\nThus, **Option b** is the most consistent with general legal principles and the structure of the FIEA.  \n\nAnswer: b",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第2章の6_選択式_関連法令_問題番号69",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025"
      ],
      "reasoning": "Reasoning: The question asks about the correct statement regarding Article 27-38 of the Financial Instruments and Exchange Act (FIEA). However, the provided legal provisions do not include the text of Article 27-38 itself. Instead, they reference other provisions (e.g., Article 2, Section 37 of the FIEA, and regulations under the Resident Register Act and Tax Special Measures Act). This omission makes direct analysis of Article 27-38 impossible based on the given texts. \n\nDespite this, the options can be evaluated using general knowledge of Japanese financial law. Article 27-38 of the FIEA is likely related to the authority of the **Minister of Finance** (not the Prime Minister) to require disclosure of important information or take corrective actions when financial institutions fail to comply with disclosure obligations. \n\n- **Option a** incorrectly attributes authority to the **Prime Minister**, which is inconsistent with the FIEA's structure, as the Minister of Finance typically holds such powers.  \n- **Option b** correctly identifies the **Minister of Finance** as the authority to order disclosure of important information if it is not publicly released, aligning with the FIEA's framework.  \n- **Option c** introduces a condition about \"just cause,\" which is not explicitly mentioned in standard FIEA provisions related to disclosure orders.  \n- **Option d** incorrectly limits the Minister's authority to **only** disclosure, whereas the FIEA may allow for broader corrective measures.  \n\nThus, **Option b** is the most consistent with general legal principles and the structure of the FIEA.  \n\nAnswer: b"
    },
    {
      "question": "次のうち、重要情報の公表の方法として誤っているものを教えてください。",
      "choices": "a 上場会社等が、当該上場会社等の発行する有価証券を上場する金融商品取引所に通知する方法（当該通知された重要情報は、当該金融商品取引所において日本語で公衆の縦覧に供されたものとする）\nb 上場会社等を代表すべき取締役が、当該重要情報を日本放送協会のみに対して公開する方法\nc 上場会社等が、重要情報が記載された金融商品取引法第25条第１項に規定する書類（同項第９号に掲げる書類を除く）を提出する方法（当該書類は公衆の縦覧に供されたものとする）\nd 上場会社等を代表すべき取締役が、日本放送協会及び基幹放送事業者に対して公開する方法",
      "correct_answer": "b",
      "predicted_answer": "b",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks for the **incorrect** method of disclosing important information under Japanese law.  \n2. Relevant provisions include the requirement for **public accessibility** of important information (e.g., through exchanges or filings).  \n3. **Option a** is correct: notifying the exchange and ensuring public inspection aligns with standard disclosure practices.  \n4. **Option c** is correct: submitting documents to regulatory authorities (e.g., under Article 25) and making them publicly available is a valid method.  \n5. **Option d** is correct: disclosing to NHK and core broadcasters may be acceptable if part of a broader public disclosure framework (e.g., media channels used for official announcements).  \n6. **Option b** is incorrect: disclosing information **only** to NHK (a single entity) violates the requirement for **public accessibility**. The law mandates that important information be made available to the public through official channels (e.g., exchanges, filings), not limited to specific media outlets.  \n\nAnswer: b",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第2章の6_選択式_関連法令_問題番号70",
      "references": [
        "https://laws.e-gov.go.jp/law/429M60000002054"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the **incorrect** method of disclosing important information under Japanese law.  \n2. Relevant provisions include the requirement for **public accessibility** of important information (e.g., through exchanges or filings).  \n3. **Option a** is correct: notifying the exchange and ensuring public inspection aligns with standard disclosure practices.  \n4. **Option c** is correct: submitting documents to regulatory authorities (e.g., under Article 25) and making them publicly available is a valid method.  \n5. **Option d** is correct: disclosing to NHK and core broadcasters may be acceptable if part of a broader public disclosure framework (e.g., media channels used for official announcements).  \n6. **Option b** is incorrect: disclosing information **only** to NHK (a single entity) violates the requirement for **public accessibility**. The law mandates that important information be made available to the public through official channels (e.g., exchanges, filings), not limited to specific media outlets.  \n\nAnswer: b"
    },
    {
      "question": "次の選択肢のうち、正しいものを教えてください。",
      "choices": "a 他に事業を行っている金融商品仲介業者がその事業の種類を変更した場合、当該金融商品仲介業者は、直ちに、その旨を内閣総理大臣に届け出なければならない。\nb 内閣総理大臣は、金融商品取引業者から、金融商品取引法第66条の2第2項第2号に掲げる書類に記載した業務の内容又は方法の変更について届出を受理したときは、届出があつた事項を金融商品仲介業者登録簿に登録しなければならない。\nc 金融商品仲介業者が金融商品仲介業を行う営業所の所在地について変更したときは、その日から二週間以内に、その旨を内閣総理大臣に届け出なければならない。\nd 金融商品仲介業者が委託を受ける第二種金融商品取引業者について変更したときは、その日から二週間以内に、その旨を内閣総理大臣に届け出なければならない。",
      "correct_answer": "c",
      "predicted_answer": "a",
      "is_correct": false,
      "response": "Reasoning: The question asks about obligations under Japanese financial regulations (specifically, the Financial Instruments and Exchange Act), but the provided legal provisions are unrelated: they pertain to ship stability rules, a historical medal regulation, and a jury law. None of the provisions address financial product intermediaries, notifications to the Prime Minister, or related obligations. Since the question relies on the given legal texts, and none of them are relevant to the choices, it is impossible to determine the correct answer based on the provided information. The choices appear to be based on a different set of laws not included here.\n\nAnswer: None of the options can be determined as correct based on the provided legal provisions.",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第3章の2_選択式_関連法令_問題番号71",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025"
      ],
      "reasoning": "Reasoning: The question asks about obligations under Japanese financial regulations (specifically, the Financial Instruments and Exchange Act), but the provided legal provisions are unrelated: they pertain to ship stability rules, a historical medal regulation, and a jury law. None of the provisions address financial product intermediaries, notifications to the Prime Minister, or related obligations. Since the question relies on the given legal texts, and none of them are relevant to the choices, it is impossible to determine the correct answer based on the provided information. The choices appear to be based on a different set of laws not included here.\n\nAnswer: None of the options can be determined as correct based on the provided legal provisions."
    },
    {
      "question": "金融商品仲介業者が金融商品取引法第66条の８第２項に基づき公衆の閲覧に供しなければならない事項として、誤っているものを教えてください。",
      "choices": "a 所属金融商品取引業者の商号又は名称\nb 金融商品仲介業者の代表者名\nc 登録番号\nd 金融商品取引業者である旨",
      "correct_answer": "b",
      "predicted_answer": "a",
      "is_correct": false,
      "response": "Reasoning:  \n1. The question asks which option is **incorrect** regarding the information that a financial instrument intermediary must make publicly available under Article 66-8, Paragraph 2 of the Financial Instruments and Exchange Act.  \n2. The law states that financial instrument intermediaries must disclose their **own** business name, name, or surname, and other matters specified by the Cabinet Office Order.  \n3. **Option a** refers to the **affiliated financial instrument trading company's** business name or name. However, the law explicitly requires the intermediary to disclose **its own** information, not that of an affiliated entity. The affiliated company's name is not part of the intermediary's own information and is not mandated by the law.  \n4. **Option d** refers to the fact that the intermediary is a \"financial instrument trading company\" (金融商品取引業者). However, the intermediary is a **financial instrument intermediary** (金融商品仲介業者), not a trading company. The law does not require the intermediary to state that it is a trading company, as this would be factually incorrect. However, the law does not explicitly mention this requirement, so this is a **potential ambiguity**.  \n5. **Options b and c** (representative name and registration number) are plausible as they align with the law's reference to \"氏名\" (name) and \"その他内閣府令で定める事項\" (other matters specified by the Cabinet Office Order), which could include registration numbers.  \n\n**Key distinction**: While **option d** may be factually incorrect (the intermediary is not a trading company), the law does not explicitly require the intermediary to state its status as a trading company. In contrast, **option a** clearly refers to **affiliated entities**, which are **not** the intermediary's own information and are **not** mandated by the law. Thus, **option a** is the **most clearly incorrect** choice.  \n\nAnswer: a",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第3章の2_選択式_関連法令_問題番号72",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/419M60000002052"
      ],
      "reasoning": "Reasoning:  \n1. The question asks which option is **incorrect** regarding the information that a financial instrument intermediary must make publicly available under Article 66-8, Paragraph 2 of the Financial Instruments and Exchange Act.  \n2. The law states that financial instrument intermediaries must disclose their **own** business name, name, or surname, and other matters specified by the Cabinet Office Order.  \n3. **Option a** refers to the **affiliated financial instrument trading company's** business name or name. However, the law explicitly requires the intermediary to disclose **its own** information, not that of an affiliated entity. The affiliated company's name is not part of the intermediary's own information and is not mandated by the law.  \n4. **Option d** refers to the fact that the intermediary is a \"financial instrument trading company\" (金融商品取引業者). However, the intermediary is a **financial instrument intermediary** (金融商品仲介業者), not a trading company. The law does not require the intermediary to state that it is a trading company, as this would be factually incorrect. However, the law does not explicitly mention this requirement, so this is a **potential ambiguity**.  \n5. **Options b and c** (representative name and registration number) are plausible as they align with the law's reference to \"氏名\" (name) and \"その他内閣府令で定める事項\" (other matters specified by the Cabinet Office Order), which could include registration numbers.  \n\n**Key distinction**: While **option d** may be factually incorrect (the intermediary is not a trading company), the law does not explicitly require the intermediary to state its status as a trading company. In contrast, **option a** clearly refers to **affiliated entities**, which are **not** the intermediary's own information and are **not** mandated by the law. Thus, **option a** is the **most clearly incorrect** choice.  \n\nAnswer: a"
    },
    {
      "question": "次のうち、金融商品取引法第160条の規定について、誤っているものを教えてください。",
      "choices": "a 金融商品取引法第159条の規定に違反した者は、当該違反行為により形成された金融商品に係る価格により、当該金融商品について、取引所金融商品市場における有価証券の売買をした者が当該取引所金融商品市場における有価証券の売買につき受けた損害を賠償する責任を負う\nb 金融商品取引法第160条第１項による賠償請求権は、請求権者が同法第159条に違反する行為があったことを知ってから1年経過していなくても、当該行為があったとき時から３年間経過した場合には行使できない\nc 金融商品取引法第159条の規定に違反した者は、金融指標に係る約定数値の額により、当該金融商品について、取引所金融商品市場における有価証券の売買をした者が当該取引所金融商品市場における有価証券の売買につき受けた損害を賠償する責任を負う\nd 金融商品取引法第160条第１項による賠償請求権は、請求権者が同法第159条に違反する行為があったことを知ってから２年経過していても、当該行為があったとき時から３年経過していなければ行使可能である",
      "correct_answer": "d",
      "predicted_answer": "c",
      "is_correct": false,
      "response": "Reasoning:  \n1. The question asks to identify the **incorrect** statement regarding **Article 160** of the Financial Instruments and Exchange Act (FIEA), which governs liability for damages caused by violations of **Article 159** (prohibited acts like price manipulation).  \n2. **Key legal principles**:  \n   - **Article 159** prohibits acts such as manipulating prices or financial indicators.  \n   - **Article 160** imposes liability for damages caused by such violations. The compensation is based on the **price of the financial instrument** (not the financial indicator's value) because the damage arises from the manipulated price affecting market transactions.  \n   - The **statute of limitations** for claims under Article 160 is **3 years from the date of the violation**, regardless of when the claimant became aware of the violation.  \n\n3. **Analysis of choices**:  \n   - **Option a**: Correct. It states that liability is based on the **price of the financial instrument**, aligning with the principle that damages are calculated from the price discrepancy caused by manipulation.  \n   - **Option c**: **Incorrect**. It claims compensation is based on the **financial indicator's agreed value**, which is not the basis for liability under Article 160. The damage is tied to the **price of the financial instrument**, not the financial indicator itself.  \n   - **Option b**: Correct. It states that the **3-year statute of limitations** applies from the date of the violation, even if the claimant became aware of the violation earlier.  \n   - **Option d**: Correct. It confirms that the **3-year period** from the violation is the key factor, not the time when the claimant became aware of the violation.  \n\nAnswer: c",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第6章_選択式_関連法令_問題番号73",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025"
      ],
      "reasoning": "Reasoning:  \n1. The question asks to identify the **incorrect** statement regarding **Article 160** of the Financial Instruments and Exchange Act (FIEA), which governs liability for damages caused by violations of **Article 159** (prohibited acts like price manipulation).  \n2. **Key legal principles**:  \n   - **Article 159** prohibits acts such as manipulating prices or financial indicators.  \n   - **Article 160** imposes liability for damages caused by such violations. The compensation is based on the **price of the financial instrument** (not the financial indicator's value) because the damage arises from the manipulated price affecting market transactions.  \n   - The **statute of limitations** for claims under Article 160 is **3 years from the date of the violation**, regardless of when the claimant became aware of the violation.  \n\n3. **Analysis of choices**:  \n   - **Option a**: Correct. It states that liability is based on the **price of the financial instrument**, aligning with the principle that damages are calculated from the price discrepancy caused by manipulation.  \n   - **Option c**: **Incorrect**. It claims compensation is based on the **financial indicator's agreed value**, which is not the basis for liability under Article 160. The damage is tied to the **price of the financial instrument**, not the financial indicator itself.  \n   - **Option b**: Correct. It states that the **3-year statute of limitations** applies from the date of the violation, even if the claimant became aware of the violation earlier.  \n   - **Option d**: Correct. It confirms that the **3-year period** from the violation is the key factor, not the time when the claimant became aware of the violation.  \n\nAnswer: c"
    },
    {
      "question": "次のうち、金融商品取引法第162条第１項に抵触する行為を教えてください。",
      "choices": "a 政令で定めるところに違反して、有価証券を有する状態でその売付けをすること\nb 政令で定めるところに違反して、その有している有価証券の売付け後遅滞なく当該有価証券を提供できることが明らかでない状態でその売付けをすること\nc 政令で定めるところに違反して、有価証券の相場が委託当時の相場より騰貴して自己の指値以上となつたときには直ちにその売付けをし、又は有価証券の相場が委託当時の相場より下落して自己の指値以下となつたときには直ちにその買付けをすべき旨の委託等をすること\nd 政令で定めるところに違反しないで、有価証券を借り入れてその売付けの受託等をすること",
      "correct_answer": "b",
      "predicted_answer": "b",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks which behavior violates **Article 162, Paragraph 1** of the **Financial Instruments and Exchange Act (FIEA)**. This provision typically governs the obligation of securities dealers to execute trades promptly and without unnecessary delay.  \n2. The provided legal texts do not directly reference Article 162, so the analysis must rely on general knowledge of Japanese law.  \n3. **Option b** describes a scenario where a party sells securities **without being able to deliver them promptly** after the sale, violating the obligation to execute trades in a timely manner. This aligns with the core principle of Article 162, which prohibits delays in fulfilling trade obligations.  \n4. **Option a** relates to short selling (violating a ministerial ordinance), which is governed by other provisions (e.g., Article 28 of the FIEA).  \n5. **Option c** involves conditional orders (e.g., stop-loss or limit orders), which are permissible under the FIEA as long as they comply with execution rules.  \n6. **Option d** describes a legitimate activity (borrowing securities for sale) that does not inherently violate Article 162.  \n\nAnswer: **b**",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第6章_選択式_関連法令_問題番号74",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/340CO0000000321"
      ],
      "reasoning": "Reasoning:  \n1. The question asks which behavior violates **Article 162, Paragraph 1** of the **Financial Instruments and Exchange Act (FIEA)**. This provision typically governs the obligation of securities dealers to execute trades promptly and without unnecessary delay.  \n2. The provided legal texts do not directly reference Article 162, so the analysis must rely on general knowledge of Japanese law.  \n3. **Option b** describes a scenario where a party sells securities **without being able to deliver them promptly** after the sale, violating the obligation to execute trades in a timely manner. This aligns with the core principle of Article 162, which prohibits delays in fulfilling trade obligations.  \n4. **Option a** relates to short selling (violating a ministerial ordinance), which is governed by other provisions (e.g., Article 28 of the FIEA).  \n5. **Option c** involves conditional orders (e.g., stop-loss or limit orders), which are permissible under the FIEA as long as they comply with execution rules.  \n6. **Option d** describes a legitimate activity (borrowing securities for sale) that does not inherently violate Article 162.  \n\nAnswer: **b**"
    },
    {
      "question": "次のうち、正しいものを教えてください。",
      "choices": "a 金融商品取引法第164条第１項の規定により上場会社等の役員又は主要株主に対して請求する権利は、利益の取得を知った日から２年間行わないときは、消滅する\nb 金融商品取引法第164条第２項の規定により上場会社等の役員又は主要株主に対して請求する権利は、利益の取得があった日から３年間行わないときは、消滅する\nc 上場会社等の役員がその職務により取得した秘密を不当に利用することを防止するため、その者が当該上場会社等の特定有価証券等について、自己の計算においてそれに係る買付け等をした後10月目に売付け等をして利益を得た場合においては、当該上場会社等は、その利益を上場会社等に提供すべきことを請求することができない\nd 当該上場会社等の株主が上場会社等に対し金融商品取引法第164条第１項の規定による請求を行うべき旨を要求した日の後30日以内に上場会社等が同項の規定による請求を行わない場合、当該株主は、上場会社等に代位して、その請求を行うことができる",
      "correct_answer": "c",
      "predicted_answer": "a",
      "is_correct": false,
      "response": "Reasoning: The question asks which statement is correct based on Japanese law, but the provided legal provisions (1)-(3) are unrelated to the Financial Instruments and Exchange Act (金融商品取引法) referenced in the choices. Since the provisions do not include any relevant text from the Financial Instruments and Exchange Act, it is impossible to verify the accuracy of the choices using the given materials. However, based on general knowledge of Japanese law:\n\n- **Option a** refers to the statute of limitations for claims under Article 164, Paragraph 1 of the Financial Instruments and Exchange Act. This provision typically states that the right to claim expires **2 years from the day the claimant becomes aware of the profit**, which aligns with the description in option a.  \n- **Option b** mentions a 3-year period from the day the profit was obtained, which may apply to a different provision (e.g., Paragraph 2 of Article 164), but the question does not clarify this distinction.  \n- **Options c and d** involve claims about insider trading and shareholder rights, but without specific legal text, their accuracy cannot be confirmed.  \n\nSince the provided legal provisions do not address the Financial Instruments and Exchange Act, the correct answer cannot be determined from the given information. However, **option a** is the most plausible based on general knowledge of Japanese law.  \n\nAnswer: a",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第6章_選択式_関連法令_問題番号75",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025"
      ],
      "reasoning": "Reasoning: The question asks which statement is correct based on Japanese law, but the provided legal provisions (1)-(3) are unrelated to the Financial Instruments and Exchange Act (金融商品取引法) referenced in the choices. Since the provisions do not include any relevant text from the Financial Instruments and Exchange Act, it is impossible to verify the accuracy of the choices using the given materials. However, based on general knowledge of Japanese law:\n\n- **Option a** refers to the statute of limitations for claims under Article 164, Paragraph 1 of the Financial Instruments and Exchange Act. This provision typically states that the right to claim expires **2 years from the day the claimant becomes aware of the profit**, which aligns with the description in option a.  \n- **Option b** mentions a 3-year period from the day the profit was obtained, which may apply to a different provision (e.g., Paragraph 2 of Article 164), but the question does not clarify this distinction.  \n- **Options c and d** involve claims about insider trading and shareholder rights, but without specific legal text, their accuracy cannot be confirmed.  \n\nSince the provided legal provisions do not address the Financial Instruments and Exchange Act, the correct answer cannot be determined from the given information. However, **option a** is the most plausible based on general knowledge of Japanese law.  \n\nAnswer: a"
    },
    {
      "question": "金融商品取引法第171条の２第１項にいう「未公開有価証券」に該当するものを教えてください。",
      "choices": "a 指定外国金融商品取引所に上場されている有価証券\nb 新株予約権付社債券でない社債券であって、金融商品取引法第24条第１項の規定による有価証券報告書であつて同法第25条第１項の規定により公衆の縦覧に供されているものの提出者が発行者であるもの\nc 金融商品取引所に上場されている有価証券\nd 新株予約権証券のうち、金融商品取引法第171条の２第２項各号のいずれにも該当しないもの",
      "correct_answer": "d",
      "predicted_answer": "d",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks which option qualifies as \"未公開有価証券\" (unlisted securities) under FIEA Article 171-2, Paragraph 1.  \n2. **Key definitions**:  \n   - \"未公開有価証券\" typically refers to securities **not listed on any exchange** and **not subject to public disclosure requirements** under the FIEA.  \n   - Options **a** and **c** explicitly mention securities listed on exchanges (foreign or domestic), which are **not** unlisted. These are excluded.  \n3. **Option b** describes a corporate bond that is **not a convertible bond** and has a **publicly available securities report** (under FIEA Article 24). While the report is public, the securities themselves are **not listed**. However, the presence of a public report may imply **some level of disclosure**, which could conflict with the \"未公開\" requirement (which emphasizes **lack of public disclosure**). This makes **option b** ambiguous but less likely to be correct.  \n4. **Option d** refers to **convertible bonds** that **do not fall under any exceptions** in FIEA Article 171-2, Paragraph 2. If Article 171-2, Paragraph 2 lists exceptions (e.g., certain convertible bonds that are not considered unlisted), then **convertible bonds not falling into those exceptions** would be classified as **unlisted securities**. This aligns with the definition of \"未公開有価証券\" (unlisted and not subject to public disclosure).  \n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第6章_選択式_関連法令_問題番号76",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/340CO0000000321"
      ],
      "reasoning": "Reasoning:  \n1. The question asks which option qualifies as \"未公開有価証券\" (unlisted securities) under FIEA Article 171-2, Paragraph 1.  \n2. **Key definitions**:  \n   - \"未公開有価証券\" typically refers to securities **not listed on any exchange** and **not subject to public disclosure requirements** under the FIEA.  \n   - Options **a** and **c** explicitly mention securities listed on exchanges (foreign or domestic), which are **not** unlisted. These are excluded.  \n3. **Option b** describes a corporate bond that is **not a convertible bond** and has a **publicly available securities report** (under FIEA Article 24). While the report is public, the securities themselves are **not listed**. However, the presence of a public report may imply **some level of disclosure**, which could conflict with the \"未公開\" requirement (which emphasizes **lack of public disclosure**). This makes **option b** ambiguous but less likely to be correct.  \n4. **Option d** refers to **convertible bonds** that **do not fall under any exceptions** in FIEA Article 171-2, Paragraph 2. If Article 171-2, Paragraph 2 lists exceptions (e.g., certain convertible bonds that are not considered unlisted), then **convertible bonds not falling into those exceptions** would be classified as **unlisted securities**. This aligns with the definition of \"未公開有価証券\" (unlisted and not subject to public disclosure).  \n\nAnswer: d"
    },
    {
      "question": "金融商品取引所に上場されている有価証券（特定上場有価証券を除く。）を発行する外国会社について、有価証券報告書の提出期間を定めた条文を教えてください。",
      "choices": "a 金融商品取引法第24条第1項第3号\nb 金融商品取引法第24条第1項第1号\nc 金融商品取引法施行令第3条の4\nd 金融商品取引法施行令第3条の6",
      "correct_answer": "c",
      "predicted_answer": "d",
      "is_correct": false,
      "response": "Reasoning:  \n1. The question asks for the legal provision that sets the **submission period** for the **securities report** (有価証券報告書) by **foreign companies** issuing securities listed on a financial exchange (excluding specific listed securities).  \n2. The provided legal texts include:  \n   - **[1]** and **[2]** from the **Cabinet Office Ordinance on Disclosure of Corporate Information**, which mention the **number of security holders** and the **date of submission** of the securities report for fiscal years ending after March 31, 2011. However, these are **regulatory provisions**, not the **main law** defining the submission period.  \n   - **[3]** from the **Company Act**, which states that foreign companies subject to the **Financial Instruments and Exchange Act (FIEA)** are **exempt** from certain provisions applicable to Japanese companies. This does not directly address the submission period.  \n3. The **FIEA** itself (not provided in the texts) likely outlines the **general obligation** to submit reports, but the **specific submission period** (e.g., deadlines) is typically detailed in the **FIEA Enforcement Order**.  \n4. Among the choices:  \n   - **a** and **b** refer to **FIEA Article 24, Paragraph 1**, which likely outlines the **obligation** to submit reports but not the **period**.  \n   - **c** and **d** refer to the **FIEA Enforcement Order**. Based on standard Japanese law, **Article 3-6** of the **FIEA Enforcement Order** specifies the **submission deadlines** for securities reports (e.g., within 120 days after the end of the fiscal year).  \n5. Therefore, **[d]** is the correct answer as it directly addresses the **submission period**.  \n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第2章_選択式_根拠条文_問題番号58",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/340CO0000000321"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the legal provision that sets the **submission period** for the **securities report** (有価証券報告書) by **foreign companies** issuing securities listed on a financial exchange (excluding specific listed securities).  \n2. The provided legal texts include:  \n   - **[1]** and **[2]** from the **Cabinet Office Ordinance on Disclosure of Corporate Information**, which mention the **number of security holders** and the **date of submission** of the securities report for fiscal years ending after March 31, 2011. However, these are **regulatory provisions**, not the **main law** defining the submission period.  \n   - **[3]** from the **Company Act**, which states that foreign companies subject to the **Financial Instruments and Exchange Act (FIEA)** are **exempt** from certain provisions applicable to Japanese companies. This does not directly address the submission period.  \n3. The **FIEA** itself (not provided in the texts) likely outlines the **general obligation** to submit reports, but the **specific submission period** (e.g., deadlines) is typically detailed in the **FIEA Enforcement Order**.  \n4. Among the choices:  \n   - **a** and **b** refer to **FIEA Article 24, Paragraph 1**, which likely outlines the **obligation** to submit reports but not the **period**.  \n   - **c** and **d** refer to the **FIEA Enforcement Order**. Based on standard Japanese law, **Article 3-6** of the **FIEA Enforcement Order** specifies the **submission deadlines** for securities reports (e.g., within 120 days after the end of the fiscal year).  \n5. Therefore, **[d]** is the correct answer as it directly addresses the **submission period**.  \n\nAnswer: d"
    },
    {
      "question": "内閣総理大臣が有価証券報告書を受理した日から公衆の縦覧に供しなければならない期間を定めた条文として、正しいものを教えてください。",
      "choices": "a 金融商品取引法第25条第1項第3号\nb 金融商品取引法第25条第1項第5号\nc 金融商品取引法第25条第1項第6号\nd 金融商品取引法第25条第1項第9号",
      "correct_answer": "a",
      "predicted_answer": "a",
      "is_correct": true,
      "response": "Reasoning: The question asks for the legal provision that sets the period during which the Prime Minister must make securities reports available for public inspection. The provided legal text [1] (金融商品取引法第27_28条第1項) explicitly states that such reports must be made available for public inspection for **five years** from the date they are received. However, the answer choices all refer to **Article 25, Section 1** of the Financial Instruments and Exchange Act, which is **not mentioned in the provided legal texts**. Since none of the given options (a–d) correspond to the relevant provision in the provided texts ([1]), the correct answer cannot be determined from the information provided. However, if the question assumes that the correct provision is [1], the answer would not be among the listed choices. \n\nAnswer: None of the provided choices (a, b, c, d) are correct based on the given legal texts.",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第2章_選択式_根拠条文_問題番号62",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025"
      ],
      "reasoning": "Reasoning: The question asks for the legal provision that sets the period during which the Prime Minister must make securities reports available for public inspection. The provided legal text [1] (金融商品取引法第27_28条第1項) explicitly states that such reports must be made available for public inspection for **five years** from the date they are received. However, the answer choices all refer to **Article 25, Section 1** of the Financial Instruments and Exchange Act, which is **not mentioned in the provided legal texts**. Since none of the given options (a–d) correspond to the relevant provision in the provided texts ([1]), the correct answer cannot be determined from the information provided. However, if the question assumes that the correct provision is [1], the answer would not be among the listed choices. \n\nAnswer: None of the provided choices (a, b, c, d) are correct based on the given legal texts."
    },
    {
      "question": "有価証券届出書の届出書のうち、重要な事項について虚偽の記載があり、又は記載すべき重要な事項若しくは誤解を生じさせないために必要な重要な事実の記載が欠けていることを理由として、当該有価証券の届出者が有価証券の取得者に対して損害賠償責任を負う場合において、請求時に当該有価証券を処分していない場合に、有価証券の取得価額から控除すべき価額を定めている条文を教えてください。",
      "choices": "a 金融商品取引法第18条第1項\nb 金融商品取引法第19条第2項\nc 金融商品取引法第19条第1項第1号\nd 金融商品取引法第19条第1項第2号",
      "correct_answer": "d",
      "predicted_answer": "d",
      "is_correct": true,
      "response": "Reasoning: The question asks for the legal provision that specifies the amount to be deducted from the purchase price of securities when a claim is made and the securities have not been disposed of. The provided legal provisions (articles 18 and 22) outline liability for damages but do not address the calculation or deduction of the amount from the purchase price. The correct answer must therefore be found in a provision not explicitly listed in the given text. Among the choices, **article 19** is the only one that could logically address the calculation of damages or deductions, as it is a common provision in Japanese law related to compensation mechanisms. Specifically, **article 19, paragraph 1, item 2** (choice **d**) is the standard provision that defines the deductible amount (e.g., the market value of the securities at the time of disposal or other relevant factors). Since the provided text does not include this, the answer is inferred based on standard legal structure and the options given.\n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第2章_選択式_根拠条文_問題番号63",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025"
      ],
      "reasoning": "Reasoning: The question asks for the legal provision that specifies the amount to be deducted from the purchase price of securities when a claim is made and the securities have not been disposed of. The provided legal provisions (articles 18 and 22) outline liability for damages but do not address the calculation or deduction of the amount from the purchase price. The correct answer must therefore be found in a provision not explicitly listed in the given text. Among the choices, **article 19** is the only one that could logically address the calculation of damages or deductions, as it is a common provision in Japanese law related to compensation mechanisms. Specifically, **article 19, paragraph 1, item 2** (choice **d**) is the standard provision that defines the deductible amount (e.g., the market value of the securities at the time of disposal or other relevant factors). Since the provided text does not include this, the answer is inferred based on standard legal structure and the options given.\n\nAnswer: d"
    },
    {
      "question": "金融商品取引法第21条により、有価証券届出書を提出した時における会社の役員が、損害賠償責任を免れることができる根拠となる条文を教えてください。",
      "choices": "a 金融商品取引法第21条第1項第1号\nb 金融商品取引法第21条第1項第3号\nc 金融商品取引法第21条第2項第1号\nd 金融商品取引法第21条第2項第2号",
      "correct_answer": "c",
      "predicted_answer": "c",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks for the legal provision under the Financial Instruments and Exchange Act (金融商品取引法) that allows company officers to avoid liability for damages when they submitted a securities registration statement (有価証券届出書) in good faith.  \n2. The key lies in understanding the structure of **Article 21** of the Act. Typically, such liability exemptions are found in **Paragraph 2** (第2項) of the article, which outlines exceptions to liability.  \n3. **Article 21, Paragraph 2, Item 1** (第21条第2項第1号) specifically states that if a company officer has made a \"reasonable effort\" (合理的な努力) to ensure the accuracy of the registration statement, they are exempt from liability for damages. This aligns with the scenario described in the question.  \n4. The other options (a, b, d) pertain to different provisions, such as liability for false statements (a, b) or other exceptions not directly related to good-faith submission (d).  \n\nAnswer: c",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第2章_選択式_根拠条文_問題番号64",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the legal provision under the Financial Instruments and Exchange Act (金融商品取引法) that allows company officers to avoid liability for damages when they submitted a securities registration statement (有価証券届出書) in good faith.  \n2. The key lies in understanding the structure of **Article 21** of the Act. Typically, such liability exemptions are found in **Paragraph 2** (第2項) of the article, which outlines exceptions to liability.  \n3. **Article 21, Paragraph 2, Item 1** (第21条第2項第1号) specifically states that if a company officer has made a \"reasonable effort\" (合理的な努力) to ensure the accuracy of the registration statement, they are exempt from liability for damages. This aligns with the scenario described in the question.  \n4. The other options (a, b, d) pertain to different provisions, such as liability for false statements (a, b) or other exceptions not directly related to good-faith submission (d).  \n\nAnswer: c"
    },
    {
      "question": "上場株券等の発行者が店頭売買有価証券市場において店頭売買有価証券の取引による買付け等を行う場合、当該買付け等は公開買付けによる必要がないことの根拠となる条文を教えてください。",
      "choices": "a 金融商品取引法第27条の22の2第1項\nb 金融商品取引法第27条の22の2第1項第2号\nc 金融商品取引法施行令第14条の3の2第2項\nd 金融商品取引法施行令第14条の3の2第3項",
      "correct_answer": "a",
      "predicted_answer": "unknown",
      "is_correct": false,
      "response": "",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第2章の2_選択式_根拠条文_問題番号65",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/340CO0000000321"
      ],
      "reasoning": ""
    },
    {
      "question": "公開買付者が行う公開買付けに係る応募株券数等の数の公表を行う場合に、公開すべき報道機関の数を規定した条文を教えてください。",
      "choices": "a 金融商品取引法施行令第9条の3第1項第1号\nb 金融商品取引法施行令第9条の3第1項第2号\nc 金融商品取引法施行令第9条の4第1項第1号\nd 発行者以外の者による株券等の公開買付けの開示に関する内閣府令",
      "correct_answer": "d",
      "predicted_answer": "d",
      "is_correct": true,
      "response": "Reasoning: The question asks for the provision that specifies the number of news agencies required for public disclosure in a tender offer. The provided legal texts (all identical) from the Financial Instruments and Exchange Act (Article 27-13, Paragraph 1) state that the acquirer must announce or disclose certain matters, but they do not mention the number of news agencies. Instead, they reference \"政令\" (cabinet orders) for the method of announcement. This implies that the specific requirement for the number of news agencies is governed by a cabinet order, not the Act itself or its implementing orders. Among the choices, **option d** explicitly refers to a cabinet order related to disclosure in public tenders, which aligns with the reference to \"政令\" in the Act. The other options (a, b, c) pertain to the Financial Instruments and Exchange Act Implementation Order, which is not the source of the number of news agencies requirement. \n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第2章の2_選択式_根拠条文_問題番号66",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/340CO0000000321"
      ],
      "reasoning": "Reasoning: The question asks for the provision that specifies the number of news agencies required for public disclosure in a tender offer. The provided legal texts (all identical) from the Financial Instruments and Exchange Act (Article 27-13, Paragraph 1) state that the acquirer must announce or disclose certain matters, but they do not mention the number of news agencies. Instead, they reference \"政令\" (cabinet orders) for the method of announcement. This implies that the specific requirement for the number of news agencies is governed by a cabinet order, not the Act itself or its implementing orders. Among the choices, **option d** explicitly refers to a cabinet order related to disclosure in public tenders, which aligns with the reference to \"政令\" in the Act. The other options (a, b, c) pertain to the Financial Instruments and Exchange Act Implementation Order, which is not the source of the number of news agencies requirement. \n\nAnswer: d"
    },
    {
      "question": "金融商品取引法第27条の32の2に定める外国証券情報について、その相手方に提供し、又は公表しなくてもよい場合について定めた条文として、誤っているものを教えてください",
      "choices": "a 金融商品取引法第27条の32の2第1項本文\nb 証券情報等の提供又は公表に関する内閣府令第13条第2号\nc 証券情報等の提供又は公表に関する内閣府令第13条第4号\nd 金融商品取引法27条の32の2第1項ただし書",
      "correct_answer": "a",
      "predicted_answer": "a",
      "is_correct": true,
      "response": "Reasoning: The question asks for the incorrect provision regarding exceptions where foreign securities information does not need to be provided or disclosed. The key is to identify which option does **not** qualify as an exception. \n\n- **Option a** refers to the main text of **Article 27-32-2, Paragraph 1** of the Financial Instruments and Exchange Act. This provision likely outlines the **general obligation** to provide or disclose foreign securities information, not an exception. Since the question focuses on **exceptions**, this option is **not** an exception and thus **incorrect** as a provision allowing non-disclosure. \n\n- **Options b and c** refer to **Article 13, Paragraphs 2 and 4** of the Cabinet Office Ordinance. While the provided text does not explicitly mention these paragraphs, they are part of the Ordinance and could potentially contain exceptions (e.g., specific exemptions under the Ordinance). \n\n- **Option d** refers to the **but clause** of **Article 27-32-2, Paragraph 1**, which may contain exceptions (e.g., \"but\" clauses often introduce exceptions to general rules). However, the provided text does not include this clause, so its validity cannot be confirmed. However, the question is about **which is incorrect**, and **Option a** is clearly not an exception, making it the correct answer.\n\nAnswer: a",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第2章の5_選択式_根拠条文_問題番号31",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/420M60000002078",
        "https://www.fsa.go.jp/common/law/kaiji/250221_kaiji.pdf"
      ],
      "reasoning": "Reasoning: The question asks for the incorrect provision regarding exceptions where foreign securities information does not need to be provided or disclosed. The key is to identify which option does **not** qualify as an exception. \n\n- **Option a** refers to the main text of **Article 27-32-2, Paragraph 1** of the Financial Instruments and Exchange Act. This provision likely outlines the **general obligation** to provide or disclose foreign securities information, not an exception. Since the question focuses on **exceptions**, this option is **not** an exception and thus **incorrect** as a provision allowing non-disclosure. \n\n- **Options b and c** refer to **Article 13, Paragraphs 2 and 4** of the Cabinet Office Ordinance. While the provided text does not explicitly mention these paragraphs, they are part of the Ordinance and could potentially contain exceptions (e.g., specific exemptions under the Ordinance). \n\n- **Option d** refers to the **but clause** of **Article 27-32-2, Paragraph 1**, which may contain exceptions (e.g., \"but\" clauses often introduce exceptions to general rules). However, the provided text does not include this clause, so its validity cannot be confirmed. However, the question is about **which is incorrect**, and **Option a** is clearly not an exception, making it the correct answer.\n\nAnswer: a"
    },
    {
      "question": "現在、Tokyo Pro Marketは、特定上場有価証券の売買等を取り扱っていますが、特定上場有価証券について投資者に明らかにされるべき情報について定めている条文を教えてください。",
      "choices": "a 金融商品取引法第27条の31第１項\nb 金融商品取引法第４条第１項\nc 証券情報等の提供又は公表に関する内閣府令第２条第１項第１号\nd 金融商品取引法施行令第14条の14",
      "correct_answer": "c",
      "predicted_answer": "a",
      "is_correct": false,
      "response": "Reasoning:  \n1. The question asks for the legal provision that specifies the information to be disclosed regarding specific listed securities.  \n2. The provided legal texts (1), (2), and (3) focus on **obligations to provide or publish information** (e.g., under FIEA Article 27-32) when a security becomes a \"specific investor security.\" However, they do **not** explicitly define the **content** of the information that must be disclosed.  \n3. Among the choices, **option a (FIEA Article 27-31, Paragraph 1)** is the most relevant. While the provided texts do not include this article, **FIEA Article 27-31** is a well-known provision in Japanese law that outlines the **specific information** (e.g., financial statements, business performance, risks) that must be disclosed to investors for listed securities. This aligns with the question’s focus on **what information must be disclosed**, not the obligation to disclose it.  \n4. Other options (b, c, d) either refer to unrelated provisions (e.g., FIEA Article 4, Cabinet Office Order Article 2, or FIEA Implementation Order Article 14-14) or are not directly tied to the disclosure of information for specific listed securities.  \n\nAnswer: a",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第2章の5_選択式_根拠条文_問題番号32",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/420M60000002078"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the legal provision that specifies the information to be disclosed regarding specific listed securities.  \n2. The provided legal texts (1), (2), and (3) focus on **obligations to provide or publish information** (e.g., under FIEA Article 27-32) when a security becomes a \"specific investor security.\" However, they do **not** explicitly define the **content** of the information that must be disclosed.  \n3. Among the choices, **option a (FIEA Article 27-31, Paragraph 1)** is the most relevant. While the provided texts do not include this article, **FIEA Article 27-31** is a well-known provision in Japanese law that outlines the **specific information** (e.g., financial statements, business performance, risks) that must be disclosed to investors for listed securities. This aligns with the question’s focus on **what information must be disclosed**, not the obligation to disclose it.  \n4. Other options (b, c, d) either refer to unrelated provisions (e.g., FIEA Article 4, Cabinet Office Order Article 2, or FIEA Implementation Order Article 14-14) or are not directly tied to the disclosure of information for specific listed securities.  \n\nAnswer: a"
    },
    {
      "question": "日本放送協会に対して重要情報を公開する方法が重要情報の公表の方法として認められていることを示す条文を教えてください。",
      "choices": "a 金融商品取引法第二章の六の規定による重要情報の公表に関する内閣府令第10条第1号\nb 金融商品取引法第二章の六の規定による重要情報の公表に関する内閣府令第10条第２号イ\nc 金融商品取引法第二章の六の規定による重要情報の公表に関する内閣府令第10条第２号ハ\nd 金融商品取引法第二章の六の規定による重要情報の公表に関する内閣府令第10条第３号",
      "correct_answer": "c",
      "predicted_answer": "d",
      "is_correct": false,
      "response": "Reasoning:  \nThe question asks which provision recognizes the Japan Broadcasting Association (NHK) as a valid recipient of important information under the Financial Instruments and Exchange Act. The provided legal text (Articles 27-38, Paragraph 1 of the Act) only outlines the Prime Minister's authority to mandate disclosure of important information when it is not voluntarily disclosed. It does not specify the **methods** of disclosure or the **entities** to which information must be disclosed.  \n\nThe correct answer must therefore be found in the **Cabinet Office Ordinance** referenced in the choices (e.g., \"内閣府令第10条\"). However, the provided legal text does not include the Ordinance's content. Based on standard Japanese legal practice, the **Cabinet Office Ordinance** under the Financial Instruments and Exchange Act (Chapter 2-6, Article 10) typically lists entities required to receive important information. For example:  \n- **Paragraph 1** might include the Japan Exchange Group (東京証券取引所).  \n- **Paragraph 2** might include the Financial Services Agency (FSA) and other regulatory bodies.  \n- **Paragraph 3** might include the Japan Broadcasting Association (NHK) as a public entity responsible for disseminating critical financial information to the public.  \n\nThus, **option d** (内閣府令第10条第3号) is the most plausible answer, as it aligns with the role of NHK in public disclosure.  \n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第2章の6_選択式_根拠条文_問題番号70",
      "references": [
        "https://laws.e-gov.go.jp/law/429M60000002054"
      ],
      "reasoning": "Reasoning:  \nThe question asks which provision recognizes the Japan Broadcasting Association (NHK) as a valid recipient of important information under the Financial Instruments and Exchange Act. The provided legal text (Articles 27-38, Paragraph 1 of the Act) only outlines the Prime Minister's authority to mandate disclosure of important information when it is not voluntarily disclosed. It does not specify the **methods** of disclosure or the **entities** to which information must be disclosed.  \n\nThe correct answer must therefore be found in the **Cabinet Office Ordinance** referenced in the choices (e.g., \"内閣府令第10条\"). However, the provided legal text does not include the Ordinance's content. Based on standard Japanese legal practice, the **Cabinet Office Ordinance** under the Financial Instruments and Exchange Act (Chapter 2-6, Article 10) typically lists entities required to receive important information. For example:  \n- **Paragraph 1** might include the Japan Exchange Group (東京証券取引所).  \n- **Paragraph 2** might include the Financial Services Agency (FSA) and other regulatory bodies.  \n- **Paragraph 3** might include the Japan Broadcasting Association (NHK) as a public entity responsible for disseminating critical financial information to the public.  \n\nThus, **option d** (内閣府令第10条第3号) is the most plausible answer, as it aligns with the role of NHK in public disclosure.  \n\nAnswer: d"
    },
    {
      "question": "次のうち、誤っているものを教えてください。",
      "choices": "a 厚生労働大臣は、医療機器の製造販売業者がその業務に関し遵守すべき事項として、医療機器の品質管理の実施方法を定めることができる\nb 体外診断用医薬品の製造販売業者は、医療機器等総括製造販売責任者の意見を尊重しなければならない\nc 医療機器の製造業者は、法令遵守のための措置を講じない場合には、その旨及び理由を記録し、適切に保存しなければならない\nd 厚生労働大臣は、医療機器の製造販売業者がその業務に関し遵守すべき事項として、製造所における医療機器の試験検査の実施方法を定めることができる",
      "correct_answer": "d",
      "predicted_answer": "b",
      "is_correct": false,
      "response": "Reasoning: The question asks to identify the incorrect statement regarding medical device regulations in Japan. The provided legal provisions (Consumer Contract Law, Specific Commercial Transactions Law, and Agricultural Cooperative Law) are unrelated to medical devices, so the analysis must rely on general knowledge of Japanese pharmaceutical and medical device laws. \n\n- **Option a** aligns with the Pharmaceutical and Medical Devices Act (PMD Act), which grants the Minister of Health, Labour and Welfare authority to set quality management requirements for medical devices. This is correct.  \n- **Option b** claims that manufacturers of in vitro diagnostic medical products \"must respect\" the opinion of the general manager responsible for medical devices. However, the PMD Act typically requires consultation or compliance with the responsible person's duties, not necessarily \"respecting\" their opinion. This phrasing may be legally inaccurate, making **b** the incorrect statement.  \n- **Option c** reflects standard record-keeping obligations under the PMD Act for non-compliance measures.  \n- **Option d** is consistent with the PMD Act, which allows the Minister to regulate testing and inspection methods at manufacturing facilities.  \n\nAnswer: b",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第5章_選択式_関連法令_問題番号38",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145"
      ],
      "reasoning": "Reasoning: The question asks to identify the incorrect statement regarding medical device regulations in Japan. The provided legal provisions (Consumer Contract Law, Specific Commercial Transactions Law, and Agricultural Cooperative Law) are unrelated to medical devices, so the analysis must rely on general knowledge of Japanese pharmaceutical and medical device laws. \n\n- **Option a** aligns with the Pharmaceutical and Medical Devices Act (PMD Act), which grants the Minister of Health, Labour and Welfare authority to set quality management requirements for medical devices. This is correct.  \n- **Option b** claims that manufacturers of in vitro diagnostic medical products \"must respect\" the opinion of the general manager responsible for medical devices. However, the PMD Act typically requires consultation or compliance with the responsible person's duties, not necessarily \"respecting\" their opinion. This phrasing may be legally inaccurate, making **b** the incorrect statement.  \n- **Option c** reflects standard record-keeping obligations under the PMD Act for non-compliance measures.  \n- **Option d** is consistent with the PMD Act, which allows the Minister to regulate testing and inspection methods at manufacturing facilities.  \n\nAnswer: b"
    },
    {
      "question": "次のうち、厚生労働大臣が登録認証機関に命じることができないことを教えてください。",
      "choices": "a 基準適合性認証の取消しその他必要な措置を採るべきこと\nb 基準適合性認証のための審査を行うべきこと、又は基準適合性認証のための審査の方法その他の業務の方法の改善に関し必要な措置を採るべきこと\nc 第二十三条の七第一項各号の規定に適合するため必要な措置を採るべきこと\nd 基準適合性認証の結果に異議を述べるべきこと",
      "correct_answer": "d",
      "predicted_answer": "d",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks which action **cannot** be ordered by the Minister of Health, Labour and Welfare under the given legal provisions.  \n2. The relevant provision (Article 23_12, Paragraph 1) states that the Minister may order a registered certification body to take **necessary measures** to comply with the requirements in Article 23_7, Paragraph 1.  \n3. **Analysis of choices**:  \n   - **Option a**: \"Canceling the conformity assessment certification or taking other necessary measures\" aligns with the Minister's authority to enforce compliance (e.g., revoking certification if standards are not met).  \n   - **Option b**: \"Conducting reviews or improving methods\" falls under \"necessary measures\" to ensure compliance with regulations.  \n   - **Option c**: Directly references the requirement in Article 23_7, which the Minister can mandate.  \n   - **Option d**: \"Expressing objections to the conformity assessment results\" is **not** within the Minister's authority. The law grants the Minister power to enforce compliance, not to compel the certification body to challenge or object to its own results.  \n4. **Conclusion**: Only **Option d** is outside the scope of the Minister's authority as defined by the law.  \n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第5章_選択式_関連法令_問題番号39",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145"
      ],
      "reasoning": "Reasoning:  \n1. The question asks which action **cannot** be ordered by the Minister of Health, Labour and Welfare under the given legal provisions.  \n2. The relevant provision (Article 23_12, Paragraph 1) states that the Minister may order a registered certification body to take **necessary measures** to comply with the requirements in Article 23_7, Paragraph 1.  \n3. **Analysis of choices**:  \n   - **Option a**: \"Canceling the conformity assessment certification or taking other necessary measures\" aligns with the Minister's authority to enforce compliance (e.g., revoking certification if standards are not met).  \n   - **Option b**: \"Conducting reviews or improving methods\" falls under \"necessary measures\" to ensure compliance with regulations.  \n   - **Option c**: Directly references the requirement in Article 23_7, which the Minister can mandate.  \n   - **Option d**: \"Expressing objections to the conformity assessment results\" is **not** within the Minister's authority. The law grants the Minister power to enforce compliance, not to compel the certification body to challenge or object to its own results.  \n4. **Conclusion**: Only **Option d** is outside the scope of the Minister's authority as defined by the law.  \n\nAnswer: d"
    },
    {
      "question": "次のうち、製造販売業者等の、薬事に関する法令遵守体制について正しいものを教えてください。",
      "choices": "a 薬機法上規定された法令遵守体制整備に関する事項についての社内規程を、新たに必ず作成する必要がある\nb 製造販売業者等において、薬事に関する法令だけでなく、会社法その他の法令等を踏まえ、既に構築している法令遵守体制を活用することはできない\nc 製造販売業者等において、既に構築している法令遵守体制を活用すること自体に問題はないが、薬事に関する法令を遵守して業務を行うことを確保するために、不十分な点がある場合には、新たな体制の構築や既存の体制の改善等の措置を講ずることが重要である\nd 既に構築している法令遵守体制がある場合には、新たな体制の構築や既存の体制の改善等の措置を講ずることまでは求められない",
      "correct_answer": "c",
      "predicted_answer": "c",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks for the correct statement regarding the legal compliance systems (法令遵守体制) for manufacturers and distributors under Japanese pharmaceutical laws.  \n2. The relevant provisions (e.g., [1], [2], [3]) emphasize the need to ensure compliance with laws through systems such as regulations, training, supervision, and record-keeping. However, they do not explicitly require the **creation of entirely new internal regulations** (as in option a) or prohibit the use of existing systems (as in option b).  \n3. **Option a** is incorrect because the provisions do not mandate the **creation of new regulations** but rather the establishment of systems that ensure compliance, which may include leveraging existing frameworks.  \n4. **Option b** is incorrect because the provisions do not restrict the use of existing compliance systems for other laws (e.g., the Company Act). The focus is on ensuring compliance with **pharmaceutical-specific laws**, not excluding other legal frameworks.  \n5. **Option d** is incorrect because the provisions require ensuring compliance, which may necessitate **improving existing systems** if they are inadequate.  \n6. **Option c** is correct because it acknowledges that existing systems can be utilized but emphasizes the need for **improvements or new measures** if they are insufficient to ensure compliance with pharmaceutical laws. This aligns with the provisions’ focus on ensuring compliance through \"necessary measures\" (e.g., [2] mentions \"necessary measures\" for ensuring proper business operations).  \n\nAnswer: c",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第5章_選択式_関連法令_問題番号40",
      "references": [],
      "reasoning": "Reasoning:  \n1. The question asks for the correct statement regarding the legal compliance systems (法令遵守体制) for manufacturers and distributors under Japanese pharmaceutical laws.  \n2. The relevant provisions (e.g., [1], [2], [3]) emphasize the need to ensure compliance with laws through systems such as regulations, training, supervision, and record-keeping. However, they do not explicitly require the **creation of entirely new internal regulations** (as in option a) or prohibit the use of existing systems (as in option b).  \n3. **Option a** is incorrect because the provisions do not mandate the **creation of new regulations** but rather the establishment of systems that ensure compliance, which may include leveraging existing frameworks.  \n4. **Option b** is incorrect because the provisions do not restrict the use of existing compliance systems for other laws (e.g., the Company Act). The focus is on ensuring compliance with **pharmaceutical-specific laws**, not excluding other legal frameworks.  \n5. **Option d** is incorrect because the provisions require ensuring compliance, which may necessitate **improving existing systems** if they are inadequate.  \n6. **Option c** is correct because it acknowledges that existing systems can be utilized but emphasizes the need for **improvements or new measures** if they are insufficient to ensure compliance with pharmaceutical laws. This aligns with the provisions’ focus on ensuring compliance through \"necessary measures\" (e.g., [2] mentions \"necessary measures\" for ensuring proper business operations).  \n\nAnswer: c"
    },
    {
      "question": "次のうち、再生医療等製品の製造販売をしようとする者に、品目ごとにその製造販売についての厚生労働大臣の承認が与えられない場合を教えてください。",
      "choices": "a 再生医療等製品を業として製造販売することについて、厚生労働大臣の許可を受けている場合\nb 申請に係る効能、効果又は性能を有すると認められる場合\nc 申請に係る効能、効果又は性能に比して有害な作用を有するが、再生医療等製品として使用価値がないとまでは認められない場合\nd 申請に係る再生医療等製品の品質が保健衛生上著しく不適当な場合",
      "correct_answer": "d",
      "predicted_answer": "d",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks for the scenario where the Minister of Health, Labour and Welfare does **not** grant approval for the manufacturing and sale of regenerative medical products on a per-item basis.  \n2. The relevant provisions are **Article 23-25, Paragraph 1** (provision [3]), which mandates that approval is required for each item. However, the conditions for denying approval are not explicitly stated in the provided legal text.  \n3. **Option d** states that the product's quality is \"seriously inappropriate from a health and hygiene perspective.\" This directly contradicts the core purpose of the law, which is to ensure the **quality, efficacy, and safety** of regenerative medical products. If the quality is seriously compromised, the Minister would logically deny approval, as the product would fail to meet basic safety and hygiene standards.  \n4. **Option c** involves a product with harmful effects but not entirely without use value. While this may raise concerns, the law does not explicitly state that such a scenario would lead to denial of approval. In contrast, **option d** clearly violates the foundational requirement of quality, making it the most direct reason for denial.  \n5. **Options a and b** relate to scenarios where approval **would** be granted (e.g., having business permission or recognized efficacy), so they are not the correct answer.  \n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第6章_選択式_関連法令_問題番号41",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145",
        "https://laws.e-gov.go.jp/law/336M50000100001"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the scenario where the Minister of Health, Labour and Welfare does **not** grant approval for the manufacturing and sale of regenerative medical products on a per-item basis.  \n2. The relevant provisions are **Article 23-25, Paragraph 1** (provision [3]), which mandates that approval is required for each item. However, the conditions for denying approval are not explicitly stated in the provided legal text.  \n3. **Option d** states that the product's quality is \"seriously inappropriate from a health and hygiene perspective.\" This directly contradicts the core purpose of the law, which is to ensure the **quality, efficacy, and safety** of regenerative medical products. If the quality is seriously compromised, the Minister would logically deny approval, as the product would fail to meet basic safety and hygiene standards.  \n4. **Option c** involves a product with harmful effects but not entirely without use value. While this may raise concerns, the law does not explicitly state that such a scenario would lead to denial of approval. In contrast, **option d** clearly violates the foundational requirement of quality, making it the most direct reason for denial.  \n5. **Options a and b** relate to scenarios where approval **would** be granted (e.g., having business permission or recognized efficacy), so they are not the correct answer.  \n\nAnswer: d"
    },
    {
      "question": "次のうち、正しいものを教えてください。",
      "choices": "a 再生医療等製品承認取得者について合併があつたとき、合併後存続する法人は、当該再生医療等製品承認取得者の地位を承継できない\nb 再生医療等製品承認取得者がその地位を承継させる目的を持たずに当該品目に係る資料等の譲渡をしたときでも、譲受人は、当該再生医療等製品承認取得者の地位を承継する\nc 再生医療等製品承認取得者の地位を承継した者は、相続の場合にあつては相続後遅滞なく、厚生労働大臣にその旨を届け出なければならない\nd 再生医療等製品承認取得者の地位を承継した者は、相続以外の場合にあつては承継後遅滞なく、厚生労働大臣にその旨を届け出なければならない",
      "correct_answer": "c",
      "predicted_answer": "d",
      "is_correct": false,
      "response": "Reasoning: The question pertains to the legal requirements for notifying the Minister of Health, Labour and Welfare regarding the succession of status as a \"regenerative medical product approval holder.\" However, the provided legal provisions (1), (2), and (3) are unrelated to this topic. They address ship stability, SME employment management, and commercial street revitalization, respectively. None of these provisions provide any basis for analyzing the options (a)-(d). \n\nSince the question relies on unspecified legal provisions (likely from the Pharmaceutical and Medical Devices Act or related regulations), and the user has not included them, it is impossible to determine the correct answer based on the given information. However, under standard Japanese law, both inheritance and non-inheritance succession scenarios typically require notification to the Minister. If forced to choose based on general knowledge, **option d** (notification required after succession in non-inheritance cases) is more likely correct than **option c** (notification required after inheritance), as inheritance cases may involve automatic legal succession without explicit notification requirements. Yet, this remains speculative due to the absence of relevant legal text.\n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第6章_選択式_関連法令_問題番号42",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145"
      ],
      "reasoning": "Reasoning: The question pertains to the legal requirements for notifying the Minister of Health, Labour and Welfare regarding the succession of status as a \"regenerative medical product approval holder.\" However, the provided legal provisions (1), (2), and (3) are unrelated to this topic. They address ship stability, SME employment management, and commercial street revitalization, respectively. None of these provisions provide any basis for analyzing the options (a)-(d). \n\nSince the question relies on unspecified legal provisions (likely from the Pharmaceutical and Medical Devices Act or related regulations), and the user has not included them, it is impossible to determine the correct answer based on the given information. However, under standard Japanese law, both inheritance and non-inheritance succession scenarios typically require notification to the Minister. If forced to choose based on general knowledge, **option d** (notification required after succession in non-inheritance cases) is more likely correct than **option c** (notification required after inheritance), as inheritance cases may involve automatic legal succession without explicit notification requirements. Yet, this remains speculative due to the absence of relevant legal text.\n\nAnswer: d"
    },
    {
      "question": "次のうち、誤っているものを教えてください。",
      "choices": "a 再生医療等製品の製造販売業者は、再生医療等製品の品質管理を行わせるために、医師、歯科医師、薬剤師、獣医師その他の一定の基準に該当する技術者を置かなければならない\nb 再生医療等製品総括製造販売責任者が、製造販売業者に対し述べる意見は、口頭でなす必要がある\nc 再生医療等製品総括製造販売責任者は、業務を遂行し、厚生労働省令で定める事項を遵守するために必要な能力及び経験を有する者である必要がある\nd 再生医療等製品の製造業者は、製造所ごとに、再生医療等製品に係る生物学的知識を有する者その他の技術者を置かなければならない",
      "correct_answer": "b",
      "predicted_answer": "b",
      "is_correct": true,
      "response": "Reasoning:  \nThe question asks to identify the incorrect statement regarding requirements for regenerative medicine product manufacturers under Japanese law. However, the provided legal provisions (Consumer Contract Law, Specific Commercial Transactions Law, and Agricultural Cooperative Law) are unrelated to regenerative medicine regulations. This suggests a possible error in the question setup. Assuming the intended reference is to the **Regenerative Medicine Products Act** (再生医療等製品の製造販売等に関する法律) and related regulations, we analyze the options:  \n\n- **Option a** is likely correct, as quality management personnel (e.g., physicians, pharmacists) are standard requirements for such facilities.  \n- **Option b** claims that the **総括製造販売責任者**'s opinions must be **oral**. However, in practice, such requirements are typically documented in writing (e.g., in reports or records), making this statement **incorrect**.  \n- **Option c** is correct, as the responsibility holder must possess the necessary qualifications and experience.  \n- **Option d** is correct, as technical staff with biological knowledge are required at each manufacturing site.  \n\nSince the provided legal texts do not address regenerative medicine, the answer relies on general knowledge of Japanese pharmaceutical regulations.  \n\nAnswer: **b**",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第6章_選択式_関連法令_問題番号43",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145"
      ],
      "reasoning": "Reasoning:  \nThe question asks to identify the incorrect statement regarding requirements for regenerative medicine product manufacturers under Japanese law. However, the provided legal provisions (Consumer Contract Law, Specific Commercial Transactions Law, and Agricultural Cooperative Law) are unrelated to regenerative medicine regulations. This suggests a possible error in the question setup. Assuming the intended reference is to the **Regenerative Medicine Products Act** (再生医療等製品の製造販売等に関する法律) and related regulations, we analyze the options:  \n\n- **Option a** is likely correct, as quality management personnel (e.g., physicians, pharmacists) are standard requirements for such facilities.  \n- **Option b** claims that the **総括製造販売責任者**'s opinions must be **oral**. However, in practice, such requirements are typically documented in writing (e.g., in reports or records), making this statement **incorrect**.  \n- **Option c** is correct, as the responsibility holder must possess the necessary qualifications and experience.  \n- **Option d** is correct, as technical staff with biological knowledge are required at each manufacturing site.  \n\nSince the provided legal texts do not address regenerative medicine, the answer relies on general knowledge of Japanese pharmaceutical regulations.  \n\nAnswer: **b**"
    },
    {
      "question": "次のうち、正しいものを教えてください。",
      "choices": "a 看板で、染毛剤の商品名のみを広告する場合、使用及び取扱い上の注意に留意すべき旨を、付記しなければならない\nb 染毛剤について商品名以外の内容も広告する場合は、使用及び取扱い上の注意に留意すべき旨を、付記又は付言しなければならない\nc 蚊取り線香について広告する場合は、使用及び取扱い上の注意に留意すべき旨を、付記しなければならない\nd 看板で、ウェーブ用剤について商品名以外の内容も広告する場合、使用及び取扱い上の注意に留意すべき旨を、付記又は付言する必要はない",
      "correct_answer": "b",
      "predicted_answer": "a",
      "is_correct": false,
      "response": "Reasoning: The question asks which statement about advertising requirements is correct based on the provided legal provisions. However, the three legal provisions listed (relating to ship stability, employment management in SMEs, and commercial street activation) do not address advertising regulations, product labeling, or precautions for usage. None of the options (a–d) pertain to the content of the given laws. Since the provisions do not cover advertising requirements, it is impossible to determine the correct answer based solely on the provided texts. The question may be based on a different set of laws not included here, but under the strict instructions to use only the given provisions, no choice can be validated.\n\nAnswer: None of the options can be determined as correct based on the provided legal provisions. However, since the user expects a single-letter answer, this may indicate an error in the question setup.",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第10章_選択式_関連法令_問題番号44",
      "references": [],
      "reasoning": "Reasoning: The question asks which statement about advertising requirements is correct based on the provided legal provisions. However, the three legal provisions listed (relating to ship stability, employment management in SMEs, and commercial street activation) do not address advertising regulations, product labeling, or precautions for usage. None of the options (a–d) pertain to the content of the given laws. Since the provisions do not cover advertising requirements, it is impossible to determine the correct answer based solely on the provided texts. The question may be based on a different set of laws not included here, but under the strict instructions to use only the given provisions, no choice can be validated.\n\nAnswer: None of the options can be determined as correct based on the provided legal provisions. However, since the user expects a single-letter answer, this may indicate an error in the question setup."
    },
    {
      "question": "次のうち、医療機器の販売・貸与業者の業務の適正を確保のために、考えられ、又は、重要となる体制として、誤っているものを教えてください。",
      "choices": "a 通報者の保護等を明確にした実効性のある内部通報制度\nb 業務を行う部門自身による内部監査\nc 監査役等による情報収集等が十分に行われる体制は\nd 営業所管理者又は修理責任技術者による業務の監督及び意見申述が適切に行われる体制",
      "correct_answer": "b",
      "predicted_answer": "b",
      "is_correct": true,
      "response": "Reasoning:  \nThe question asks which option is **incorrect** as a system to ensure the proper conduct of medical device sales/rental businesses. The key is to analyze each choice against the provided legal provisions.  \n\n- **Option a** (internal reporting system with whistleblower protections) is not explicitly mentioned in the provisions, but such systems are standard in compliance frameworks. However, the question focuses on **what is required by law**, not general best practices.  \n- **Option b** (internal audit by the same department) is problematic. While internal audits are common, the provisions do not mandate this. Instead, they emphasize **external collaboration** (e.g., Article 68_5, Paragraph 3) and **supervision by designated roles** (e.g., Article 40, Paragraph 2). Internal audits by the same department may lack objectivity, making this system **not aligned with the legal emphasis on independent oversight**.  \n- **Option c** (adequate information collection by auditors) aligns with the requirement for \"necessary cooperation\" (Article 68_5, Paragraph 3) and quality assurance (Article 40, Paragraph 2).  \n- **Option d** (supervision by managers/technicians) directly corresponds to the \"management methods\" and \"supervision\" mentioned in Article 40, Paragraph 2.  \n\nSince the law does not require **internal audits by the same department** (option b) and instead emphasizes **external collaboration and independent oversight**, this option is **incorrect** as a system to ensure proper conduct.  \n\nAnswer: **b**",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第5章_選択式_関連法令_問題番号45",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145"
      ],
      "reasoning": "Reasoning:  \nThe question asks which option is **incorrect** as a system to ensure the proper conduct of medical device sales/rental businesses. The key is to analyze each choice against the provided legal provisions.  \n\n- **Option a** (internal reporting system with whistleblower protections) is not explicitly mentioned in the provisions, but such systems are standard in compliance frameworks. However, the question focuses on **what is required by law**, not general best practices.  \n- **Option b** (internal audit by the same department) is problematic. While internal audits are common, the provisions do not mandate this. Instead, they emphasize **external collaboration** (e.g., Article 68_5, Paragraph 3) and **supervision by designated roles** (e.g., Article 40, Paragraph 2). Internal audits by the same department may lack objectivity, making this system **not aligned with the legal emphasis on independent oversight**.  \n- **Option c** (adequate information collection by auditors) aligns with the requirement for \"necessary cooperation\" (Article 68_5, Paragraph 3) and quality assurance (Article 40, Paragraph 2).  \n- **Option d** (supervision by managers/technicians) directly corresponds to the \"management methods\" and \"supervision\" mentioned in Article 40, Paragraph 2.  \n\nSince the law does not require **internal audits by the same department** (option b) and instead emphasizes **external collaboration and independent oversight**, this option is **incorrect** as a system to ensure proper conduct.  \n\nAnswer: **b**"
    },
    {
      "question": "医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律 第23条の2の23における 、医療機器等の製造販売についての登録認証機関の認証について、正しいものを教えてください。",
      "choices": "a 外国指定高度管理医療機器製造等事業者が申請者である場合には、自ら第二十三条の二第一項の許可（申請をした品目の種類に応じた許可に限る。）を受けていないときには、登録認証機関の認証を受けられない\nb 指定高度管理医療機器等を製造する製造所は、登録認証機関の認証を受けるのに、特に登録は必要ない\nc 一般医療機器については、登録認証機関の認証は必要とされていない\nd 指定高度管理医療機器等が厚生労働大臣が指定する基準に適合していなくても、登録認証機関の認証を得られる可能性はある",
      "correct_answer": "c",
      "predicted_answer": "c",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks for the correct statement regarding certification by a registration certification agency under the Medical Devices Act (Article 23-2-23).  \n2. The provided legal provisions pertain to the Administrative Procedure Act and are unrelated to the Medical Devices Act, so they are not directly applicable.  \n3. Based on general knowledge of Japanese law:  \n   - **Option a** is incorrect because foreign applicants may still obtain certification if they meet other requirements, though permits might be required.  \n   - **Option b** is incorrect because manufacturing facilities typically need to meet specific criteria or registrations to qualify for certification.  \n   - **Option c** is correct because general medical devices (非高度管理医療機器) generally do not require certification from a registration certification agency, unlike high-risk devices (指定高度管理医療機器).  \n   - **Option d** is incorrect because certification requires compliance with the Minister's standards.  \n\nAnswer: c",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第5章_選択式_関連法令_問題番号46",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the correct statement regarding certification by a registration certification agency under the Medical Devices Act (Article 23-2-23).  \n2. The provided legal provisions pertain to the Administrative Procedure Act and are unrelated to the Medical Devices Act, so they are not directly applicable.  \n3. Based on general knowledge of Japanese law:  \n   - **Option a** is incorrect because foreign applicants may still obtain certification if they meet other requirements, though permits might be required.  \n   - **Option b** is incorrect because manufacturing facilities typically need to meet specific criteria or registrations to qualify for certification.  \n   - **Option c** is correct because general medical devices (非高度管理医療機器) generally do not require certification from a registration certification agency, unlike high-risk devices (指定高度管理医療機器).  \n   - **Option d** is incorrect because certification requires compliance with the Minister's standards.  \n\nAnswer: c"
    },
    {
      "question": "次のうち、正しいものを教えてください。",
      "choices": "a 外国において医療機器を製造等する者は、自ら当該医療機器の製造販売について承認を受ける代わりに、選任した医療機器の製造販売業者に製造販売をさせることについての承認を受けることができる\nb 一般医療機器の製造販売には、品目ごとにその製造販売についての承認が必要である\nc 外国製造医療機器等特例承認受けようとする者は、医療機器の製造販売業者を当該承認の申請後に遅滞なく選任しなければならない\nd 選任外国製造医療機器等製造販売業者が当該承認に係る品目の製造販売を行うには、別途製造販売についての厚生労働大臣の承認を受けなければならない",
      "correct_answer": "a",
      "predicted_answer": "c",
      "is_correct": false,
      "response": "Reasoning: The question asks for the correct statement regarding medical device regulations in Japan, but the provided legal provisions (1)-(3) pertain to ship stability, SME employment management, and commercial street revitalization—none of which relate to medical devices or approval processes. Since the choices (a-d) involve medical device regulations (e.g., \"foreign medical device manufacturing,\" \"Pharmaceutical and Medical Devices Act\"), there is a clear mismatch between the question's subject matter and the cited legal provisions. Without relevant provisions about medical device approvals, it is impossible to validate any of the choices against the given texts. However, if we assume the question intends to reference standard Japanese medical device law (not provided here), the correct answer would typically be **c** (as foreign manufacturers must appoint a local manufacturer promptly after applying for approval). But strictly based on the provided provisions, the question cannot be answered.\n\nAnswer: None of the choices can be validated against the provided legal provisions. However, if assuming standard Japanese medical device law (not included here), the answer would be **c**. Given the mismatch, the question is invalid as presented.",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第5章_選択式_関連法令_問題番号47",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145"
      ],
      "reasoning": "Reasoning: The question asks for the correct statement regarding medical device regulations in Japan, but the provided legal provisions (1)-(3) pertain to ship stability, SME employment management, and commercial street revitalization—none of which relate to medical devices or approval processes. Since the choices (a-d) involve medical device regulations (e.g., \"foreign medical device manufacturing,\" \"Pharmaceutical and Medical Devices Act\"), there is a clear mismatch between the question's subject matter and the cited legal provisions. Without relevant provisions about medical device approvals, it is impossible to validate any of the choices against the given texts. However, if we assume the question intends to reference standard Japanese medical device law (not provided here), the correct answer would typically be **c** (as foreign manufacturers must appoint a local manufacturer promptly after applying for approval). But strictly based on the provided provisions, the question cannot be answered.\n\nAnswer: None of the choices can be validated against the provided legal provisions. However, if assuming standard Japanese medical device law (not included here), the answer would be **c**. Given the mismatch, the question is invalid as presented."
    },
    {
      "question": "次のうち、厚生労働大臣が省令で、医療機器の製造業者がその業務に関し遵守すべき事項を定めることができる根拠となる医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律の条文を教えてください。",
      "choices": "a 第23条の2の15第1項\nb 第23条の2の15第2項\nc 第23条の2の15第3項\nd 第23条の2の15第4項",
      "correct_answer": "c",
      "predicted_answer": "a",
      "is_correct": false,
      "response": "Reasoning:  \n1. The question asks for the legal basis in the Pharmaceutical and Medical Device Act that allows the Minister of Health, Labour and Welfare to set regulations for medical device manufacturers.  \n2. The relevant provisions are **Article 23-2-15** of the Act.  \n   - **Paragraph 1** (Choice a) explicitly states that the Minister can establish regulations on **manufacturing management, quality management, post-marketing safety management**, and the duties of the **overall manufacturing and sales responsibility officer**. These are general obligations for manufacturers.  \n   - **Paragraph 3** (Choice c) focuses on **testing and inspection methods** and the duties of **technical officers**, which are more specific and narrower in scope compared to the general obligations in Paragraph 1.  \n3. Since the question refers to **general compliance requirements** for medical device manufacturers, **Paragraph 1** (Choice a) is the correct legal basis.  \n\nAnswer: a",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第5章_選択式_根拠条文_問題番号38",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the legal basis in the Pharmaceutical and Medical Device Act that allows the Minister of Health, Labour and Welfare to set regulations for medical device manufacturers.  \n2. The relevant provisions are **Article 23-2-15** of the Act.  \n   - **Paragraph 1** (Choice a) explicitly states that the Minister can establish regulations on **manufacturing management, quality management, post-marketing safety management**, and the duties of the **overall manufacturing and sales responsibility officer**. These are general obligations for manufacturers.  \n   - **Paragraph 3** (Choice c) focuses on **testing and inspection methods** and the duties of **technical officers**, which are more specific and narrower in scope compared to the general obligations in Paragraph 1.  \n3. Since the question refers to **general compliance requirements** for medical device manufacturers, **Paragraph 1** (Choice a) is the correct legal basis.  \n\nAnswer: a"
    },
    {
      "question": "次のうち、基準適合性認証を受けようとする者に、登録認証機関の基準適合性認証の結果に異議のある場合の、厚生労働大臣に対する申請を認めている根拠条文を教えてください。",
      "choices": "a 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第23条の11の2\nb 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第23条の12\nc 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第23条の13\nd 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第23条の14第１項",
      "correct_answer": "d",
      "predicted_answer": "d",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks for the legal provision that allows an applicant to request the Minister of Health, Labour and Welfare to order a re-examination by a registered certification body if they disagree with the certification result.  \n2. The provided legal provisions [1] and [2] both cite **Article 23-14, Paragraph 1** of the law, which explicitly states that applicants may apply to the Minister in cases where the certification body does not conduct a review or if they disagree with the certification result.  \n3. Provision [3] (Article 23-10, Paragraph 3) pertains to the Minister ordering changes to certification body regulations, which is unrelated to the applicant’s right to dispute a certification result.  \n4. The choices a, b, and c (Articles 23-11-2, 23-12, 23-13) are not mentioned in the provided legal text and thus cannot be correct.  \n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第5章_選択式_根拠条文_問題番号39",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the legal provision that allows an applicant to request the Minister of Health, Labour and Welfare to order a re-examination by a registered certification body if they disagree with the certification result.  \n2. The provided legal provisions [1] and [2] both cite **Article 23-14, Paragraph 1** of the law, which explicitly states that applicants may apply to the Minister in cases where the certification body does not conduct a review or if they disagree with the certification result.  \n3. Provision [3] (Article 23-10, Paragraph 3) pertains to the Minister ordering changes to certification body regulations, which is unrelated to the applicant’s right to dispute a certification result.  \n4. The choices a, b, and c (Articles 23-11-2, 23-12, 23-13) are not mentioned in the provided legal text and thus cannot be correct.  \n\nAnswer: d"
    },
    {
      "question": "次のうち、外国において医療機器を製造等する者が、選任した医療機器の製造販売業者に製造販売をさせることについての承認を受けることができることを定めている医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律の条文を教えてください。",
      "choices": "a 第23条の2の5第1項\nb 第23条の2の17第1項\nc 第23条の2の17第3項\nd 第23条の2の17第4項",
      "correct_answer": "b",
      "predicted_answer": "d",
      "is_correct": false,
      "response": "Reasoning:  \n1. The question asks which legal provision allows a foreign medical device manufacturer to obtain approval for a selected domestic manufacturer to produce and sell the device.  \n2. The relevant provisions are [2] and [3], which both reference **Article 23-2-17, paragraph 4**. This paragraph explicitly states that a foreign manufacturer who has received \"special approval\" (外国製造医療機器等特例承認取得者) can select a domestic manufacturer (選任外国製造医療機器等製造販売業者), and that selected manufacturer is permitted to produce and sell the product under the approval.  \n3. Other options are incorrect:  \n   - **a** (Article 23-2-5, paragraph 1) is mentioned as being overridden by the provisions but is not the approval mechanism itself.  \n   - **b** (Article 23-2-17, paragraph 1) refers to the initial approval but not the selection process.  \n   - **c** (Article 23-2-17, paragraph 3) is not referenced in the provided texts.  \n4. **d** (Article 23-2-17, paragraph 4) directly addresses the approval for the selected manufacturer, aligning with the question's focus.  \n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第5章_選択式_根拠条文_問題番号47",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145"
      ],
      "reasoning": "Reasoning:  \n1. The question asks which legal provision allows a foreign medical device manufacturer to obtain approval for a selected domestic manufacturer to produce and sell the device.  \n2. The relevant provisions are [2] and [3], which both reference **Article 23-2-17, paragraph 4**. This paragraph explicitly states that a foreign manufacturer who has received \"special approval\" (外国製造医療機器等特例承認取得者) can select a domestic manufacturer (選任外国製造医療機器等製造販売業者), and that selected manufacturer is permitted to produce and sell the product under the approval.  \n3. Other options are incorrect:  \n   - **a** (Article 23-2-5, paragraph 1) is mentioned as being overridden by the provisions but is not the approval mechanism itself.  \n   - **b** (Article 23-2-17, paragraph 1) refers to the initial approval but not the selection process.  \n   - **c** (Article 23-2-17, paragraph 3) is not referenced in the provided texts.  \n4. **d** (Article 23-2-17, paragraph 4) directly addresses the approval for the selected manufacturer, aligning with the question's focus.  \n\nAnswer: d"
    },
    {
      "question": "次のうち、敷金を返還してもらえる時期として正しいものを教えてください。",
      "choices": "a 建物賃貸借契約で時期を定めていない限り、賃借人が賃貸人に建物を明け渡した後\nb 建物賃貸借契約で時期を定めていない限り、賃借人が賃貸人に建物を明け渡す前\nc 建物賃貸借契約で時期を定めていない限り、賃借人が賃貸人に建物賃貸借契約の終了を申し込んだとき\nd 建物賃貸借契約で賃借人が賃貸人に建物を明け渡す前に敷金返還請求権が発生するとされている場合であっても、賃借人が賃貸人に建物を明け渡した後",
      "correct_answer": "a",
      "predicted_answer": "d",
      "is_correct": false,
      "response": "Reasoning: The question asks about the correct timing for returning the deposit (敷金) under Japanese civil rehabilitation law. The provided legal provisions (民事再生法第92条第3項) focus on how the deposit return claim (敷金の返還請求権) is treated as a common benefit debt (共益債権) during rehabilitation proceedings, specifically when the debtor (e.g., a tenant) pays rent debts after the rehabilitation process begins. However, these provisions do not directly address the **timing** of deposit return (before or after vacating the property). \n\nThe key to answering lies in general principles of Japanese law. Under the Civil Code, the deposit is typically returned **after** the lease ends and the tenant vacates the property, unless otherwise agreed. The options (a) and (d) align with this principle. However, **option d** explicitly states that even if the deposit return claim arises before vacating, it is returned **after** vacating, which is consistent with general law. The provisions in the question do not contradict this, as they focus on the **status** of the claim during rehabilitation, not the **timing** of return. Therefore, **option d** is the correct answer.\n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "借地借家法_原状回復をめぐるトラブルとガイドライン_選択式_関連法令_問題番号20",
      "references": [
        "https://www.mlit.go.jp/common/001016469.pdf"
      ],
      "reasoning": "Reasoning: The question asks about the correct timing for returning the deposit (敷金) under Japanese civil rehabilitation law. The provided legal provisions (民事再生法第92条第3項) focus on how the deposit return claim (敷金の返還請求権) is treated as a common benefit debt (共益債権) during rehabilitation proceedings, specifically when the debtor (e.g., a tenant) pays rent debts after the rehabilitation process begins. However, these provisions do not directly address the **timing** of deposit return (before or after vacating the property). \n\nThe key to answering lies in general principles of Japanese law. Under the Civil Code, the deposit is typically returned **after** the lease ends and the tenant vacates the property, unless otherwise agreed. The options (a) and (d) align with this principle. However, **option d** explicitly states that even if the deposit return claim arises before vacating, it is returned **after** vacating, which is consistent with general law. The provisions in the question do not contradict this, as they focus on the **status** of the claim during rehabilitation, not the **timing** of return. Therefore, **option d** is the correct answer.\n\nAnswer: d"
    },
    {
      "question": "次のうち敷金返還請求訴訟として利用できる訴訟制度について正しいものを教えてください。",
      "choices": "a 敷金返還請求として60万円以下の金銭の支払いを求める訴えであれば、少額訴訟制度という訴訟制度を利用できるが、それ以上の額の場合は当該訴訟制度を利用することはできない\nb 敷金返還請求として50万円の金銭の支払いを求める訴えであれば少額訴訟制度を利用でき、自分の住所を管轄する地方裁判所に訴えを提起することになる\nc 敷金返還請求訴訟として100万円以下の金銭の支払いを求める訴えであれば、少額訴訟制度を利用しなければならない\nd 敷金返還請求として60万円以下の金銭の支払いを求める訴えであれば、少額訴訟制度を利用することができるが、審理は原則として3回行われ、判決が言い渡されることになる",
      "correct_answer": "a",
      "predicted_answer": "a",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks which statement correctly describes the litigation system for a deposit return claim (敷金返還請求訴訟).  \n2. The provided legal provisions (民事再生法, 投資信託法施行規則, 相続税法施行規則) do not directly address litigation procedures for deposit claims. Instead, the answer must rely on general principles of Japanese civil procedure.  \n3. Under the Japanese Civil Procedure Code, the **少額訴訟制度** (small claims procedure) applies to claims **up to 600,000 yen (60万円)**. This system is designed for simplified, expedited resolution of small monetary disputes.  \n4. **Analysis of choices**:  \n   - **a** correctly states that claims **up to 600,000 yen** can use the small claims system, and higher amounts cannot.  \n   - **b** incorrectly specifies the plaintiff’s residence as the jurisdiction (the small claims system is typically filed at the defendant’s residence or where the cause of action arose).  \n   - **c** is incorrect because the small claims system applies only up to 600,000 yen, not 1,000,000 yen.  \n   - **d** is incorrect because the small claims procedure does not involve a fixed number of trials (e.g., three trials).  \n\nAnswer: a",
      "retrieved_docs_count": 3,
      "file_name": "借地借家法_原状回復をめぐるトラブルとガイドライン_選択式_関連法令_問題番号21",
      "references": [
        "https://www.mlit.go.jp/common/001016469.pdf"
      ],
      "reasoning": "Reasoning:  \n1. The question asks which statement correctly describes the litigation system for a deposit return claim (敷金返還請求訴訟).  \n2. The provided legal provisions (民事再生法, 投資信託法施行規則, 相続税法施行規則) do not directly address litigation procedures for deposit claims. Instead, the answer must rely on general principles of Japanese civil procedure.  \n3. Under the Japanese Civil Procedure Code, the **少額訴訟制度** (small claims procedure) applies to claims **up to 600,000 yen (60万円)**. This system is designed for simplified, expedited resolution of small monetary disputes.  \n4. **Analysis of choices**:  \n   - **a** correctly states that claims **up to 600,000 yen** can use the small claims system, and higher amounts cannot.  \n   - **b** incorrectly specifies the plaintiff’s residence as the jurisdiction (the small claims system is typically filed at the defendant’s residence or where the cause of action arose).  \n   - **c** is incorrect because the small claims system applies only up to 600,000 yen, not 1,000,000 yen.  \n   - **d** is incorrect because the small claims procedure does not involve a fixed number of trials (e.g., three trials).  \n\nAnswer: a"
    },
    {
      "question": "次のうち、借地借家法第13条の建物の買取請求権の説明として、正しいものを教えてください。",
      "choices": "a 借地権設定者と借地権者間の借地契約において、借地権者は借地権設定者に対して一切建物の買取を請求することができないとの規定は有効である\nb 借地権の存続期間が満了した場合において、契約の更新がないときは、借地権者は借地権設定者に対し、借地権者が無断で土地に附属させた物を時価で買い取るべきことを請求することができる\nc 借地権の存続期間が満了する前に借地権設定者の承諾を得ないで残存期間の範囲内で新たに建造された建物について、裁判所は、借地権設定者の請求により、代金の一部の支払について相当の期限を許与することができる\nd 借地権の存続期間が満了した場合において、契約の更新がないときは、転借地権者は、借地権設定者に対して、建物を時価で買い取るべきことを請求することができる",
      "correct_answer": "d",
      "predicted_answer": "b",
      "is_correct": false,
      "response": "Reasoning:  \nThe question asks for the correct explanation of the \"right of purchase of buildings\" under Article 13 of the Borrowed Land and House Law. While the provided legal provisions do not explicitly mention Article 13, we can infer the correct answer by analyzing the options against general principles of Japanese law and the context of the given provisions.  \n\n- **Option a** claims that a clause in the lease agreement preventing the lessee from requesting the purchase of the building is valid. However, under Japanese law, statutory rights (such as those under Article 13) typically override contractual clauses. Thus, such a clause would likely be invalid, making **a incorrect**.  \n\n- **Option b** states that if the lease term expires without renewal, the lessee can request the lessor to buy the building at market price. This aligns with the general principle that the lessee retains the right to sell the building to the lessor upon lease expiration, especially if the lease is not renewed. This is consistent with the intent of Article 13, which aims to protect the lessee's interests in the building. Thus, **b is plausible**.  \n\n- **Option c** refers to a scenario where a building is constructed without the lessor's consent during the lease term. This situation is more likely governed by provisions related to unauthorized construction (e.g., Article 19 of the Borrowed Land and House Law), not Article 13. Therefore, **c is unrelated to the question**.  \n\n- **Option d** mentions the \"sub-lessee\" (転借地権者) requesting the purchase of the building. However, the right under Article 13 belongs to the original lessee, not the sub-lessee. Thus, **d is incorrect**.  \n\nBased on this analysis, **option b** correctly reflects the statutory right under Article 13.  \n\nAnswer: b",
      "retrieved_docs_count": 3,
      "file_name": "借地借家法_第2章_選択式_関連法令_問題番号22",
      "references": [
        "https://laws.e-gov.go.jp/law/403AC0000000090"
      ],
      "reasoning": "Reasoning:  \nThe question asks for the correct explanation of the \"right of purchase of buildings\" under Article 13 of the Borrowed Land and House Law. While the provided legal provisions do not explicitly mention Article 13, we can infer the correct answer by analyzing the options against general principles of Japanese law and the context of the given provisions.  \n\n- **Option a** claims that a clause in the lease agreement preventing the lessee from requesting the purchase of the building is valid. However, under Japanese law, statutory rights (such as those under Article 13) typically override contractual clauses. Thus, such a clause would likely be invalid, making **a incorrect**.  \n\n- **Option b** states that if the lease term expires without renewal, the lessee can request the lessor to buy the building at market price. This aligns with the general principle that the lessee retains the right to sell the building to the lessor upon lease expiration, especially if the lease is not renewed. This is consistent with the intent of Article 13, which aims to protect the lessee's interests in the building. Thus, **b is plausible**.  \n\n- **Option c** refers to a scenario where a building is constructed without the lessor's consent during the lease term. This situation is more likely governed by provisions related to unauthorized construction (e.g., Article 19 of the Borrowed Land and House Law), not Article 13. Therefore, **c is unrelated to the question**.  \n\n- **Option d** mentions the \"sub-lessee\" (転借地権者) requesting the purchase of the building. However, the right under Article 13 belongs to the original lessee, not the sub-lessee. Thus, **d is incorrect**.  \n\nBased on this analysis, **option b** correctly reflects the statutory right under Article 13.  \n\nAnswer: b"
    },
    {
      "question": "次のうち、地代等の増減請求権について誤っているものを教えてください。",
      "choices": "a 地代が、近傍類似の土地の地代等と比較して不相当となったときは、当該期間内に地代を増額しない旨の特約があったとしても、賃貸人は賃借人に対して地代の増額を請求することができる。\nb 地代の増額について当事者間で協議が調わないときは、その請求を受けた者は、増額を正当とする裁判が確定するまでは、相当と認める額の地代等を支払うことで足りる\nc 地代の増額又は減額に関する裁判が確定した場合、不足額又は超過額に対して付すべき利息は年一割の割合である\nd 地代が不相応となったとして、将来に向かって地代等の額の増減を請求できる場合には、土地に対する租税その他の公課の増減以外の場合も含まれる",
      "correct_answer": "a",
      "predicted_answer": "a",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks to identify the **incorrect** statement regarding the right to request adjustment of rent (地代等の増減請求権).  \n2. **Relevant provisions**:  \n   - **[1]** 借地借家法第11条第1項: Allows parties to request rent adjustments if rent is disproportionate due to tax changes, economic fluctuations, or comparison with nearby land. However, **if there is a special agreement to avoid rent increases for a certain period, this exception applies**.  \n   - **[2]** 借地借家法第11条第2項: If parties cannot agree on rent increases, the payer may pay a \"reasonable\" amount until a court decision is finalized. If the court later rules in favor of an increase, the shortfall must be paid with **10% annual interest**.  \n   - **[3]** 都市再開発法第103条第2項: Not directly relevant to the question but confirms that rent adjustments under urban redevelopment are subject to specific rules.  \n\n3. **Analysis of choices**:  \n   - **a**: Incorrect. **[1]** explicitly states that if there is a special agreement to avoid rent increases for a certain period, this exception applies. Thus, **a** is wrong because it claims the landlord can still request an increase despite such an agreement.  \n   - **b**: Correct. **[2]** confirms that until a court decision is finalized, paying a \"reasonable\" amount suffices.  \n   - **c**: Correct. **[2]** specifies that if a court decision is finalized and there is a shortfall, **10% annual interest** applies.  \n   - **d**: Correct. **[1]** explicitly includes economic fluctuations and comparisons with nearby land as valid reasons for rent adjustments, beyond tax changes.  \n\nAnswer: a",
      "retrieved_docs_count": 3,
      "file_name": "借地借家法_第2章_選択式_関連法令_問題番号23",
      "references": [
        "https://laws.e-gov.go.jp/law/403AC0000000090"
      ],
      "reasoning": "Reasoning:  \n1. The question asks to identify the **incorrect** statement regarding the right to request adjustment of rent (地代等の増減請求権).  \n2. **Relevant provisions**:  \n   - **[1]** 借地借家法第11条第1項: Allows parties to request rent adjustments if rent is disproportionate due to tax changes, economic fluctuations, or comparison with nearby land. However, **if there is a special agreement to avoid rent increases for a certain period, this exception applies**.  \n   - **[2]** 借地借家法第11条第2項: If parties cannot agree on rent increases, the payer may pay a \"reasonable\" amount until a court decision is finalized. If the court later rules in favor of an increase, the shortfall must be paid with **10% annual interest**.  \n   - **[3]** 都市再開発法第103条第2項: Not directly relevant to the question but confirms that rent adjustments under urban redevelopment are subject to specific rules.  \n\n3. **Analysis of choices**:  \n   - **a**: Incorrect. **[1]** explicitly states that if there is a special agreement to avoid rent increases for a certain period, this exception applies. Thus, **a** is wrong because it claims the landlord can still request an increase despite such an agreement.  \n   - **b**: Correct. **[2]** confirms that until a court decision is finalized, paying a \"reasonable\" amount suffices.  \n   - **c**: Correct. **[2]** specifies that if a court decision is finalized and there is a shortfall, **10% annual interest** applies.  \n   - **d**: Correct. **[1]** explicitly includes economic fluctuations and comparisons with nearby land as valid reasons for rent adjustments, beyond tax changes.  \n\nAnswer: a"
    },
    {
      "question": "次のうち、借地契約の存続期間について誤っているものを教えてください。",
      "choices": "a 借地権の存続期間について当事者で10年と定めた場合であっても、存続期間は30年となる\nb 当事者が借地契約の更新を初めて行い、更新期間を10年とした場合でも、その期間は更新の日から20年となる\nc 借地権の存続期間について当事者で40年と定めた場合でも、存族期間は30年となる\nd 当事者が借地契約の2回目の更新を行い、更新期間を20年とした場合には、その期間は更新の日から20年となる",
      "correct_answer": "c",
      "predicted_answer": "a",
      "is_correct": false,
      "response": "The question asks which of the options is **incorrect** based on the provisions of the **借地借家法 (Land and House Lease Law)** and related laws. Let's analyze each option carefully:\n\n---\n\n### **Option a:**\n> \"If the parties agree to 10 years, the duration is 30.\"\n\n- **Analysis:**  \n  According to **借地借家法 第4条 第1項**, the default lease term for renewal is **10 years** (or **20 years** for the first renewal after the lease right is established). The law **only allows parties to agree to a longer term** than the default, not a shorter one.  \n  - If the parties agree to **10 years**, the lease term should be **10 years**, not **30**.  \n  - There is **no provision** in the given laws that would extend the lease term to **30 years** unless explicitly agreed upon by the parties, which is not the case here.  \n  - **Conclusion:** This option is **incorrect**.\n\n---\n\n### **Option b:**\n> \"First renewal, parties agree to 10 years, duration is 20.\"\n\n- **Analysis:**  \n  For the **first renewal**, the **default term is 20 years**. The law allows parties to agree to a **longer** term than the default, but **not a shorter** one.  \n  - If the parties agree to **10 years**, the lease term should be **10 years**, not **20**.  \n  - However, the option says the **duration is 20**, which is **correct** under the default rule **if the parties did not agree to a shorter term**.  \n  - **Conclusion:** This option is **correct**.\n\n---\n\n### **Option c:**\n> \"If the parties agree to 40 years, the duration is 30.\"\n\n- **Analysis:**  \n  The law allows parties to agree to a **longer** term than the default (10 or 20 years).  \n  - If the parties agree to **40 years**, the lease term should be **40 years**, not **30**.  \n  - There is **no provision** in the given laws that would cap the lease term at **30 years**.  \n  - **Conclusion:** This option is **incorrect**.\n\n---\n\n### **Option d:**\n> \"Second renewal, parties agree to 20 years, duration is 20.\"\n\n- **Analysis:**  \n  For the **second renewal**, the **default term is 10 years**.  \n  - If the parties agree to **20 years**, the lease term should be **20 years**, which matches the option.  \n  - **Conclusion:** This option is **correct**.\n\n---\n\n### **Final Evaluation:**\n\n- **Option a** is **incorrect**.\n- **Option c** is **incorrect**.\n- **Option b** and **d** are **correct**.\n\nHowever, the question asks for **\"the incorrect one\"**, implying a **single answer**. In such cases, the **most clearly incorrect** option is typically the intended answer.\n\n---\n\n### ✅ **Answer:**\n$$\n\\boxed{a}\n$$",
      "retrieved_docs_count": 3,
      "file_name": "借地借家法_第2章_選択式_関連法令_問題番号24",
      "references": [
        "https://laws.e-gov.go.jp/law/403AC0000000090"
      ],
      "reasoning": "The question asks which of the options is **incorrect** based on the provisions of the **借地借家法 (Land and House Lease Law)** and related laws. Let's analyze each option carefully:\n\n---\n\n### **Option a:**\n> \"If the parties agree to 10 years, the duration is 30.\"\n\n- **Analysis:**  \n  According to **借地借家法 第4条 第1項**, the default lease term for renewal is **10 years** (or **20 years** for the first renewal after the lease right is established). The law **only allows parties to agree to a longer term** than the default, not a shorter one.  \n  - If the parties agree to **10 years**, the lease term should be **10 years**, not **30**.  \n  - There is **no provision** in the given laws that would extend the lease term to **30 years** unless explicitly agreed upon by the parties, which is not the case here.  \n  - **Conclusion:** This option is **incorrect**.\n\n---\n\n### **Option b:**\n> \"First renewal, parties agree to 10 years, duration is 20.\"\n\n- **Analysis:**  \n  For the **first renewal**, the **default term is 20 years**. The law allows parties to agree to a **longer** term than the default, but **not a shorter** one.  \n  - If the parties agree to **10 years**, the lease term should be **10 years**, not **20**.  \n  - However, the option says the **duration is 20**, which is **correct** under the default rule **if the parties did not agree to a shorter term**.  \n  - **Conclusion:** This option is **correct**.\n\n---\n\n### **Option c:**\n> \"If the parties agree to 40 years, the duration is 30.\"\n\n- **Analysis:**  \n  The law allows parties to agree to a **longer** term than the default (10 or 20 years).  \n  - If the parties agree to **40 years**, the lease term should be **40 years**, not **30**.  \n  - There is **no provision** in the given laws that would cap the lease term at **30 years**.  \n  - **Conclusion:** This option is **incorrect**.\n\n---\n\n### **Option d:**\n> \"Second renewal, parties agree to 20 years, duration is 20.\"\n\n- **Analysis:**  \n  For the **second renewal**, the **default term is 10 years**.  \n  - If the parties agree to **20 years**, the lease term should be **20 years**, which matches the option.  \n  - **Conclusion:** This option is **correct**.\n\n---\n\n### **Final Evaluation:**\n\n- **Option a** is **incorrect**.\n- **Option c** is **incorrect**.\n- **Option b** and **d** are **correct**.\n\nHowever, the question asks for **\"the incorrect one\"**, implying a **single answer**. In such cases, the **most clearly incorrect** option is typically the intended answer.\n\n---\n\n### ✅ **Answer:**\n$$\n\\boxed{a}\n$$"
    },
    {
      "question": "次のうち、借地権設定者の先取特権の優先劣後関係について誤っているものを教えてください。",
      "choices": "a 借地権設定者の先取特権と、不動産工事の先取特権とでは、借地権設定者の先取特権の方が劣後する\nb 借地権設定者の先取特権と、地上権又は土地の賃貸借の登記よりも後に登記された質権とでは、借地権の先取特権の方が劣後する\nc 借地権設定者の先取特権と、地上権又は土地の賃貸借の登記より前に登記された抵当権の優先順位は、地上権又は土地賃貸借の登記より前に登記された抵当権が優先する\nd 借地権設定者の先取特権と、共益費用の優先順位は、共益費用の方が優先する",
      "correct_answer": "b",
      "predicted_answer": "b",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks to identify the **incorrect** statement regarding the priority of the land leaseholder's mortgage right (先取特権) under 借地借家法第12条第1項.  \n2. The key provision (Article 12, Paragraph 1 of the Land Lease and House Law) establishes that the land leaseholder has a statutory mortgage right over the building for the last two years of unpaid rent. This right is **statutory** and generally **superior** to later-registered mortgages (質権) under general principles of Japanese law.  \n3. **Analysis of choices**:  \n   - **Option a**: The mortgage right from construction work (不動産工事の先取特権) typically has **priority** over the land leaseholder's statutory mortgage right. Thus, the statement that the land leaseholder's right is **inferior** is **correct**, making this option valid.  \n   - **Option b**: If a mortgage (質権) is registered **after** the land lease or leasehold registration, the **statutory mortgage right** under 借地借家法 should **take precedence** over the later-registered mortgage. However, the statement claims the land leaseholder's right is **inferior**, which is **incorrect**.  \n   - **Option c**: A mortgage (抵当権) registered **before** the lease or leasehold registration would have **priority** over the statutory mortgage right. This aligns with general registration priority rules, making the statement **correct**.  \n   - **Option d**: Common expenses (共益費用) are generally considered to have **priority** over the land leaseholder's mortgage right, as they are treated as a form of lien. Thus, the statement is **correct**.  \n4. The **incorrect** statement is **Option b**, as it contradicts the statutory priority of the land leaseholder's mortgage right over later-registered mortgages.  \n\nAnswer: b",
      "retrieved_docs_count": 3,
      "file_name": "借地借家法_第2章_選択式_関連法令_問題番号25",
      "references": [
        "https://laws.e-gov.go.jp/law/403AC0000000090"
      ],
      "reasoning": "Reasoning:  \n1. The question asks to identify the **incorrect** statement regarding the priority of the land leaseholder's mortgage right (先取特権) under 借地借家法第12条第1項.  \n2. The key provision (Article 12, Paragraph 1 of the Land Lease and House Law) establishes that the land leaseholder has a statutory mortgage right over the building for the last two years of unpaid rent. This right is **statutory** and generally **superior** to later-registered mortgages (質権) under general principles of Japanese law.  \n3. **Analysis of choices**:  \n   - **Option a**: The mortgage right from construction work (不動産工事の先取特権) typically has **priority** over the land leaseholder's statutory mortgage right. Thus, the statement that the land leaseholder's right is **inferior** is **correct**, making this option valid.  \n   - **Option b**: If a mortgage (質権) is registered **after** the land lease or leasehold registration, the **statutory mortgage right** under 借地借家法 should **take precedence** over the later-registered mortgage. However, the statement claims the land leaseholder's right is **inferior**, which is **incorrect**.  \n   - **Option c**: A mortgage (抵当権) registered **before** the lease or leasehold registration would have **priority** over the statutory mortgage right. This aligns with general registration priority rules, making the statement **correct**.  \n   - **Option d**: Common expenses (共益費用) are generally considered to have **priority** over the land leaseholder's mortgage right, as they are treated as a form of lien. Thus, the statement is **correct**.  \n4. The **incorrect** statement is **Option b**, as it contradicts the statutory priority of the land leaseholder's mortgage right over later-registered mortgages.  \n\nAnswer: b"
    },
    {
      "question": "次のうち、借地権について誤っているものを教えてください。",
      "choices": "a 建物の所有を目的とする土地の賃借権の存続期間は、40年となることはない\nb 借地借家法第3条で、借地権の存続期間は原則として30年とされているが、これは建物の所有を目的とするものである\nc 当事者が土地の賃借権を設定し、20年の存続期間を定めた場合、当該土地が建物の所有を目的とする場合は、30年の存続期間となる\nd 建物の所有を目的とする地上権の存続期間について、地上権を有する者に不利な契約は無効である",
      "correct_answer": "a",
      "predicted_answer": "a",
      "is_correct": true,
      "response": "To determine which statement is **incorrect**, we must analyze the options in the context of Japanese civil law, particularly the **Leasehold Rights Act (借地借家法)**, which governs the rights and obligations of leasehold and tenancy agreements in Japan.\n\n---\n\n### **Option A:**\n> \"The duration of a leasehold right for land intended for building ownership cannot be 40 years.\"\n\n- **Analysis:**  \n  Under the **Leasehold Rights Act**, the **default term** for a leasehold right is **30 years**. However, the law **does not impose a maximum limit** on the lease term. If the parties agree to a longer term (e.g., 40 years), such an agreement is **valid and enforceable**, provided it is in writing and complies with other legal requirements.\n\n- **Conclusion:**  \n  This statement is **incorrect** because it **incorrectly asserts** that a lease term of 40 years is **not allowed**. In fact, such a term is **permissible** under Japanese law.\n\n---\n\n### **Option B:**\n> \"The Leasehold Rights Act (借地借家法) Article 3 states that the duration is 30 years as a principle, and this applies to those with the purpose of building ownership.\"\n\n- **Analysis:**  \n  This is a **correct** interpretation of the **Leasehold Rights Act**. Article 3 of the Act indeed establishes the **default lease term of 30 years** for leasehold rights, and this applies to **leaseholds intended for building purposes**.\n\n- **Conclusion:**  \n  This statement is **correct**.\n\n---\n\n### **Option C:**\n> \"If parties set 20 years for land intended for building ownership, it becomes 30 years.\"\n\n- **Analysis:**  \n  This statement is **incorrect**. Under the Leasehold Rights Act, **parties are free to agree on a lease term** that is **shorter than the default 30 years**, provided the agreement is **mutual and in writing**. There is **no legal requirement** that the lease term must be adjusted to 30 years if the parties agree to a shorter term.\n\n- **Conclusion:**  \n  This statement is **incorrect** because it **misrepresents the law** by suggesting that the lease term is **automatically adjusted** to 30 years, even if the parties agree to a shorter term.\n\n---\n\n### **Option D:**\n> \"For the duration of an emphyteusis (地上権) for building ownership, any contract unfavorable to the holder is invalid.\"\n\n- **Analysis:**  \n  This statement is **correct** in principle. Under Japanese law, **emphyteusis (地上権)** is a type of **long-term land use right**, and the law **prohibits unfair or one-sided terms** in such agreements. If a contract is **unfavorable to the holder**, it may be **deemed invalid** under the **Civil Code** or **Leasehold Rights Act**, depending on the specific circumstances.\n\n- **Conclusion:**  \n  This statement is **correct**.\n\n---\n\n### **Final Determination:**\n\n- **Option A** is **incorrect**, but **Option C** is **more clearly incorrect** in its **misinterpretation of the law** regarding **mutual agreement on lease terms**.\n- Since the question asks for **which statement is incorrect**, and **Option C** is **more directly and clearly wrong**, it is the **best answer**.\n\n---\n\n### ✅ **Answer:**\n$$\n\\boxed{\\text{C}}\n$$",
      "retrieved_docs_count": 3,
      "file_name": "借地借家法_第1章_選択式_関連法令_問題番号26",
      "references": [
        "https://laws.e-gov.go.jp/law/403AC0000000090"
      ],
      "reasoning": "To determine which statement is **incorrect**, we must analyze the options in the context of Japanese civil law, particularly the **Leasehold Rights Act (借地借家法)**, which governs the rights and obligations of leasehold and tenancy agreements in Japan.\n\n---\n\n### **Option A:**\n> \"The duration of a leasehold right for land intended for building ownership cannot be 40 years.\"\n\n- **Analysis:**  \n  Under the **Leasehold Rights Act**, the **default term** for a leasehold right is **30 years**. However, the law **does not impose a maximum limit** on the lease term. If the parties agree to a longer term (e.g., 40 years), such an agreement is **valid and enforceable**, provided it is in writing and complies with other legal requirements.\n\n- **Conclusion:**  \n  This statement is **incorrect** because it **incorrectly asserts** that a lease term of 40 years is **not allowed**. In fact, such a term is **permissible** under Japanese law.\n\n---\n\n### **Option B:**\n> \"The Leasehold Rights Act (借地借家法) Article 3 states that the duration is 30 years as a principle, and this applies to those with the purpose of building ownership.\"\n\n- **Analysis:**  \n  This is a **correct** interpretation of the **Leasehold Rights Act**. Article 3 of the Act indeed establishes the **default lease term of 30 years** for leasehold rights, and this applies to **leaseholds intended for building purposes**.\n\n- **Conclusion:**  \n  This statement is **correct**.\n\n---\n\n### **Option C:**\n> \"If parties set 20 years for land intended for building ownership, it becomes 30 years.\"\n\n- **Analysis:**  \n  This statement is **incorrect**. Under the Leasehold Rights Act, **parties are free to agree on a lease term** that is **shorter than the default 30 years**, provided the agreement is **mutual and in writing**. There is **no legal requirement** that the lease term must be adjusted to 30 years if the parties agree to a shorter term.\n\n- **Conclusion:**  \n  This statement is **incorrect** because it **misrepresents the law** by suggesting that the lease term is **automatically adjusted** to 30 years, even if the parties agree to a shorter term.\n\n---\n\n### **Option D:**\n> \"For the duration of an emphyteusis (地上権) for building ownership, any contract unfavorable to the holder is invalid.\"\n\n- **Analysis:**  \n  This statement is **correct** in principle. Under Japanese law, **emphyteusis (地上権)** is a type of **long-term land use right**, and the law **prohibits unfair or one-sided terms** in such agreements. If a contract is **unfavorable to the holder**, it may be **deemed invalid** under the **Civil Code** or **Leasehold Rights Act**, depending on the specific circumstances.\n\n- **Conclusion:**  \n  This statement is **correct**.\n\n---\n\n### **Final Determination:**\n\n- **Option A** is **incorrect**, but **Option C** is **more clearly incorrect** in its **misinterpretation of the law** regarding **mutual agreement on lease terms**.\n- Since the question asks for **which statement is incorrect**, and **Option C** is **more directly and clearly wrong**, it is the **best answer**.\n\n---\n\n### ✅ **Answer:**\n$$\n\\boxed{\\text{C}}\n$$"
    },
    {
      "question": "次のうち、誤っているものを教えてください。",
      "choices": "a 建物の賃借人が建物を転貸している場合、当該建物の転借人は当該建物の賃貸人に対して借地借家法第33条第1項に基づき、造作の買い取りを請求できる\nb 建物賃貸人の同意を得ないで建物に付加した造作については、建物の賃借人が造作の買い取りを請求できない\nc 建物の賃借人は、建物の賃貸人の同意を得て建物に付加した造作がある場合には、建物の賃借人は、建物の賃貸借が解約の申入れによって終了するときに、建物の賃貸人に対し、その造作を購入価額で買い取るべきことを請求することができる\nd 建物の賃借人は、建物の賃貸人から買い受けた造作について、建物の賃貸借が期間の満了によって終了するときに、建物の賃貸人に対し、その造作を時価で買い取るべきことを請求することができる",
      "correct_answer": "c",
      "predicted_answer": "d",
      "is_correct": false,
      "response": "Reasoning: The question asks to identify the incorrect statement regarding the rights of tenants under Japanese law concerning fixtures (造作) in lease agreements. \n\n- **Option a** claims that a subtenant (転借人) can request the purchase of fixtures under 借地借家法第33条第1項. However, this provision applies to the **original tenant (賃借人)**, not the subtenant. Subtenants do not have the same rights as the original tenant, making **option a incorrect**.\n\n- **Option d** states that when a lease ends by expiration, the tenant can request purchase at **market value (時価)**. However, under 借地借家法第33条第1項, the tenant is entitled to purchase fixtures at the **purchase price (購入価額)** they paid for the fixture, not the market value. This makes **option d incorrect** as well.\n\nBoth **a** and **d** are incorrect. However, the question likely expects a single answer. **Option d** directly contradicts the legal provision regarding the **purchase price** versus **market value**, which is a clearer and more definitive error compared to **option a**, which involves a nuanced distinction between tenants and subtenants. Thus, **d** is the most clearly incorrect choice.\n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "借地借家法_第3章_選択式_関連法令_問題番号27",
      "references": [
        "https://laws.e-gov.go.jp/law/403AC0000000090"
      ],
      "reasoning": "Reasoning: The question asks to identify the incorrect statement regarding the rights of tenants under Japanese law concerning fixtures (造作) in lease agreements. \n\n- **Option a** claims that a subtenant (転借人) can request the purchase of fixtures under 借地借家法第33条第1項. However, this provision applies to the **original tenant (賃借人)**, not the subtenant. Subtenants do not have the same rights as the original tenant, making **option a incorrect**.\n\n- **Option d** states that when a lease ends by expiration, the tenant can request purchase at **market value (時価)**. However, under 借地借家法第33条第1項, the tenant is entitled to purchase fixtures at the **purchase price (購入価額)** they paid for the fixture, not the market value. This makes **option d incorrect** as well.\n\nBoth **a** and **d** are incorrect. However, the question likely expects a single answer. **Option d** directly contradicts the legal provision regarding the **purchase price** versus **market value**, which is a clearer and more definitive error compared to **option a**, which involves a nuanced distinction between tenants and subtenants. Thus, **d** is the most clearly incorrect choice.\n\nAnswer: d"
    },
    {
      "question": "次のうち、取壊し予定の建物賃貸借について誤っているものを教えてください。",
      "choices": "a 建物を取り壊すこととなるときを建物賃貸借契約の終期とする場合は、その特約を建物を取り壊すべき事由を電磁的記録によって記録することも認められる\nb 建物賃貸借契約の目的たる建物を一定期間経過後に取り壊すべきことが法令上明らかな場合は、建物を取り壊すこととなるときに賃貸借契約が終了する旨を定めることができる\nc 建物を取り壊すこととなるときを建物賃貸借契約の終期とする場合は、その特約を取り壊すべき理由を記載した書面によってしなければならない\nd 建物を取り壊すこととなるときを建物賃貸借契約の終期とすることは、建物賃借人にとって不利であるため、認められない",
      "correct_answer": "d",
      "predicted_answer": "d",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks to identify the **incorrect** statement regarding demolition of a leased building.  \n2. **Provision [2]** (借地借家法 第39条 第1項) allows the lease to end upon demolition if it is clear by law or contract that the building must be demolished after a certain period. This directly supports **option b** as correct.  \n3. **Option d** claims that ending the lease upon demolition is **not allowed** because it is unfavorable to the tenant. This contradicts **Provision [2]**, which explicitly permits such an arrangement. Thus, **option d is incorrect**.  \n4. **Option c** states that the agreement must be in writing with the reason for demolition. However, **Provision [2]** does not mention any requirement for written documentation. While Japanese law may have general rules about written contracts, the provided provisions do not address this, so **option c is not definitively incorrect** based solely on the given text.  \n5. **Option a** mentions electronic records, which are not explicitly prohibited or required by the provisions. Since the law does not restrict this, **option a is not incorrect**.  \n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "借地借家法_第3章_選択式_関連法令_問題番号28",
      "references": [
        "https://laws.e-gov.go.jp/law/403AC0000000090"
      ],
      "reasoning": "Reasoning:  \n1. The question asks to identify the **incorrect** statement regarding demolition of a leased building.  \n2. **Provision [2]** (借地借家法 第39条 第1項) allows the lease to end upon demolition if it is clear by law or contract that the building must be demolished after a certain period. This directly supports **option b** as correct.  \n3. **Option d** claims that ending the lease upon demolition is **not allowed** because it is unfavorable to the tenant. This contradicts **Provision [2]**, which explicitly permits such an arrangement. Thus, **option d is incorrect**.  \n4. **Option c** states that the agreement must be in writing with the reason for demolition. However, **Provision [2]** does not mention any requirement for written documentation. While Japanese law may have general rules about written contracts, the provided provisions do not address this, so **option c is not definitively incorrect** based solely on the given text.  \n5. **Option a** mentions electronic records, which are not explicitly prohibited or required by the provisions. Since the law does not restrict this, **option a is not incorrect**.  \n\nAnswer: d"
    },
    {
      "question": "次のうち、借地上の建物の賃借人の保護について正しいものを教えてください。",
      "choices": "a 土地の賃借人が当該土地上に建物を所有し、当該建物を建物の賃借人に賃貸した場合、土地賃貸借契約が満了したときは、いかなる場合でも建物の賃借人は土地を明け渡さなければならない\nb 土地の賃借人が当該土地上に建物を所有し、当該建物を建物の賃借人に賃貸した場合、土地賃貸借契約が満了したときは、建物の賃借人が借地権の存続期間が満了することを1年前までに知っていた場合は、土地明渡しにつき相当の期限の許与を受けることができない\nc 裁判所は、借地借家法第35条第1項の規定により、土地の明渡しにつき2年間の期限を許与することができる\nd 借地借家法第35条第1項の規定により裁判所が期限の許与をしたときは、建物の賃貸借は、その期限が無期限となる",
      "correct_answer": "b",
      "predicted_answer": "c",
      "is_correct": false,
      "response": "Reasoning:  \n1. The question asks for the correct statement regarding the protection of a building tenant (建物の賃借人) when the land lease (借地権) expires.  \n2. The key provision is **借地借家法第35条第1項**, which allows the court to grant a **2-year extension** for the landowner to decide whether to renew the lease, protecting the building tenant from sudden eviction.  \n3. **Option a** is incorrect because it claims the building tenant must vacate the land regardless of circumstances, which contradicts the protective intent of the law.  \n4. **Option b** is incorrect because it suggests the building tenant cannot request an extension if they knew the land lease would expire one year in advance, but the law does not impose such a restriction.  \n5. **Option c** is correct as it directly reflects the provision allowing a **2-year extension** under Article 35.  \n6. **Option d** is incorrect because the extension is temporary (up to 2 years), not indefinite.  \n\nAnswer: c",
      "retrieved_docs_count": 3,
      "file_name": "借地借家法_第3章_選択式_関連法令_問題番号29",
      "references": [
        "https://laws.e-gov.go.jp/law/403AC0000000090"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the correct statement regarding the protection of a building tenant (建物の賃借人) when the land lease (借地権) expires.  \n2. The key provision is **借地借家法第35条第1項**, which allows the court to grant a **2-year extension** for the landowner to decide whether to renew the lease, protecting the building tenant from sudden eviction.  \n3. **Option a** is incorrect because it claims the building tenant must vacate the land regardless of circumstances, which contradicts the protective intent of the law.  \n4. **Option b** is incorrect because it suggests the building tenant cannot request an extension if they knew the land lease would expire one year in advance, but the law does not impose such a restriction.  \n5. **Option c** is correct as it directly reflects the provision allowing a **2-year extension** under Article 35.  \n6. **Option d** is incorrect because the extension is temporary (up to 2 years), not indefinite.  \n\nAnswer: c"
    },
    {
      "question": "次のうち、建物賃貸借終了の場合における転借人の保護について正しいものを教えてください。",
      "choices": "a 建物の転貸借がされている場合で、建物の賃貸借が期間の満了により終了するときは、建物の賃貸借の終了により、当然に建物の転貸借も終了する\nb 建物の転貸借がされている場合で、建物の賃貸借が期間の満了により終了するときは、建物の賃貸人が建物の転貸人に建物の賃貸借の終了を対抗するためには、建物の転借人の承諾が必要である\nc 建物の転貸借がされている場合で、建物の賃貸借が期間の満了により終了するときにおいて、建物賃貸人が建物転借人に対してその旨の通知をした場合には、建物の転貸借は、その通知がされた日から1年を経過することによって終了する\nd 建物の転貸借がされている場合で、建物の賃貸借が期間の満了により終了するときにおいて、建物の賃貸借が終了するときは、建物の転貸借も当然に終了するという特約は無効である",
      "correct_answer": "d",
      "predicted_answer": "d",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks for the correct statement regarding the protection of a subtenant (転借人) when a building lease ends.  \n2. The relevant provision is **借地借家法第33条第2項**, which states that the rules from the preceding paragraph (第1項) apply to the subtenant and lessor when the main lease ends due to expiration or termination notice.  \n3. **Analysis of choices**:  \n   - **Option a** claims the sublease ends automatically with the main lease. However, the law implies that the subtenant may have protections (e.g., requiring notice or other procedures), so automatic termination is unlikely.  \n   - **Option b** suggests the lessor needs the subtenant’s consent to terminate the sublease. This is not supported by the provision, which focuses on the application of rules, not consent.  \n   - **Option c** introduces a one-year period after notification, which is not mentioned in the provided legal text.  \n   - **Option d** states that a clause making the sublease end automatically is invalid. This aligns with the law’s intent to protect the subtenant, as the provision implies that the subtenant’s rights must be respected (e.g., requiring notice or other procedures), making automatic termination clauses invalid.  \n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "借地借家法_第3章_選択式_関連法令_問題番号30",
      "references": [
        "https://laws.e-gov.go.jp/law/403AC0000000090"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the correct statement regarding the protection of a subtenant (転借人) when a building lease ends.  \n2. The relevant provision is **借地借家法第33条第2項**, which states that the rules from the preceding paragraph (第1項) apply to the subtenant and lessor when the main lease ends due to expiration or termination notice.  \n3. **Analysis of choices**:  \n   - **Option a** claims the sublease ends automatically with the main lease. However, the law implies that the subtenant may have protections (e.g., requiring notice or other procedures), so automatic termination is unlikely.  \n   - **Option b** suggests the lessor needs the subtenant’s consent to terminate the sublease. This is not supported by the provision, which focuses on the application of rules, not consent.  \n   - **Option c** introduces a one-year period after notification, which is not mentioned in the provided legal text.  \n   - **Option d** states that a clause making the sublease end automatically is invalid. This aligns with the law’s intent to protect the subtenant, as the provision implies that the subtenant’s rights must be respected (e.g., requiring notice or other procedures), making automatic termination clauses invalid.  \n\nAnswer: d"
    },
    {
      "question": "従業員持株会を通じた株式所有スキームのうち、金商法第２条第２項第５号に掲げる権利とならないものを教えてください。",
      "choices": "a 従業員持株会を通じた株式所有スキームのうち、定義府令第 16 条第１項第７号の２イに掲げる要件のみに該当する行為\nb 従業員持株会を通じた株式所有スキームのうち、定義府令第 16 条第１項第７号の２イからホまでに掲げる要件のみに該当する行為\nc 従業員持株会を通じた株式所有スキームのうち、定義府令第 16 条第１項第７号の２イ（１）又は（２）に掲げる買付けを行うことを内容とするスキームに係る権利\nd 従業員持株会を通じた株式所有スキームのうち、定義府令第 16 条第１項第７号の２イ（１）又は（２）に掲げる売付けを行うことを内容とするスキームに係る権利",
      "correct_answer": "c",
      "predicted_answer": "d",
      "is_correct": false,
      "response": "Reasoning:  \nThe question asks which option is **not** considered a right under the **金商法第2条第2項第5号** (Article 2, Paragraph 2, Item 5 of the Financial Instruments and Exchange Act). The key lies in understanding the scope of rights defined in the **定義府令第16条第1項第7号の2イ** (Definition Ordinance Article 16, Paragraph 1, Item 7-2-i), which is referenced in the options.  \n\n1. **Legal Context**:  \n   - The provided provisions (労働金庫法 and 信用金庫法) discuss scenarios where **voting rights** (議決権) may be **inexercisable** (e.g., due to legal restrictions or events outside the entity’s control). These provisions imply that **inexercisable rights** (e.g., those under [2] where voting rights cannot be exercised) may not be treated as \"rights\" under certain legal frameworks.  \n   - The **金商法** defines \"rights\" in a way that excludes certain types of rights, such as those that are **not exercisable** or **not aligned with typical shareholder rights**.  \n\n2. **Analysis of Options**:  \n   - **Option a**: Refers to behavior meeting only **定義府令第16条第1項第7号の2イ** (a specific requirement). This may still qualify as a right under the 金商法.  \n   - **Option b**: Refers to behavior meeting **multiple requirements** (イからホまで). This is broader and likely includes rights recognized under the 金商法.  \n   - **Option c**: Involves **buying rights** (買付け) under specific conditions. Buying rights are typically considered valid rights under the 金商法.  \n   - **Option d**: Involves **selling rights** (売付け) under specific conditions. However, the **信用金庫法施行規則第65条第1項第2号** (provision [2]) explicitly states that **inexercisable rights** (e.g., those acquired due to external events) are treated as rights. However, **selling rights** may not be directly tied to the **exercisable rights** defined in the 金商法. If the **定義府令** excludes selling rights from the scope of \"rights\" under the 金商法, then **option d** would be the correct answer.  \n\n3. **Conclusion**:  \n   The **金商法** likely excludes **selling rights** (option d) from its definition of \"rights\" because they are not directly aligned with the typical exercisable rights (e.g., voting or buying rights) that the law focuses on.  \n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第1章_選択式_関連法令_問題番号41",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025"
      ],
      "reasoning": "Reasoning:  \nThe question asks which option is **not** considered a right under the **金商法第2条第2項第5号** (Article 2, Paragraph 2, Item 5 of the Financial Instruments and Exchange Act). The key lies in understanding the scope of rights defined in the **定義府令第16条第1項第7号の2イ** (Definition Ordinance Article 16, Paragraph 1, Item 7-2-i), which is referenced in the options.  \n\n1. **Legal Context**:  \n   - The provided provisions (労働金庫法 and 信用金庫法) discuss scenarios where **voting rights** (議決権) may be **inexercisable** (e.g., due to legal restrictions or events outside the entity’s control). These provisions imply that **inexercisable rights** (e.g., those under [2] where voting rights cannot be exercised) may not be treated as \"rights\" under certain legal frameworks.  \n   - The **金商法** defines \"rights\" in a way that excludes certain types of rights, such as those that are **not exercisable** or **not aligned with typical shareholder rights**.  \n\n2. **Analysis of Options**:  \n   - **Option a**: Refers to behavior meeting only **定義府令第16条第1項第7号の2イ** (a specific requirement). This may still qualify as a right under the 金商法.  \n   - **Option b**: Refers to behavior meeting **multiple requirements** (イからホまで). This is broader and likely includes rights recognized under the 金商法.  \n   - **Option c**: Involves **buying rights** (買付け) under specific conditions. Buying rights are typically considered valid rights under the 金商法.  \n   - **Option d**: Involves **selling rights** (売付け) under specific conditions. However, the **信用金庫法施行規則第65条第1項第2号** (provision [2]) explicitly states that **inexercisable rights** (e.g., those acquired due to external events) are treated as rights. However, **selling rights** may not be directly tied to the **exercisable rights** defined in the 金商法. If the **定義府令** excludes selling rights from the scope of \"rights\" under the 金商法, then **option d** would be the correct answer.  \n\n3. **Conclusion**:  \n   The **金商法** likely excludes **selling rights** (option d) from its definition of \"rights\" because they are not directly aligned with the typical exercisable rights (e.g., voting or buying rights) that the law focuses on.  \n\nAnswer: d"
    },
    {
      "question": "金商法第２条第８項第 11号に掲げる行為に関して、「金融商品取引業」に該当しないものを教えてください。",
      "choices": "a 有価証券の価値等に関し、投資顧問契約を締結し、当該投資顧問契約に基づき、助言を行うことを業として行うこと。\nb 厚生年金基金との間で投資一任業者の選任に関する事項に係るコンサルタント契約を締結し、有価証券の価値等について助言を行うことを業として行うこと\nc 有価証券の価値等に関し、報酬を受け取ることを約して助言を行うことを業として行うこと\nd 有価証券の価値等に関し、新聞を通じて、助言を行うこと",
      "correct_answer": "d",
      "predicted_answer": "b",
      "is_correct": false,
      "response": "Reasoning:  \n1. The question asks which option **does not** fall under the definition of \"金融商品取引業\" (financial instruments trading business) under 金商法第2条第8項第11号.  \n2. The key provision is **金商法第2条第8項第11号**, which defines activities related to financial instruments trading. While the provided legal texts do not explicitly list the 11号, the context of the question and the choices suggest that the focus is on **investment advisory services**.  \n3. **Options a, c, and d** all involve providing investment advice on the value of securities, either through a contract (a, c), for a fee (c), or via newspapers (d). These align with the typical scope of \"金融商品取引業\" as defined in the law.  \n4. **Option b** involves a **consultant contract with the厚生年金基金** (Health Insurance Pension Fund) regarding the **selection of an investment manager**. This activity is **not directly related to providing investment advice on the value of securities** but rather to **manager selection for a pension fund**, which falls under a different category of financial services (e.g., fiduciary or asset management services). This distinction excludes it from the definition of \"金融商品取引業\" under 金商法.  \n\nAnswer: b",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第1章_選択式_関連法令_問題番号42",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025"
      ],
      "reasoning": "Reasoning:  \n1. The question asks which option **does not** fall under the definition of \"金融商品取引業\" (financial instruments trading business) under 金商法第2条第8項第11号.  \n2. The key provision is **金商法第2条第8項第11号**, which defines activities related to financial instruments trading. While the provided legal texts do not explicitly list the 11号, the context of the question and the choices suggest that the focus is on **investment advisory services**.  \n3. **Options a, c, and d** all involve providing investment advice on the value of securities, either through a contract (a, c), for a fee (c), or via newspapers (d). These align with the typical scope of \"金融商品取引業\" as defined in the law.  \n4. **Option b** involves a **consultant contract with the厚生年金基金** (Health Insurance Pension Fund) regarding the **selection of an investment manager**. This activity is **not directly related to providing investment advice on the value of securities** but rather to **manager selection for a pension fund**, which falls under a different category of financial services (e.g., fiduciary or asset management services). This distinction excludes it from the definition of \"金融商品取引業\" under 金商法.  \n\nAnswer: b"
    },
    {
      "question": "暗号等資産について、各規定が定める金銭とみなしてこの法令（これに基づく命令を含む。）の規定が適用される場合に該当しないものを教えてください。",
      "choices": "a 金融商品取引法第2条第2項第5号の金銭\nb 金融商品取引法第2条第8項第1号の売買に係る金銭\nc 金融商品取引法第42条の7の金銭\nd 金融商品取引法第41条の4の金銭",
      "correct_answer": "c",
      "predicted_answer": "d",
      "is_correct": false,
      "response": "Reasoning: The question asks which option does **not** fall under the provisions where \"暗号等資産\" (crypto-related assets) are treated as money under the Financial Instruments and Exchange Act (FIEA). The relevant provision (FIEA Article 2_2, Paragraph 1) states that crypto assets are treated as money under:  \n1. **Article 2, Paragraph 2, Item 5** (Option a),  \n2. **Article 2, Paragraph 8, Item 1** (Option b),  \n3. **Other provisions specified by cabinet orders**.  \n\nOptions **a** and **b** are explicitly listed in the provision, so they are valid. The remaining options (**c** and **d**) depend on whether they are included in the \"other provisions specified by cabinet orders.\" However, **Article 41-4** (Option d) is not a provision related to crypto assets or financial instruments regulation in the FIEA. In contrast, **Article 42-7** (Option c) is part of the FIEA's framework for regulating crypto assets (e.g., licensing requirements for exchanges). Since **Article 41-4** is unrelated to crypto assets and not specified by cabinet orders, it does **not** fall under the provision.  \n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第1章_選択式_関連法令_問題番号43",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/340CO0000000321"
      ],
      "reasoning": "Reasoning: The question asks which option does **not** fall under the provisions where \"暗号等資産\" (crypto-related assets) are treated as money under the Financial Instruments and Exchange Act (FIEA). The relevant provision (FIEA Article 2_2, Paragraph 1) states that crypto assets are treated as money under:  \n1. **Article 2, Paragraph 2, Item 5** (Option a),  \n2. **Article 2, Paragraph 8, Item 1** (Option b),  \n3. **Other provisions specified by cabinet orders**.  \n\nOptions **a** and **b** are explicitly listed in the provision, so they are valid. The remaining options (**c** and **d**) depend on whether they are included in the \"other provisions specified by cabinet orders.\" However, **Article 41-4** (Option d) is not a provision related to crypto assets or financial instruments regulation in the FIEA. In contrast, **Article 42-7** (Option c) is part of the FIEA's framework for regulating crypto assets (e.g., licensing requirements for exchanges). Since **Article 41-4** is unrelated to crypto assets and not specified by cabinet orders, it does **not** fall under the provision.  \n\nAnswer: d"
    },
    {
      "question": "金融商品取引法第２条第１項が定める「有価証券」に該当しないものを教えてください。",
      "choices": "a 相互会社の社債券\nb 株券\nc 外国の者の発行する証券又は証書で新株予約権証券の性質を有するもの\nd 信託の受益権",
      "correct_answer": "d",
      "predicted_answer": "d",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks which option **does not** fall under the definition of \"有価証券\" (securities) under the Financial Instruments and Exchange Act (金融商品取引法) Article 2, Paragraph 1.  \n2. According to the legal provisions provided, \"有価証券\" is defined broadly to include securities under the Financial Instruments and Exchange Act, such as stocks (株券, option b), corporate bonds (e.g., 相互会社の社債券, option a), and foreign securities with subscription rights (option c).  \n3. Option d, \"信託の受益権\" (beneficiary rights in a trust), is not explicitly included in the definition of \"有価証券\" under the Financial Instruments and Exchange Act. Trust beneficiary rights are property rights, not tradable securities, and are not typically classified as \"有価証券\" under Japanese law.  \n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第1章_選択式_関連法令_問題番号44",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025"
      ],
      "reasoning": "Reasoning:  \n1. The question asks which option **does not** fall under the definition of \"有価証券\" (securities) under the Financial Instruments and Exchange Act (金融商品取引法) Article 2, Paragraph 1.  \n2. According to the legal provisions provided, \"有価証券\" is defined broadly to include securities under the Financial Instruments and Exchange Act, such as stocks (株券, option b), corporate bonds (e.g., 相互会社の社債券, option a), and foreign securities with subscription rights (option c).  \n3. Option d, \"信託の受益権\" (beneficiary rights in a trust), is not explicitly included in the definition of \"有価証券\" under the Financial Instruments and Exchange Act. Trust beneficiary rights are property rights, not tradable securities, and are not typically classified as \"有価証券\" under Japanese law.  \n\nAnswer: d"
    },
    {
      "question": "証券会社等が顧客に適切に通知していない場合に、金商業等府令第123条第1項第8号の規定「顧客の有価証券の売買その他の取引等に関し、受渡状況その他の顧客に必要な情報を適切に通知していないと認められる状況」に該当しない事項を教えてください。",
      "choices": "a 金商法第37条の４第１項に規定する契約締結時等の書面に記載すべき事項\nb 顧客が国債の入札前取引を行った場合であって、当該国債に係る入札が成立した後においては、当該取引に係る銘柄、単価及び金額\nc 顧客が国債の入札前取引を行った場合であって、当該取引契約に係る停止条件が不成就となった後においては、当該事実及び当該取引の成否に係る事項（顧客からの同意はないものとする）\nd 顧客との間で直接金銭の受渡しを行わない場合における当該金銭の受渡しに関する事項",
      "correct_answer": "d",
      "predicted_answer": "d",
      "is_correct": true,
      "response": "Reasoning:  \nThe question asks which option **does not** fall under the situation described in the provision (金商法等府令第123条第1項第8号), which involves failing to notify customers about necessary information regarding their transactions.  \n\n- **Option a** refers to matters required under Article 37-4 of the Financial Instruments and Exchange Act (e.g., contract terms). These are standard disclosures, and failure to notify would likely fall under the provision.  \n- **Option b** involves informing customers about transaction details (e.g., price, amount) after a successful government bond bid. This is directly related to transaction information, which aligns with the provision.  \n- **Option c** pertains to informing customers about the failure of a stop condition in a pre-bidding transaction. This is also transaction-related information, so it would fall under the provision.  \n- **Option d** concerns the **method of money transfer** (e.g., non-direct cash transfers). This is **not** about the content of the transaction itself but rather the **logistics of payment**. The provision in question focuses on **transaction details** (e.g., price, outcome, terms), not the **mechanism of money transfer**. Thus, **option d** does not fall under the described situation.  \n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第3章_選択式_関連法令_問題番号45",
      "references": [
        "https://www.fsa.go.jp/common/law/guide/kinyushohin.pdf"
      ],
      "reasoning": "Reasoning:  \nThe question asks which option **does not** fall under the situation described in the provision (金商法等府令第123条第1項第8号), which involves failing to notify customers about necessary information regarding their transactions.  \n\n- **Option a** refers to matters required under Article 37-4 of the Financial Instruments and Exchange Act (e.g., contract terms). These are standard disclosures, and failure to notify would likely fall under the provision.  \n- **Option b** involves informing customers about transaction details (e.g., price, amount) after a successful government bond bid. This is directly related to transaction information, which aligns with the provision.  \n- **Option c** pertains to informing customers about the failure of a stop condition in a pre-bidding transaction. This is also transaction-related information, so it would fall under the provision.  \n- **Option d** concerns the **method of money transfer** (e.g., non-direct cash transfers). This is **not** about the content of the transaction itself but rather the **logistics of payment**. The provision in question focuses on **transaction details** (e.g., price, outcome, terms), not the **mechanism of money transfer**. Thus, **option d** does not fall under the described situation.  \n\nAnswer: d"
    },
    {
      "question": "金融機関が行おうとするとき、内閣総理大臣の登録を受けなければならないとされているものに該当しないものを教えてください。",
      "choices": "a 投資助言・代理業\nb 有価証券管理業務\nc 他の法律の定めるところにより投資の目的をもつて、又は信託契約に基づいて信託をする者の計算において行う有価証券関連デリバティブ取引\nd 第二条第八項第七号に掲げる行為を業として行うこと",
      "correct_answer": "c",
      "predicted_answer": "c",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks which activity **does not** require registration with the Prime Minister (内閣総理大臣) when performed by a financial institution.  \n2. **Legal Provision [2]** states that **financial service intermediaries** must be registered with the Prime Minister. This implies that activities classified as financial service intermediaries (e.g., investment advice, securities management) require registration.  \n3. **Option c** refers to **derivative transactions** conducted under other laws or trust contracts. These activities are explicitly **exempt** from the registration requirement under **Legal Provision [2]**, as they fall outside the scope of \"financial service intermediaries\" and are governed by other legal frameworks (e.g., trust laws or specific derivative regulations).  \n4. **Options a, b, and d** are directly tied to financial service intermediaries or regulated activities under the Financial Instruments and Exchange Act, which require Prime Minister registration.  \n\nAnswer: c",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第3章_選択式_関連法令_問題番号46",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025"
      ],
      "reasoning": "Reasoning:  \n1. The question asks which activity **does not** require registration with the Prime Minister (内閣総理大臣) when performed by a financial institution.  \n2. **Legal Provision [2]** states that **financial service intermediaries** must be registered with the Prime Minister. This implies that activities classified as financial service intermediaries (e.g., investment advice, securities management) require registration.  \n3. **Option c** refers to **derivative transactions** conducted under other laws or trust contracts. These activities are explicitly **exempt** from the registration requirement under **Legal Provision [2]**, as they fall outside the scope of \"financial service intermediaries\" and are governed by other legal frameworks (e.g., trust laws or specific derivative regulations).  \n4. **Options a, b, and d** are directly tied to financial service intermediaries or regulated activities under the Financial Instruments and Exchange Act, which require Prime Minister registration.  \n\nAnswer: c"
    },
    {
      "question": "金融商品取引業者等が、金融商品取引法第37条第1項各号に掲げる事項を表示しなければならない行為に該当しないものを教えてください。",
      "choices": "a 広告\nb 郵便により多数の者に対して同様の内容で行う情報の提供\nc 法令又は法令に基づく行政官庁の処分に基づき作成された書類を配布する方法により多数の者に対して同様の内容で行う情報の提供\nd 電子メールを送信する方法により多数の者に対して同様の内容で行う情報の提供",
      "correct_answer": "c",
      "predicted_answer": "c",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks to identify the behavior **not** requiring disclosure under FIEA Article 37, Paragraph 1 (excluding the second item).  \n2. The legal provisions (1), (2), and (3) all reference FIEA Article 37, Paragraph 1 (excluding the second item), which mandates disclosure of specific matters in certain activities.  \n3. **Analysis of choices**:  \n   - **a. Advertising**: Directly falls under FIEA Article 37, Paragraph 1 (e.g., advertising is explicitly covered).  \n   - **b. Postal mass communication**: Covered under the same provisions as advertising (mass distribution of information).  \n   - **c. Distribution of legal/administrative documents**: Exempt, as these are **not promotional** but official documents created by administrative authorities. FIEA Article 37, Paragraph 1 does not apply to such non-commercial, legally mandated communications.  \n   - **d. Email mass communication**: Similar to postal mail, this is considered a form of mass information dissemination requiring disclosure.  \n4. **Conclusion**: Only **c** is not subject to the disclosure requirements under FIEA Article 37, Paragraph 1.  \n\nAnswer: c",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第3章_選択式_関連法令_問題番号47",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/419M60000002052"
      ],
      "reasoning": "Reasoning:  \n1. The question asks to identify the behavior **not** requiring disclosure under FIEA Article 37, Paragraph 1 (excluding the second item).  \n2. The legal provisions (1), (2), and (3) all reference FIEA Article 37, Paragraph 1 (excluding the second item), which mandates disclosure of specific matters in certain activities.  \n3. **Analysis of choices**:  \n   - **a. Advertising**: Directly falls under FIEA Article 37, Paragraph 1 (e.g., advertising is explicitly covered).  \n   - **b. Postal mass communication**: Covered under the same provisions as advertising (mass distribution of information).  \n   - **c. Distribution of legal/administrative documents**: Exempt, as these are **not promotional** but official documents created by administrative authorities. FIEA Article 37, Paragraph 1 does not apply to such non-commercial, legally mandated communications.  \n   - **d. Email mass communication**: Similar to postal mail, this is considered a form of mass information dissemination requiring disclosure.  \n4. **Conclusion**: Only **c** is not subject to the disclosure requirements under FIEA Article 37, Paragraph 1.  \n\nAnswer: c"
    },
    {
      "question": "金融商品取引業者等が、その行う金融商品取引業又は登録金融機関業務を適確に遂行するために整備しなければならない業務管理体制に関し、正しいものを教えてください。",
      "choices": "a 金融商品取引業者等には、業務管理体制を整備することは求められていない\nb 金融商品取引業者等として高速取引行為を行わない者も、高速取引行為に係る電子情報処理組織その他の設備の管理を十分に行うための措置をとる必要がある\nc 外国会社が親会社でない場合でも、金融庁長官が定めるところにより、親会社との間において、業務の継続的な実施を確保するための措置をとる必要がある\nd 金融商品取引業者等は、金融商品取引業等を適確に遂行するための社内規則等を整備し、当該社内規則等を遵守するための従業員に対する研修その他の措置をとる必要がある",
      "correct_answer": "d",
      "predicted_answer": "d",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks for the correct statement regarding the business management systems required under the Financial Instruments and Exchange Act.  \n2. The legal provisions (all identical) state that financial instrument trading operators must establish a business management system in accordance with cabinet orders to properly perform their business.  \n3. **Option a** is incorrect because it directly contradicts the law, which mandates the establishment of a business management system.  \n4. **Option b** introduces \"high-speed trading\" and related equipment management, which is not mentioned in the provided legal text. The law is general and does not specify high-speed trading.  \n5. **Option c** discusses foreign companies and parent company measures, which are unrelated to the provisions given.  \n6. **Option d** states that operators must establish internal rules and provide employee training to ensure compliance. While the law does not explicitly mention \"internal rules\" or \"training,\" the requirement to establish a \"business management system\" (as per the law) inherently includes such measures. This aligns with the broader intent of the provision to ensure proper business execution through structured systems and employee compliance.  \n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第3章_選択式_関連法令_問題番号48",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/419M60000002052"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the correct statement regarding the business management systems required under the Financial Instruments and Exchange Act.  \n2. The legal provisions (all identical) state that financial instrument trading operators must establish a business management system in accordance with cabinet orders to properly perform their business.  \n3. **Option a** is incorrect because it directly contradicts the law, which mandates the establishment of a business management system.  \n4. **Option b** introduces \"high-speed trading\" and related equipment management, which is not mentioned in the provided legal text. The law is general and does not specify high-speed trading.  \n5. **Option c** discusses foreign companies and parent company measures, which are unrelated to the provisions given.  \n6. **Option d** states that operators must establish internal rules and provide employee training to ensure compliance. While the law does not explicitly mention \"internal rules\" or \"training,\" the requirement to establish a \"business management system\" (as per the law) inherently includes such measures. This aligns with the broader intent of the provision to ensure proper business execution through structured systems and employee compliance.  \n\nAnswer: d"
    },
    {
      "question": "金融商品取引業者等がしてはならない行為に該当しないものを教えてください。",
      "choices": "a 外国貿易その他の外国為替取引に関する業務を行う法人に対する勧誘であって、当該法人が保有する資産及び負債に係る為替変動による損失の可能性を減殺するために店頭金融先物取引に係る金融商品取引契約の締結の勧誘をする行為\nb 金融商品取引契約（投資者の保護を図ることが特に必要なものとして政令で定めるものに限る。）の締結の勧誘の要請をしていない顧客に対し、電話をかけて、金融商品取引契約の締結の勧誘をする行為\nc 顧客に対し、不確実な事項について断定的判断を提供し、金融商品取引契約の締結の勧誘をする行為\nd 金融商品取引契約の締結の勧誘に関して、顧客に対し虚偽のことを告げる行為",
      "correct_answer": "a",
      "predicted_answer": "a",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks which behavior **does not** constitute a prohibited act for financial instrument traders under Japanese law.  \n2. The relevant provisions include **金融商品取引法** (Financial Instruments and Exchange Act) and **預金保険法施行令** (Deposit Insurance Act Implementation Order). Key points:  \n   - **[1]** Excludes transactions not related to a financial institution's business activities.  \n   - **[2]** Prohibits unregistered individuals from engaging in financial trading.  \n   - **[3]** Prohibits actions that make a financial instrument trader ineligible (e.g., violating regulations).  \n3. **Analysis of choices**:  \n   - **Option a**: Advising a foreign trade company on hedging via derivatives is a **legitimate business activity** (e.g., providing risk management services). This aligns with the institution's business scope and is **not prohibited**.  \n   - **Option b**: Unsolicited calls to customers who did not request advice violate regulations (e.g., **金融商品取引法** prohibits unsolicited solicitation without proper safeguards).  \n   - **Option c**: Providing definitive judgments on uncertain matters is **prohibited** as it misleads customers (violates principles of transparency and fairness).  \n   - **Option d**: Giving false information is explicitly **prohibited** under the law (e.g., **金融商品取引法** prohibits deceptive practices).  \n4. **Conclusion**: Only **Option a** is not a prohibited act.  \n\nAnswer: a",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第3章_選択式_関連法令_問題番号49",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/419M60000002052"
      ],
      "reasoning": "Reasoning:  \n1. The question asks which behavior **does not** constitute a prohibited act for financial instrument traders under Japanese law.  \n2. The relevant provisions include **金融商品取引法** (Financial Instruments and Exchange Act) and **預金保険法施行令** (Deposit Insurance Act Implementation Order). Key points:  \n   - **[1]** Excludes transactions not related to a financial institution's business activities.  \n   - **[2]** Prohibits unregistered individuals from engaging in financial trading.  \n   - **[3]** Prohibits actions that make a financial instrument trader ineligible (e.g., violating regulations).  \n3. **Analysis of choices**:  \n   - **Option a**: Advising a foreign trade company on hedging via derivatives is a **legitimate business activity** (e.g., providing risk management services). This aligns with the institution's business scope and is **not prohibited**.  \n   - **Option b**: Unsolicited calls to customers who did not request advice violate regulations (e.g., **金融商品取引法** prohibits unsolicited solicitation without proper safeguards).  \n   - **Option c**: Providing definitive judgments on uncertain matters is **prohibited** as it misleads customers (violates principles of transparency and fairness).  \n   - **Option d**: Giving false information is explicitly **prohibited** under the law (e.g., **金融商品取引法** prohibits deceptive practices).  \n4. **Conclusion**: Only **Option a** is not a prohibited act.  \n\nAnswer: a"
    },
    {
      "question": "金融商品取引業者等が顧客の注文について、政令で定めるところにより、最良執行方針等を定めなくてもよいものを教えてください。",
      "choices": "a 上場株券等の売買で、デリバティブ取引に該当するもの\nb 店頭売買有価証券の売買で、デリバティブ取引に該当しないもの\nc 取扱有価証券の売買で、デリバティブ取引に該当しないもの\nd 金融商品取引法施行令第16条の6第1項第1号イ、ロ及びハに掲げるものを除く有価証券の売買",
      "correct_answer": "a",
      "predicted_answer": "d",
      "is_correct": false,
      "response": "Reasoning:  \n1. The question asks for the scenario where financial institutions are **not required** to establish a best execution policy.  \n2. The relevant provision (Article 40-2, Paragraph 1 of the Financial Instruments and Exchange Act) states that financial institutions **must** establish best execution policies for **securities trading and derivatives transactions**, **except** those specified by ordinance.  \n3. The key exception lies in transactions **excluded by the ordinance**.  \n4. **Option d** explicitly refers to transactions **excluded** by the Financial Instruments and Exchange Act Implementation Ordinance (Article 16-6, Paragraph 1, Item 1, i, ro, and ha). This directly aligns with the legal provision’s exception.  \n5. Other options (a, b, c) involve transactions that are **not explicitly excluded** by the ordinance, meaning the obligation to establish a best execution policy would still apply.  \n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第3章_選択式_関連法令_問題番号50",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/340CO0000000321"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the scenario where financial institutions are **not required** to establish a best execution policy.  \n2. The relevant provision (Article 40-2, Paragraph 1 of the Financial Instruments and Exchange Act) states that financial institutions **must** establish best execution policies for **securities trading and derivatives transactions**, **except** those specified by ordinance.  \n3. The key exception lies in transactions **excluded by the ordinance**.  \n4. **Option d** explicitly refers to transactions **excluded** by the Financial Instruments and Exchange Act Implementation Ordinance (Article 16-6, Paragraph 1, Item 1, i, ro, and ha). This directly aligns with the legal provision’s exception.  \n5. Other options (a, b, c) involve transactions that are **not explicitly excluded** by the ordinance, meaning the obligation to establish a best execution policy would still apply.  \n\nAnswer: d"
    },
    {
      "question": "外務員が、その所属する金融商品取引業者等に代わつて、権限を有するものとみなされるものを教えてください。",
      "choices": "a 金融商品取引法第2条第2項により有価証券とみなされる同項各号に掲げる権利に係る金融商品取引法第64条第1項第1号イに掲げる行為に関する裁判外の行為を行う権限\nb 金融商品取引法第2条第8項第9号に掲げる行為に関する裁判外の行為を行う権限\nc その所属する金融商品取引業者等に代わって、金融商品取引法第64条第1項各号に掲げる行為に関し、一切の裁判上の行為を行う権限\nd 店頭デリバティブ取引等の申込みの勧誘に関し、裁判外の行為を行う権限",
      "correct_answer": "d",
      "predicted_answer": "a",
      "is_correct": false,
      "response": "Reasoning:  \n1. The question asks which option correctly describes the authority of an 外務員 under the 金融商品取引法.  \n2. The relevant provision is **金融商品取引法第64_3条第1項**, which states that an 外務員 has the authority to perform **一切の裁判外の行為** (all non-judicial acts) related to the behaviors listed in **金融商品取引法第64条第1項各号**.  \n3. **Option a** refers to **金融商品取引法第64条第1項第1号イ** (a specific item under Article 64, Paragraph 1), which is part of the broader scope of behaviors covered by the provision. While the law applies to **all** items under Article 64, Paragraph 1, **option a** is the only choice that explicitly references **Article 64, Paragraph 1**, aligning with the legal text.  \n4. **Option b** refers to **Article 2, Paragraph 8, Item 9**, which is unrelated to the provision in question.  \n5. **Option c** incorrectly states **\"一切の裁判上の行為\"** (judicial acts), contradicting the law’s explicit mention of **non-judicial** acts.  \n6. **Option d** mentions **店頭デリバティブ取引** (off-exchange derivatives), which may or may not be covered by Article 64, but the provision does not specifically address derivatives.  \n\nAnswer: a",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第3章_選択式_関連法令_問題番号51",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025"
      ],
      "reasoning": "Reasoning:  \n1. The question asks which option correctly describes the authority of an 外務員 under the 金融商品取引法.  \n2. The relevant provision is **金融商品取引法第64_3条第1項**, which states that an 外務員 has the authority to perform **一切の裁判外の行為** (all non-judicial acts) related to the behaviors listed in **金融商品取引法第64条第1項各号**.  \n3. **Option a** refers to **金融商品取引法第64条第1項第1号イ** (a specific item under Article 64, Paragraph 1), which is part of the broader scope of behaviors covered by the provision. While the law applies to **all** items under Article 64, Paragraph 1, **option a** is the only choice that explicitly references **Article 64, Paragraph 1**, aligning with the legal text.  \n4. **Option b** refers to **Article 2, Paragraph 8, Item 9**, which is unrelated to the provision in question.  \n5. **Option c** incorrectly states **\"一切の裁判上の行為\"** (judicial acts), contradicting the law’s explicit mention of **non-judicial** acts.  \n6. **Option d** mentions **店頭デリバティブ取引** (off-exchange derivatives), which may or may not be covered by Article 64, but the provision does not specifically address derivatives.  \n\nAnswer: a"
    },
    {
      "question": "金融商品取引業者等の、その行う投資運用業に関する、顧客に対し金銭若しくは有価証券を貸し付け、又は顧客への第三者による金銭若しくは有価証券の貸付けにつき媒介、取次ぎ若しくは代理の禁止の適用除外に該当しないものを教えてください。",
      "choices": "a 第一種金融商品取引業を行う者が、金融商品取引法施行令第16条の13第2号ロに掲げる行為を行う場合\nb 金融商品取引業者が、他の金融商品取引業者が信用取引に付随して行う顧客への金銭又は有価証券の貸付けの媒介又は代理を行う場合\nc 金融商品取引業者が第百五十六条の二十四第一項に規定する信用取引に付随して顧客に対し金銭又は有価証券を貸し付ける場合\nd 第二種金融商品取引業を行う者が、法第三十五条第一項に規定する業務として行う顧客への金銭又は有価証券の貸付け（信用取引に付随するものを除く。）を行う場合",
      "correct_answer": "d",
      "predicted_answer": "d",
      "is_correct": true,
      "response": "Reasoning:  \nThe question asks which option **does not** qualify as an exception to the prohibition on financial service providers lending money or securities to customers or acting as intermediaries for such loans. The relevant provisions (particularly [2]) prohibit such activities in investment advisory services, but exceptions exist for specific cases like **credit trading** (信用取引).  \n\n- **Option a**: Refers to a first-type financial service provider performing a behavior under Article 16-13(2)(ロ) of the Financial Instruments and Exchange Act Implementation Order. This likely falls under an exception (e.g., specific permitted activities in credit trading).  \n- **Option b**: Involves acting as an intermediary for another’s loan in credit trading. Credit trading is explicitly an exception, so this is allowed.  \n- **Option c**: Directly involves lending in credit trading, which is a recognized exception under Japanese law.  \n- **Option d**: Refers to a second-type financial service provider performing loans under Article 35(1) of the law **excluding** those attached to credit trading. Since the exception applies **only** to credit trading, this scenario is **not** an exception and thus **prohibited**.  \n\nAnswer: **d**",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第3章_選択式_関連法令_問題番号52",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/340CO0000000321"
      ],
      "reasoning": "Reasoning:  \nThe question asks which option **does not** qualify as an exception to the prohibition on financial service providers lending money or securities to customers or acting as intermediaries for such loans. The relevant provisions (particularly [2]) prohibit such activities in investment advisory services, but exceptions exist for specific cases like **credit trading** (信用取引).  \n\n- **Option a**: Refers to a first-type financial service provider performing a behavior under Article 16-13(2)(ロ) of the Financial Instruments and Exchange Act Implementation Order. This likely falls under an exception (e.g., specific permitted activities in credit trading).  \n- **Option b**: Involves acting as an intermediary for another’s loan in credit trading. Credit trading is explicitly an exception, so this is allowed.  \n- **Option c**: Directly involves lending in credit trading, which is a recognized exception under Japanese law.  \n- **Option d**: Refers to a second-type financial service provider performing loans under Article 35(1) of the law **excluding** those attached to credit trading. Since the exception applies **only** to credit trading, this scenario is **not** an exception and thus **prohibited**.  \n\nAnswer: **d**"
    },
    {
      "question": "金融商品取引法第168条に違反する行為を教えてください。",
      "choices": "a 有価証券の売出しをする者が、公示し又は頒布する目的なく、有価証券等の相場を誤って記載した文書を作成すること\nb 引受人の請託を受けて、公示する目的をもって当該引受人の発行に係る有価証券に関し重要な事項について虚偽の記載をした文書を作成すること\nc 特定投資家向け売付け勧誘等をする者が、自らの分担する有価証券に関し重要でない事項についてのみ虚偽の記載をした文書を頒布するよう請託すること\nd 有価証券等の相場を正しく公示すること",
      "correct_answer": "b",
      "predicted_answer": "b",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks which behavior violates **金融商品取引法第168条** (FIEA Article 168). This provision prohibits the creation or dissemination of documents containing **false information about important matters** in securities offerings.  \n2. The provided legal provisions (from the Agricultural Cooperative Law and Asset Securitization Act) reference **FIEA Articles 38 and 39**, but **not Article 168**. Therefore, the answer must rely on general knowledge of FIEA Article 168.  \n3. **Option b** describes a scenario where a document with **false information about important matters** is created **at the request of an underwriter** for the purpose of disclosure. This directly aligns with the prohibited acts under FIEA Article 168, which targets deliberate falsification of critical information in securities-related documents.  \n4. **Option a** involves incorrect market price information without the intent to disclose, which may not constitute a violation under FIEA 168. **Option c** involves false information about **non-important matters**, which is not prohibited. **Option d** is compliant behavior.  \n\nAnswer: b",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第6章_選択式_関連法令_問題番号53",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025"
      ],
      "reasoning": "Reasoning:  \n1. The question asks which behavior violates **金融商品取引法第168条** (FIEA Article 168). This provision prohibits the creation or dissemination of documents containing **false information about important matters** in securities offerings.  \n2. The provided legal provisions (from the Agricultural Cooperative Law and Asset Securitization Act) reference **FIEA Articles 38 and 39**, but **not Article 168**. Therefore, the answer must rely on general knowledge of FIEA Article 168.  \n3. **Option b** describes a scenario where a document with **false information about important matters** is created **at the request of an underwriter** for the purpose of disclosure. This directly aligns with the prohibited acts under FIEA Article 168, which targets deliberate falsification of critical information in securities-related documents.  \n4. **Option a** involves incorrect market price information without the intent to disclose, which may not constitute a violation under FIEA 168. **Option c** involves false information about **non-important matters**, which is not prohibited. **Option d** is compliant behavior.  \n\nAnswer: b"
    },
    {
      "question": "金融商品取引法第170条に違反する行為を教えてください。",
      "choices": "a 新たに発行される株券に係る有価証券の不特定多数者向け勧誘等を行うに際し、不特定かつ多数の者に対して、これらの者の取得する当該株券を、自己が、あらかじめ特定した価格により買い付ける旨の表示をすること\nb 新たに発行される国債証券に係る有価証券の不特定多数者向け勧誘等を行うに際し、不特定かつ多数の者に対して、これらの者の取得する当該国債証券を、自己が、あらかじめ特定した価格により買い付ける旨の表示をすること\nc 新たに発行される新株予約権証券に係る有価証券の不特定多数者向け勧誘等を行うに際し、特定かつ少数の者に対して、これらの者の取得する当該新株予約権証券を、自己が、あらかじめ特定した価格により買い付けることをあっせんする旨の表示をすること\nd 新たに発行される地方債証券に係る有価証券の不特定多数者向け勧誘等を行うに際し、不特定かつ多数の者に対して、これらの者の取得する当該地方債証券を、自己が、あらかじめ特定した価格により買い付けることをあっせんする旨の表示をすること",
      "correct_answer": "a",
      "predicted_answer": "a",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks which behavior violates **金融商品取引法第170条** (FIEA Article 170).  \n2. **FIEA Article 170** prohibits the act of making a statement during the offering of new securities that the issuer will repurchase the securities from purchasers at a predetermined price. This is to prevent market manipulation and ensure fair dealing.  \n3. **Option a** describes a scenario where a company offers new shares (株券) to the general public (不特定多数者) and states it will repurchase them at a set price. This directly matches the prohibited act under FIEA Article 170.  \n4. **Options b and d** involve government bonds (国債証券) and local government bonds (地方債証券). While FIEA generally applies to these instruments, the prohibition under Article 170 is not limited to shares. However, the question likely focuses on the **classic example** of new share offerings, which is explicitly covered by Article 170.  \n5. **Option c** involves advising a **specific and small group** (特定かつ少数の者) about repurchasing new share subscription rights (新株予約権証券). Since FIEA Article 170 targets **unspecific and large groups** (不特定多数者), this scenario does not violate the article.  \n\nAnswer: a",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第6章_選択式_関連法令_問題番号54",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025"
      ],
      "reasoning": "Reasoning:  \n1. The question asks which behavior violates **金融商品取引法第170条** (FIEA Article 170).  \n2. **FIEA Article 170** prohibits the act of making a statement during the offering of new securities that the issuer will repurchase the securities from purchasers at a predetermined price. This is to prevent market manipulation and ensure fair dealing.  \n3. **Option a** describes a scenario where a company offers new shares (株券) to the general public (不特定多数者) and states it will repurchase them at a set price. This directly matches the prohibited act under FIEA Article 170.  \n4. **Options b and d** involve government bonds (国債証券) and local government bonds (地方債証券). While FIEA generally applies to these instruments, the prohibition under Article 170 is not limited to shares. However, the question likely focuses on the **classic example** of new share offerings, which is explicitly covered by Article 170.  \n5. **Option c** involves advising a **specific and small group** (特定かつ少数の者) about repurchasing new share subscription rights (新株予約権証券). Since FIEA Article 170 targets **unspecific and large groups** (不特定多数者), this scenario does not violate the article.  \n\nAnswer: a"
    },
    {
      "question": "次のうち、金融商品取引法第二条に規定する定義に関する内閣府令第十六条第一項第八号イ若しくはロ又は金融商品取引業等に関する内閣府令第百二十三条第十三号ロからホまでに規定する契約に基づき行う有価証券の売買として行ってはならないとされるものを教えてください。",
      "choices": "a 金融商品取引業者等が、自己の計算において行う有価証券の売買\nb 金融商品取引業者等が、当該契約の委任の本旨又は当該契約の金額に照らし過当と認められる数量の売買で取引所金融商品市場又は店頭売買有価証券市場の秩序を害すると認められる有価証券の売買\nc 取引所取引許可業者が、自己の計算において行う有価証券の売買\nd 取引所取引許可業者が、当該契約の委任の本旨又は当該契約の金額に照らし過当と認められる数量の売買で取引所金融商品市場又は店頭売買有価証券市場の秩序を害すると認められる有価証券の売買",
      "correct_answer": "b",
      "predicted_answer": "d",
      "is_correct": false,
      "response": "Reasoning:  \n1. The question asks which transaction is prohibited under the definitions in the Financial Instruments and Exchange Act (FIEA) and related cabinet orders. Specifically, it refers to transactions that cannot be conducted as securities transactions under the definitions in the cabinet order Article 16, Paragraph 1, Item 8, I or Ro, or Article 123, Paragraph 13, Items Ro to Ho.  \n\n2. The key provision is **FIEA Article 28, Paragraph 8, Item 5**, which prohibits transactions that harm the order of the financial markets (e.g., excessive trading volumes). This aligns with the description in the options involving \"over-the-counter\" or \"exchange\" markets and \"excessive quantity\" harming market order.  \n\n3. **Option b** and **d** both describe transactions that are excessive in quantity and harm market order. However, the distinction lies in the actor:  \n   - **Option b** refers to **financial instrument dealers** (金融商品取引業者等).  \n   - **Option d** refers to **exchange-trading license holders** (取引所取引許可業者).  \n\n4. Under the FIEA and related cabinet orders, **both types of entities** are prohibited from engaging in transactions that disrupt market order (e.g., market manipulation). However, the question specifies **\"the ones that cannot be conducted as securities transactions\"** under the definitions in the cabinet orders.  \n\n5. The **cabinet order Article 123, Paragraph 13, Items Ro to Ho** explicitly prohibits **exchange-trading license holders** (取引所取引許可業者) from engaging in such transactions. This is because exchange-trading license holders are subject to stricter rules under the FIEA to maintain market integrity.  \n\n6. Therefore, **option d** is the correct answer, as it directly aligns with the prohibition under the cabinet order and FIEA for exchange-trading license holders.  \n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第6章_選択式_関連法令_問題番号55",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/419M60000002059"
      ],
      "reasoning": "Reasoning:  \n1. The question asks which transaction is prohibited under the definitions in the Financial Instruments and Exchange Act (FIEA) and related cabinet orders. Specifically, it refers to transactions that cannot be conducted as securities transactions under the definitions in the cabinet order Article 16, Paragraph 1, Item 8, I or Ro, or Article 123, Paragraph 13, Items Ro to Ho.  \n\n2. The key provision is **FIEA Article 28, Paragraph 8, Item 5**, which prohibits transactions that harm the order of the financial markets (e.g., excessive trading volumes). This aligns with the description in the options involving \"over-the-counter\" or \"exchange\" markets and \"excessive quantity\" harming market order.  \n\n3. **Option b** and **d** both describe transactions that are excessive in quantity and harm market order. However, the distinction lies in the actor:  \n   - **Option b** refers to **financial instrument dealers** (金融商品取引業者等).  \n   - **Option d** refers to **exchange-trading license holders** (取引所取引許可業者).  \n\n4. Under the FIEA and related cabinet orders, **both types of entities** are prohibited from engaging in transactions that disrupt market order (e.g., market manipulation). However, the question specifies **\"the ones that cannot be conducted as securities transactions\"** under the definitions in the cabinet orders.  \n\n5. The **cabinet order Article 123, Paragraph 13, Items Ro to Ho** explicitly prohibits **exchange-trading license holders** (取引所取引許可業者) from engaging in such transactions. This is because exchange-trading license holders are subject to stricter rules under the FIEA to maintain market integrity.  \n\n6. Therefore, **option d** is the correct answer, as it directly aligns with the prohibition under the cabinet order and FIEA for exchange-trading license holders.  \n\nAnswer: d"
    },
    {
      "question": "金融商品取引業等に関する内閣府令第123条第1項第6号が定める、その取り扱う個人である顧客に関する情報の安全管理について、当該情報の漏えい、滅失又は毀損の防止を図るために必要かつ適切な措置として、金融商品取引業者等向けの総合的な監督指針に挙げられているものを教えてください。",
      "choices": "a 金融分野ガイドライン第９条の規定に基づく措置\nb 実務指針Ⅱの規定に基づく措置\nc 金融分野ガイドライン第 10 条の規定に基づく措置\nd 金融分野ガイドライン第８条の規定に基づく措置",
      "correct_answer": "d",
      "predicted_answer": "d",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks which provision in the **Financial Field Guidelines** is cited as a necessary measure under **Financial Instruments and Exchange Act Cabinet Office Order Article 123, Paragraph 1, Item 6** for preventing information leaks, loss, or damage.  \n2. The provided legal provisions (from the Credit Union Law and Financial Services Intermediary Act) emphasize the obligation to take \"necessary and appropriate measures\" for information security, but they do not directly reference the Financial Field Guidelines.  \n3. The **Financial Field Guidelines** (金融分野ガイドライン) are a set of standards issued by Japan’s Financial Services Agency (FSA) to guide financial institutions on compliance with laws like the Act on the Protection of Personal Information (APPI) and other regulations.  \n4. **Article 8** of the Financial Field Guidelines specifically outlines requirements for **information security management systems**, including measures to prevent unauthorized access, data breaches, and other risks. This aligns with the obligation to prevent leaks, loss, or damage of customer information.  \n5. Other options (e.g., Article 9 or 10) address different topics (e.g., data retention, third-party management), while **Article 8** is directly tied to information security measures.  \n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第3章_選択式_関連法令_問題番号56",
      "references": [
        "https://laws.e-gov.go.jp/law/419M60000002052",
        "https://www.fsa.go.jp/common/law/guide/kinyushohin.pdf"
      ],
      "reasoning": "Reasoning:  \n1. The question asks which provision in the **Financial Field Guidelines** is cited as a necessary measure under **Financial Instruments and Exchange Act Cabinet Office Order Article 123, Paragraph 1, Item 6** for preventing information leaks, loss, or damage.  \n2. The provided legal provisions (from the Credit Union Law and Financial Services Intermediary Act) emphasize the obligation to take \"necessary and appropriate measures\" for information security, but they do not directly reference the Financial Field Guidelines.  \n3. The **Financial Field Guidelines** (金融分野ガイドライン) are a set of standards issued by Japan’s Financial Services Agency (FSA) to guide financial institutions on compliance with laws like the Act on the Protection of Personal Information (APPI) and other regulations.  \n4. **Article 8** of the Financial Field Guidelines specifically outlines requirements for **information security management systems**, including measures to prevent unauthorized access, data breaches, and other risks. This aligns with the obligation to prevent leaks, loss, or damage of customer information.  \n5. Other options (e.g., Article 9 or 10) address different topics (e.g., data retention, third-party management), while **Article 8** is directly tied to information security measures.  \n\nAnswer: d"
    },
    {
      "question": "暗号等資産が、金融商品取引法第2条第8項第１号の売買に係る金銭とみなしてこの法令（これに基づく命令を含む。）の規定が適用されることの根拠となる条文を教えてください。",
      "choices": "a 金融商品取引法第2条の2\nb 金融商品取引法第2条第2項第5号\nc 金融商品取引法施行令第1条の23\nd 金融商品取引法第41条の4",
      "correct_answer": "a",
      "predicted_answer": "a",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks for the legal basis that treats \"暗号等資産\" (crypto assets) as \"金銭\" (money) related to the sale under **Article 2, Paragraph 8, Item 1** of the Financial Instruments and Exchange Act, thereby applying the law's provisions.  \n2. The relevant provisions are **[2] and [3]**, which both cite **Article 2-2, Paragraph 1** of the Financial Instruments and Exchange Act. This article explicitly states that crypto assets are treated as money under specific provisions (including Article 2, Paragraph 8, Item 1) and that the law's provisions apply to them.  \n3. **Choice a** (\"金融商品取引法第2条の2\") directly corresponds to **Article 2-2, Paragraph 1**, which is the root legal text establishing this treatment.  \n4. Other choices (b, c, d) either refer to unrelated provisions or are not mentioned in the provided legal texts.  \n\nAnswer: a",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第1章_選択式_根拠条文_問題番号43",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/340CO0000000321"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the legal basis that treats \"暗号等資産\" (crypto assets) as \"金銭\" (money) related to the sale under **Article 2, Paragraph 8, Item 1** of the Financial Instruments and Exchange Act, thereby applying the law's provisions.  \n2. The relevant provisions are **[2] and [3]**, which both cite **Article 2-2, Paragraph 1** of the Financial Instruments and Exchange Act. This article explicitly states that crypto assets are treated as money under specific provisions (including Article 2, Paragraph 8, Item 1) and that the law's provisions apply to them.  \n3. **Choice a** (\"金融商品取引法第2条の2\") directly corresponds to **Article 2-2, Paragraph 1**, which is the root legal text establishing this treatment.  \n4. Other choices (b, c, d) either refer to unrelated provisions or are not mentioned in the provided legal texts.  \n\nAnswer: a"
    },
    {
      "question": "相互会社の社債券が、金融商品取引法第２条第１項が定める「有価証券」に該当することの根拠となる条文を１つ教えてください。",
      "choices": "a 金融商品取引法第2条第2項第1号\nb 金融商品取引法第2条第1項第5号\nc 金融商品取引法第2条第1項第17号\nd 金融商品取引法第2条第1項第1号",
      "correct_answer": "b",
      "predicted_answer": "d",
      "is_correct": false,
      "response": "Reasoning: The question asks for the legal basis under the Financial Instruments and Exchange Act (金融商品取引法) that classifies a mutual company's corporate bonds as \"有価証券\" (securities). The key provisions provided are [1], [2], and [3]. \n\n- **[1]** (Insurance Business Act Article 54-7, Paragraph 4) discusses exemptions for mutual companies from submitting securities reports under the Financial Instruments and Exchange Act, but this does not define what constitutes a security. \n- **[2]** and **[3]** reference specific types of bonds (e.g., \"特定社債\") that are classified as securities under the Financial Instruments and Exchange Act, but these are limited to bonds defined under Items 4 or 5 of Article 2, Paragraph 1. However, the question is about **mutual company's corporate bonds**, not the specific bonds mentioned in [2] and [3]. \n\nThe **general definition** of \"有価証券\" (securities) under the Financial Instruments and Exchange Act is provided in **Article 2, Paragraph 1, Item 1**, which includes **bonds** (社債) as a category of securities. Since the question is about the **root provision** that classifies mutual company's corporate bonds as securities, the answer must be the **general definition** in **Article 2, Paragraph 1, Item 1** (option **d**). \n\nWhile [2] and [3] mention Items 4 or 5, they apply to **specific types of bonds** (e.g., those under agricultural cooperatives), not the **general case** of mutual company's corporate bonds. Thus, the correct answer is the general definition in **Article 2, Paragraph 1, Item 1**.\n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第1章_選択式_根拠条文_問題番号44",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025"
      ],
      "reasoning": "Reasoning: The question asks for the legal basis under the Financial Instruments and Exchange Act (金融商品取引法) that classifies a mutual company's corporate bonds as \"有価証券\" (securities). The key provisions provided are [1], [2], and [3]. \n\n- **[1]** (Insurance Business Act Article 54-7, Paragraph 4) discusses exemptions for mutual companies from submitting securities reports under the Financial Instruments and Exchange Act, but this does not define what constitutes a security. \n- **[2]** and **[3]** reference specific types of bonds (e.g., \"特定社債\") that are classified as securities under the Financial Instruments and Exchange Act, but these are limited to bonds defined under Items 4 or 5 of Article 2, Paragraph 1. However, the question is about **mutual company's corporate bonds**, not the specific bonds mentioned in [2] and [3]. \n\nThe **general definition** of \"有価証券\" (securities) under the Financial Instruments and Exchange Act is provided in **Article 2, Paragraph 1, Item 1**, which includes **bonds** (社債) as a category of securities. Since the question is about the **root provision** that classifies mutual company's corporate bonds as securities, the answer must be the **general definition** in **Article 2, Paragraph 1, Item 1** (option **d**). \n\nWhile [2] and [3] mention Items 4 or 5, they apply to **specific types of bonds** (e.g., those under agricultural cooperatives), not the **general case** of mutual company's corporate bonds. Thus, the correct answer is the general definition in **Article 2, Paragraph 1, Item 1**.\n\nAnswer: d"
    },
    {
      "question": "金融機関が業として行おうとするとき、内閣総理大臣の登録を受けなければならない行為を掲げている条文として誤っているものを教えてください。",
      "choices": "a 金融商品取引法第33条第1項\nb 金融商品取引法第33条の2第4号\nc 金融商品取引法第33条の2第1号\nd 金融商品取引法第33条の2第3号",
      "correct_answer": "a",
      "predicted_answer": "a",
      "is_correct": true,
      "response": "Reasoning:  \nThe question asks which option incorrectly lists a provision requiring registration with the Prime Minister (内閣総理大臣) for financial institutions conducting certain business activities.  \n\n1. **Understanding the Legal Context**:  \n   - The provisions in the question relate to **金融商品取引法** (Financial Instruments and Exchange Act).  \n   - **Article 33-2** (第33条の2) of this Act typically outlines the **registration requirements** for financial institutions.  \n   - The options (b, c, d) refer to **Article 33-2, Items 1, 3, and 4**, which are likely to involve registration requirements.  \n   - **Option a** refers to **Article 33, Item 1**, which is a **different article** (not 33-2) and is unrelated to registration with the Prime Minister.  \n\n2. **Analyzing the Options**:  \n   - **Option a (Article 33, Item 1)**: This article likely deals with general provisions (e.g., definitions or scope) rather than registration requirements. It does **not** require registration with the Prime Minister.  \n   - **Options b, c, d (Article 33-2, Items 1, 3, 4)**: These items are part of the registration process under the Financial Instruments and Exchange Act, which **do** require registration with the Prime Minister (as per the legal provisions provided, such as [2] and [3]).  \n\n3. **Conclusion**:  \n   - The **incorrect** option is **a**, as it refers to a provision unrelated to registration with the Prime Minister.  \n\nAnswer: a",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第3章_選択式_根拠条文_問題番号46",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025"
      ],
      "reasoning": "Reasoning:  \nThe question asks which option incorrectly lists a provision requiring registration with the Prime Minister (内閣総理大臣) for financial institutions conducting certain business activities.  \n\n1. **Understanding the Legal Context**:  \n   - The provisions in the question relate to **金融商品取引法** (Financial Instruments and Exchange Act).  \n   - **Article 33-2** (第33条の2) of this Act typically outlines the **registration requirements** for financial institutions.  \n   - The options (b, c, d) refer to **Article 33-2, Items 1, 3, and 4**, which are likely to involve registration requirements.  \n   - **Option a** refers to **Article 33, Item 1**, which is a **different article** (not 33-2) and is unrelated to registration with the Prime Minister.  \n\n2. **Analyzing the Options**:  \n   - **Option a (Article 33, Item 1)**: This article likely deals with general provisions (e.g., definitions or scope) rather than registration requirements. It does **not** require registration with the Prime Minister.  \n   - **Options b, c, d (Article 33-2, Items 1, 3, 4)**: These items are part of the registration process under the Financial Instruments and Exchange Act, which **do** require registration with the Prime Minister (as per the legal provisions provided, such as [2] and [3]).  \n\n3. **Conclusion**:  \n   - The **incorrect** option is **a**, as it refers to a provision unrelated to registration with the Prime Minister.  \n\nAnswer: a"
    },
    {
      "question": "金融商品取引業者等が、多数の者に対して同様の内容で行う情報の提供を行う場合で、金融商品取引法第37条第1項各号に掲げる事項を表示しなくてもよい方法について定めた条文を教えてください。",
      "choices": "a 金融商品取引業等に関する内閣府令第72条第2号\nb 金融商品取引法第37条第1項\nc 金融商品取引法第37条第1項第1号\nd 金融商品取引法第37条第1項第2号",
      "correct_answer": "a",
      "predicted_answer": "b",
      "is_correct": false,
      "response": "Reasoning: The question asks for the provision that allows financial institutions to omit disclosing information when providing the same content to multiple parties. The relevant provision is [2], which is from the **Cabinet Office Order on Financial Instruments Trading Business, Article 125-5, Paragraph 3**. This provision explicitly states that if one financial institution has already informed a customer about a specific matter, other institutions are not required to repeat the same disclosure. However, **none of the provided answer choices (a–d)** directly reference this provision. The options instead focus on **FIEA Article 37**, which outlines the **required disclosures** (not exemptions). Since the correct answer ([2]) is not listed among the choices, the question may contain an error. However, if forced to choose from the given options, **none are correct**, but the closest to the intent of the question (though not the actual provision) might be **b** (FIEA Article 37, Paragraph 1), as it is the general rule requiring disclosure. However, this is not the correct answer to the question as phrased.\n\nAnswer: None of the options are correct. However, if forced to choose, **b** is the closest to the general rule, though it does not address the exemption for multiple parties.",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第3章_選択式_根拠条文_問題番号47",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/419M60000002052"
      ],
      "reasoning": "Reasoning: The question asks for the provision that allows financial institutions to omit disclosing information when providing the same content to multiple parties. The relevant provision is [2], which is from the **Cabinet Office Order on Financial Instruments Trading Business, Article 125-5, Paragraph 3**. This provision explicitly states that if one financial institution has already informed a customer about a specific matter, other institutions are not required to repeat the same disclosure. However, **none of the provided answer choices (a–d)** directly reference this provision. The options instead focus on **FIEA Article 37**, which outlines the **required disclosures** (not exemptions). Since the correct answer ([2]) is not listed among the choices, the question may contain an error. However, if forced to choose from the given options, **none are correct**, but the closest to the intent of the question (though not the actual provision) might be **b** (FIEA Article 37, Paragraph 1), as it is the general rule requiring disclosure. However, this is not the correct answer to the question as phrased.\n\nAnswer: None of the options are correct. However, if forced to choose, **b** is the closest to the general rule, though it does not address the exemption for multiple parties."
    },
    {
      "question": "外務員が、その所属する金融商品取引業者等に代わつて、一切の裁判外の行為を行う権限を有することができる行為を掲げている条文として誤っているものを教えてください。",
      "choices": "a 金融商品取引法第64条第1項第1号イ\nb 金融商品取引法第64条第1項第2号イ\nc 金融商品取引法第２条第２項\nd 金融商品取引法第64条第1項第3号",
      "correct_answer": "c",
      "predicted_answer": "c",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks to identify the **incorrect** provision that lists behaviors for which an external officer (外務員) can perform non-judicial acts.  \n2. The provided legal provisions (all identical) state that an external officer has authority for acts listed in **Article 64, Paragraph 1** of the Financial Instruments and Exchange Act.  \n3. The choices are evaluated as follows:  \n   - **a, b, d** refer to **Article 64, Paragraph 1** (items 1, 2, and 3, respectively), which aligns directly with the legal text. These are **correct** provisions.  \n   - **c** refers to **Article 2, Paragraph 2**, which is unrelated to Article 64, Paragraph 1. Since the legal text explicitly limits the external officer’s authority to Article 64, Paragraph 1, **Article 2, Paragraph 2** is **not covered** and thus **incorrect**.  \n4. Therefore, **c** is the incorrect choice.  \n\nAnswer: c",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第3章_選択式_根拠条文_問題番号51",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025"
      ],
      "reasoning": "Reasoning:  \n1. The question asks to identify the **incorrect** provision that lists behaviors for which an external officer (外務員) can perform non-judicial acts.  \n2. The provided legal provisions (all identical) state that an external officer has authority for acts listed in **Article 64, Paragraph 1** of the Financial Instruments and Exchange Act.  \n3. The choices are evaluated as follows:  \n   - **a, b, d** refer to **Article 64, Paragraph 1** (items 1, 2, and 3, respectively), which aligns directly with the legal text. These are **correct** provisions.  \n   - **c** refers to **Article 2, Paragraph 2**, which is unrelated to Article 64, Paragraph 1. Since the legal text explicitly limits the external officer’s authority to Article 64, Paragraph 1, **Article 2, Paragraph 2** is **not covered** and thus **incorrect**.  \n4. Therefore, **c** is the incorrect choice.  \n\nAnswer: c"
    },
    {
      "question": "金融商品取引業者等が、定義府令第十六条第一項第八号イ若しくはロ又は金融商品取引業等に関する内閣府令第百二十三条第十三号ロからホまでに規定する契約に基づき有価証券の売買を行う場合に、当該契約の委任の本旨又は当該契約の金額に照らし過当と認められる数量の売買で取引所金融商品市場又は店頭売買有価証券市場の秩序を害すると認められるものを行ってはならないことの根拠条文を教えてください。",
      "choices": "a 金融商品取引法第161条第１項\nb 金融商品取引法第161条第２項\nc 有価証券の取引等の規制に関する内閣府令第９条第１項\nd 有価証券の取引等の規制に関する内閣府令第９条第２項",
      "correct_answer": "c",
      "predicted_answer": "c",
      "is_correct": true,
      "response": "Reasoning: The question asks for the legal basis (根拠条文) of the prohibition against engaging in trades that harm market order when acting under specific contracts. The provided legal provisions [2] and [3] explicitly cite **有価証券の取引等の規制に関する内閣府令第9条第1項** (Cabinet Order on the Regulation of Securities Transactions, Article 9, Paragraph 1) as the direct source of the prohibition. This article states that financial instrument traders must not engage in trades that harm market order under the specified contracts. While the Financial Instruments and Exchange Act (Article 161, Paragraph 1) is referenced as the overarching law, the specific regulation implementing this prohibition is found in the Cabinet Order's Article 9, Paragraph 1. Thus, the correct answer is the provision that directly prohibits the action, not the higher-level law.\n\nAnswer: c",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第6章_選択式_根拠条文_問題番号55",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/419M60000002059"
      ],
      "reasoning": "Reasoning: The question asks for the legal basis (根拠条文) of the prohibition against engaging in trades that harm market order when acting under specific contracts. The provided legal provisions [2] and [3] explicitly cite **有価証券の取引等の規制に関する内閣府令第9条第1項** (Cabinet Order on the Regulation of Securities Transactions, Article 9, Paragraph 1) as the direct source of the prohibition. This article states that financial instrument traders must not engage in trades that harm market order under the specified contracts. While the Financial Instruments and Exchange Act (Article 161, Paragraph 1) is referenced as the overarching law, the specific regulation implementing this prohibition is found in the Cabinet Order's Article 9, Paragraph 1. Thus, the correct answer is the provision that directly prohibits the action, not the higher-level law.\n\nAnswer: c"
    },
    {
      "question": "次のうち、テレビ、ラジオの提供番組等における広告について、医薬品等適正広告基準の解説及び留意事項の記載に照らして、正しいものを教えてください。",
      "choices": "a タレントがＣＭにおいて「胸やけ、胃痛は肝臓が衰えているからです」と視聴者に伝えるCMは、医薬品等適正広告基準の解説及び留意事項に反するものではない\nb テレビにおいて、医薬品の名称を10回連呼する行為は、10回程度であれば医薬品等適正広告基準の解説及び留意事項に反する可能性はない\nc テレビの番組等において手術場面等の露骨な表現を放送することも、視聴者に病気を分かりやすく伝えることができるから、医薬品等適正広告基準の解説及び留意事項に反するものではない\nd テレビの番組等において、大声で奇声を上げることは、視聴者に著しい不快感を与える場合には、医薬品等適正広告基準の解説及び留意事項に反し、認められない",
      "correct_answer": "d",
      "predicted_answer": "d",
      "is_correct": true,
      "response": "Reasoning:  \nThe question asks which statement about pharmaceutical advertising in TV/radio programs complies with the \"Medicinal Products Appropriate Advertising Standards Explanation and Notes.\" The key legal provisions provided are from Japan's Act on Ensuring the Quality, Efficacy, and Safety of Pharmaceuticals, etc. Specifically, **Article 66, Paragraph 2** prohibits advertising that could be **misunderstood as a guarantee by a medical professional** (e.g., doctors) regarding the efficacy or performance of products.  \n\n- **Option a** involves a talent making a medical claim (\"liver weakness causes heartburn\"). While this may be misleading, the provision does not explicitly prohibit **non-medical professionals** making such claims. The law focuses on **implied guarantees by medical professionals**, not general medical statements. Thus, **a** may not violate the provision.  \n- **Option b** involves repeating a drug name 10 times. The provision does not address repetition of product names, so **b** is not directly prohibited by the given law.  \n- **Option c** involves showing explicit surgery scenes. The provision does not mention restrictions on graphic content, so **c** is not directly prohibited.  \n- **Option d** involves loud, strange noises causing discomfort. While the provision does not explicitly mention this, the **\"Notes\"** in the advertising standards likely include **general principles** such as avoiding content that causes **unnecessary discomfort or disturbance** to viewers. This aligns with broader advertising ethics, even if not explicitly stated in the provided legal text. Thus, **d** is the most likely correct answer, as it reflects a violation of **general advertising standards** (even if not directly covered by the specific provisions).  \n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第10章_選択式_関連法令_問題番号21",
      "references": [],
      "reasoning": "Reasoning:  \nThe question asks which statement about pharmaceutical advertising in TV/radio programs complies with the \"Medicinal Products Appropriate Advertising Standards Explanation and Notes.\" The key legal provisions provided are from Japan's Act on Ensuring the Quality, Efficacy, and Safety of Pharmaceuticals, etc. Specifically, **Article 66, Paragraph 2** prohibits advertising that could be **misunderstood as a guarantee by a medical professional** (e.g., doctors) regarding the efficacy or performance of products.  \n\n- **Option a** involves a talent making a medical claim (\"liver weakness causes heartburn\"). While this may be misleading, the provision does not explicitly prohibit **non-medical professionals** making such claims. The law focuses on **implied guarantees by medical professionals**, not general medical statements. Thus, **a** may not violate the provision.  \n- **Option b** involves repeating a drug name 10 times. The provision does not address repetition of product names, so **b** is not directly prohibited by the given law.  \n- **Option c** involves showing explicit surgery scenes. The provision does not mention restrictions on graphic content, so **c** is not directly prohibited.  \n- **Option d** involves loud, strange noises causing discomfort. While the provision does not explicitly mention this, the **\"Notes\"** in the advertising standards likely include **general principles** such as avoiding content that causes **unnecessary discomfort or disturbance** to viewers. This aligns with broader advertising ethics, even if not explicitly stated in the provided legal text. Thus, **d** is the most likely correct answer, as it reflects a violation of **general advertising standards** (even if not directly covered by the specific provisions).  \n\nAnswer: d"
    },
    {
      "question": "医薬品の注意事項等情報のうち、誤っているものを教えてください。",
      "choices": "a 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第68条の2第2項第1号ロの医薬品については、日本薬局方において当該医薬品の品質、有効性及び安全性に関連する事項として公表されるように定められなかった事項も、注意事項等情報となる\nb 用法、用量その他使用及び取扱い上必要な情報は、注意事項等情報に該当する\nc 厚生労働大臣が保健衛生上特別の注意を要する医薬品につき、薬事審議会の意見を聴いて、その製法、性状、品質、貯法等に関し、必要な基準を定めた場合、その基準において当該医薬品の品質、有効性及び安全性に関する事項として公表するように定められた事項は、注意事項等情報となる\nd 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第68条の2第２項の医薬品からは、同法第52条第2項に規定する厚生労働省令で定める医薬品が除外されている",
      "correct_answer": "a",
      "predicted_answer": "d",
      "is_correct": false,
      "response": "Reasoning:  \nThe question asks to identify the incorrect statement regarding \"notice information\" (注意事項等情報) under Japanese law. The provided legal provisions are from the **Animal Medicinal Products and Other Regulations** (動物用医薬品等取締規則), specifically Articles 110-7 and 175-4. These provisions outline requirements for information disclosure by pharmacists and registered sellers, including details like drug names, active ingredients, usage, safety precautions, etc.  \n\n- **Option a** refers to the **Pharmaceutical and Medical Device Act (薬機法)** Article 68-2, which is not directly addressed in the provided provisions. However, the statement itself aligns with general principles of including non-Japanese Pharmacopoeia information as notice information, which is plausible.  \n- **Option b** correctly states that usage, dosage, and handling information are part of notice information, which is explicitly covered in the provisions (e.g., [1] and [2] mention \"用法及び用量\" and \"使用上の注意\").  \n- **Option c** discusses standards set by the Minister of Health, Labour and Welfare, which are not directly addressed in the provided provisions. However, the statement about including such standards as notice information is consistent with the general intent of ensuring safety and efficacy.  \n- **Option d** claims that certain drugs are excluded under the **Pharmaceutical and Medical Device Act** Article 52-2. However, the provided provisions (from the Animal Medicinal Products Regulation) do **not** mention such exclusions. Since the question is based on the given legal texts, **option d** introduces a reference to a different law (薬機法) and a provision not covered in the provided materials, making it **incorrect** in the context of the question.  \n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第11章_選択式_関連法令_問題番号22",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145"
      ],
      "reasoning": "Reasoning:  \nThe question asks to identify the incorrect statement regarding \"notice information\" (注意事項等情報) under Japanese law. The provided legal provisions are from the **Animal Medicinal Products and Other Regulations** (動物用医薬品等取締規則), specifically Articles 110-7 and 175-4. These provisions outline requirements for information disclosure by pharmacists and registered sellers, including details like drug names, active ingredients, usage, safety precautions, etc.  \n\n- **Option a** refers to the **Pharmaceutical and Medical Device Act (薬機法)** Article 68-2, which is not directly addressed in the provided provisions. However, the statement itself aligns with general principles of including non-Japanese Pharmacopoeia information as notice information, which is plausible.  \n- **Option b** correctly states that usage, dosage, and handling information are part of notice information, which is explicitly covered in the provisions (e.g., [1] and [2] mention \"用法及び用量\" and \"使用上の注意\").  \n- **Option c** discusses standards set by the Minister of Health, Labour and Welfare, which are not directly addressed in the provided provisions. However, the statement about including such standards as notice information is consistent with the general intent of ensuring safety and efficacy.  \n- **Option d** claims that certain drugs are excluded under the **Pharmaceutical and Medical Device Act** Article 52-2. However, the provided provisions (from the Animal Medicinal Products Regulation) do **not** mention such exclusions. Since the question is based on the given legal texts, **option d** introduces a reference to a different law (薬機法) and a provision not covered in the provided materials, making it **incorrect** in the context of the question.  \n\nAnswer: d"
    },
    {
      "question": "次のうち、正しいものを教えてください。",
      "choices": "a 特定生物由来品については、その直接の容器又は直接の被包に、白地に黒枠、黒字をもって「生物」の文字が記載されていなければならない\nb 特定生物由来品については、その直接の容器又は直接の被包に、白地に赤枠、赤字をもって「特生物」の文字が記載されていなければならない\nc 生物由来製品（特定生物由来製品を除く。）については、医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律施行規則第230条第1号の表示以外の事項も、記載する必要がある\nd 生物由来製品（特定生物由来製品を除く。）については、白地に黒枠、黒字をもって「危険」の文字が記載されていなければならない",
      "correct_answer": "c",
      "predicted_answer": "unknown",
      "is_correct": false,
      "response": "Reasoning: The question asks for the correct statement regarding labeling requirements for biological products. However, none of the provided legal provisions (related to ship stability, employment management in SMEs, or commercial street activation) address product labeling, biological products, or specific labeling requirements such as those mentioned in the choices (e.g., \"生物,\" \"特生物,\" \"危険\"). The provisions listed are entirely unrelated to the subject matter of the question. Since the choices depend on legal provisions not included in the given text, none of the options can be validated or invalidated based on the provided information. However, the question assumes that one of the choices is correct, which implies an error in the setup. Under strict adherence to the given provisions, no answer is supported.\n\nAnswer: None of the options are correct based on the provided legal provisions. However, since this is not an available choice, the question may contain an error.",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第12章_選択式_関連法令_問題番号23",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145",
        "https://laws.e-gov.go.jp/law/336M50000100001"
      ],
      "reasoning": "Reasoning: The question asks for the correct statement regarding labeling requirements for biological products. However, none of the provided legal provisions (related to ship stability, employment management in SMEs, or commercial street activation) address product labeling, biological products, or specific labeling requirements such as those mentioned in the choices (e.g., \"生物,\" \"特生物,\" \"危険\"). The provisions listed are entirely unrelated to the subject matter of the question. Since the choices depend on legal provisions not included in the given text, none of the options can be validated or invalidated based on the provided information. However, the question assumes that one of the choices is correct, which implies an error in the setup. Under strict adherence to the given provisions, no answer is supported.\n\nAnswer: None of the options are correct based on the provided legal provisions. However, since this is not an available choice, the question may contain an error."
    },
    {
      "question": "次のうち、機構による立入検査等の実施について正しいものを教えてください。",
      "choices": "a 特別区の区長は、機構の職員に、地域連携薬局等に立ち入り、その構造設備を検査させることができる。\nb 保健所を設置する市の市長は、機構の職員に、経理の状況に関し、登録認証機関の事務所に立入検査をさせることができる。\nc 厚生労働大臣は、機構の職員に、基準適合性認証の業務に関し、登録認証機関の事務所に立入検査をさせることができる。\nd 厚生労働大臣は、犯罪捜査のために必要であれば、機構の職員に、基準適合性認証の業務の状況に関し、登録認証機関の事務所に立入検査をさせることができる。",
      "correct_answer": "c",
      "predicted_answer": "c",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks which statement correctly describes the implementation of entry inspections by the \"機構\" (institution) under Japanese law.  \n2. The relevant provisions are:  \n   - **[1]**: Administrative agencies can order the institution to conduct inspections, but only to verify compliance with procedures under Chapters 3 and 4 of the relevant law (related to victims' compensation for criminal funds).  \n   - **[2]**: The institution conducts inspections under the **Labor Safety and Health Law** (specifically Article 96-2).  \n   - **[3]**: The institution must report results of inspections under the **Home Goods Quality Labeling Law** to the Minister of Economy, Trade and Industry.  \n\n3. **Analysis of choices**:  \n   - **Option a**: Mentions a \"ward mayor\" inspecting a pharmacy. This is unrelated to the provisions, which do not mention pharmacies or ward mayors. **Incorrect**.  \n   - **Option b**: Refers to a mayor inspecting a certification agency's accounting. The provisions do not mention accounting inspections or mayors. **Incorrect**.  \n   - **Option c**: States the **Minister of Health, Labour and Welfare** can order the institution to inspect a **registered certification agency** regarding **conformity assessment**. This aligns with **[2]**, which mandates the institution to conduct inspections under the **Labor Safety and Health Law**. The Minister of Health, Labour and Welfare is the administrative agency overseeing this law, and the institution's role includes such inspections. **Correct**.  \n   - **Option d**: Claims the Minister can order inspections for **criminal investigations**. This would fall under **[1]**, but **[1]** is limited to verifying compliance with procedures under Chapters 3 and 4 (not criminal investigations). Additionally, the term \"conformity assessment\" in **[2]** is unrelated to criminal investigations. **Incorrect**.  \n\nAnswer: c",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第13章_選択式_関連法令_問題番号24",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145"
      ],
      "reasoning": "Reasoning:  \n1. The question asks which statement correctly describes the implementation of entry inspections by the \"機構\" (institution) under Japanese law.  \n2. The relevant provisions are:  \n   - **[1]**: Administrative agencies can order the institution to conduct inspections, but only to verify compliance with procedures under Chapters 3 and 4 of the relevant law (related to victims' compensation for criminal funds).  \n   - **[2]**: The institution conducts inspections under the **Labor Safety and Health Law** (specifically Article 96-2).  \n   - **[3]**: The institution must report results of inspections under the **Home Goods Quality Labeling Law** to the Minister of Economy, Trade and Industry.  \n\n3. **Analysis of choices**:  \n   - **Option a**: Mentions a \"ward mayor\" inspecting a pharmacy. This is unrelated to the provisions, which do not mention pharmacies or ward mayors. **Incorrect**.  \n   - **Option b**: Refers to a mayor inspecting a certification agency's accounting. The provisions do not mention accounting inspections or mayors. **Incorrect**.  \n   - **Option c**: States the **Minister of Health, Labour and Welfare** can order the institution to inspect a **registered certification agency** regarding **conformity assessment**. This aligns with **[2]**, which mandates the institution to conduct inspections under the **Labor Safety and Health Law**. The Minister of Health, Labour and Welfare is the administrative agency overseeing this law, and the institution's role includes such inspections. **Correct**.  \n   - **Option d**: Claims the Minister can order inspections for **criminal investigations**. This would fall under **[1]**, but **[1]** is limited to verifying compliance with procedures under Chapters 3 and 4 (not criminal investigations). Additionally, the term \"conformity assessment\" in **[2]** is unrelated to criminal investigations. **Incorrect**.  \n\nAnswer: c"
    },
    {
      "question": "次のうち、輸入の確認について正しいものを教えてください。",
      "choices": "a 臨床試験その他の試験研究の用に供する目的で当該医薬品を輸入する必要があると認められる場合は、厚生労働大臣は輸入について確認をしない\nb 個人的使用に供せられ、かつ、売買の対象とならないと認められる程度の数量を超えない数量の医薬品の輸入をする場合は、厚生労働大臣は輸入について確認をしない\nc 外国に輸出した医薬品を輸入する必要があると認められない場合は、厚生労働大臣は輸入について確認をしない\nd 医薬品を輸入しようとする者は、申請書を都道府県知事に提出し、その輸入についての都道府県知事の確認を受けなければならない",
      "correct_answer": "c",
      "predicted_answer": "a",
      "is_correct": false,
      "response": "Reasoning:  \n1. The question asks for the correct statement regarding import confirmation under Japanese law.  \n2. **Provision [1]** specifies that the application for import confirmation must be submitted to the **Minister of Health, Labour and Welfare** using a specific form. This directly contradicts **Option d**, which claims the application must be submitted to the **prefectural governor**.  \n3. **Options a, b, and c** discuss scenarios where import confirmation is **not required**. However, the provided legal provisions **do not mention any exemptions** for clinical trials (a), personal use (b), or unnecessary imports (c). Thus, these options are **not supported** by the given texts.  \n4. Since **Option d** is explicitly incorrect based on **Provision [1]**, and the other options lack legal basis in the provided provisions, **none of the options are fully supported**. However, the question requires selecting the **most accurate answer** based on the given texts.  \n\nAnswer: **a**  \n(Note: While the provided provisions do not explicitly address exemptions for clinical trials, **Option a** is the **least incorrect** among the choices, as it aligns with the general principle that import confirmation is required unless explicitly exempted by law. However, this conclusion is based on the assumption that the question expects an answer despite the lack of direct legal support for the options.)  \n\n**Correction**: Upon re-evaluation, **none of the options are correct** based on the provided provisions. However, since the question requires selecting an answer, **Option a** is the **least incorrect** due to its alignment with the general requirement for import confirmation.  \n\n**Final Answer**: **a**",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第9章_選択式_関連法令_問題番号25",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145",
        "https://laws.e-gov.go.jp/law/336M50000100001"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the correct statement regarding import confirmation under Japanese law.  \n2. **Provision [1]** specifies that the application for import confirmation must be submitted to the **Minister of Health, Labour and Welfare** using a specific form. This directly contradicts **Option d**, which claims the application must be submitted to the **prefectural governor**.  \n3. **Options a, b, and c** discuss scenarios where import confirmation is **not required**. However, the provided legal provisions **do not mention any exemptions** for clinical trials (a), personal use (b), or unnecessary imports (c). Thus, these options are **not supported** by the given texts.  \n4. Since **Option d** is explicitly incorrect based on **Provision [1]**, and the other options lack legal basis in the provided provisions, **none of the options are fully supported**. However, the question requires selecting the **most accurate answer** based on the given texts.  \n\nAnswer: **a**  \n(Note: While the provided provisions do not explicitly address exemptions for clinical trials, **Option a** is the **least incorrect** among the choices, as it aligns with the general principle that import confirmation is required unless explicitly exempted by law. However, this conclusion is based on the assumption that the question expects an answer despite the lack of direct legal support for the options.)  \n\n**Correction**: Upon re-evaluation, **none of the options are correct** based on the provided provisions. However, since the question requires selecting an answer, **Option a** is the **least incorrect** due to its alignment with the general requirement for import confirmation.  \n\n**Final Answer**: **a**"
    },
    {
      "question": "次のうち、正しいものを教えてください。",
      "choices": "a 専ら動物のために使用される黄熱ワクチンも、生物由来製品に該当する\nb 黄熱ワクチンは、特定生物由来製品に該当する\nc 黄熱ワクチンは、特定生物由来製品ではない\nd 黄熱ワクチンは、植物に由来するものを原料又は材料として製造される",
      "correct_answer": "c",
      "predicted_answer": "c",
      "is_correct": true,
      "response": "Reasoning: The question asks about the classification of the yellow fever vaccine under Japanese law, but none of the provided legal provisions (relating to maritime stability, labor management, and commercial street activation) address biological products, vaccines, or their categorization. Since the legal texts do not contain any information relevant to the options (a–d), it is impossible to determine the correct answer based solely on the given provisions. However, if we consider general knowledge outside the provided texts:  \n- **Yellow fever vaccine** is typically classified as a **biological product** (e.g., under Japan's **Pharmaceutical and Medical Devices Act**), and **specific biological products** (特定生物由来製品) may include vaccines derived from biological sources.  \n- **Option c** (\"黄熱ワクチンは、特定生物由来製品ではない\") would be incorrect if the vaccine is indeed a biological product.  \n- **Option b** (\"黄熱ワクチンは、特定生物由来製品に該当する\") would be correct if the vaccine is classified as such.  \n\nHowever, since the question explicitly instructs to use **only the provided legal provisions**, and none of them address this topic, the correct answer **cannot be determined** from the given information.  \n\nAnswer: **c** (Note: This answer assumes general knowledge, as the provided legal texts are irrelevant to the question.)",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第1章_選択式_関連法令_問題番号26",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145"
      ],
      "reasoning": "Reasoning: The question asks about the classification of the yellow fever vaccine under Japanese law, but none of the provided legal provisions (relating to maritime stability, labor management, and commercial street activation) address biological products, vaccines, or their categorization. Since the legal texts do not contain any information relevant to the options (a–d), it is impossible to determine the correct answer based solely on the given provisions. However, if we consider general knowledge outside the provided texts:  \n- **Yellow fever vaccine** is typically classified as a **biological product** (e.g., under Japan's **Pharmaceutical and Medical Devices Act**), and **specific biological products** (特定生物由来製品) may include vaccines derived from biological sources.  \n- **Option c** (\"黄熱ワクチンは、特定生物由来製品ではない\") would be incorrect if the vaccine is indeed a biological product.  \n- **Option b** (\"黄熱ワクチンは、特定生物由来製品に該当する\") would be correct if the vaccine is classified as such.  \n\nHowever, since the question explicitly instructs to use **only the provided legal provisions**, and none of them address this topic, the correct answer **cannot be determined** from the given information.  \n\nAnswer: **c** (Note: This answer assumes general knowledge, as the provided legal texts are irrelevant to the question.)"
    },
    {
      "question": "次のうち、医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第1条の3、第1条の4及び第1条の５において、その責務が記載されていない者を教えて下さい。",
      "choices": "a 都道府県\nb 医薬品等の製造販売を業として行う者\nc 医薬品の運送を業として行う者\nd 薬剤師",
      "correct_answer": "c",
      "predicted_answer": "c",
      "is_correct": true,
      "response": "Reasoning:  \nThe question asks which of the options is **not** mentioned in the duties under the law's Articles 1-3, 1-4, and 1-5. However, the provided legal texts do not include these specific articles but instead reference **Article 17** of the main law and an Ordinance. Based on the given provisions:  \n\n1. **[1]** (Ordinance) and **[2]/[3]** (Article 17 of the main law) focus on **pharmaceutical manufacturers/sellers** (option **b**) and their responsibilities, such as appointing **safety management implementation responsible persons** and **pharmaceutical overall manufacturing/sales responsible persons**. These provisions explicitly assign duties to **option b**.  \n\n2. **Option a** (prefectural governments) and **option d** (pharmacists) are not mentioned in the provided texts. However, **option c** (pharmaceutical transporters) is also not mentioned in the given provisions.  \n\n3. The key distinction lies in the **scope of the law**. Articles 1-3, 1-4, and 1-5 of the law likely outline **general obligations** for entities involved in pharmaceutical regulation. **Pharmaceutical transporters** (option **c**) are not typically subject to the same direct regulatory duties as manufacturers/sellers (option **b**) or pharmacists (option **d**), who are explicitly mentioned in other parts of the law. Prefectural governments (option **a**) may have oversight roles under administrative provisions, but the question specifically asks about **duties** under the cited articles.  \n\nSince the provided texts do not mention **pharmaceutical transporters** (option **c**) and the question focuses on **duties** (not oversight roles), **option c** is the correct answer.  \n\nAnswer: **c**",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第1章_選択式_関連法令_問題番号27",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145"
      ],
      "reasoning": "Reasoning:  \nThe question asks which of the options is **not** mentioned in the duties under the law's Articles 1-3, 1-4, and 1-5. However, the provided legal texts do not include these specific articles but instead reference **Article 17** of the main law and an Ordinance. Based on the given provisions:  \n\n1. **[1]** (Ordinance) and **[2]/[3]** (Article 17 of the main law) focus on **pharmaceutical manufacturers/sellers** (option **b**) and their responsibilities, such as appointing **safety management implementation responsible persons** and **pharmaceutical overall manufacturing/sales responsible persons**. These provisions explicitly assign duties to **option b**.  \n\n2. **Option a** (prefectural governments) and **option d** (pharmacists) are not mentioned in the provided texts. However, **option c** (pharmaceutical transporters) is also not mentioned in the given provisions.  \n\n3. The key distinction lies in the **scope of the law**. Articles 1-3, 1-4, and 1-5 of the law likely outline **general obligations** for entities involved in pharmaceutical regulation. **Pharmaceutical transporters** (option **c**) are not typically subject to the same direct regulatory duties as manufacturers/sellers (option **b**) or pharmacists (option **d**), who are explicitly mentioned in other parts of the law. Prefectural governments (option **a**) may have oversight roles under administrative provisions, but the question specifically asks about **duties** under the cited articles.  \n\nSince the provided texts do not mention **pharmaceutical transporters** (option **c**) and the question focuses on **duties** (not oversight roles), **option c** is the correct answer.  \n\nAnswer: **c**"
    },
    {
      "question": "次のうち、指定に際して、厚生労働大臣が薬事審議会の意見を聴く必要のないものを教えてください。",
      "choices": "a 管理医療機器\nb 再生医療等製品\nc 生物由来製品\nd 一般医療機器",
      "correct_answer": "b",
      "predicted_answer": "d",
      "is_correct": false,
      "response": "Reasoning:  \n1. The question asks which designation **does not require** the Minister to consult the Pharmaceutical Affairs and Food Sanitation Council (薬事審議会).  \n2. **Legal Provision [1]** allows the Minister to skip consultation **only if** the designation is under **Article 2, Paragraph 15** and there is an urgent need.  \n3. **Legal Provisions [2] and [3]** mandate consultation **for designations under Article 36-7, Paragraph 1, Items 1 or 2**.  \n4. The options (a–d) correspond to different categories of medical devices or products. Based on Japanese law:  \n   - **General medical devices (一般医療機器, d)** are typically subject to standard regulatory procedures that may not require consultation unless there is an urgent need (falling under the exception in [1]).  \n   - **Specialized categories** like **managed medical devices (管理医療機器, a)**, **regenerative medicine products (再生医療等製品, b)**, and **biological products (生物由来製品, c)** are more likely to be governed by provisions requiring consultation (e.g., [2] and [3]).  \n5. Thus, **d (一般医療機器)** is the only option that may fall under the exception in [1], where consultation is not required in urgent cases.  \n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第1章_選択式_関連法令_問題番号28",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145"
      ],
      "reasoning": "Reasoning:  \n1. The question asks which designation **does not require** the Minister to consult the Pharmaceutical Affairs and Food Sanitation Council (薬事審議会).  \n2. **Legal Provision [1]** allows the Minister to skip consultation **only if** the designation is under **Article 2, Paragraph 15** and there is an urgent need.  \n3. **Legal Provisions [2] and [3]** mandate consultation **for designations under Article 36-7, Paragraph 1, Items 1 or 2**.  \n4. The options (a–d) correspond to different categories of medical devices or products. Based on Japanese law:  \n   - **General medical devices (一般医療機器, d)** are typically subject to standard regulatory procedures that may not require consultation unless there is an urgent need (falling under the exception in [1]).  \n   - **Specialized categories** like **managed medical devices (管理医療機器, a)**, **regenerative medicine products (再生医療等製品, b)**, and **biological products (生物由来製品, c)** are more likely to be governed by provisions requiring consultation (e.g., [2] and [3]).  \n5. Thus, **d (一般医療機器)** is the only option that may fall under the exception in [1], where consultation is not required in urgent cases.  \n\nAnswer: d"
    },
    {
      "question": "次のうち、正しいものを教えてください。",
      "choices": "a 地域連携薬局と称するには、厚生労働大臣の認定を受ける必要がある。\nb 地域連携薬局の認定を受けるには、一定の事項を記載した申請書の提出が必要である。\nc 地域連携薬局でなくても、地域連携薬局という名称を用いてよい。\nd 一度地域連携薬局の認定を受ければ、当該認定の更新は必要ない。",
      "correct_answer": "b",
      "predicted_answer": "a",
      "is_correct": false,
      "response": "Reasoning: The question asks about the correct statement regarding \"地域連携薬局\" (regional collaborative pharmacies), but none of the provided legal provisions (related to maritime regulations, SME employment management, and commercial street activation) address pharmacy certification, naming, or requirements. The provisions listed are entirely unrelated to the topic of the question. Since the answer must be derived strictly from the given legal texts, and no relevant law is included, none of the choices (a–d) can be confirmed as correct based on the provided information. However, the question assumes that one of the options is correct, implying a possible omission in the legal provisions provided.\n\nAnswer: None of the options can be confirmed as correct based on the given legal provisions. However, if forced to choose from the options, **b** (requiring submission of an application with specific details) is a common requirement in certification processes, though this is speculative and not supported by the provided texts. \n\n**Note:** The question likely contains an error, as the necessary legal provisions about \"地域連携薬局\" are not included in the provided texts.",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第3章_選択式_関連法令_問題番号29",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145"
      ],
      "reasoning": "Reasoning: The question asks about the correct statement regarding \"地域連携薬局\" (regional collaborative pharmacies), but none of the provided legal provisions (related to maritime regulations, SME employment management, and commercial street activation) address pharmacy certification, naming, or requirements. The provisions listed are entirely unrelated to the topic of the question. Since the answer must be derived strictly from the given legal texts, and no relevant law is included, none of the choices (a–d) can be confirmed as correct based on the provided information. However, the question assumes that one of the options is correct, implying a possible omission in the legal provisions provided.\n\nAnswer: None of the options can be confirmed as correct based on the given legal provisions. However, if forced to choose from the options, **b** (requiring submission of an application with specific details) is a common requirement in certification processes, though this is speculative and not supported by the provided texts. \n\n**Note:** The question likely contains an error, as the necessary legal provisions about \"地域連携薬局\" are not included in the provided texts."
    },
    {
      "question": "医師又は歯科医師から交付された処方箋により調剤された薬剤（以下「当該薬剤」という。）に関する記載のうち、正しいものを教えて下さい。",
      "choices": "a 薬局開設者は、当該薬剤を販売する場合には、薬剤師に、必要な情報を提供させる義務があるが、対面には限られない\nb 薬局開設者は、薬剤師による情報の提供を行わせるに当たつては、当該薬剤師に、当該薬剤を使用しようとする者の年齢を確認させる必要はない\nc 薬局開設者は、薬剤師による情報の提供ができないときでも、当該薬剤を販売することはできる\nd 薬局開設者は、当該薬剤を購入しようとする者から相談があつた場合には、薬剤師に、必要な情報を提供させなければならない",
      "correct_answer": "d",
      "predicted_answer": "d",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks for the correct statement regarding obligations under Japanese law concerning the dispensing of medications based on a prescription.  \n2. The relevant provision is [3], which mandates that pharmacy operators ensure pharmacists provide necessary information and guidance to users of dispensed medications when necessary for proper use.  \n3. **Option a** states that the obligation is not limited to in-person interactions. The law does not specify the method of information provision, so this is correct.  \n4. **Option b** claims age verification is unnecessary. The law does not mention age checks, so this is also correct. However, the question likely expects only one correct answer.  \n5. **Option c** asserts that the pharmacy can sell the medication even if the pharmacist cannot provide information. This contradicts the law’s requirement to ensure information is provided, making this incorrect.  \n6. **Option d** states that if a purchaser requests consultation, the pharmacist must provide information. Since the law requires information when necessary, and a consultation request qualifies as a \"necessary\" case, this is correct.  \n\nWhile both **a** and **d** are technically correct, **d** directly aligns with the law’s explicit requirement to provide information in response to a consultation, which is a clear example of a \"necessary\" scenario. **a** is also correct but less specific. However, the question likely expects **d** as the most precise answer.  \n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第3章_選択式_関連法令_問題番号30",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the correct statement regarding obligations under Japanese law concerning the dispensing of medications based on a prescription.  \n2. The relevant provision is [3], which mandates that pharmacy operators ensure pharmacists provide necessary information and guidance to users of dispensed medications when necessary for proper use.  \n3. **Option a** states that the obligation is not limited to in-person interactions. The law does not specify the method of information provision, so this is correct.  \n4. **Option b** claims age verification is unnecessary. The law does not mention age checks, so this is also correct. However, the question likely expects only one correct answer.  \n5. **Option c** asserts that the pharmacy can sell the medication even if the pharmacist cannot provide information. This contradicts the law’s requirement to ensure information is provided, making this incorrect.  \n6. **Option d** states that if a purchaser requests consultation, the pharmacist must provide information. Since the law requires information when necessary, and a consultation request qualifies as a \"necessary\" case, this is correct.  \n\nWhile both **a** and **d** are technically correct, **d** directly aligns with the law’s explicit requirement to provide information in response to a consultation, which is a clear example of a \"necessary\" scenario. **a** is also correct but less specific. However, the question likely expects **d** as the most precise answer.  \n\nAnswer: d"
    },
    {
      "question": "次のうち、薬局の名称を付することができないもの又は場合を教えて下さい。",
      "choices": "a その所在地が保健所を設置する市の区域にある場合で、市長の許可を受けている場合\nb その所在地が保健所を設置する特別区の区域にある場合で、区長の許可を受けていない場合\nc 病院の調剤所\nd 診療所の調剤所",
      "correct_answer": "b",
      "predicted_answer": "b",
      "is_correct": true,
      "response": "Reasoning:  \nThe question asks which option **cannot** use the name of a pharmacy (薬局). The key provision is **Article 6, Paragraph 1** of the Japanese Pharmaceutical and Medical Device Act, which states that **only licensed pharmacies (薬局)** can use the term \"pharmacy\" in their name. Exceptions apply to **places specified by the Ministry of Health, Labour and Welfare regulations**, but **local permissions (e.g., from mayors or district mayors)** are not mentioned in the law.  \n\n- **Options c and d** (hospital and clinic dispensing offices) are likely **licensed pharmacies** (as hospitals and clinics typically have licensed pharmacies in Japan). Thus, they **can** use the name.  \n- **Options a and b** involve locations with **health centers** and **local permissions**. However, the law does **not** link local permissions to the exception. The exception is strictly for **Ministry-specified places**, not local approvals. Therefore, **unless the location is explicitly covered by the Ministry's regulations**, they **cannot** use the name.  \n\nBetween **a and b**, **option b** explicitly states **no permission from the district mayor**. However, the law does **not** tie local permissions to the exception. Thus, **even if a place has local permission**, it still **cannot** use the name **unless** it is in the Ministry's exception. Since **no information** is given about the Ministry's exception in the options, **the only clear disqualifier is the absence of a license**.  \n\nHowever, **options a and b** do **not** explicitly state whether the places are licensed pharmacies. This ambiguity makes it difficult to definitively rule them out. **Options c and d**, on the other hand, are **clearly associated with licensed pharmacies** (as hospitals and clinics have licensed pharmacies).  \n\nThus, the **only option that cannot use the name** is **option b**, as it **lacks local permission** and **does not fall under the Ministry's exception** (which is not specified in the options).  \n\n**Answer:**  \n**b**",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第3章_選択式_関連法令_問題番号31",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145",
        "https://laws.e-gov.go.jp/law/336M50000100001"
      ],
      "reasoning": "Reasoning:  \nThe question asks which option **cannot** use the name of a pharmacy (薬局). The key provision is **Article 6, Paragraph 1** of the Japanese Pharmaceutical and Medical Device Act, which states that **only licensed pharmacies (薬局)** can use the term \"pharmacy\" in their name. Exceptions apply to **places specified by the Ministry of Health, Labour and Welfare regulations**, but **local permissions (e.g., from mayors or district mayors)** are not mentioned in the law.  \n\n- **Options c and d** (hospital and clinic dispensing offices) are likely **licensed pharmacies** (as hospitals and clinics typically have licensed pharmacies in Japan). Thus, they **can** use the name.  \n- **Options a and b** involve locations with **health centers** and **local permissions**. However, the law does **not** link local permissions to the exception. The exception is strictly for **Ministry-specified places**, not local approvals. Therefore, **unless the location is explicitly covered by the Ministry's regulations**, they **cannot** use the name.  \n\nBetween **a and b**, **option b** explicitly states **no permission from the district mayor**. However, the law does **not** tie local permissions to the exception. Thus, **even if a place has local permission**, it still **cannot** use the name **unless** it is in the Ministry's exception. Since **no information** is given about the Ministry's exception in the options, **the only clear disqualifier is the absence of a license**.  \n\nHowever, **options a and b** do **not** explicitly state whether the places are licensed pharmacies. This ambiguity makes it difficult to definitively rule them out. **Options c and d**, on the other hand, are **clearly associated with licensed pharmacies** (as hospitals and clinics have licensed pharmacies).  \n\nThus, the **only option that cannot use the name** is **option b**, as it **lacks local permission** and **does not fall under the Ministry's exception** (which is not specified in the options).  \n\n**Answer:**  \n**b**"
    },
    {
      "question": "次のうち、医薬品の製造販売後安全管理に関する業務の遂行が法令に適合することを確保するための体制の記載として正しくないものを教えてください。",
      "choices": "a 製造販売業者等の役職員が遵守すべき規範を、社内規程において明確に定める\nb 適正に業務を遂行するための意思決定の仕組みを定める\nc 指揮命令権限を有する者、当該権限の範囲及び指揮命令の方法、並びに業務の手順等を明確にする\nd 一度導入した意思決定や業務遂行の仕組みについては、見直しを行わず恒久的に運用する",
      "correct_answer": "d",
      "predicted_answer": "d",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks for the **incorrect** statement regarding the establishment of systems to ensure compliance with post-marketing safety management laws.  \n2. The relevant provisions (e.g., [2] and [3]) emphasize the need for **dynamic and adaptable** systems, including mechanisms for **supervision, decision-making, and continuous improvement**.  \n3. **Option a** is correct because defining internal rules aligns with ensuring compliance.  \n4. **Option b** is correct as establishing decision-making mechanisms supports proper business execution.  \n5. **Option c** is correct because clarifying authority and procedures ensures accountability.  \n6. **Option d** is incorrect because it contradicts the legal requirement for **periodic review and adjustment** of systems. The law implies that systems must be updated as needed, not left unchanged indefinitely.  \n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第4章_選択式_関連法令_問題番号32",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the **incorrect** statement regarding the establishment of systems to ensure compliance with post-marketing safety management laws.  \n2. The relevant provisions (e.g., [2] and [3]) emphasize the need for **dynamic and adaptable** systems, including mechanisms for **supervision, decision-making, and continuous improvement**.  \n3. **Option a** is correct because defining internal rules aligns with ensuring compliance.  \n4. **Option b** is correct as establishing decision-making mechanisms supports proper business execution.  \n5. **Option c** is correct because clarifying authority and procedures ensures accountability.  \n6. **Option d** is incorrect because it contradicts the legal requirement for **periodic review and adjustment** of systems. The law implies that systems must be updated as needed, not left unchanged indefinitely.  \n\nAnswer: d"
    },
    {
      "question": "次のうち、医薬品の製造販売許可の申請書に氏名を記載する「薬事に関する業務に責任を有する役員」に該当するものを教えてください。",
      "choices": "a 指名委員会等設置会社以外の株式会社の監査役\nb 指名委員会等設置会社以外の株式会社の薬事に関する法令に関する業務を担当しない取締役\nc 指名委員会等設置会社の執行役員\nd 持分会社の会社を代表する社員",
      "correct_answer": "d",
      "predicted_answer": "c",
      "is_correct": false,
      "response": "Reasoning: The question asks which role qualifies as the \"person in charge of pharmaceutical affairs\" required in the application for a pharmaceutical manufacturing/sales permit. The legal provisions (1, 2, 3) all specify that if the applicant is a corporation, the name of the **officer (役員)** responsible for pharmaceutical-related business must be listed. The key requirement is that the officer must have **responsibility for pharmaceutical affairs**.\n\n- **Option a** refers to an **auditor (監査役)** of a non-naming committee company. Auditors are not part of the management and typically have oversight roles, not operational responsibility. Thus, they are unlikely to be the officer responsible for pharmaceutical affairs.\n- **Option b** describes a **director (取締役)** who does **not** handle pharmaceutical affairs. Since the officer must have **responsibility** for pharmaceutical business, this option is explicitly incorrect.\n- **Option c** refers to an **executive officer (執行役員)** of a naming committee company. In Japanese corporate law, executive officers are part of the management and may be responsible for specific business areas. If the company is involved in pharmaceutical affairs, the executive officer could be the designated officer. While the option does not explicitly state that the officer is responsible for pharmaceutical affairs, the term \"執行役員\" (executive officer) in naming committee companies (which are typically public companies) is more likely to align with the role of someone directly managing the business, including pharmaceutical affairs.\n- **Option d** refers to a **representative of a holding company (持分会社)**. However, the representative of a holding company may not necessarily be involved in the pharmaceutical business of the applicant company, unless explicitly stated. The provision requires **responsibility for pharmaceutical affairs**, which is not guaranteed by being a representative of a holding company.\n\nThus, **Option c** is the most plausible answer, as it aligns with the role of an executive officer in a naming committee company, which is more likely to involve direct management of pharmaceutical affairs.\n\nAnswer: c",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第4章_選択式_関連法令_問題番号33",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145"
      ],
      "reasoning": "Reasoning: The question asks which role qualifies as the \"person in charge of pharmaceutical affairs\" required in the application for a pharmaceutical manufacturing/sales permit. The legal provisions (1, 2, 3) all specify that if the applicant is a corporation, the name of the **officer (役員)** responsible for pharmaceutical-related business must be listed. The key requirement is that the officer must have **responsibility for pharmaceutical affairs**.\n\n- **Option a** refers to an **auditor (監査役)** of a non-naming committee company. Auditors are not part of the management and typically have oversight roles, not operational responsibility. Thus, they are unlikely to be the officer responsible for pharmaceutical affairs.\n- **Option b** describes a **director (取締役)** who does **not** handle pharmaceutical affairs. Since the officer must have **responsibility** for pharmaceutical business, this option is explicitly incorrect.\n- **Option c** refers to an **executive officer (執行役員)** of a naming committee company. In Japanese corporate law, executive officers are part of the management and may be responsible for specific business areas. If the company is involved in pharmaceutical affairs, the executive officer could be the designated officer. While the option does not explicitly state that the officer is responsible for pharmaceutical affairs, the term \"執行役員\" (executive officer) in naming committee companies (which are typically public companies) is more likely to align with the role of someone directly managing the business, including pharmaceutical affairs.\n- **Option d** refers to a **representative of a holding company (持分会社)**. However, the representative of a holding company may not necessarily be involved in the pharmaceutical business of the applicant company, unless explicitly stated. The provision requires **responsibility for pharmaceutical affairs**, which is not guaranteed by being a representative of a holding company.\n\nThus, **Option c** is the most plausible answer, as it aligns with the role of an executive officer in a naming committee company, which is more likely to involve direct management of pharmaceutical affairs.\n\nAnswer: c"
    },
    {
      "question": "次のうち、医薬品の品質管理及び製造販売後安全管理を行う者として置かれる者（以下「総括製造販売責任者等」という。）の義務として正しいものを教えてください。",
      "choices": "a 認識した問題点について、製造販売業者等に対して一定の期間ごとにまとめて報告すれば、適時に報告する必要はない\nb 認識した問題点について、必要な改善のための措置を含む意見は述べてはならない\nc 関係する部門並びにその責任者及び担当者と密接な連携を図らなければならない\nd 製造販売業者等への意見申述は、原則として口頭で行う",
      "correct_answer": "c",
      "predicted_answer": "c",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks for the correct obligation of the \"総括製造販売責任者等\" (the person responsible for pharmaceutical quality management and post-marketing safety management).  \n2. The relevant provisions are **[1]** and **[2]**, which state that the responsible person must have the **necessary ability and experience** to perform their duties and comply with regulations. However, these provisions do not explicitly list specific obligations.  \n3. **[3]** mentions clarifying the authority of the responsible person, but this relates to **roles and responsibilities**, not direct obligations.  \n4. **Option c** (\"関係する部門並びにその責任者及び担当者と密接な連携を図らなければならない\") implies the need for **collaboration with relevant departments**, which aligns with the general understanding of quality management roles (e.g., ensuring compliance, addressing issues, and coordinating across departments). While not explicitly stated in the provided legal text, this is a **reasonable inference** based on the implied duties of a quality management role.  \n5. Other options are incorrect:  \n   - **a** contradicts the expectation of timely reporting (not periodic).  \n   - **b** is directly opposed to the role of providing improvement measures.  \n   - **d** is not supported by the law, as no method of communication is specified.  \n\nAnswer: c",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第4章_選択式_関連法令_問題番号34",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the correct obligation of the \"総括製造販売責任者等\" (the person responsible for pharmaceutical quality management and post-marketing safety management).  \n2. The relevant provisions are **[1]** and **[2]**, which state that the responsible person must have the **necessary ability and experience** to perform their duties and comply with regulations. However, these provisions do not explicitly list specific obligations.  \n3. **[3]** mentions clarifying the authority of the responsible person, but this relates to **roles and responsibilities**, not direct obligations.  \n4. **Option c** (\"関係する部門並びにその責任者及び担当者と密接な連携を図らなければならない\") implies the need for **collaboration with relevant departments**, which aligns with the general understanding of quality management roles (e.g., ensuring compliance, addressing issues, and coordinating across departments). While not explicitly stated in the provided legal text, this is a **reasonable inference** based on the implied duties of a quality management role.  \n5. Other options are incorrect:  \n   - **a** contradicts the expectation of timely reporting (not periodic).  \n   - **b** is directly opposed to the role of providing improvement measures.  \n   - **d** is not supported by the law, as no method of communication is specified.  \n\nAnswer: c"
    },
    {
      "question": "次のうち、正しいものを教えてください。",
      "choices": "a 医薬品の製造業の許可を受けていない者でも、業として、医薬品の製造ができる\nb 化粧品の製造業の許可を受けた者は、品質管理の方法が厚生労働省令で定める基準に適合しているかどうかについて、厚生労働大臣に対し、製造工程の区分ごとに、その確認を求めることができる\nc 厚生労働大臣は、医薬品の製造業の許可を受けている者から、品質管理の方法が厚生労働省令で定める基準に適合しているかどうかについて確認を求められたときは、必ず書面でなく実地による調査を行わなければならない\nd 基準確認証は、製造工程全体に対して一括して付与される",
      "correct_answer": "b",
      "predicted_answer": "b",
      "is_correct": true,
      "response": "Reasoning: The question asks about pharmaceutical and cosmetic regulations, but the provided legal provisions are unrelated to these areas (they pertain to ship stability, SME employment, and commercial street revitalization). None of the options (a–d) can be validated or refuted using the given legal texts. However, since the user expects an answer based on the provided provisions, and no relevant laws are included, the correct response is that **none of the options are supported by the given legal provisions**. Despite this, the question format implies a single correct answer must be selected, which suggests a possible error in the setup. If forced to choose based on standard Japanese law (not the provided texts), **option b** would be correct under the Pharmaceutical and Medical Devices Act, but this is outside the scope of the given provisions.\n\nAnswer: None of the options are supported by the provided legal provisions. However, if an answer must be selected despite this, **b** is likely correct under standard Japanese law (not reflected in the given texts).",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第4章_選択式_関連法令_問題番号35",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145"
      ],
      "reasoning": "Reasoning: The question asks about pharmaceutical and cosmetic regulations, but the provided legal provisions are unrelated to these areas (they pertain to ship stability, SME employment, and commercial street revitalization). None of the options (a–d) can be validated or refuted using the given legal texts. However, since the user expects an answer based on the provided provisions, and no relevant laws are included, the correct response is that **none of the options are supported by the given legal provisions**. Despite this, the question format implies a single correct answer must be selected, which suggests a possible error in the setup. If forced to choose based on standard Japanese law (not the provided texts), **option b** would be correct under the Pharmaceutical and Medical Devices Act, but this is outside the scope of the given provisions.\n\nAnswer: None of the options are supported by the provided legal provisions. However, if an answer must be selected despite this, **b** is likely correct under standard Japanese law (not reflected in the given texts)."
    },
    {
      "question": "次のうち、正しいものを教えてください。",
      "choices": "a 第十四条の承認の申請者が製造販売をしようとする物が、一定の要件を満たす場合には、その適正な使用の確保のために必要な条件及び三年を超えない範囲内の期限を付してその品目に係る同条の承認を与えることができる\nb 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第14条の２の２第1項に基づく承認を得るためには、同条第1項第1号に該当する場合には、同条第1項第2号や第３号に該当する必要はない\nc 医薬品として使用価値がないと推定される場合には、医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第14条の２の２第1項に基づく承認が与えられることはない\nd 厚生労働大臣は、薬事審議会の意見を聴いて、第十四条第一項の期限を一年を超えて延長する場合がある",
      "correct_answer": "c",
      "predicted_answer": "a",
      "is_correct": false,
      "response": "Reasoning: The question asks about provisions related to pharmaceuticals and medical devices, specifically referencing the Japanese Act on the Quality, Efficacy, and Safety of Pharmaceuticals and Medical Devices (e.g., \"第14条の２の２\"). However, the provided legal provisions [1][2][3] pertain to **ship stability rules**, **employment management for SMEs**, and **commercial street revitalization**, none of which are relevant to pharmaceutical regulations. Since the question's subject matter (pharmaceutical law) is entirely disconnected from the given legal texts, **none of the answer choices can be evaluated or validated** based on the provided provisions. The options (a–d) require knowledge of pharmaceutical law provisions not included in the question's legal text.\n\nAnswer: None of the options can be determined from the provided legal provisions. However, since the question requires selecting one of the choices, and the user may have intended to include the relevant law (which was omitted), the correct answer based on general knowledge of Japanese pharmaceutical law would be **c** (as it aligns with the principle that approval is not granted for substances deemed to have no medicinal value). But strictly based on the given provisions, **no answer is valid**. \n\n**Note**: The discrepancy between the question's subject matter and the provided legal text suggests a possible error in the question setup.",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第4章_選択式_関連法令_問題番号36",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145"
      ],
      "reasoning": "Reasoning: The question asks about provisions related to pharmaceuticals and medical devices, specifically referencing the Japanese Act on the Quality, Efficacy, and Safety of Pharmaceuticals and Medical Devices (e.g., \"第14条の２の２\"). However, the provided legal provisions [1][2][3] pertain to **ship stability rules**, **employment management for SMEs**, and **commercial street revitalization**, none of which are relevant to pharmaceutical regulations. Since the question's subject matter (pharmaceutical law) is entirely disconnected from the given legal texts, **none of the answer choices can be evaluated or validated** based on the provided provisions. The options (a–d) require knowledge of pharmaceutical law provisions not included in the question's legal text.\n\nAnswer: None of the options can be determined from the provided legal provisions. However, since the question requires selecting one of the choices, and the user may have intended to include the relevant law (which was omitted), the correct answer based on general knowledge of Japanese pharmaceutical law would be **c** (as it aligns with the principle that approval is not granted for substances deemed to have no medicinal value). But strictly based on the given provisions, **no answer is valid**. \n\n**Note**: The discrepancy between the question's subject matter and the provided legal text suggests a possible error in the question setup."
    },
    {
      "question": "次のうち、誤っているものを教えてください。",
      "choices": "a 製造販売の承認の際に、厚生労働大臣から新医薬品として指示された医薬品は、所定の期間内に申請して、厚生労働大臣の再審査を受けなければならない\nb 厚生労働大臣は、いかなる場合でも調査期間の延長はできない\nc 希少疾病用医薬品の調査期間は、その承認のあつた日後六年を超え十年を超えない範囲内において厚生労働大臣の指定する期間である\nd 再審査の申請は、申請書にその医薬品の使用成績に関する資料を添付して行わなければならない",
      "correct_answer": "b",
      "predicted_answer": "b",
      "is_correct": true,
      "response": "Reasoning:  \nThe question involves pharmaceutical regulations under Japanese law, but the provided legal provisions (Consumer Contract Law, Specific Commercial Transactions Law, and Agricultural Cooperative Law) are unrelated to pharmaceutical approvals or procedures. However, based on general knowledge of Japanese pharmaceutical law (e.g., the Pharmaceutical Affairs Act), the incorrect statement is **b**. The Ministry of Health, Labour and Welfare **can** extend the investigation period under certain conditions (e.g., for rare diseases or complex cases), so the claim that \"the Ministry cannot extend the investigation period in any case\" is false.  \n\nAnswer: b",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第4章_選択式_関連法令_問題番号37",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145"
      ],
      "reasoning": "Reasoning:  \nThe question involves pharmaceutical regulations under Japanese law, but the provided legal provisions (Consumer Contract Law, Specific Commercial Transactions Law, and Agricultural Cooperative Law) are unrelated to pharmaceutical approvals or procedures. However, based on general knowledge of Japanese pharmaceutical law (e.g., the Pharmaceutical Affairs Act), the incorrect statement is **b**. The Ministry of Health, Labour and Welfare **can** extend the investigation period under certain conditions (e.g., for rare diseases or complex cases), so the claim that \"the Ministry cannot extend the investigation period in any case\" is false.  \n\nAnswer: b"
    },
    {
      "question": "黄熱ワクチンが生物由来製品である根拠とは無関係の条文を教えてください。",
      "choices": "a 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律 第２条 第10項\nb 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律 第２条 第11項\nc 厚生労働大臣が指定する生物由来製品及び特定生物由来製品 第1号\nd 厚生労働大臣が指定する生物由来製品及び特定生物由来製品 別表第一",
      "correct_answer": "b",
      "predicted_answer": "b",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks for a legal provision **unrelated** to the basis for classifying the yellow fever vaccine as a \"biological product.\"  \n2. **Provision [1]** (PMD Act, Article 2, Paragraph 10) directly defines \"biological products\" and is central to determining whether a product (like the yellow fever vaccine) qualifies.  \n3. **Provision [2]** and **[3]** (Medica Act, Article 4, Paragraph 7) refine the definition by excluding products exclusively for animal use, further supporting the classification.  \n4. **Option a** (PMD Act, Article 2, Paragraph 10) is directly relevant, as it defines \"biological products.\"  \n5. **Option b** (PMD Act, Article 2, Paragraph 11) is **not mentioned** in the provided legal texts and does not relate to the definition of \"biological products.\" Since the question focuses on the basis for classification, **Option b** is unrelated.  \n6. **Options c and d** (references to the Minister's designation) are not explicitly provided in the legal texts but are logically connected to the definition process. However, the question explicitly asks for a **unrelated** provision, making **Option b** the correct answer.  \n\nAnswer: b",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第1章_選択式_根拠条文_問題番号26",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for a legal provision **unrelated** to the basis for classifying the yellow fever vaccine as a \"biological product.\"  \n2. **Provision [1]** (PMD Act, Article 2, Paragraph 10) directly defines \"biological products\" and is central to determining whether a product (like the yellow fever vaccine) qualifies.  \n3. **Provision [2]** and **[3]** (Medica Act, Article 4, Paragraph 7) refine the definition by excluding products exclusively for animal use, further supporting the classification.  \n4. **Option a** (PMD Act, Article 2, Paragraph 10) is directly relevant, as it defines \"biological products.\"  \n5. **Option b** (PMD Act, Article 2, Paragraph 11) is **not mentioned** in the provided legal texts and does not relate to the definition of \"biological products.\" Since the question focuses on the basis for classification, **Option b** is unrelated.  \n6. **Options c and d** (references to the Minister's designation) are not explicitly provided in the legal texts but are logically connected to the definition process. However, the question explicitly asks for a **unrelated** provision, making **Option b** the correct answer.  \n\nAnswer: b"
    },
    {
      "question": "地域連携薬局の認定を受けるための申請書の提出先について記載した条文を教えてください",
      "choices": "a 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律 第６条 の２第１項第２号\nb 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律 第６条の２第1項第３号\nc 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律 第６条の２第4項\nd 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律 第６条 の２第2項",
      "correct_answer": "d",
      "predicted_answer": "c",
      "is_correct": false,
      "response": "Reasoning: The question asks for the legal provision specifying the submission location for the application to obtain certification for a regional collaborative pharmacy. The provided legal text [3] states that for renewal of certification, the application must be submitted to the prefectural governor. However, the question is about the initial application, not renewal. The answer choices refer to the main law (法律), not the implementation rules (施行規則). Since the provided text does not directly address the initial application, but the options are all from the main law's Article 6-2, the correct answer must be inferred from the context. Among the options, only **c** (Article 6-2, 4th item) aligns with the requirement to submit to the prefectural governor, as implied by the implementation rules. \n\nAnswer: c",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第3章_選択式_根拠条文_問題番号29",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145"
      ],
      "reasoning": "Reasoning: The question asks for the legal provision specifying the submission location for the application to obtain certification for a regional collaborative pharmacy. The provided legal text [3] states that for renewal of certification, the application must be submitted to the prefectural governor. However, the question is about the initial application, not renewal. The answer choices refer to the main law (法律), not the implementation rules (施行規則). Since the provided text does not directly address the initial application, but the options are all from the main law's Article 6-2, the correct answer must be inferred from the context. Among the options, only **c** (Article 6-2, 4th item) aligns with the requirement to submit to the prefectural governor, as implied by the implementation rules. \n\nAnswer: c"
    },
    {
      "question": "次のうち、製造所における医薬品、医薬部外品又は化粧品の製造管理又は品質管理の方法が厚生労働省令で定める基準に適合している場合に交付される書面について記載した条文を教えてください。",
      "choices": "a 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第13条第1項\nb 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第14条の2第1項\nc 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第14条の2第2項\nd 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第14条の2第3項",
      "correct_answer": "d",
      "predicted_answer": "a",
      "is_correct": false,
      "response": "Reasoning: The question asks which legal provision mentions the document delivered when manufacturing or quality management methods comply with the standards. The provided legal provisions (all identical) describe the **investigation process** (written or on-site checks) required during confirmation of changes, but **do not mention the document itself**. The options (a–d) refer to different articles of the same law. Since none of the options directly address the document delivery (which is not covered in the given provisions), the correct answer is not listed among the choices. However, the question may be testing recognition that the provisions in the query (Article 14-7-2, 4) are **not** the ones that mention the document, and the options provided (a–d) are unrelated to the document's delivery. Thus, the answer must be inferred as **none of the options** are correct, but since this is not an option, the best interpretation is that the question is flawed or incomplete.  \n\nAnswer: None of the options (a–d) are correct based on the provided provisions. However, since this is not an available choice, the question may contain an error.",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第4章_選択式_根拠条文_問題番号35",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145"
      ],
      "reasoning": "Reasoning: The question asks which legal provision mentions the document delivered when manufacturing or quality management methods comply with the standards. The provided legal provisions (all identical) describe the **investigation process** (written or on-site checks) required during confirmation of changes, but **do not mention the document itself**. The options (a–d) refer to different articles of the same law. Since none of the options directly address the document delivery (which is not covered in the given provisions), the correct answer is not listed among the choices. However, the question may be testing recognition that the provisions in the query (Article 14-7-2, 4) are **not** the ones that mention the document, and the options provided (a–d) are unrelated to the document's delivery. Thus, the answer must be inferred as **none of the options** are correct, but since this is not an option, the best interpretation is that the question is flawed or incomplete.  \n\nAnswer: None of the options (a–d) are correct based on the provided provisions. However, since this is not an available choice, the question may contain an error."
    },
    {
      "question": "次のうち、医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第14条の2の２に定める期限を延長することができる旨を記載した条文を教えてください。",
      "choices": "a 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第14条の2の2第1項第1号\nb 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第14条の2の2第1項第2号\nc 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第14条の2の2第1項第3号\nd 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第14条の2の2第3項",
      "correct_answer": "d",
      "predicted_answer": "d",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks for the provision that allows the extension of the period specified in **Article 14-2-2** of the **Pharmaceutical and Medical Device Act (PMD Act)**.  \n2. The provided legal texts do not directly reference **Article 14-2-2** of the PMD Act. However, based on standard legal structures in Japanese law, provisions allowing extensions of deadlines or periods are often found in **subsequent paragraphs** (e.g., the third paragraph) of the same article, as they typically outline exceptions or special circumstances.  \n3. **Option d** refers to **Article 14-2-2, Paragraph 3**, which is the most likely location for a provision permitting an extension of the period. In contrast, **options a, b, and c** refer to **Paragraph 1, Items 1–3**, which are more likely to outline general requirements or conditions rather than exceptions or extensions.  \n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第4章_選択式_根拠条文_問題番号36",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the provision that allows the extension of the period specified in **Article 14-2-2** of the **Pharmaceutical and Medical Device Act (PMD Act)**.  \n2. The provided legal texts do not directly reference **Article 14-2-2** of the PMD Act. However, based on standard legal structures in Japanese law, provisions allowing extensions of deadlines or periods are often found in **subsequent paragraphs** (e.g., the third paragraph) of the same article, as they typically outline exceptions or special circumstances.  \n3. **Option d** refers to **Article 14-2-2, Paragraph 3**, which is the most likely location for a provision permitting an extension of the period. In contrast, **options a, b, and c** refer to **Paragraph 1, Items 1–3**, which are more likely to outline general requirements or conditions rather than exceptions or extensions.  \n\nAnswer: d"
    },
    {
      "question": "次のうち、希少疾病用医薬品として指定された医薬品について、厚生労働大臣の再審査を受けなければならない申請の期間について記載した条文を教えてください。",
      "choices": "a 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第14条第1項\nb 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第14条の4第1項第1号\nc 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第14条の4第3項\nd 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第14条の4第4項",
      "correct_answer": "b",
      "predicted_answer": "c",
      "is_correct": false,
      "response": "Reasoning: The question asks for the legal provision specifying the period for applying for re-examination by the Minister of Health, Labour and Welfare for a rare disease drug. The relevant provision is [3], which is **Article 14_4, paragraph 2** of the law. This provision states that applicants who received conditional approval must apply for re-examination within a specified period. However, the provided choices do not include **Article 14_4, paragraph 2** (option [3] in the text). Among the given choices, **option c** (Article 14_4, paragraph 3) is the only one related to re-examination, though it addresses **extending** the review period (up to 12 years) rather than the **initial application period**. Since the question explicitly asks for the **period for applying**, and none of the choices directly match the correct provision, there may be an error in the options. However, **option c** is the closest to the topic of re-examination, even if it does not precisely answer the question. \n\nAnswer: c",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第4章_選択式_根拠条文_問題番号37",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145"
      ],
      "reasoning": "Reasoning: The question asks for the legal provision specifying the period for applying for re-examination by the Minister of Health, Labour and Welfare for a rare disease drug. The relevant provision is [3], which is **Article 14_4, paragraph 2** of the law. This provision states that applicants who received conditional approval must apply for re-examination within a specified period. However, the provided choices do not include **Article 14_4, paragraph 2** (option [3] in the text). Among the given choices, **option c** (Article 14_4, paragraph 3) is the only one related to re-examination, though it addresses **extending** the review period (up to 12 years) rather than the **initial application period**. Since the question explicitly asks for the **period for applying**, and none of the choices directly match the correct provision, there may be an error in the options. However, **option c** is the closest to the topic of re-examination, even if it does not precisely answer the question. \n\nAnswer: c"
    },
    {
      "question": "次のうち、金融商品取引法第5条第１項に基づく届書の提出が必要となる有価証券の募集又は売出しを教えてください。",
      "choices": "a 金融商品取引法第2条第1項第10号に掲げる有価証券の募集又は売出し\nb 金融商品取引法第2条第1項第14号に掲げる有価証券で、有価証券信託受益証券に該当するもの募集又は売出し\nc 金融商品取引法第2条第1項第13号に掲げる有価証券の募集又は売出し\nd 金融商品取引法第2条第1項第4号に掲げる有価証券の募集又は売出し",
      "correct_answer": "b",
      "predicted_answer": "a",
      "is_correct": false,
      "response": "Reasoning:  \n1. The question asks which type of securities issuance or sale requires submission under **Article 5, Paragraph 1** of the **Financial Instruments and Exchange Act (FIEA)**. This provision mandates the submission of a prospectus for certain public offerings of securities.  \n2. The relevant legal provisions (from the **FIEA Implementation Order, Article 20, Paragraph 2, Item 1**) reference **Article 5, Paragraph 1** of the FIEA and **Article 21, Paragraph 4** (which governs principal underwriting agreements). These provisions apply to securities offerings that require a prospectus submission.  \n3. **Article 2, Paragraph 1** of the FIEA categorizes securities. Key categories include:  \n   - **Item 10**: Investment trust shares (e.g., shares of investment trusts).  \n   - **Item 13**: Investment company securities (e.g., shares of investment companies).  \n   - **Item 14**: Trust beneficiary securities (e.g., beneficiary certificates of trust funds).  \n   - **Item 4**: Corporate bonds (e.g., bonds issued by corporations).  \n4. **Analysis of choices**:  \n   - **Option a (Item 10)**: Investment trust shares are **explicitly subject to the FIEA's registration requirements**. Public offerings of these shares require a prospectus under Article 5, Paragraph 1.  \n   - **Option b (Item 14)**: Trust beneficiary securities may be exempt if the trust is already registered under the FIEA, so they may not require a prospectus.  \n   - **Option c (Item 13)**: Investment company securities are also subject to registration, but the question may prioritize **Item 10** as the most direct example.  \n   - **Option d (Item 4)**: Corporate bonds are generally **not subject to the same registration requirements** unless they are public offerings, but they are typically exempt.  \n5. **Conclusion**: **Option a** (investment trust shares) is the clearest example of securities requiring a prospectus submission under Article 5, Paragraph 1 of the FIEA.  \n\nAnswer: a",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第2章_選択式_関連法令_問題番号10",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/340CO0000000321"
      ],
      "reasoning": "Reasoning:  \n1. The question asks which type of securities issuance or sale requires submission under **Article 5, Paragraph 1** of the **Financial Instruments and Exchange Act (FIEA)**. This provision mandates the submission of a prospectus for certain public offerings of securities.  \n2. The relevant legal provisions (from the **FIEA Implementation Order, Article 20, Paragraph 2, Item 1**) reference **Article 5, Paragraph 1** of the FIEA and **Article 21, Paragraph 4** (which governs principal underwriting agreements). These provisions apply to securities offerings that require a prospectus submission.  \n3. **Article 2, Paragraph 1** of the FIEA categorizes securities. Key categories include:  \n   - **Item 10**: Investment trust shares (e.g., shares of investment trusts).  \n   - **Item 13**: Investment company securities (e.g., shares of investment companies).  \n   - **Item 14**: Trust beneficiary securities (e.g., beneficiary certificates of trust funds).  \n   - **Item 4**: Corporate bonds (e.g., bonds issued by corporations).  \n4. **Analysis of choices**:  \n   - **Option a (Item 10)**: Investment trust shares are **explicitly subject to the FIEA's registration requirements**. Public offerings of these shares require a prospectus under Article 5, Paragraph 1.  \n   - **Option b (Item 14)**: Trust beneficiary securities may be exempt if the trust is already registered under the FIEA, so they may not require a prospectus.  \n   - **Option c (Item 13)**: Investment company securities are also subject to registration, but the question may prioritize **Item 10** as the most direct example.  \n   - **Option d (Item 4)**: Corporate bonds are generally **not subject to the same registration requirements** unless they are public offerings, but they are typically exempt.  \n5. **Conclusion**: **Option a** (investment trust shares) is the clearest example of securities requiring a prospectus submission under Article 5, Paragraph 1 of the FIEA.  \n\nAnswer: a"
    },
    {
      "question": "金融商品取引法第３条第１項の規定により、第２章の規定が適用されない有価証券として、誤っているものを教えてください。",
      "choices": "a 国債証券及び地方債証券\nb 金融商品取引法第２条第２項の規定により有価証券とみなされる同項各号に掲げる権利で、金融商品取引法第３条第３号イ及びロに掲げるものを除いたもの\nc 医療法（昭和二十三年法律第二百五号）に規定する社会医療法人債券\nd 政府が元本の償還及び利息の支払について保証している社債券",
      "correct_answer": "c",
      "predicted_answer": "c",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks for the **incorrect** example of a security not subject to Chapter 2 of the Financial Instruments and Exchange Act (FIEA), based on FIEA Article 3, Paragraph 1.  \n2. **FIEA Article 3, Paragraph 1** typically lists exceptions where Chapter 2 provisions do not apply. Common exceptions include government bonds (国債), local government bonds (地方債), and certain other securities explicitly excluded by law.  \n3. **Option a** (国債証券及び地方債証券) is a standard exception and is **correct**.  \n4. **Option b** refers to securities deemed under FIEA Article 2, Paragraph 2, excluding those in Article 3, Paragraph 3, items i and ro. This aligns with the structure of exceptions in FIEA Article 3, Paragraph 1, making it **correct**.  \n5. **Option d** (政府が元本の償還及び利息の支払について保証している社債券) involves government-guaranteed corporate bonds. These are **not** explicitly excluded under FIEA Article 3, Paragraph 1 and remain subject to Chapter 2 provisions. However, the question focuses on **which is incorrect**, and **Option c** is more clearly not an exception.  \n6. **Option c** (医療法に規定する社会医療法人債券) refers to bonds issued by social medical corporations under the Medical Care Act. These are **not** listed as exceptions in FIEA Article 3, Paragraph 1 and are therefore **subject to Chapter 2 provisions**, making this the **incorrect** example of an exception.  \n\nAnswer: c",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第2章_選択式_関連法令_問題番号11",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/340CO0000000321"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the **incorrect** example of a security not subject to Chapter 2 of the Financial Instruments and Exchange Act (FIEA), based on FIEA Article 3, Paragraph 1.  \n2. **FIEA Article 3, Paragraph 1** typically lists exceptions where Chapter 2 provisions do not apply. Common exceptions include government bonds (国債), local government bonds (地方債), and certain other securities explicitly excluded by law.  \n3. **Option a** (国債証券及び地方債証券) is a standard exception and is **correct**.  \n4. **Option b** refers to securities deemed under FIEA Article 2, Paragraph 2, excluding those in Article 3, Paragraph 3, items i and ro. This aligns with the structure of exceptions in FIEA Article 3, Paragraph 1, making it **correct**.  \n5. **Option d** (政府が元本の償還及び利息の支払について保証している社債券) involves government-guaranteed corporate bonds. These are **not** explicitly excluded under FIEA Article 3, Paragraph 1 and remain subject to Chapter 2 provisions. However, the question focuses on **which is incorrect**, and **Option c** is more clearly not an exception.  \n6. **Option c** (医療法に規定する社会医療法人債券) refers to bonds issued by social medical corporations under the Medical Care Act. These are **not** listed as exceptions in FIEA Article 3, Paragraph 1 and are therefore **subject to Chapter 2 provisions**, making this the **incorrect** example of an exception.  \n\nAnswer: c"
    },
    {
      "question": "金融商品取引法第156条の38及び第156条の42により、指定紛争解決機関が行う紛争解決業務として、正しいものを教えてください。",
      "choices": "a 苦情処理手続、紛争解決手続及び訴訟手続\nb 紛争解決手続及び訴訟\nc 苦情処理手続及び紛争解決手続\nd 苦情処理手続、紛争解決手続及び調停",
      "correct_answer": "c",
      "predicted_answer": "c",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks for the correct dispute resolution procedures under the Financial Instruments and Exchange Act, referencing Articles 156-38 and 156-42.  \n2. **Provision [3]** (Article 156-44, 2nd paragraph, 1st item) explicitly states that designated dispute resolution institutions must initiate **complaint handling procedures** (苦情処理手続) or **dispute resolution procedures** (紛争解決手続) based on customer complaints or party applications.  \n3. **Provision [2]** (Article 156-45, 2nd paragraph) emphasizes prevention and resolution of disputes through consultation and information provision but does not mention litigation or mediation.  \n4. **Provision [1]** (Article 156-50, 1st paragraph) requires written explanations for customers but does not introduce new procedures.  \n5. **Analysis of choices**:  \n   - **Option a** and **b** include \"litigation\" (訴訟), which is not mentioned in the provided provisions.  \n   - **Option d** includes \"mediation\" (調停), which is not referenced in the given legal text.  \n   - **Option c** (苦情処理手続及び紛争解決手続) directly aligns with the procedures explicitly outlined in **Provision [3]**.  \n\nAnswer: c",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第5章の5_選択式_関連法令_問題番号20",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the correct dispute resolution procedures under the Financial Instruments and Exchange Act, referencing Articles 156-38 and 156-42.  \n2. **Provision [3]** (Article 156-44, 2nd paragraph, 1st item) explicitly states that designated dispute resolution institutions must initiate **complaint handling procedures** (苦情処理手続) or **dispute resolution procedures** (紛争解決手続) based on customer complaints or party applications.  \n3. **Provision [2]** (Article 156-45, 2nd paragraph) emphasizes prevention and resolution of disputes through consultation and information provision but does not mention litigation or mediation.  \n4. **Provision [1]** (Article 156-50, 1st paragraph) requires written explanations for customers but does not introduce new procedures.  \n5. **Analysis of choices**:  \n   - **Option a** and **b** include \"litigation\" (訴訟), which is not mentioned in the provided provisions.  \n   - **Option d** includes \"mediation\" (調停), which is not referenced in the given legal text.  \n   - **Option c** (苦情処理手続及び紛争解決手続) directly aligns with the procedures explicitly outlined in **Provision [3]**.  \n\nAnswer: c"
    },
    {
      "question": "金融商品取引法第166条第1項により、「売買等」に該当するものを教えてください。",
      "choices": "a 上場会社等の特定有価証券等に係る無償の譲渡\nb 上場会社等の特定有価証券等に係る有償の譲受け\nc 上場会社等以外の会社の特定有価証券等に係る売買\nd 上場会社等の特定有価証券等の相続による承継",
      "correct_answer": "b",
      "predicted_answer": "b",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks which option qualifies as \"売買等\" under the Financial Instruments and Exchange Act Article 166, Paragraph 1.  \n2. The provided legal provisions include definitions from the Special Account Law (Article 71-3) and the Tax Special Measures Act Implementation Order (Article 25_13_8). However, these do not directly address the definition of \"売買等\" in the Financial Instruments and Exchange Act.  \n3. In general Japanese law, \"売買等\" typically refers to transactions involving the purchase and sale of financial instruments, including paid transfers (有償の譲受け). Free transfers (無償の譲渡, option a) or inheritance (相続による承継, option d) are not considered \"売買\" but may fall under other categories.  \n4. Option c involves non-listed companies, but the question does not specify that non-listed companies are excluded. However, the key distinction lies in whether the transaction is paid or not.  \n5. Based on standard interpretations, **paid transfers (option b)** are most likely to be classified as \"売買等\" under the Financial Instruments and Exchange Act.  \n\nAnswer: b",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第6章_選択式_関連法令_問題番号21",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025"
      ],
      "reasoning": "Reasoning:  \n1. The question asks which option qualifies as \"売買等\" under the Financial Instruments and Exchange Act Article 166, Paragraph 1.  \n2. The provided legal provisions include definitions from the Special Account Law (Article 71-3) and the Tax Special Measures Act Implementation Order (Article 25_13_8). However, these do not directly address the definition of \"売買等\" in the Financial Instruments and Exchange Act.  \n3. In general Japanese law, \"売買等\" typically refers to transactions involving the purchase and sale of financial instruments, including paid transfers (有償の譲受け). Free transfers (無償の譲渡, option a) or inheritance (相続による承継, option d) are not considered \"売買\" but may fall under other categories.  \n4. Option c involves non-listed companies, but the question does not specify that non-listed companies are excluded. However, the key distinction lies in whether the transaction is paid or not.  \n5. Based on standard interpretations, **paid transfers (option b)** are most likely to be classified as \"売買等\" under the Financial Instruments and Exchange Act.  \n\nAnswer: b"
    },
    {
      "question": "記載すべき重要な事項の記載が欠けている発行開示書類を提出した発行者が、当該発行開示書類に基づく募集により株券を取得させたとき、当該発行者において、国庫に納付しなければならない課徴金の額はいくらか、教えてください。",
      "choices": "a 当該取得させた有価証券の発行価額の総額の百分の二・二五に相当する額\nb 当該取得させた有価証券の発行価額の総額の百分の四・五に相当する額\nc 当該取得させた有価証券の発行価額の総額の二・二五倍に相当する額\nd 当該取得させた有価証券の発行価額の総額の四・五倍に相当する額",
      "correct_answer": "b",
      "predicted_answer": "b",
      "is_correct": true,
      "response": "Reasoning: The question asks about the penalty (課徴金) that the issuer (発行者) must pay when they submit an incomplete disclosure document and issue shares (株券を取得させた). However, the relevant legal provision (金融商品取引法第172_2条第2項) specifically targets the **officers or employees** (役員等) of the issuer who **sold their own securities** (有価証券を売り付けた) after participating in the submission of an incomplete disclosure document. The provision does **not** impose a penalty on the issuer itself for the incomplete disclosure, but rather on the officers or employees who sold their own securities. \n\nThe options provided (a, b, c, d) all reference percentages (2.25% or 4.5%) derived from the provision, but these percentages apply **only** to the officers or employees who sold their own securities, not to the issuer. Since the question explicitly refers to the **issuer** (発行者) and not the officers, the legal provision does **not** apply to the issuer in this context. However, the options do not include a choice indicating that the issuer is not subject to the penalty under this provision. \n\nGiven the ambiguity in the question and the assumption that the intended focus is on the **officers** (despite the wording referring to the issuer), the penalty for **stock certificates** (株券等) is **4.5%** (option b), as specified in the provision. This is the only option that aligns with the percentages in the legal text, even though the application to the issuer is not explicitly covered by the provision.\n\nAnswer: b",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第6章の2_選択式_関連法令_問題番号22",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025"
      ],
      "reasoning": "Reasoning: The question asks about the penalty (課徴金) that the issuer (発行者) must pay when they submit an incomplete disclosure document and issue shares (株券を取得させた). However, the relevant legal provision (金融商品取引法第172_2条第2項) specifically targets the **officers or employees** (役員等) of the issuer who **sold their own securities** (有価証券を売り付けた) after participating in the submission of an incomplete disclosure document. The provision does **not** impose a penalty on the issuer itself for the incomplete disclosure, but rather on the officers or employees who sold their own securities. \n\nThe options provided (a, b, c, d) all reference percentages (2.25% or 4.5%) derived from the provision, but these percentages apply **only** to the officers or employees who sold their own securities, not to the issuer. Since the question explicitly refers to the **issuer** (発行者) and not the officers, the legal provision does **not** apply to the issuer in this context. However, the options do not include a choice indicating that the issuer is not subject to the penalty under this provision. \n\nGiven the ambiguity in the question and the assumption that the intended focus is on the **officers** (despite the wording referring to the issuer), the penalty for **stock certificates** (株券等) is **4.5%** (option b), as specified in the provision. This is the only option that aligns with the percentages in the legal text, even though the application to the issuer is not explicitly covered by the provision.\n\nAnswer: b"
    },
    {
      "question": "金融商品取引法第185条の22の規定に抵触する行為を教えてください。",
      "choices": "a 暗号等資産関連デリバティブ取引等を誘引する目的をもって、金銭を取得すること\nb 暗号等資産関連デリバティブ取引等について、重要でない事項についてのみ虚偽の表示がある文書を使用して金銭を取得すること\nc 暗号等資産の売買を誘引する目的なく、虚偽の相場を利用すること\nd 暗号等資産関連金融指標に係るデリバティブ取引等について、不正の計画をすること",
      "correct_answer": "d",
      "predicted_answer": "b",
      "is_correct": false,
      "response": "Reasoning:  \n1. The question asks which behavior violates **Financial Instruments and Exchange Act (FIEA) Article 185-22**.  \n2. The provided legal provisions reference **FIEA Articles 38 and 39**, which pertain to prohibited acts such as providing false information or failing to disclose required information. However, the question specifically targets **Article 185-22**, which is not explicitly detailed in the given provisions.  \n3. Based on general knowledge of the FIEA, **Article 185-22** prohibits acts involving **fraudulent or deceptive practices**, including the provision of **false information** or **misleading statements** in connection with financial instruments.  \n4. **Option b** states: *\"Using documents with false information on non-essential matters to obtain money for crypto-related derivatives.\"* While the false information pertains to \"non-essential matters,\" the FIEA generally prohibits **any** false or misleading information that could mislead investors, regardless of whether the matter is essential. This aligns with the prohibition under Article 185-22.  \n5. Other options (a, c, d) involve acts that may relate to other provisions (e.g., inducement, market manipulation, or dishonest plans), but **option b** directly involves **false information**, which is a core focus of Article 185-22.  \n\nAnswer: **b**",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第6章の3_選択式_関連法令_問題番号23",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025"
      ],
      "reasoning": "Reasoning:  \n1. The question asks which behavior violates **Financial Instruments and Exchange Act (FIEA) Article 185-22**.  \n2. The provided legal provisions reference **FIEA Articles 38 and 39**, which pertain to prohibited acts such as providing false information or failing to disclose required information. However, the question specifically targets **Article 185-22**, which is not explicitly detailed in the given provisions.  \n3. Based on general knowledge of the FIEA, **Article 185-22** prohibits acts involving **fraudulent or deceptive practices**, including the provision of **false information** or **misleading statements** in connection with financial instruments.  \n4. **Option b** states: *\"Using documents with false information on non-essential matters to obtain money for crypto-related derivatives.\"* While the false information pertains to \"non-essential matters,\" the FIEA generally prohibits **any** false or misleading information that could mislead investors, regardless of whether the matter is essential. This aligns with the prohibition under Article 185-22.  \n5. Other options (a, c, d) involve acts that may relate to other provisions (e.g., inducement, market manipulation, or dishonest plans), but **option b** directly involves **false information**, which is a core focus of Article 185-22.  \n\nAnswer: **b**"
    },
    {
      "question": "金商法第2条第3項に規定する電子記録移転権利の説明として、正しいものを教えてください。",
      "choices": "a 契約上又は実態上、電子帳簿の書換え（財産的価値の移転）と権利の移転が一連として行われる場合には、必ず電子記録移転権利に該当する。\nb 電子帳簿の書換え（財産的価値の移転）と権利の移転が一連として行われる場合には、その電子帳簿が発行者等の内部で事務的に作成されているものにすぎず、取引の当事者又は媒介者が当該電子帳簿を参照することができないなど売主の権利保有状況を知り得る状態にない場合であっても、基本的に、電子記録移転権利に該当する。\nc 契約上又は実態上、電子帳簿の書換え（財産的価値の移転）と権利の移転が一連として行われる場合でも、必ずしも電子記録移転権利に該当するとは限らない。\nd 電子帳簿の書換え（財産的価値の移転）と権利の移転が一連として行われない場合でも、基本的に、電子記録移転権利に該当する。",
      "correct_answer": "c",
      "predicted_answer": "c",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks for the correct description of \"電子記録移転権利\" (electronic record transfer rights) under the Financial Instruments and Exchange Act (金商法).  \n2. The relevant provisions are [1] and [2]. [1] defines electronic record transfer rights as those under Article 2, Paragraph 2, Item 4 of the Act, which are considered securities. [2] clarifies that specific securities (excluding electronic record transfer rights) are rights under Article 2, Paragraph 2.  \n3. The key issue is whether the simultaneous transfer of electronic records (book entry) and rights automatically qualifies as an electronic record transfer right.  \n   - **Option a** claims it \"must\" qualify, but the law does not explicitly state this.  \n   - **Option b** assumes it qualifies even if the electronic record is not accessible to parties, but this ignores the requirement for proper system structure (e.g., book-entry systems).  \n   - **Option c** states that even if the two transfers occur together, it is \"not necessarily\" an electronic record transfer right. This aligns with the law’s focus on structural requirements (e.g., proper book-entry systems) rather than mere simultaneity.  \n   - **Option d** incorrectly claims that the absence of simultaneous transfer still qualifies, which contradicts the definition.  \n4. The law emphasizes that electronic record transfer rights require a structured system where the electronic record directly reflects ownership (e.g., book-entry systems). Thus, **simultaneity alone is insufficient** to classify a right as an electronic record transfer right.  \n\nAnswer: c",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第1章_選択式_関連法令_問題番号24",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the correct description of \"電子記録移転権利\" (electronic record transfer rights) under the Financial Instruments and Exchange Act (金商法).  \n2. The relevant provisions are [1] and [2]. [1] defines electronic record transfer rights as those under Article 2, Paragraph 2, Item 4 of the Act, which are considered securities. [2] clarifies that specific securities (excluding electronic record transfer rights) are rights under Article 2, Paragraph 2.  \n3. The key issue is whether the simultaneous transfer of electronic records (book entry) and rights automatically qualifies as an electronic record transfer right.  \n   - **Option a** claims it \"must\" qualify, but the law does not explicitly state this.  \n   - **Option b** assumes it qualifies even if the electronic record is not accessible to parties, but this ignores the requirement for proper system structure (e.g., book-entry systems).  \n   - **Option c** states that even if the two transfers occur together, it is \"not necessarily\" an electronic record transfer right. This aligns with the law’s focus on structural requirements (e.g., proper book-entry systems) rather than mere simultaneity.  \n   - **Option d** incorrectly claims that the absence of simultaneous transfer still qualifies, which contradicts the definition.  \n4. The law emphasizes that electronic record transfer rights require a structured system where the electronic record directly reflects ownership (e.g., book-entry systems). Thus, **simultaneity alone is insufficient** to classify a right as an electronic record transfer right.  \n\nAnswer: c"
    },
    {
      "question": "トークン化された合同会社等の社員権が電子記録移転権利となるか否かの説明について、正しいものを教えてください。",
      "choices": "a トークン化された合同会社等の社員権は、原則として、電子記録移転権利とならない\nb トークン化された合同会社等の社員権は、常に電子記録移転権利となる\nc 金融商品取引法第二条に規定する定義に関する内閣府令第9条の2第1項第2号ロに該当する場合は、電子記録移転債権とならない\nd トークン化された合同会社等の社員権は、電子記録移転権利とはなり得ない",
      "correct_answer": "c",
      "predicted_answer": "a",
      "is_correct": false,
      "response": "Reasoning:  \n1. The question asks whether tokenized membership rights in a contract company (e.g., a joint-stock company) are considered **electronic record transfer rights** under Japanese law.  \n2. **Relevant provisions**:  \n   - **[1]** and **[2]** define conditions under which certain rights (e.g., membership rights) are classified as **electronic record transfer rights** (a type of **security** under the Financial Instruments and Exchange Act).  \n   - **[1]** specifies that rights held by members of a company conducting business are considered securities **only if** they are **electronic record transfer rights**.  \n   - **[2]** clarifies that **membership rights** of a company using **over 50% of its capital for investment in securities** are classified as **electronic record transfer rights**.  \n3. **Analysis of choices**:  \n   - **Option a**: \"Tokenized membership rights are **principally not** electronic record transfer rights.\"  \n     - This is **correct** because **[2]** requires the company to use **over 50% of its capital for investment in securities** for the membership rights to qualify. If this condition is not met (which is likely the **principle** case), the rights are **not** classified as electronic record transfer rights.  \n   - **Option b**: \"They are **always** electronic record transfer rights.\"  \n     - Incorrect, as the classification depends on the **50% capital condition**.  \n   - **Option c**: References **Article 9-2**, which is **not provided** in the legal texts. This makes the option **irrelevant** and **incorrect**.  \n   - **Option d**: \"They **cannot** be electronic record transfer rights.\"  \n     - Incorrect, as **[2]** explicitly allows for such classification **if** the 50% condition is met.  \n\nAnswer: **a**",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第1章_選択式_関連法令_問題番号25",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025"
      ],
      "reasoning": "Reasoning:  \n1. The question asks whether tokenized membership rights in a contract company (e.g., a joint-stock company) are considered **electronic record transfer rights** under Japanese law.  \n2. **Relevant provisions**:  \n   - **[1]** and **[2]** define conditions under which certain rights (e.g., membership rights) are classified as **electronic record transfer rights** (a type of **security** under the Financial Instruments and Exchange Act).  \n   - **[1]** specifies that rights held by members of a company conducting business are considered securities **only if** they are **electronic record transfer rights**.  \n   - **[2]** clarifies that **membership rights** of a company using **over 50% of its capital for investment in securities** are classified as **electronic record transfer rights**.  \n3. **Analysis of choices**:  \n   - **Option a**: \"Tokenized membership rights are **principally not** electronic record transfer rights.\"  \n     - This is **correct** because **[2]** requires the company to use **over 50% of its capital for investment in securities** for the membership rights to qualify. If this condition is not met (which is likely the **principle** case), the rights are **not** classified as electronic record transfer rights.  \n   - **Option b**: \"They are **always** electronic record transfer rights.\"  \n     - Incorrect, as the classification depends on the **50% capital condition**.  \n   - **Option c**: References **Article 9-2**, which is **not provided** in the legal texts. This makes the option **irrelevant** and **incorrect**.  \n   - **Option d**: \"They **cannot** be electronic record transfer rights.\"  \n     - Incorrect, as **[2]** explicitly allows for such classification **if** the 50% condition is met.  \n\nAnswer: **a**"
    },
    {
      "question": "違反者が有価証券の売付け又は有価証券の買付け等をした場合、金融商品取引法第173条第5項に基づき、自己の計算においてしたものとみなされる場合として、正しいものを教えてください。",
      "choices": "a 違反者の関連会社\nb 違反者の子会社の取引先\nc 違反者と同一の親会社をもつ会社\nd 違反者の親会社の従業員",
      "correct_answer": "c",
      "predicted_answer": "a",
      "is_correct": false,
      "response": "Reasoning: The question asks which entity is considered as having conducted a transaction under the investor's own calculation under Article 173, Paragraph 5 of the Financial Instruments and Exchange Act. The provided legal provisions (all identical) relate to the calculation of amounts for violations under Article 174-3, but the key principle is that affiliated entities (e.g., subsidiaries, parent companies, or companies under the same parent) are treated as part of the same group for regulatory purposes. \n\n- **Option a (related company)**: In Japanese law, \"related companies\" (関連会社) typically include entities under common control, such as subsidiaries or parent companies. These are explicitly considered part of the same group for regulatory calculations, aligning with the principle that transactions by affiliated entities are treated as the investor's own.  \n- **Option b (subsidiary's business partner)**: Not part of the same group, so not considered.  \n- **Option c (same parent company)**: While this would be a sibling company, the term \"related company\" (option a) is broader and more directly tied to the legal framework.  \n- **Option d (parent company's employee)**: Not a company, so irrelevant.  \n\nThus, **option a** is the correct answer as it directly corresponds to the legal principle of treating affiliated entities as part of the same calculation.  \n\nAnswer: a",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第6章の2_選択式_関連法令_問題番号26",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025"
      ],
      "reasoning": "Reasoning: The question asks which entity is considered as having conducted a transaction under the investor's own calculation under Article 173, Paragraph 5 of the Financial Instruments and Exchange Act. The provided legal provisions (all identical) relate to the calculation of amounts for violations under Article 174-3, but the key principle is that affiliated entities (e.g., subsidiaries, parent companies, or companies under the same parent) are treated as part of the same group for regulatory purposes. \n\n- **Option a (related company)**: In Japanese law, \"related companies\" (関連会社) typically include entities under common control, such as subsidiaries or parent companies. These are explicitly considered part of the same group for regulatory calculations, aligning with the principle that transactions by affiliated entities are treated as the investor's own.  \n- **Option b (subsidiary's business partner)**: Not part of the same group, so not considered.  \n- **Option c (same parent company)**: While this would be a sibling company, the term \"related company\" (option a) is broader and more directly tied to the legal framework.  \n- **Option d (parent company's employee)**: Not a company, so irrelevant.  \n\nThus, **option a** is the correct answer as it directly corresponds to the legal principle of treating affiliated entities as part of the same calculation.  \n\nAnswer: a"
    },
    {
      "question": "金融商品取引法第165条第1号の特定取引に該当するものを教えてください。",
      "choices": "a 特定有価証券の買付け\nb 特定有価証券の売買に係るオプションを表示する関連有価証券の売付けであって、当該オプションの行使により当該行使をした者が当該売買において買主としての地位を取得するもの\nc 特別有価証券の売付け\nd 特定有価証券の売買に係るオプションを表示する関連有価証券の買付けであって当該オプションの行使により当該行使をした者が当該売買において売主としての地位を取得しないもの",
      "correct_answer": "b",
      "predicted_answer": "b",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks which option falls under **Article 165, Paragraph 1, Item 1** of the Financial Instruments and Exchange Act. However, the provided legal provisions only include **Article 156_38, Paragraph 2**, which defines \"特定第一種金融商品取引業務\" (specific first-type financial instruments trading business). Since the critical text for Article 165 is not provided, the answer must be inferred based on standard interpretations of Japanese financial law and the structure of the options.  \n\n2. **Article 165, Paragraph 1, Item 1** typically refers to **specific transactions** involving **options** related to the **sale or purchase of specific securities** (特定有価証券). These transactions are subject to strict disclosure requirements under Japanese law.  \n\n3. **Option b** describes a scenario where an **option to sell specific securities** is exercised, and the **exerciser becomes the buyer** in the underlying transaction. This aligns with the definition of a \"specific transaction\" under Article 165, as it involves an **option tied to a sale** and the **acquisition of a buyer's position** upon exercise.  \n\n4. **Option d** involves a **buying option** where the exerciser does **not become a seller**, which does not directly match the typical structure of transactions regulated under Article 165.  \n\n5. **Options a and c** are too general or unrelated to the specific regulatory focus on **options** and **position changes** under Article 165.  \n\nAnswer: **b**",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第6章_選択式_関連法令_問題番号27",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/340CO0000000321"
      ],
      "reasoning": "Reasoning:  \n1. The question asks which option falls under **Article 165, Paragraph 1, Item 1** of the Financial Instruments and Exchange Act. However, the provided legal provisions only include **Article 156_38, Paragraph 2**, which defines \"特定第一種金融商品取引業務\" (specific first-type financial instruments trading business). Since the critical text for Article 165 is not provided, the answer must be inferred based on standard interpretations of Japanese financial law and the structure of the options.  \n\n2. **Article 165, Paragraph 1, Item 1** typically refers to **specific transactions** involving **options** related to the **sale or purchase of specific securities** (特定有価証券). These transactions are subject to strict disclosure requirements under Japanese law.  \n\n3. **Option b** describes a scenario where an **option to sell specific securities** is exercised, and the **exerciser becomes the buyer** in the underlying transaction. This aligns with the definition of a \"specific transaction\" under Article 165, as it involves an **option tied to a sale** and the **acquisition of a buyer's position** upon exercise.  \n\n4. **Option d** involves a **buying option** where the exerciser does **not become a seller**, which does not directly match the typical structure of transactions regulated under Article 165.  \n\n5. **Options a and c** are too general or unrelated to the specific regulatory focus on **options** and **position changes** under Article 165.  \n\nAnswer: **b**"
    },
    {
      "question": "金融商品取引法第167条第2項に定める公開買付け等の実施に関する事実に該当するものを教えてください。",
      "choices": "a 公開買付者等が、公開買付け等を行うことについての決定をしたこと。ただし、各年に買い集める株券等の数が当該株券等の発行者の総株主等の議決権の百分の二・〇である場合\nb 公開買付者等が、当該決定（公表がされていないもの）に係る公開買付け等を行わないことを決定したこと\nc 公開買付者等が、公開買付け等を行うことについての決定をしたこと。ただし、各年に買い集める株券等の数が当該株券等の発行者の総株主等の議決権の百分の三・〇である場合\nd 公開買付者等が、公開買付け等を行うことについての決定をしたこと。ただし、各年に買い集める株券等の数が当該株券等の発行者の総株主等の議決権の百分の一・〇である場合",
      "correct_answer": "c",
      "predicted_answer": "d",
      "is_correct": false,
      "response": "Reasoning: The question asks which option corresponds to the implementation of a public tender offer under Article 167, Paragraph 2 of the FIEA. Under Japanese law, the FIEA requires a public tender offer when the acquisition of shares reaches **1% of the total voting rights in the first year** and **2% in subsequent years**. If the acquisition is part of a business combination, the threshold increases to **3%**. \n\n- **Option a** (2%) and **option d** (1%) both refer to the percentage thresholds. However, the \"ただし\" (but) clause in each option introduces a condition. For example, **option d** states that the condition is \"each year's acquisition is 1% of the total voting rights.\" This aligns with the standard threshold for the **first year** (1%), which triggers the obligation to implement a public tender offer. \n- **Option c** (3%) would apply to business combinations, but the question does not specify this context. \n- **Option b** refers to the **termination** of a public tender offer, which is unrelated to the implementation (the question focuses on the **triggering event**, not the termination). \n\nThus, **option d** correctly identifies the **1% threshold** for the first year, which is the standard requirement for initiating a public tender offer under the FIEA.\n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第6章_選択式_関連法令_問題番号28",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/419M60000002059"
      ],
      "reasoning": "Reasoning: The question asks which option corresponds to the implementation of a public tender offer under Article 167, Paragraph 2 of the FIEA. Under Japanese law, the FIEA requires a public tender offer when the acquisition of shares reaches **1% of the total voting rights in the first year** and **2% in subsequent years**. If the acquisition is part of a business combination, the threshold increases to **3%**. \n\n- **Option a** (2%) and **option d** (1%) both refer to the percentage thresholds. However, the \"ただし\" (but) clause in each option introduces a condition. For example, **option d** states that the condition is \"each year's acquisition is 1% of the total voting rights.\" This aligns with the standard threshold for the **first year** (1%), which triggers the obligation to implement a public tender offer. \n- **Option c** (3%) would apply to business combinations, but the question does not specify this context. \n- **Option b** refers to the **termination** of a public tender offer, which is unrelated to the implementation (the question focuses on the **triggering event**, not the termination). \n\nThus, **option d** correctly identifies the **1% threshold** for the first year, which is the standard requirement for initiating a public tender offer under the FIEA.\n\nAnswer: d"
    },
    {
      "question": "金融商品仲介業者は、その行う金融商品仲介業の内容について広告を行う場合、表示しなければならない事項として誤っているものを教えてください。",
      "choices": "a 金融商品仲介業者である旨\nb 当該金融商品仲介業者の商号、名称又は氏名\nc 金融商品仲介行為に係る金融商品取引契約に関して顧客が預託すべき委託証拠金がある場合における預託の相手方\nd 当該金融商品仲介業者の登録番号",
      "correct_answer": "c",
      "predicted_answer": "c",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks for the **incorrect** statement regarding mandatory disclosures by financial product intermediaries in advertising.  \n2. The relevant provisions are **Article 66-10, Paragraph 2** of the Financial Instruments and Exchange Act and **Cabinet Office Order Article 267, Paragraph 1**, which require intermediaries to clearly and accurately disclose specific matters in advertisements.  \n3. **Options a, b, and d** (status as an intermediary, business name, and registration number) are standard mandatory disclosures under Japanese law for financial intermediaries. These align with the requirement to \"display matters specified by the Cabinet Office Order\" (e.g., business type, identity, and registration details).  \n4. **Option c** (the party to which margin must be deposited) is not explicitly listed as a mandatory disclosure in the provided legal provisions. While margin requirements may be relevant to contract terms, the law does not mandate disclosing the specific party (e.g., a third-party custodian) in advertisements. This makes **option c** the incorrect statement.  \n\nAnswer: c",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第3章の2_選択式_関連法令_問題番号29",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/340CO0000000321"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the **incorrect** statement regarding mandatory disclosures by financial product intermediaries in advertising.  \n2. The relevant provisions are **Article 66-10, Paragraph 2** of the Financial Instruments and Exchange Act and **Cabinet Office Order Article 267, Paragraph 1**, which require intermediaries to clearly and accurately disclose specific matters in advertisements.  \n3. **Options a, b, and d** (status as an intermediary, business name, and registration number) are standard mandatory disclosures under Japanese law for financial intermediaries. These align with the requirement to \"display matters specified by the Cabinet Office Order\" (e.g., business type, identity, and registration details).  \n4. **Option c** (the party to which margin must be deposited) is not explicitly listed as a mandatory disclosure in the provided legal provisions. While margin requirements may be relevant to contract terms, the law does not mandate disclosing the specific party (e.g., a third-party custodian) in advertisements. This makes **option c** the incorrect statement.  \n\nAnswer: c"
    },
    {
      "question": "銀行、協同組織金融機関その他政令で定める金融機関以外の者（第一種金融商品取引業を行う者及び登録金融機関の役員及び使用人を除く。）が内閣総理大臣の登録を受けて金融商品仲介業を行う場合、登録申請書に記載すべき事項として正しくないものを教えてください。",
      "choices": "a 商号、名称又は氏名\nb 所属金融商品取引業者等の商号又は名称\nc 個人である場合において、他の会社の常務に従事しているときは、当該他の会社の商号、代表者の氏名及び事業の種類\nd 法人である場合において、その役員が他の会社の常務に従事し、又は事業を行っているときは、当該役員の氏名並びに当該他の会社の商号及び事業の種類又は行っている事業の種類",
      "correct_answer": "c",
      "predicted_answer": "c",
      "is_correct": true,
      "response": "Reasoning:  \nThe question asks for the **incorrect** statement regarding the required information in the registration application for financial product intermediary services. The legal provisions provided (Article 66, Paragraph 1 of the Financial Instruments and Exchange Act) only state that non-banks (excluding certain entities) may register as financial product intermediaries. However, the specific requirements for the registration application are not explicitly detailed in the provided text.  \n\nTo determine the correct answer, we must infer based on standard legal requirements for such applications in Japan. Typically, registration applications require:  \n- **a** (商号、名称又は氏名): The applicant’s name (for individuals or entities).  \n- **b** (所属金融商品取引業者等の商号又は名称): The name of the affiliated financial institution (if applicable).  \n- **d** (法人である場合において、その役員が他の会社の常務に従事し、又は事業を行っているときは、当該役員の氏名並びに当該他の会社の商号及び事業の種類又は行っている事業の種類): For corporations, if an officer is employed elsewhere, the officer’s name and the other company’s name and business type must be disclosed.  \n\n**Option c** (個人である場合において、他の会社の常務に従事しているときは、当該他の会社の商号、代表者の氏名及び事業の種類) is **not standard**. While it is reasonable to require disclosure of the other company’s name and business type for an individual employed elsewhere, **requiring the representative’s name of the other company** is **not typically mandated** in such applications. This level of detail is unnecessary and likely incorrect under the law.  \n\nAnswer: **c**",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第3章の2_選択式_関連法令_問題番号30",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/419M60000002052"
      ],
      "reasoning": "Reasoning:  \nThe question asks for the **incorrect** statement regarding the required information in the registration application for financial product intermediary services. The legal provisions provided (Article 66, Paragraph 1 of the Financial Instruments and Exchange Act) only state that non-banks (excluding certain entities) may register as financial product intermediaries. However, the specific requirements for the registration application are not explicitly detailed in the provided text.  \n\nTo determine the correct answer, we must infer based on standard legal requirements for such applications in Japan. Typically, registration applications require:  \n- **a** (商号、名称又は氏名): The applicant’s name (for individuals or entities).  \n- **b** (所属金融商品取引業者等の商号又は名称): The name of the affiliated financial institution (if applicable).  \n- **d** (法人である場合において、その役員が他の会社の常務に従事し、又は事業を行っているときは、当該役員の氏名並びに当該他の会社の商号及び事業の種類又は行っている事業の種類): For corporations, if an officer is employed elsewhere, the officer’s name and the other company’s name and business type must be disclosed.  \n\n**Option c** (個人である場合において、他の会社の常務に従事しているときは、当該他の会社の商号、代表者の氏名及び事業の種類) is **not standard**. While it is reasonable to require disclosure of the other company’s name and business type for an individual employed elsewhere, **requiring the representative’s name of the other company** is **not typically mandated** in such applications. This level of detail is unnecessary and likely incorrect under the law.  \n\nAnswer: **c**"
    },
    {
      "question": "金融商品取引法第27条の32の2に定める外国証券情報の公表について正しいものを教えてください。",
      "choices": "a 外国証券売出しの相手方が適格機関投資家である場合は、常に外国証券情報を提供又は公表しなくてもよい\nb 外国証券売出しについては、売出し外国証券を売り付ける際に、常に、外国証券情報を、あらかじめ又は同時に、その相手方に提供し、又は公表しなければならない\nc 外国証券売出しであって、売出し外国証券の発行者が未だ当該売出し外国証券について特定証券情報を公表していない場合には、売出し外国証券を売り付ける際に、あらかじめ又は同時に外国証券情報を提供又は公表する必要がない\nd 外国証券売出しの相手方が適格機関投資家であっても、当該適格機関投資家から外国証券情報の提供の請求があった場合には、外国証券情報を当該適格機関投資家に提供し、又は公表しなければならない",
      "correct_answer": "d",
      "predicted_answer": "d",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks for the correct statement regarding the disclosure of foreign securities information under Japan's Financial Instruments and Exchange Act (Article 27-32-2).  \n2. Key provisions:  \n   - **[1]** (Cabinet Office Ordinance, Article 17, Paragraph 3): Requires immediate provision or disclosure of foreign securities information upon request or when specific conditions (e.g., under Article 15(1)) are met.  \n   - **[2]** (Article 27-32-2(3)): Mandates that financial institutions provide or disclose foreign securities information either directly, through others, or via internet methods.  \n   - **[3]** (Cabinet Office Ordinance, Article 13(1)(2)): Applies only if the issuer has already disclosed specific information and the provided information includes it.  \n\n3. **Analysis of choices**:  \n   - **Option a**: Incorrect. No exemption exists for qualified institutional investors under the provisions.  \n   - **Option b**: Incorrect. While disclosure is required, the phrasing \"always\" is overly broad. Exceptions may exist (e.g., under [3]), but the question focuses on the correct statement, not absolute rules.  \n   - **Option c**: Incorrect. [3] does not exempt institutions from disclosure if the issuer has not already disclosed specific information. The requirement in [2] still applies.  \n   - **Option d**: Correct. [1] explicitly states that even if the counterparty is a qualified institutional investor, a request for foreign securities information must be fulfilled immediately.  \n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第2章の5_選択式_関連法令_問題番号31",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/420M60000002078"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the correct statement regarding the disclosure of foreign securities information under Japan's Financial Instruments and Exchange Act (Article 27-32-2).  \n2. Key provisions:  \n   - **[1]** (Cabinet Office Ordinance, Article 17, Paragraph 3): Requires immediate provision or disclosure of foreign securities information upon request or when specific conditions (e.g., under Article 15(1)) are met.  \n   - **[2]** (Article 27-32-2(3)): Mandates that financial institutions provide or disclose foreign securities information either directly, through others, or via internet methods.  \n   - **[3]** (Cabinet Office Ordinance, Article 13(1)(2)): Applies only if the issuer has already disclosed specific information and the provided information includes it.  \n\n3. **Analysis of choices**:  \n   - **Option a**: Incorrect. No exemption exists for qualified institutional investors under the provisions.  \n   - **Option b**: Incorrect. While disclosure is required, the phrasing \"always\" is overly broad. Exceptions may exist (e.g., under [3]), but the question focuses on the correct statement, not absolute rules.  \n   - **Option c**: Incorrect. [3] does not exempt institutions from disclosure if the issuer has not already disclosed specific information. The requirement in [2] still applies.  \n   - **Option d**: Correct. [1] explicitly states that even if the counterparty is a qualified institutional investor, a request for foreign securities information must be fulfilled immediately.  \n\nAnswer: d"
    },
    {
      "question": "特定上場有価証券に係る特定証券情報の説明として、正しいものを教えてください。",
      "choices": "a 特定上場有価証券等に係る特定証券情報は、金融商品取引法施行令で定められる\nb TOKYO Pro Marketは、債券市場である\nc 特定投資家向け取得勧誘を行うときまでに、特定証券情報を相手方に提供、又は公表する必要がある\nd 金融商品取引所が開設するアマ向け市場が特定取引所金融商品市場である",
      "correct_answer": "c",
      "predicted_answer": "c",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks for the correct statement regarding specific securities information related to specific listed securities.  \n2. **Provision [1]** states that the information is defined by the **Cabinet Office Ordinance** (証券情報等の提供又は公表に関する内閣府令) and the **specific exchange rules** (特定取引所規則). **Provision [2]** specifies that the **content, method, timing, etc.** of the information are governed by the **Financial Instruments and Exchange Act (FIEA)**.  \n3. **Option a** claims the information is set by the **FIEA Implementation Ordinance** (金融商品取引法施行令). However, **Provision [1]** and **[2]** clearly attribute this to the **Cabinet Office Ordinance** and **FIEA**, not the **FIEA Implementation Ordinance**. Thus, **a is incorrect**.  \n4. **Option b** states that **TOKYO Pro Market** is a bond market. The provided legal texts do not mention **TOKYO Pro Market** or its classification, so **b is unsupported** and likely incorrect.  \n5. **Option c** asserts that specific securities information must be provided **before conducting a specific investment solicitation**. While the **timing** of disclosure is mentioned in **Provision [2]**, the exact timing (e.g., before investment solicitation) is not explicitly stated in the provided texts. However, **Provision [2]** mandates that the **issuer must provide or disclose** the information, and **investment solicitation** is a context where such disclosure is logically required under Japanese law. Thus, **c aligns with the general intent of the provisions**.  \n6. **Option d** claims that the **specific financial instruments market** is for **amateur investors**. The term **\"アマ向け\"** (amateur) is not mentioned in the provisions, and **Provision [3]** defines the market as one where **specific listed securities** are traded, without reference to investor type. Hence, **d is incorrect**.  \n\nAnswer: c",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第2章の5_選択式_関連法令_問題番号32",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/420M60000002078"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the correct statement regarding specific securities information related to specific listed securities.  \n2. **Provision [1]** states that the information is defined by the **Cabinet Office Ordinance** (証券情報等の提供又は公表に関する内閣府令) and the **specific exchange rules** (特定取引所規則). **Provision [2]** specifies that the **content, method, timing, etc.** of the information are governed by the **Financial Instruments and Exchange Act (FIEA)**.  \n3. **Option a** claims the information is set by the **FIEA Implementation Ordinance** (金融商品取引法施行令). However, **Provision [1]** and **[2]** clearly attribute this to the **Cabinet Office Ordinance** and **FIEA**, not the **FIEA Implementation Ordinance**. Thus, **a is incorrect**.  \n4. **Option b** states that **TOKYO Pro Market** is a bond market. The provided legal texts do not mention **TOKYO Pro Market** or its classification, so **b is unsupported** and likely incorrect.  \n5. **Option c** asserts that specific securities information must be provided **before conducting a specific investment solicitation**. While the **timing** of disclosure is mentioned in **Provision [2]**, the exact timing (e.g., before investment solicitation) is not explicitly stated in the provided texts. However, **Provision [2]** mandates that the **issuer must provide or disclose** the information, and **investment solicitation** is a context where such disclosure is logically required under Japanese law. Thus, **c aligns with the general intent of the provisions**.  \n6. **Option d** claims that the **specific financial instruments market** is for **amateur investors**. The term **\"アマ向け\"** (amateur) is not mentioned in the provisions, and **Provision [3]** defines the market as one where **specific listed securities** are traded, without reference to investor type. Hence, **d is incorrect**.  \n\nAnswer: c"
    },
    {
      "question": "株主名簿に記載され、又は記録されている株主に対して有価証券の募集又は売出しを行う場合に、金融商品取引法第4条第4項に基づく二十五日前までの届出が要求されない募集又は売出しに該当するものを教えてください。",
      "choices": "a 増資説明会において、株主等に対して口頭で説明する方法による有価証券の募集又は売出し\nb インターネット広告による有価証券の募集又は売出し\nc 時価又は時価に近い一定の価格で発行する株券の募集又は売出し\nd 立看板を使用した広告による有価証券の募集又は売出し",
      "correct_answer": "c",
      "predicted_answer": "c",
      "is_correct": true,
      "response": "Reasoning: The question asks which scenario does not require the 25-day prior notice under Article 4, Paragraph 4 of the Financial Instruments and Exchange Act. Key provisions include:\n\n1. **Article 3, Paragraph 1** (Legal Provision [1]) specifies that the 25-day rule applies to offerings after 25 days from implementation, but the question focuses on exemptions from this requirement.\n2. **Article 23-3, Paragraph 3** (Legal Provision [2]) states that if securities are registered (issuance registration), the provisions of Article 4, Paragraphs 1–3 do not apply. However, this does not explicitly address Paragraph 4 (the 25-day notice).\n3. **Article 20, Paragraph 2, Item 1** (Legal Provision [3]) relates to prospectus submission and underwriting agreements but does not directly address the 25-day notice.\n\n**Analysis of Options**:\n- **Option a**: Oral explanations at a shareholders' meeting are direct communications to existing shareholders, but they still require the 25-day notice unless explicitly exempted. This is not an exemption.\n- **Option b**: Internet advertising is a public offering, which typically requires the 25-day notice unless exempted.\n- **Option c**: Issuance at market price or near market price is a **common exemption** under Japanese law. Such offerings are considered less risky and do not require the 25-day notice because the price aligns with market value, reducing the need for prior disclosure.\n- **Option d**: Billboard advertising is a public offering, requiring the 25-day notice unless exempted.\n\n**Conclusion**: Option **c** is the correct answer as it falls under an exemption for market-price offerings, which are explicitly excluded from the 25-day notice requirement.\n\nAnswer: c",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第2章_選択式_関連法令_問題番号33",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025"
      ],
      "reasoning": "Reasoning: The question asks which scenario does not require the 25-day prior notice under Article 4, Paragraph 4 of the Financial Instruments and Exchange Act. Key provisions include:\n\n1. **Article 3, Paragraph 1** (Legal Provision [1]) specifies that the 25-day rule applies to offerings after 25 days from implementation, but the question focuses on exemptions from this requirement.\n2. **Article 23-3, Paragraph 3** (Legal Provision [2]) states that if securities are registered (issuance registration), the provisions of Article 4, Paragraphs 1–3 do not apply. However, this does not explicitly address Paragraph 4 (the 25-day notice).\n3. **Article 20, Paragraph 2, Item 1** (Legal Provision [3]) relates to prospectus submission and underwriting agreements but does not directly address the 25-day notice.\n\n**Analysis of Options**:\n- **Option a**: Oral explanations at a shareholders' meeting are direct communications to existing shareholders, but they still require the 25-day notice unless explicitly exempted. This is not an exemption.\n- **Option b**: Internet advertising is a public offering, which typically requires the 25-day notice unless exempted.\n- **Option c**: Issuance at market price or near market price is a **common exemption** under Japanese law. Such offerings are considered less risky and do not require the 25-day notice because the price aligns with market value, reducing the need for prior disclosure.\n- **Option d**: Billboard advertising is a public offering, requiring the 25-day notice unless exempted.\n\n**Conclusion**: Option **c** is the correct answer as it falls under an exemption for market-price offerings, which are explicitly excluded from the 25-day notice requirement.\n\nAnswer: c"
    },
    {
      "question": "届出を要しない有価証券の募集又は売出しに該当するものを教えてください。",
      "choices": "a 有価証券の発行価額又は売出価額の総額と、過去一年以内に募集又は売出しが開始された同一の種類の有価証券の発行価額又は売出価額の総額を合算した金額が二億円である募集又は売出し\nb 発行価額の総額が一億円である募集\nc 発行価額又は売出価額の総額が一億円未満である募集又は売出しで企業内容等の開示に関する内閣府令第2条第5項各号に掲げるものに該当するもの\nd 有価証券の発行価額又は売出価額の総額と、過去１年以内に払込期日又は売渡期日が到来した同一の種類の有価証券の発行価額又は売出価額の総額を合算した金額が九千万円である募集又は売出し",
      "correct_answer": "d",
      "predicted_answer": "c",
      "is_correct": false,
      "response": "Reasoning:  \nThe question asks which scenario involves a securities offering or sale that **does not require a filing** under Japanese law. The key provisions to consider are:  \n\n1. **FIEA Article 4** generally requires filings for certain offerings, but **Article 23-3, paragraph 3** states that **if a securities registration (発行登録)** has been completed, the filing requirements under Article 4 do not apply. However, this provision does not directly address the **thresholds** for when filings are **not required**.  \n\n2. **The threshold for filing requirements** under FIEA Article 4 is typically **100 million yen** (1億円) for the total issuance or sale amount. If the amount is **below this threshold**, filings are **not required**.  \n\n3. **Option c** states:  \n   - The total issuance/sale amount is **under 100 million yen**.  \n   - It also meets the conditions in **Article 2, paragraph 5** of the Cabinet Office Ordinance on Disclosure of Information Concerning Corporate Information, etc.  \n   - This likely refers to **exemptions** (e.g., private placements to qualified institutional investors), which are **not subject to filing requirements** even if the amount is below the threshold.  \n\n4. **Option d** states:  \n   - The total amount (current + past year’s same type) is **90 million yen**.  \n   - However, the **threshold** for filing is based on the **current offering alone**, not combined with past offerings. If the current offering is **under 100 million yen**, filing is **not required**, regardless of past offerings.  \n\n5. **Option c** explicitly includes **both** the **amount threshold** and **exemption conditions**, making it the **most comprehensive** and legally accurate choice.  \n\nAnswer: c",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第2章_選択式_関連法令_問題番号34",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025"
      ],
      "reasoning": "Reasoning:  \nThe question asks which scenario involves a securities offering or sale that **does not require a filing** under Japanese law. The key provisions to consider are:  \n\n1. **FIEA Article 4** generally requires filings for certain offerings, but **Article 23-3, paragraph 3** states that **if a securities registration (発行登録)** has been completed, the filing requirements under Article 4 do not apply. However, this provision does not directly address the **thresholds** for when filings are **not required**.  \n\n2. **The threshold for filing requirements** under FIEA Article 4 is typically **100 million yen** (1億円) for the total issuance or sale amount. If the amount is **below this threshold**, filings are **not required**.  \n\n3. **Option c** states:  \n   - The total issuance/sale amount is **under 100 million yen**.  \n   - It also meets the conditions in **Article 2, paragraph 5** of the Cabinet Office Ordinance on Disclosure of Information Concerning Corporate Information, etc.  \n   - This likely refers to **exemptions** (e.g., private placements to qualified institutional investors), which are **not subject to filing requirements** even if the amount is below the threshold.  \n\n4. **Option d** states:  \n   - The total amount (current + past year’s same type) is **90 million yen**.  \n   - However, the **threshold** for filing is based on the **current offering alone**, not combined with past offerings. If the current offering is **under 100 million yen**, filing is **not required**, regardless of past offerings.  \n\n5. **Option c** explicitly includes **both** the **amount threshold** and **exemption conditions**, making it the **most comprehensive** and legally accurate choice.  \n\nAnswer: c"
    },
    {
      "question": "公開買付者による買付等の期間の変更について、正しいものを教えてください。",
      "choices": "a 公開買付者は、買付期間を60営業日を超えてを延長することは一切できない\nb 公開買付者は、買付等の期間の短縮をできる\nc 独占禁止法上の株式取得の事前届出を行った場合において、公開買付け期間中に措置期間が終了しないときも、公開買付等の期間を60営業日を超えて延長することができるとは限らない\nd 公開買付者は、80営業日を超えない範囲であれば、買付期間を延長することができる",
      "correct_answer": "c",
      "predicted_answer": "c",
      "is_correct": true,
      "response": "Reasoning:  \nThe question concerns the extension of the acquisition period in a public tender offer under Japanese law. However, the provided legal provisions (all identical versions of Article 27-7, Paragraph 2 of the Financial Instruments and Exchange Act) only address the **correction of announcements** by the Prime Minister, not the **duration or extension of the acquisition period**. This means the answer must rely on **general knowledge of Japanese law** rather than the given provisions.  \n\nUnder Japanese law, the standard acquisition period for a public tender offer is **60 business days** (per the Financial Instruments and Exchange Act). Extensions beyond this period are **not permitted** unless explicitly allowed by law (e.g., in exceptional circumstances, such as delays caused by regulatory reviews). However, **if the antitrust law's pre-notification period (under the Antimonopoly Act) has not ended**, the acquisition period **may not be extended** beyond 60 days, as the antitrust process could interfere with the timeline. This aligns with **Choice c**, which states that even in such cases, extension beyond 60 days is **not guaranteed**.  \n\nChoices a and d incorrectly assume fixed limits (60 or 80 days) without considering exceptions. Choice b is incorrect because shortening the period is not a standard practice.  \n\nAnswer: c",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第2章の2_選択式_関連法令_問題番号35",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/340CO0000000321",
        "https://www.fsa.go.jp/common/law/kaiji/koukaikaitsuke.pdf"
      ],
      "reasoning": "Reasoning:  \nThe question concerns the extension of the acquisition period in a public tender offer under Japanese law. However, the provided legal provisions (all identical versions of Article 27-7, Paragraph 2 of the Financial Instruments and Exchange Act) only address the **correction of announcements** by the Prime Minister, not the **duration or extension of the acquisition period**. This means the answer must rely on **general knowledge of Japanese law** rather than the given provisions.  \n\nUnder Japanese law, the standard acquisition period for a public tender offer is **60 business days** (per the Financial Instruments and Exchange Act). Extensions beyond this period are **not permitted** unless explicitly allowed by law (e.g., in exceptional circumstances, such as delays caused by regulatory reviews). However, **if the antitrust law's pre-notification period (under the Antimonopoly Act) has not ended**, the acquisition period **may not be extended** beyond 60 days, as the antitrust process could interfere with the timeline. This aligns with **Choice c**, which states that even in such cases, extension beyond 60 days is **not guaranteed**.  \n\nChoices a and d incorrectly assume fixed limits (60 or 80 days) without considering exceptions. Choice b is incorrect because shortening the period is not a standard practice.  \n\nAnswer: c"
    },
    {
      "question": "公開買付けの撤回事由に該当しないものを教えてください。ただし、公開買付開始公告及び公開買付届出書において、撤回事由が生じたときは公開買付けの撤回等をすることがある旨の条件が付されていることを前提とします。",
      "choices": "a 株券等の発行者が、合併の決定をしたこと\nb 公開買付者が、公開買付けに要する資金について、公開買付けの開始後に第三者から貸付けを受けることができないこと\nc 公開買付者に関し、破産手続開始の決定がされたこと\nd 株券等の発行者の子会社が、多額の借財の決定をしたこと",
      "correct_answer": "b",
      "predicted_answer": "d",
      "is_correct": false,
      "response": "Reasoning:  \nThe question asks which option is **not** a valid reason for retracting a public tender offer (公開買付けの撤回事由). The key is to determine which scenario does **not** constitute a legitimate reason under Japanese law, based on the provided legal provisions.  \n\n1. **Legal Context**:  \n   - The provisions in [1] and [2]/[3] focus on **conditions for exceptions** (e.g., pre-existing contracts to avoid public tender) and **requirements for disclosing reasons** for withdrawal, but **do not explicitly list specific valid reasons** for withdrawal.  \n   - The question assumes that the retraction conditions are already included in the public tender announcement and application, implying that the answer hinges on whether the options align with **common legal principles** or **are unrelated** to the tender offer's feasibility.  \n\n2. **Analysis of Options**:  \n   - **Option a**: A merger decision by the issuer could render the tender offer unnecessary or conflicting with the merger, making it a plausible reason for withdrawal.  \n   - **Option b**: If the acquirer cannot secure financing **after** the tender offer begins, this directly impacts the feasibility of the offer, which could justify withdrawal.  \n   - **Option c**: Bankruptcy of the acquirer would make the tender offer legally or practically impossible, a clear reason for withdrawal.  \n   - **Option d**: A subsidiary’s decision to take on a large loan is **unrelated** to the tender offer’s execution or legality. Unless the loan directly affects the issuer’s ability to proceed (e.g., financial instability), this is **not a valid reason** for withdrawal.  \n\n3. **Conclusion**:  \n   Only **Option d** involves a scenario that does **not** directly affect the tender offer’s feasibility or legality, making it the **invalid** reason for withdrawal.  \n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第2章の2_選択式_関連法令_問題番号36",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/340CO0000000321",
        "https://www.fsa.go.jp/common/law/kaiji/koukaikaitsuke.pdf"
      ],
      "reasoning": "Reasoning:  \nThe question asks which option is **not** a valid reason for retracting a public tender offer (公開買付けの撤回事由). The key is to determine which scenario does **not** constitute a legitimate reason under Japanese law, based on the provided legal provisions.  \n\n1. **Legal Context**:  \n   - The provisions in [1] and [2]/[3] focus on **conditions for exceptions** (e.g., pre-existing contracts to avoid public tender) and **requirements for disclosing reasons** for withdrawal, but **do not explicitly list specific valid reasons** for withdrawal.  \n   - The question assumes that the retraction conditions are already included in the public tender announcement and application, implying that the answer hinges on whether the options align with **common legal principles** or **are unrelated** to the tender offer's feasibility.  \n\n2. **Analysis of Options**:  \n   - **Option a**: A merger decision by the issuer could render the tender offer unnecessary or conflicting with the merger, making it a plausible reason for withdrawal.  \n   - **Option b**: If the acquirer cannot secure financing **after** the tender offer begins, this directly impacts the feasibility of the offer, which could justify withdrawal.  \n   - **Option c**: Bankruptcy of the acquirer would make the tender offer legally or practically impossible, a clear reason for withdrawal.  \n   - **Option d**: A subsidiary’s decision to take on a large loan is **unrelated** to the tender offer’s execution or legality. Unless the loan directly affects the issuer’s ability to proceed (e.g., financial instability), this is **not a valid reason** for withdrawal.  \n\n3. **Conclusion**:  \n   Only **Option d** involves a scenario that does **not** directly affect the tender offer’s feasibility or legality, making it the **invalid** reason for withdrawal.  \n\nAnswer: d"
    },
    {
      "question": "金融商品取引業者が金融商品取引法第40条の規定に基づいて行うべき内容として、誤っているものを教えてください。",
      "choices": "a 金融商品取引法第40条第1号により、不適当と認められる勧誘を行って投資者の保護に欠けることとならないように、業務を行わなければならない\nb 顧客のリスク管理判断能力に応じた取引内容や取引条件に留意する必要はない\nc 金融商品の内容が顧客の属性等に適合することの合理的な理由があるかどうかの検討・評価を行うことが必要がある\nd 提供する金融商品の内容を適切に把握するための体制を確立する必要がある",
      "correct_answer": "b",
      "predicted_answer": "b",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks to identify the **incorrect** statement regarding obligations under **Article 40** of the Financial Instruments and Exchange Act (FIEA).  \n2. While the provided legal text does not explicitly include **Article 40**, the relevant provisions (e.g., **Article 37-2** of FIEA and **Article 6-1** of the Financial Services Act) emphasize obligations such as avoiding misleading information, ensuring suitability of financial products, and compensating customers for damages caused by non-compliance. These principles align with the general obligations under **Article 40** of the FIEA, which typically requires financial institutions to act in the best interests of customers, ensure suitability of products, and avoid inappropriate conduct.  \n3. **Option b** states: *\"顧客のリスク管理判断能力に応じた取引内容や取引条件に留意する必要はない\"* (No need to consider the customer's risk management judgment ability regarding transaction content or conditions). This directly contradicts the core obligation under **Article 40** (and related laws) to assess the customer's risk profile and ensure that financial products are suitable for their attributes.  \n4. **Options a, c, and d** all align with the obligations under **Article 40**, such as avoiding inappropriate inducements (a), evaluating product suitability (c), and establishing systems to understand product content (d).  \n\nAnswer: b",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第3章_選択式_関連法令_問題番号37",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://www.fsa.go.jp/common/law/guide/kinyushohin.pdf"
      ],
      "reasoning": "Reasoning:  \n1. The question asks to identify the **incorrect** statement regarding obligations under **Article 40** of the Financial Instruments and Exchange Act (FIEA).  \n2. While the provided legal text does not explicitly include **Article 40**, the relevant provisions (e.g., **Article 37-2** of FIEA and **Article 6-1** of the Financial Services Act) emphasize obligations such as avoiding misleading information, ensuring suitability of financial products, and compensating customers for damages caused by non-compliance. These principles align with the general obligations under **Article 40** of the FIEA, which typically requires financial institutions to act in the best interests of customers, ensure suitability of products, and avoid inappropriate conduct.  \n3. **Option b** states: *\"顧客のリスク管理判断能力に応じた取引内容や取引条件に留意する必要はない\"* (No need to consider the customer's risk management judgment ability regarding transaction content or conditions). This directly contradicts the core obligation under **Article 40** (and related laws) to assess the customer's risk profile and ensure that financial products are suitable for their attributes.  \n4. **Options a, c, and d** all align with the obligations under **Article 40**, such as avoiding inappropriate inducements (a), evaluating product suitability (c), and establishing systems to understand product content (d).  \n\nAnswer: b"
    },
    {
      "question": "金商法第52条第2項の規定に基づき当該役員の解任命令等の処分を検討する場合に該当するものはどれか。",
      "choices": "a 金融商品取引業者の役員が、金商法第52条第1項第8号に該当することとなったとき\nb 金融商品取引業者の役員が、金商法第29条の登録当時既に金商法第29条の4第1項第2号ハに該当していたことが判明したとき\nc 金融商品取引業者の役員が、金商法第29条の４第１項第1号イに該当することとなったとき\nd 金融商品取引業者の役員が、金商法第29条の4第１項第4号イに該当することとなったとき",
      "correct_answer": "b",
      "predicted_answer": "a",
      "is_correct": false,
      "response": "Reasoning: The question asks which scenario would trigger a removal order under Article 52, Paragraph 2 of the Financial Instruments and Exchange Act (FIEA). The provided legal provisions include **Trust Business Act Article 202, Paragraph 2**, which links deregistration or removal under the old Trust Business Act to the FIEA's Article 52, Paragraph 2. However, the options focus on the FIEA's own provisions, not the Trust Business Act. \n\nKey analysis of the options:  \n- **Option a** refers to disqualification under **Article 52, Paragraph 1, Item 8** of the FIEA. This is a direct condition for removal under Article 52, Paragraph 2, as it outlines specific disqualifying behaviors.  \n- **Option b** involves a situation where the officer was already disqualified at registration under **Article 29, Paragraph 4, Item 1, Subitem 2, Ha**. This would likely trigger a removal order under Article 52, Paragraph 2, as pre-existing disqualifications are grounds for action.  \n- **Options c and d** refer to disqualifications under **Article 29, Paragraph 4, Item 1, Subitem 1, I** and **Item 4, I**, respectively. These may also be relevant, but the question requires identifying the **correct** scenario.  \n\nThe Trust Business Act provision (Article 202, Paragraph 2) is not directly applicable here, as the options pertain to the FIEA. **Article 52, Paragraph 1, Item 8** of the FIEA explicitly lists disqualifying behaviors (e.g., fraud, misconduct), which would directly justify a removal order under Article 52, Paragraph 2. **Option a** aligns with this, while **option b** involves a pre-existing disqualification that may not necessarily trigger removal unless explicitly tied to Article 52, Paragraph 2.  \n\nAnswer: a",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第3章_選択式_関連法令_問題番号38",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://www.fsa.go.jp/common/law/guide/kinyushohin.pdf"
      ],
      "reasoning": "Reasoning: The question asks which scenario would trigger a removal order under Article 52, Paragraph 2 of the Financial Instruments and Exchange Act (FIEA). The provided legal provisions include **Trust Business Act Article 202, Paragraph 2**, which links deregistration or removal under the old Trust Business Act to the FIEA's Article 52, Paragraph 2. However, the options focus on the FIEA's own provisions, not the Trust Business Act. \n\nKey analysis of the options:  \n- **Option a** refers to disqualification under **Article 52, Paragraph 1, Item 8** of the FIEA. This is a direct condition for removal under Article 52, Paragraph 2, as it outlines specific disqualifying behaviors.  \n- **Option b** involves a situation where the officer was already disqualified at registration under **Article 29, Paragraph 4, Item 1, Subitem 2, Ha**. This would likely trigger a removal order under Article 52, Paragraph 2, as pre-existing disqualifications are grounds for action.  \n- **Options c and d** refer to disqualifications under **Article 29, Paragraph 4, Item 1, Subitem 1, I** and **Item 4, I**, respectively. These may also be relevant, but the question requires identifying the **correct** scenario.  \n\nThe Trust Business Act provision (Article 202, Paragraph 2) is not directly applicable here, as the options pertain to the FIEA. **Article 52, Paragraph 1, Item 8** of the FIEA explicitly lists disqualifying behaviors (e.g., fraud, misconduct), which would directly justify a removal order under Article 52, Paragraph 2. **Option a** aligns with this, while **option b** involves a pre-existing disqualification that may not necessarily trigger removal unless explicitly tied to Article 52, Paragraph 2.  \n\nAnswer: a"
    },
    {
      "question": "投資運用業を行おうとする場合に、登録申請者が内閣総理大臣から金商法第29条第1項第4号に該当するとして、登録を拒否される場合の説明として、正しいものを教えてください。",
      "choices": "a 登録申請者が、外国法人である場合\nb 登録申請者が、国内に事務所を有している法人である場合\nc 登録申請者が資本金額4千万円の法人である場合\nd 登録申請者が、協会に加入していないが、協会の定款その他の規則を作成し、かつ、当該社内規則を遵守するための体制を整備している場合",
      "correct_answer": "c",
      "predicted_answer": "d",
      "is_correct": false,
      "response": "Reasoning: The question asks which scenario correctly explains a denial under Article 29, Paragraph 1, Item 4 of the Financial Instruments and Exchange Act (金商法). This provision typically requires applicants to meet specific conditions, such as having proper internal regulations, organizational structure, and membership in relevant associations. \n\n- **Option a** (foreign corporation) is not inherently disqualifying, as foreign entities can apply under certain conditions.  \n- **Option b** (domestic office) is a requirement, not a reason for denial.  \n- **Option c** (capital of 40 million yen) may relate to other provisions (e.g., minimum capital requirements under different articles), not directly to Article 29, Paragraph 1, Item 4.  \n- **Option d** highlights a scenario where the applicant is **not a member of the association** but has **created internal regulations and compliance systems**. Under Japanese law, membership in the Japan Securities Association (協会) is a key requirement for registration. If the applicant is not a member, this would typically lead to denial under Article 29, Paragraph 1, Item 4, even if they have internal rules. Thus, **option d** correctly identifies a scenario where registration is denied due to non-compliance with membership requirements.  \n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第3章_選択式_関連法令_問題番号39",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/340CO0000000321"
      ],
      "reasoning": "Reasoning: The question asks which scenario correctly explains a denial under Article 29, Paragraph 1, Item 4 of the Financial Instruments and Exchange Act (金商法). This provision typically requires applicants to meet specific conditions, such as having proper internal regulations, organizational structure, and membership in relevant associations. \n\n- **Option a** (foreign corporation) is not inherently disqualifying, as foreign entities can apply under certain conditions.  \n- **Option b** (domestic office) is a requirement, not a reason for denial.  \n- **Option c** (capital of 40 million yen) may relate to other provisions (e.g., minimum capital requirements under different articles), not directly to Article 29, Paragraph 1, Item 4.  \n- **Option d** highlights a scenario where the applicant is **not a member of the association** but has **created internal regulations and compliance systems**. Under Japanese law, membership in the Japan Securities Association (協会) is a key requirement for registration. If the applicant is not a member, this would typically lead to denial under Article 29, Paragraph 1, Item 4, even if they have internal rules. Thus, **option d** correctly identifies a scenario where registration is denied due to non-compliance with membership requirements.  \n\nAnswer: d"
    },
    {
      "question": "銀行等が、金商法第33条第1項により行ってはならないとされている業務に該当しないとされているものを教えてください。",
      "choices": "a 有価証券関連業（金融商品取引法第33条第1項ただし書に該当する場合を除く）\nb 引受金融商品取引業者に対し株式公開等が可能な取引先企業を紹介する業務\nc 当該銀行等の店舗に、金融商品取引業者が自らを紹介する宣伝媒体を掲示するにとどまらず、勧誘を行う業務\nd 当該銀行等と金融商品取引業者の関係について説明をした上で、勧誘行為を行う業務",
      "correct_answer": "b",
      "predicted_answer": "a",
      "is_correct": false,
      "response": "Reasoning:  \nThe question asks which business is **not prohibited** under the Financial Instruments and Exchange Act (金商法) Article 33, Paragraph 1. This provision generally prohibits banks from acting as agents for financial instruments trading or providing investment advice unless licensed. However, exceptions may apply.  \n\n- **Option a** refers to \"securities-related business (except in cases covered by the exception in Article 33, Paragraph 1).\" If the business falls under the exception (e.g., when conducted by a licensed entity or under specific conditions), it would be **allowed**. The wording implies that the business is **permitted unless it falls under the exception**, which aligns with the structure of legal exceptions. Thus, this option could be **non-prohibited** if the exception applies.  \n\n- **Option b** involves introducing companies to financial instruments trading operators. This is a referral service and does not directly involve acting as an agent or providing investment advice, which may be **permitted**.  \n\n- **Option c** describes a scenario where a financial institution displays promotional materials and conducts solicitation in a bank's premises. If the bank is **not directly involved** in the solicitation, this might be **allowed**, but the wording suggests the bank is facilitating the solicitation, which could be **prohibited**.  \n\n- **Option d** involves the bank explaining its relationship with a financial institution and then conducting solicitation. This directly involves the bank in solicitation, which would likely be **prohibited** under Article 33, Paragraph 1.  \n\nAmong the options, **Option a** is the most directly tied to the exception in Article 33, Paragraph 1, which would make it **non-prohibited** if the exception applies. While **Option b** may also be permissible, the wording of **Option a** explicitly references the exception, making it the most precise answer.  \n\nAnswer: a",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第3章_選択式_関連法令_問題番号40",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://www.fsa.go.jp/common/law/guide/kinyushohin.pdf"
      ],
      "reasoning": "Reasoning:  \nThe question asks which business is **not prohibited** under the Financial Instruments and Exchange Act (金商法) Article 33, Paragraph 1. This provision generally prohibits banks from acting as agents for financial instruments trading or providing investment advice unless licensed. However, exceptions may apply.  \n\n- **Option a** refers to \"securities-related business (except in cases covered by the exception in Article 33, Paragraph 1).\" If the business falls under the exception (e.g., when conducted by a licensed entity or under specific conditions), it would be **allowed**. The wording implies that the business is **permitted unless it falls under the exception**, which aligns with the structure of legal exceptions. Thus, this option could be **non-prohibited** if the exception applies.  \n\n- **Option b** involves introducing companies to financial instruments trading operators. This is a referral service and does not directly involve acting as an agent or providing investment advice, which may be **permitted**.  \n\n- **Option c** describes a scenario where a financial institution displays promotional materials and conducts solicitation in a bank's premises. If the bank is **not directly involved** in the solicitation, this might be **allowed**, but the wording suggests the bank is facilitating the solicitation, which could be **prohibited**.  \n\n- **Option d** involves the bank explaining its relationship with a financial institution and then conducting solicitation. This directly involves the bank in solicitation, which would likely be **prohibited** under Article 33, Paragraph 1.  \n\nAmong the options, **Option a** is the most directly tied to the exception in Article 33, Paragraph 1, which would make it **non-prohibited** if the exception applies. While **Option b** may also be permissible, the wording of **Option a** explicitly references the exception, making it the most precise answer.  \n\nAnswer: a"
    },
    {
      "question": "金融商品取引法第２条第１項第15号に掲げる有価証券が、金融商品取引法第5条第1項で定める特定有価証券に該当することを定めている条文を教えてください。",
      "choices": "a 金融商品取引法施行令第2条の13第1号\nb 金融商品取引法施行令第2条の13第3号\nc 金融商品取引法施行令第2条の13第2号\nd 金融商品取引法第2条第1項第15号",
      "correct_answer": "a",
      "predicted_answer": "c",
      "is_correct": false,
      "response": "Reasoning:  \n1. The question asks for the legal provision that defines when financial instruments listed in **FIEA Article 2, Paragraph 1, Item 15** are considered **specific financial instruments** under **FIEA Article 5, Paragraph 1**.  \n2. The provided legal texts ([1][2][3]) do not directly address this link. However, the answer choices refer to **FIEA Implementation Order Article 2-13**, which is a common location for such definitions in Japanese law.  \n3. In Japanese legal practice, **FIEA Implementation Order Article 2-13** typically lists which items from **FIEA Article 2, Paragraph 1** are classified as **specific financial instruments** under **FIEA Article 5, Paragraph 1**.  \n4. Based on standard legal structure and precedent, **FIEA Implementation Order Article 2-13, Item 2** (choice **c**) is the provision that explicitly links **Item 15** of **FIEA Article 2, Paragraph 1** to **specific financial instruments** under **FIEA Article 5, Paragraph 1**.  \n\nAnswer: c",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第2章_選択式_根拠条文_問題番号10",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/340CO0000000321"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the legal provision that defines when financial instruments listed in **FIEA Article 2, Paragraph 1, Item 15** are considered **specific financial instruments** under **FIEA Article 5, Paragraph 1**.  \n2. The provided legal texts ([1][2][3]) do not directly address this link. However, the answer choices refer to **FIEA Implementation Order Article 2-13**, which is a common location for such definitions in Japanese law.  \n3. In Japanese legal practice, **FIEA Implementation Order Article 2-13** typically lists which items from **FIEA Article 2, Paragraph 1** are classified as **specific financial instruments** under **FIEA Article 5, Paragraph 1**.  \n4. Based on standard legal structure and precedent, **FIEA Implementation Order Article 2-13, Item 2** (choice **c**) is the provision that explicitly links **Item 15** of **FIEA Article 2, Paragraph 1** to **specific financial instruments** under **FIEA Article 5, Paragraph 1**.  \n\nAnswer: c"
    },
    {
      "question": "金融商品取引法第３条第２号の規定により、企業内容等の開示を行わせることが公益又は投資者保護のため必要かつ適当なものとして政令で定めるものを定めた条文を教えてください。",
      "choices": "a 金融商品取引法施行令第２条の8\nb 金融商品取引法第2条第1項第3号\nc 金融商品取引法第3条第1項第5号\nd 金融商品取引法第3条第1項第4号",
      "correct_answer": "a",
      "predicted_answer": "a",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks for the provision that defines the items required to be disclosed under **Article 3, Paragraph 2, Item 2** of the Financial Instruments and Exchange Act (FIEA), as specified by an ordinance for public interest or investor protection.  \n2. The provided legal texts (Articles 46_3 and 57_3) pertain to **disclosure of business reports by financial institutions** (not corporate disclosure under Article 3). These are unrelated to the question.  \n3. The key clue is the phrase **\"政令で定めるところにより\"** (as defined by an ordinance), which indicates that the specific items to be disclosed are detailed in an **implementation ordinance** (施行令), not the FIEA itself.  \n4. Among the choices, **a** (Financial Instruments and Exchange Act Implementation Ordinance Article 2-8) is the only one that refers to an **ordinance** (施行令), aligning with the requirement for ordinance-based definitions. The other choices (b, c, d) refer to provisions within the FIEA itself, not the implementation ordinance.  \n\nAnswer: a",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第2章_選択式_根拠条文_問題番号11",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/340CO0000000321"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the provision that defines the items required to be disclosed under **Article 3, Paragraph 2, Item 2** of the Financial Instruments and Exchange Act (FIEA), as specified by an ordinance for public interest or investor protection.  \n2. The provided legal texts (Articles 46_3 and 57_3) pertain to **disclosure of business reports by financial institutions** (not corporate disclosure under Article 3). These are unrelated to the question.  \n3. The key clue is the phrase **\"政令で定めるところにより\"** (as defined by an ordinance), which indicates that the specific items to be disclosed are detailed in an **implementation ordinance** (施行令), not the FIEA itself.  \n4. Among the choices, **a** (Financial Instruments and Exchange Act Implementation Ordinance Article 2-8) is the only one that refers to an **ordinance** (施行令), aligning with the requirement for ordinance-based definitions. The other choices (b, c, d) refer to provisions within the FIEA itself, not the implementation ordinance.  \n\nAnswer: a"
    },
    {
      "question": "記載すべき重要な事項の記載が欠けている発行開示書類を提出した発行者が、当該発行開示書類に基づく募集により株券を取得させたとき、当該発行者において、国庫に納付しなければならない課徴金の額は、当該取得させた有価証券の発行価額の総額の百分の四・五に相当する額であることの根拠条文を教えてください。",
      "choices": "a 金融商品取引法第172条の3第１項\nb 金融商品取引法第172条の２第１項第１号\nc 金融商品取引法第172条の２第１項第２号\nd 金融商品取引法第172条の２第１項第３号",
      "correct_answer": "b",
      "predicted_answer": "b",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks for the legal basis of a 4.5% surcharge (課徴金) on the total issuance price of **stock certificates (株券)** when a **missing important disclosure** exists in the offering documents.  \n2. The relevant provision is **[3]**, which states that if securities are acquired through the offering based on the disclosure documents, the surcharge is **2.25%** (or **4.5% for stock certificates**). This directly matches the scenario described in the question.  \n3. The choices are analyzed as follows:  \n   - **a** (Article 172-3, Item 1) is not mentioned in the provided text.  \n   - **b** (Article 172-2, Item 1, No. 1) corresponds exactly to **[3]**, which applies to the issuer’s liability for missing disclosures in the offering documents.  \n   - **c** and **d** (Items 2 and 3 of Article 172-2) pertain to **officers/employees** who sold securities after knowing about the disclosure issues, not the issuer itself.  \n4. Since the question involves the **issuer** (発行者) and **stock certificates**, **[3]** (choice **b**) is the correct answer.  \n\nAnswer: b",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第6章の2_選択式_根拠条文_問題番号22",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the legal basis of a 4.5% surcharge (課徴金) on the total issuance price of **stock certificates (株券)** when a **missing important disclosure** exists in the offering documents.  \n2. The relevant provision is **[3]**, which states that if securities are acquired through the offering based on the disclosure documents, the surcharge is **2.25%** (or **4.5% for stock certificates**). This directly matches the scenario described in the question.  \n3. The choices are analyzed as follows:  \n   - **a** (Article 172-3, Item 1) is not mentioned in the provided text.  \n   - **b** (Article 172-2, Item 1, No. 1) corresponds exactly to **[3]**, which applies to the issuer’s liability for missing disclosures in the offering documents.  \n   - **c** and **d** (Items 2 and 3 of Article 172-2) pertain to **officers/employees** who sold securities after knowing about the disclosure issues, not the issuer itself.  \n4. Since the question involves the **issuer** (発行者) and **stock certificates**, **[3]** (choice **b**) is the correct answer.  \n\nAnswer: b"
    },
    {
      "question": "暗号等資産の価格及び利率等並びにこれらに基づいて算出した数値に係る金融指標を暗号等資産関連金融指標と定義している条文を教えてください。",
      "choices": "a 金融商品取引法第185条の22第１項第１号\nb 金融商品取引法第185条の22第１項第２号\nc 金融商品取引法第185条の22第１項第３号\nd 金融商品取引法第185条の22第２項",
      "correct_answer": "a",
      "predicted_answer": "a",
      "is_correct": true,
      "response": "Reasoning: The question asks for the legal provision that defines \"暗号等資産関連金融指標\" (cryptocurrency-related financial indicators) as indicators related to the price, interest rates, and calculated values of cryptocurrencies. The provided legal texts (specifically [1], [2], and [3]) repeatedly reference \"同法第百八十五条の二十二第一項第一号\" (Article 185-22, Paragraph 1, Item 1 of the Financial Instruments and Exchange Act). This indicates that the definition of \"暗号等資産関連金融指標\" is located in this provision. Among the choices, **a** corresponds directly to this article and item. Other options (b, c, d) refer to different items or paragraphs not linked to this definition in the provided texts.\n\nAnswer: a",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第6章の3_選択式_根拠条文_問題番号23",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025"
      ],
      "reasoning": "Reasoning: The question asks for the legal provision that defines \"暗号等資産関連金融指標\" (cryptocurrency-related financial indicators) as indicators related to the price, interest rates, and calculated values of cryptocurrencies. The provided legal texts (specifically [1], [2], and [3]) repeatedly reference \"同法第百八十五条の二十二第一項第一号\" (Article 185-22, Paragraph 1, Item 1 of the Financial Instruments and Exchange Act). This indicates that the definition of \"暗号等資産関連金融指標\" is located in this provision. Among the choices, **a** corresponds directly to this article and item. Other options (b, c, d) refer to different items or paragraphs not linked to this definition in the provided texts.\n\nAnswer: a"
    },
    {
      "question": "以下の、［　　　］に入る条文として正しいものを教えてください。\n金融商品取引法施行令第27条の7は、金融商品取引法第165条第1号に規定する政令で定める取引として、［　　　］第１項から第３号までに掲げる取引を引用している。",
      "choices": "a 金融商品取引法第165条\nb 金融商品取引法施行令第27条の6\nc 金融商品取引法第163条\nd 有価証券の取引等の規制に関する内閣府令第27条",
      "correct_answer": "b",
      "predicted_answer": "b",
      "is_correct": true,
      "response": "Reasoning: The question asks which provision correctly fills the blank in the statement about the Financial Instruments and Exchange Act Implementation Order Article 27-7. The provided legal text (from the Tax Special Measures Act Implementation Order) references the Financial Instruments and Exchange Act Implementation Order Article 1-9, Item 5, but this is unrelated to the question's focus on Article 27-7. Since the question involves a self-referential structure within the Financial Instruments and Exchange Act Implementation Order, the most logical answer is that Article 27-7 cites transactions defined in a preceding article of the same order (e.g., Article 27-6). This aligns with standard legal drafting practices where later articles reference earlier ones for definitions. None of the other options (a, c, d) are directly relevant to the structure of the Financial Instruments and Exchange Act Implementation Order. \n\nAnswer: b",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第6章_選択式_根拠条文_問題番号27",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/340CO0000000321"
      ],
      "reasoning": "Reasoning: The question asks which provision correctly fills the blank in the statement about the Financial Instruments and Exchange Act Implementation Order Article 27-7. The provided legal text (from the Tax Special Measures Act Implementation Order) references the Financial Instruments and Exchange Act Implementation Order Article 1-9, Item 5, but this is unrelated to the question's focus on Article 27-7. Since the question involves a self-referential structure within the Financial Instruments and Exchange Act Implementation Order, the most logical answer is that Article 27-7 cites transactions defined in a preceding article of the same order (e.g., Article 27-6). This aligns with standard legal drafting practices where later articles reference earlier ones for definitions. None of the other options (a, c, d) are directly relevant to the structure of the Financial Instruments and Exchange Act Implementation Order. \n\nAnswer: b"
    },
    {
      "question": "投資運用業（適格投資家向け投資運用業を除く）を行おうとする場合に、資本金の額又は出資の総額の下限を定めている政令の条文を教えて下さい。",
      "choices": "a 金融商品取引法施行令第15条の7第1項第4号\nb 金融商品取引法第29条の4第１項第4号ロ\nc 金融商品取引法施行令第15条の7第1項第3号\nd 金融商品取引法第29条の4第１項第4号イ",
      "correct_answer": "a",
      "predicted_answer": "c",
      "is_correct": false,
      "response": "Reasoning:  \n1. The question asks for the **minimum capital or total investment amount** (下限) required for investment management businesses (excluding those for qualified investors).  \n2. The provided legal provisions (2 and 3) from the **Financial Instruments and Exchange Act (FIEA) Article 29-5** discuss **upper limits** (超えない) for total managed assets, not minimums. These are irrelevant to the question.  \n3. The **Insurance Business Act** provision (1) relates to insurance companies, not investment management businesses, so it is also irrelevant.  \n4. The correct answer must be found in the **FIEA Implementation Ordinance** (施行令), as minimum capital requirements for investment management businesses are typically set in implementing regulations.  \n5. **Article 15-7, 1st paragraph, 3rd item** of the **FIEA Implementation Ordinance** specifies the **minimum capital requirements** for investment management businesses. This matches the question’s focus on the **lower limit** (下限).  \n\nAnswer: c",
      "retrieved_docs_count": 3,
      "file_name": "金商法_第3章_選択式_根拠条文_問題番号39",
      "references": [
        "https://laws.e-gov.go.jp/law/323AC0000000025",
        "https://laws.e-gov.go.jp/law/340CO0000000321"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the **minimum capital or total investment amount** (下限) required for investment management businesses (excluding those for qualified investors).  \n2. The provided legal provisions (2 and 3) from the **Financial Instruments and Exchange Act (FIEA) Article 29-5** discuss **upper limits** (超えない) for total managed assets, not minimums. These are irrelevant to the question.  \n3. The **Insurance Business Act** provision (1) relates to insurance companies, not investment management businesses, so it is also irrelevant.  \n4. The correct answer must be found in the **FIEA Implementation Ordinance** (施行令), as minimum capital requirements for investment management businesses are typically set in implementing regulations.  \n5. **Article 15-7, 1st paragraph, 3rd item** of the **FIEA Implementation Ordinance** specifies the **minimum capital requirements** for investment management businesses. This matches the question’s focus on the **lower limit** (下限).  \n\nAnswer: c"
    },
    {
      "question": "指定薬物についての説明として、正しいものを教えてください。",
      "choices": "a 指定薬物については、一切広告を行うことはできない\nb 厚生労働大臣は、医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第７６条の4の規定に違反して製造された指定薬物を取り扱う者に対して、販売中止を命じることができるが、廃棄を命じることはできない\nc 都道府県知事は、医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第76条の7第1項の規定による命令を受けた者がその命令に従わない場合には、公衆衛生上の危険の発生を防止するため必要がない場合であっても、当該職員に指定薬物を廃棄させることができる\nd 指定薬物は、医療等の用途での製造や輸入は禁止されていない",
      "correct_answer": "d",
      "predicted_answer": "d",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks for the correct statement about \"指定薬物\" (designated drugs) based on the provided legal provisions.  \n2. **Article 2-15** defines \"指定薬物\" as substances with potential central nervous system effects (e.g., stimulant, hallucinogenic) that could pose health risks, excluding narcotics and psychotropics under other laws.  \n3. **Article 76-4** prohibits the **manufacture, import, sale, possession, or use** of designated drugs **for non-medical purposes** (i.e., purposes other than diagnosis, treatment, prevention, or uses with no health risk). This implies that **medical purposes are explicitly permitted**.  \n4. **Analysis of choices**:  \n   - **a** is incorrect because the provisions do not mention advertising restrictions.  \n   - **b** is incorrect because the provisions do not address the Minister’s authority to order disposal.  \n   - **c** is incorrect because the referenced article (76-7) is not included in the provided text, and the claim about \"even if not necessary\" contradicts typical legal principles.  \n   - **d** is correct because **Article 76-4** explicitly allows designated drugs for **medical purposes** (diagnosis, treatment, prevention), as the prohibition applies only to non-medical uses.  \n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第15章_選択式_関連法令_問題番号19",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the correct statement about \"指定薬物\" (designated drugs) based on the provided legal provisions.  \n2. **Article 2-15** defines \"指定薬物\" as substances with potential central nervous system effects (e.g., stimulant, hallucinogenic) that could pose health risks, excluding narcotics and psychotropics under other laws.  \n3. **Article 76-4** prohibits the **manufacture, import, sale, possession, or use** of designated drugs **for non-medical purposes** (i.e., purposes other than diagnosis, treatment, prevention, or uses with no health risk). This implies that **medical purposes are explicitly permitted**.  \n4. **Analysis of choices**:  \n   - **a** is incorrect because the provisions do not mention advertising restrictions.  \n   - **b** is incorrect because the provisions do not address the Minister’s authority to order disposal.  \n   - **c** is incorrect because the referenced article (76-7) is not included in the provided text, and the claim about \"even if not necessary\" contradicts typical legal principles.  \n   - **d** is correct because **Article 76-4** explicitly allows designated drugs for **medical purposes** (diagnosis, treatment, prevention), as the prohibition applies only to non-medical uses.  \n\nAnswer: d"
    },
    {
      "question": "次のうち、正しいものを教えてください。",
      "choices": "a 特定電気通信役務提供者は、特定違法広告である特定電気通信による情報の送信を防止する措置を講じた場合、当該措置により送信を防止された情報の発信者に生じた損害について、賠償する責任を免れることができる場合がある\nb 特定電気通信役務提供者は、特定違法広告である特定電気通信による情報の送信を防止する措置を講じた場合でも、発生したすべての損害の賠償責任を負う\nc 都道府県知事は、特定電気通信による情報の送信があるとき、特定電気通信役務提供者に対して、当該送信を防止する措置を講ずることを要請することができない。\nd 厚生労働大臣が、特定電気通信による情報の送信があるときに、特定電気通信役務提供者に対して、当該送信を防止する措置を講ずることを要請した場合、厚生労働省が発生したすべての損害の賠償責任を負う",
      "correct_answer": "a",
      "predicted_answer": "a",
      "is_correct": true,
      "response": "Reasoning: The question involves legal provisions related to telecommunications service providers' liability for damages caused by illegal advertisements. However, the provided legal texts (船舶復原性規則, 中小企業雇用管理改善法律, 商店街活性化法律) are unrelated to telecommunications, liability, or authority requests. None of the choices (a–d) can be evaluated against the given provisions. Assuming the question intended to reference the Act on the Regulation of Specific Telecommunications Services (which is not listed here), general legal principles suggest that service providers may be exempt from liability if they take reasonable measures to prevent illegal content (supporting choice **a**). However, since the provided legal texts do not address this, the correct answer cannot be determined from the given information. \n\nAnswer: a",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第13章_選択式_関連法令_問題番号20",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145"
      ],
      "reasoning": "Reasoning: The question involves legal provisions related to telecommunications service providers' liability for damages caused by illegal advertisements. However, the provided legal texts (船舶復原性規則, 中小企業雇用管理改善法律, 商店街活性化法律) are unrelated to telecommunications, liability, or authority requests. None of the choices (a–d) can be evaluated against the given provisions. Assuming the question intended to reference the Act on the Regulation of Specific Telecommunications Services (which is not listed here), general legal principles suggest that service providers may be exempt from liability if they take reasonable measures to prevent illegal content (supporting choice **a**). However, since the provided legal texts do not address this, the correct answer cannot be determined from the given information. \n\nAnswer: a"
    },
    {
      "question": "医療等の用途以外の用途に供するために輸入れた指定薬物を取り扱う者に対して、厚生労働大臣が廃棄の措置をとるべきことを命じたが、命令を受けた者がその命令に従わなかった場合に取ることができる手段について説明した条文を教えて下さい。",
      "choices": "a 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第76条の4\nb 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律施76条の5\nc 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第76条の7第1項\nd 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第76条の7第2項",
      "correct_answer": "d",
      "predicted_answer": "d",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks about the legal provision that allows the Minister of Health, Labour and Welfare to take action **if the person handling the drugs fails to comply** with an order to dispose of specified drugs imported for non-medical purposes.  \n2. **Article 76_7 (第76_7条 第1項)** in the provided text states that the Minister or prefectural governor **can order** disposal, collection, or other measures to prevent public health risks **if** the drugs are illegally stored, displayed, or used. However, this provision only outlines the **authority to issue orders**, not the **consequences of non-compliance**.  \n3. The question specifically focuses on **measures taken when the order is not followed**. Since the provided text does not include the **second paragraph** of Article 76_7 (which would address enforcement actions for non-compliance), the correct answer must be inferred based on the structure of such laws. Typically, such laws include a **second paragraph** (e.g., 第2項) that specifies **penalties or enforcement mechanisms** for non-compliance.  \n4. Among the choices, **option d (第76条の7第2項)** directly addresses the **enforcement measures** for non-compliance, which aligns with the question’s context.  \n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第15章_選択式_根拠条文_問題番号19",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145"
      ],
      "reasoning": "Reasoning:  \n1. The question asks about the legal provision that allows the Minister of Health, Labour and Welfare to take action **if the person handling the drugs fails to comply** with an order to dispose of specified drugs imported for non-medical purposes.  \n2. **Article 76_7 (第76_7条 第1項)** in the provided text states that the Minister or prefectural governor **can order** disposal, collection, or other measures to prevent public health risks **if** the drugs are illegally stored, displayed, or used. However, this provision only outlines the **authority to issue orders**, not the **consequences of non-compliance**.  \n3. The question specifically focuses on **measures taken when the order is not followed**. Since the provided text does not include the **second paragraph** of Article 76_7 (which would address enforcement actions for non-compliance), the correct answer must be inferred based on the structure of such laws. Typically, such laws include a **second paragraph** (e.g., 第2項) that specifies **penalties or enforcement mechanisms** for non-compliance.  \n4. Among the choices, **option d (第76条の7第2項)** directly addresses the **enforcement measures** for non-compliance, which aligns with the question’s context.  \n\nAnswer: d"
    },
    {
      "question": "特定電気通信役務提供者が、特定違法広告である特定電気通信による情報の送信を防止する措置を講じた場合に、損害賠償を免れることができる場合を定めた条文を教えてください。",
      "choices": "a 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第72条の5第1項\nb 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第72条の5第2項\nc 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第72条の6\nd 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第66条第1項",
      "correct_answer": "c",
      "predicted_answer": "c",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks for the legal provision that allows a specific electric communication service provider to avoid liability for damages when taking measures to prevent the transmission of specific illegal advertisements.  \n2. The provided legal provisions include three excerpts:  \n   - [1] and [2] refer to **Article 76-7-3, first paragraph** of the Pharmaceutical and Medical Device Act, which addresses measures to prevent illegal ads related to **specified drugs**.  \n   - [3] refers to **Article 72-6, first paragraph** of the same Act, which explicitly mentions **specific illegal advertisements** (not limited to drugs) and states that service providers are not liable for damages if measures are taken within the necessary limits to prevent transmission to unspecified recipients.  \n3. The question focuses on **specific illegal advertisements** (not limited to drugs), which aligns with **Article 72-6** (provision [3]).  \n4. The answer choices include **c** as **Article 72-6**, which matches the relevant provision.  \n\nAnswer: c",
      "retrieved_docs_count": 3,
      "file_name": "薬機法_第13章_選択式_根拠条文_問題番号20",
      "references": [
        "https://laws.e-gov.go.jp/law/335AC0000000145"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the legal provision that allows a specific electric communication service provider to avoid liability for damages when taking measures to prevent the transmission of specific illegal advertisements.  \n2. The provided legal provisions include three excerpts:  \n   - [1] and [2] refer to **Article 76-7-3, first paragraph** of the Pharmaceutical and Medical Device Act, which addresses measures to prevent illegal ads related to **specified drugs**.  \n   - [3] refers to **Article 72-6, first paragraph** of the same Act, which explicitly mentions **specific illegal advertisements** (not limited to drugs) and states that service providers are not liable for damages if measures are taken within the necessary limits to prevent transmission to unspecified recipients.  \n3. The question focuses on **specific illegal advertisements** (not limited to drugs), which aligns with **Article 72-6** (provision [3]).  \n4. The answer choices include **c** as **Article 72-6**, which matches the relevant provision.  \n\nAnswer: c"
    },
    {
      "question": "次のうち、正しいものを教えてください。",
      "choices": "a 原状回復とは、賃借人が入居時の状態に戻すことである\nb 賃借人が借りていた部屋を契約により定められた使用方法に従い、かつ、社会通念上通常の使用方法により使用していた状態であれば、借りていた部屋をそのまま賃貸人に返せばよいとするのが一般的である\nc 賃借人の故意や不注意、通常でない使用方法等により賃借物に汚損・破損などの損害を生じさせた場合でも、その損害を賠償する必要はない\nd 汚損や損耗が経年変化による自然的なものや通常使用によるものだけでなくても、賃借人がそのような費用を負担することにはならない",
      "correct_answer": "b",
      "predicted_answer": "b",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks for the correct statement regarding lease agreements in Japanese law. The provided legal provisions are unrelated to lease law (they pertain to maritime safety, labor management, and commercial revitalization). Thus, the answer must rely on general principles of Japanese civil law, particularly the Civil Code.  \n\n2. **Option a** is partially correct but incomplete. \"原状回復\" (restoration to the original condition) typically excludes normal wear and tear, which is not the tenant's responsibility. However, the statement does not clarify this nuance, making it potentially misleading.  \n\n3. **Option b** aligns with Japanese civil law. If a tenant uses the property according to the contract and social norms, they are not required to repair normal wear and tear. This is a widely accepted principle in lease agreements.  \n\n4. **Option c** is incorrect. The tenant is legally obligated to compensate for damages caused by their negligence or improper use, even if the damage is not due to natural aging or normal wear.  \n\n5. **Option d** is incorrect. While the tenant is not responsible for damage caused by natural aging or normal use, the statement claims they are not liable even if the damage is not solely from these causes. This is false, as the tenant would still be liable for damages caused by their fault (e.g., negligence).  \n\nAnswer: b",
      "retrieved_docs_count": 3,
      "file_name": "借地借家法_原状回復をめぐるトラブルとガイドライン_選択式_関連法令_問題番号10",
      "references": [
        "https://www.mlit.go.jp/common/001016469.pdf"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the correct statement regarding lease agreements in Japanese law. The provided legal provisions are unrelated to lease law (they pertain to maritime safety, labor management, and commercial revitalization). Thus, the answer must rely on general principles of Japanese civil law, particularly the Civil Code.  \n\n2. **Option a** is partially correct but incomplete. \"原状回復\" (restoration to the original condition) typically excludes normal wear and tear, which is not the tenant's responsibility. However, the statement does not clarify this nuance, making it potentially misleading.  \n\n3. **Option b** aligns with Japanese civil law. If a tenant uses the property according to the contract and social norms, they are not required to repair normal wear and tear. This is a widely accepted principle in lease agreements.  \n\n4. **Option c** is incorrect. The tenant is legally obligated to compensate for damages caused by their negligence or improper use, even if the damage is not due to natural aging or normal wear.  \n\n5. **Option d** is incorrect. While the tenant is not responsible for damage caused by natural aging or normal use, the statement claims they are not liable even if the damage is not solely from these causes. This is false, as the tenant would still be liable for damages caused by their fault (e.g., negligence).  \n\nAnswer: b"
    },
    {
      "question": "次のうち、敷金について正しいものを教えてください。",
      "choices": "a 敷金は、賃借物の明け渡しまでに、未払賃料や損害賠償金債務等、賃貸人に対する賃借人の債務が生じていなくても、返還されることはない\nb 敷金は、賃借人から賃貸人に対して、お礼として支払われるものなので、返還されることはない\nc 敷金の返還請求は、契約で特に別の時期を定めた場合には、建物の明け渡しを行った後でなくてもできる可能性がある\nd 敷金は、賃貸借契約終了までの損害金を担保するものであるため、賃借人の敷金返還請求権は、賃貸借契約の終了時に発生する",
      "correct_answer": "c",
      "predicted_answer": "c",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks for the correct statement about \"敷金\" (security deposit) based on the provided legal provisions.  \n2. **Legal Provision [1]** states that the rent and deposit collected from employees must not exceed what is paid to general landlords, but this does not directly address the return of the deposit.  \n3. **Legal Provision [3]** references the 公営住宅法 (Public Housing Law), which governs the collection and return of deposits. Under this law, deposits are typically returned upon termination of the lease unless there are outstanding debts (e.g., unpaid rent or damages).  \n4. **Analysis of choices**:  \n   - **Option a** is incorrect because the deposit should be returned if no debts exist.  \n   - **Option b** is incorrect because the deposit is not a gift but a refundable security deposit.  \n   - **Option c** is correct because, if the contract specifies a different return period (e.g., before vacating the property), the tenant may request the return of the deposit even before the lease ends. This aligns with the principle that contractual agreements can override default rules unless prohibited by law.  \n   - **Option d** is incorrect because the deposit is not strictly tied to the end of the lease; it can be returned earlier if the contract allows.  \n\nAnswer: c",
      "retrieved_docs_count": 3,
      "file_name": "借地借家法_原状回復をめぐるトラブルとガイドライン_選択式_関連法令_問題番号11",
      "references": [
        "https://www.mlit.go.jp/common/001016469.pdf"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the correct statement about \"敷金\" (security deposit) based on the provided legal provisions.  \n2. **Legal Provision [1]** states that the rent and deposit collected from employees must not exceed what is paid to general landlords, but this does not directly address the return of the deposit.  \n3. **Legal Provision [3]** references the 公営住宅法 (Public Housing Law), which governs the collection and return of deposits. Under this law, deposits are typically returned upon termination of the lease unless there are outstanding debts (e.g., unpaid rent or damages).  \n4. **Analysis of choices**:  \n   - **Option a** is incorrect because the deposit should be returned if no debts exist.  \n   - **Option b** is incorrect because the deposit is not a gift but a refundable security deposit.  \n   - **Option c** is correct because, if the contract specifies a different return period (e.g., before vacating the property), the tenant may request the return of the deposit even before the lease ends. This aligns with the principle that contractual agreements can override default rules unless prohibited by law.  \n   - **Option d** is incorrect because the deposit is not strictly tied to the end of the lease; it can be returned earlier if the contract allows.  \n\nAnswer: c"
    },
    {
      "question": "次のうち、誤っているものを教えてください。",
      "choices": "a 建物の賃貸借契約は、借地借家法の適用があるのが原則であり、借地借家法が定める一定事項については、借主に不利な特約として無効となるものがある\nb 賃貸借契約では、借主に不利な特約はすべて無効となる\nc 強行法規に反しない限り、契約自由の原則により、合意された契約内容は有効となり、賃借人に不利な特約がすべて無効になるわけではない\nd 審議誠実の原則に反し、消費者の利益を一方的に害する者は無効と規定しているのは消費者契約法である",
      "correct_answer": "b",
      "predicted_answer": "b",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks to identify the **incorrect** statement among the choices.  \n2. **Option a** refers to the **Borrowing and Lending Law (借地借家法)**, which indeed applies to building lease agreements by principle. It also states that certain terms unfavorable to the lessee (e.g., excessive rent increases) are invalid under the law. This aligns with legal provisions, so **a is correct**.  \n3. **Option b** claims that **all** unfavorable terms in lease contracts are invalid. This is **incorrect** because the **Civil Code** (民法) upholds the principle of **contract freedom** (契約自由の原則), meaning terms are valid unless they violate **mandatory laws** (強行法規). Only specific terms (e.g., those violating the Borrowing and Lending Law) are invalid, not all unfavorable terms.  \n4. **Option c** correctly states that **contract freedom** applies unless terms violate mandatory laws, and not all unfavorable terms are invalid. This aligns with the **Civil Code** and legal principles.  \n5. **Option d** refers to the **Consumer Contract Law (消費者契約法)**, which invalidates acts that mislead consumers (e.g., false statements). This matches **Legal Provision [1]**, so **d is correct**.  \n\nAnswer: b",
      "retrieved_docs_count": 3,
      "file_name": "借地借家法_原状回復をめぐるトラブルとガイドライン_選択式_関連法令_問題番号12",
      "references": [
        "https://www.mlit.go.jp/common/001016469.pdf"
      ],
      "reasoning": "Reasoning:  \n1. The question asks to identify the **incorrect** statement among the choices.  \n2. **Option a** refers to the **Borrowing and Lending Law (借地借家法)**, which indeed applies to building lease agreements by principle. It also states that certain terms unfavorable to the lessee (e.g., excessive rent increases) are invalid under the law. This aligns with legal provisions, so **a is correct**.  \n3. **Option b** claims that **all** unfavorable terms in lease contracts are invalid. This is **incorrect** because the **Civil Code** (民法) upholds the principle of **contract freedom** (契約自由の原則), meaning terms are valid unless they violate **mandatory laws** (強行法規). Only specific terms (e.g., those violating the Borrowing and Lending Law) are invalid, not all unfavorable terms.  \n4. **Option c** correctly states that **contract freedom** applies unless terms violate mandatory laws, and not all unfavorable terms are invalid. This aligns with the **Civil Code** and legal principles.  \n5. **Option d** refers to the **Consumer Contract Law (消費者契約法)**, which invalidates acts that mislead consumers (e.g., false statements). This matches **Legal Provision [1]**, so **d is correct**.  \n\nAnswer: b"
    },
    {
      "question": "次のうち、損害賠償額の定めについて誤っているものを教えてください。",
      "choices": "a 賠償額を予定してそれを契約しても、常に無効となる\nb 損害賠償額の予定は、賃借人が賃貸借契約に関して賃貸人に損害を与えた場合に備えて規定するものである\nc 契約の当事者は、損害賠償の額を予定し、契約で定めることができる\nd 賠償額を予定してそれを契約しても、予定賠償額どおりに請求できない場合はある",
      "correct_answer": "a",
      "predicted_answer": "a",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks to identify the **incorrect** statement regarding the determination of damages.  \n2. The provided legal provisions (from 渔船損害等補償法, 農業協同組合法, and 森林組合法) emphasize the importance of factual basis and proper compensation amounts in liability scenarios. However, these provisions do not directly address **pre-determined damages in contracts**, which is the focus of the question.  \n3. **Civil Code of Japan, Article 418** (not listed in the provided provisions) governs pre-determined damages:  \n   - Parties may agree on a predetermined compensation amount in a contract (supporting **option c**).  \n   - Such agreements are **not always invalid** (refuting **option a**).  \n   - If the actual damage exceeds the predetermined amount, the injured party may claim the higher amount (supporting **option d**).  \n   - **Option b** is plausible as pre-determined damages are common in lease agreements to cover tenant-caused damage.  \n4. **Option a** is incorrect because it claims that pre-determined damages are **always invalid**, which contradicts the Civil Code’s allowance of such agreements unless they are grossly unfair.  \n\nAnswer: a",
      "retrieved_docs_count": 3,
      "file_name": "借地借家法_原状回復をめぐるトラブルとガイドライン_選択式_関連法令_問題番号13",
      "references": [
        "https://www.mlit.go.jp/common/001016469.pdf"
      ],
      "reasoning": "Reasoning:  \n1. The question asks to identify the **incorrect** statement regarding the determination of damages.  \n2. The provided legal provisions (from 渔船損害等補償法, 農業協同組合法, and 森林組合法) emphasize the importance of factual basis and proper compensation amounts in liability scenarios. However, these provisions do not directly address **pre-determined damages in contracts**, which is the focus of the question.  \n3. **Civil Code of Japan, Article 418** (not listed in the provided provisions) governs pre-determined damages:  \n   - Parties may agree on a predetermined compensation amount in a contract (supporting **option c**).  \n   - Such agreements are **not always invalid** (refuting **option a**).  \n   - If the actual damage exceeds the predetermined amount, the injured party may claim the higher amount (supporting **option d**).  \n   - **Option b** is plausible as pre-determined damages are common in lease agreements to cover tenant-caused damage.  \n4. **Option a** is incorrect because it claims that pre-determined damages are **always invalid**, which contradicts the Civil Code’s allowance of such agreements unless they are grossly unfair.  \n\nAnswer: a"
    },
    {
      "question": "次のうち、借地契約の更新後に建物の滅失があった場合の取扱いについて正しいものを教えてください。",
      "choices": "a 契約の更新の後に建物の滅失があった場合、借地権者は土地賃貸借契約の解約の申し入れをすることができない\nb 契約の更新の後に建物の滅失があった場合、借地権者が借地権設定者の承諾を得ないで残存期間を超えて存続すべき建物を築造したときは、借地権設定者は土地賃貸借契約の解約の申し入れをすることができる\nc 契約の更新の後に建物の滅失があった場合において、借地権者から土地賃貸借契約の解約申し入れがなされた場合、申し入れ日から1か月を経過することにより借地権は消滅する\nd 契約更新の後に建物の滅失があった場合、借地権者は土地の賃貸借契約の解約申し入れをすることはできるが、地上権の放棄をすることはできない",
      "correct_answer": "b",
      "predicted_answer": "a",
      "is_correct": false,
      "response": "To determine the correct answer, we must analyze the scenario and the legal provisions provided in the context of the lease renewal and the subsequent destruction of the building.\n\n---\n\n### **Key Legal Provision:**\n> **[1]** *If the building is destroyed, the lessee may post a notice, and the lease right continues. However, if two years have passed since the destruction, the lease right is only valid if the lessee has rebuilt and registered the property.*\n\nThis provision outlines the **continuation of the lease right** even after the destruction of the building, **provided** the lessee posts the required notice. It does **not** explicitly address the **right of the lessee to terminate the lease** or the **right of the lessor to terminate the lease** in the absence of such notice.\n\n---\n\n### **Analysis of the Options:**\n\n#### **Option A:**\n> *You cannot request termination of the lease if the building is destroyed after the lease is renewed.*\n\n- **Evaluation:** This is **not supported** by the given provision. The law does **not** prohibit the lessee from requesting termination of the lease. In fact, the lessee may still have the right to terminate the lease, even if the lease right continues due to the posting of the notice.\n- **Conclusion:** **Incorrect.**\n\n---\n\n#### **Option B:**\n> *If the lessee rebuilds the building without the lessor's consent, the lessor may request termination of the lease.*\n\n- **Evaluation:** This is **not explicitly stated** in the given provision. The law does not mention that the **lessor has the right to terminate** the lease if the lessee rebuilds **without consent**. However, this could be interpreted as a **breach of contract**, which may allow the lessor to terminate the lease under general contract law principles. But **since the question is based solely on the provided legal text**, this is **not directly supported**.\n- **Conclusion:** **Not directly supported by the given provision.**\n\n---\n\n#### **Option C:**\n> *If the lessee requests termination of the lease, the lease right expires after one month.*\n\n- **Evaluation:** This is **not mentioned** in the provided legal text. There is **no mention of a one-month period** or any automatic expiration of the lease right upon termination request.\n- **Conclusion:** **Incorrect.**\n\n---\n\n#### **Option D:**\n> *The lessee may request termination of the lease, but cannot abandon the land right.*\n\n- **Evaluation:** This is **not addressed** in the given provision. The law does **not mention** anything about the **lessee's right to abandon the land** or the **consequences of such an action**.\n- **Conclusion:** **Incorrect.**\n\n---\n\n### **Conclusion:**\n\nWhile **Option B** may be **plausible** under general contract law principles (i.e., the lessor may have the right to terminate if the lessee rebuilds without consent), **none of the options are explicitly supported** by the **given legal text**. However, **Option B** is the **most reasonable** among the choices, as it reflects a **potential breach of contract** that could justify termination by the lessor.\n\n---\n\n### ✅ **Final Answer:**\n$$\n\\boxed{\\text{B}}\n$$",
      "retrieved_docs_count": 3,
      "file_name": "借地借家法_第2章_選択式_関連法令_問題番号14",
      "references": [
        "https://laws.e-gov.go.jp/law/403AC0000000090"
      ],
      "reasoning": "To determine the correct answer, we must analyze the scenario and the legal provisions provided in the context of the lease renewal and the subsequent destruction of the building.\n\n---\n\n### **Key Legal Provision:**\n> **[1]** *If the building is destroyed, the lessee may post a notice, and the lease right continues. However, if two years have passed since the destruction, the lease right is only valid if the lessee has rebuilt and registered the property.*\n\nThis provision outlines the **continuation of the lease right** even after the destruction of the building, **provided** the lessee posts the required notice. It does **not** explicitly address the **right of the lessee to terminate the lease** or the **right of the lessor to terminate the lease** in the absence of such notice.\n\n---\n\n### **Analysis of the Options:**\n\n#### **Option A:**\n> *You cannot request termination of the lease if the building is destroyed after the lease is renewed.*\n\n- **Evaluation:** This is **not supported** by the given provision. The law does **not** prohibit the lessee from requesting termination of the lease. In fact, the lessee may still have the right to terminate the lease, even if the lease right continues due to the posting of the notice.\n- **Conclusion:** **Incorrect.**\n\n---\n\n#### **Option B:**\n> *If the lessee rebuilds the building without the lessor's consent, the lessor may request termination of the lease.*\n\n- **Evaluation:** This is **not explicitly stated** in the given provision. The law does not mention that the **lessor has the right to terminate** the lease if the lessee rebuilds **without consent**. However, this could be interpreted as a **breach of contract**, which may allow the lessor to terminate the lease under general contract law principles. But **since the question is based solely on the provided legal text**, this is **not directly supported**.\n- **Conclusion:** **Not directly supported by the given provision.**\n\n---\n\n#### **Option C:**\n> *If the lessee requests termination of the lease, the lease right expires after one month.*\n\n- **Evaluation:** This is **not mentioned** in the provided legal text. There is **no mention of a one-month period** or any automatic expiration of the lease right upon termination request.\n- **Conclusion:** **Incorrect.**\n\n---\n\n#### **Option D:**\n> *The lessee may request termination of the lease, but cannot abandon the land right.*\n\n- **Evaluation:** This is **not addressed** in the given provision. The law does **not mention** anything about the **lessee's right to abandon the land** or the **consequences of such an action**.\n- **Conclusion:** **Incorrect.**\n\n---\n\n### **Conclusion:**\n\nWhile **Option B** may be **plausible** under general contract law principles (i.e., the lessor may have the right to terminate if the lessee rebuilds without consent), **none of the options are explicitly supported** by the **given legal text**. However, **Option B** is the **most reasonable** among the choices, as it reflects a **potential breach of contract** that could justify termination by the lessor.\n\n---\n\n### ✅ **Final Answer:**\n$$\n\\boxed{\\text{B}}\n$$"
    },
    {
      "question": "次のうち、建物の再築による借地権の期間の延長について正しいものを教えてください。",
      "choices": "a 残存期間10年の借地権の存続期間が満了する前に建物の滅失があった場合に、借地権者が借地権設定者の事前の承諾を得て、承諾があった日から30年の残存期間を定め、建物を築造したときは、借地権は承諾があった日から20年間存続する\nb 残存期間10年の借地権の存続期間が満了する前に建物の滅失があった場合、借地権者が借地権設定者の事前の承諾を得て、承諾があった日から30年の残存期間を定め、建物を築造したときは、借地権は承諾のあった日から30年間存続する\nc 借地権者が借地権設定者に対して残存期間を超えて存続すべき建物を新たに築造する旨を通知した場合、借地権設定者が1か月以内に異議を述べなかったときは、その建物を築造するにつき承諾があったものとみなされる\nd 残存期間10年の借地権の存続期間が満了する前に建物の滅失があった場合、借地権者が借地権設定者の事前の承諾を得て、承諾があった日から15年の残存期間を定め、建物を築造したときは、借地権は承諾のあった日から15年間存続する",
      "correct_answer": "b",
      "predicted_answer": "b",
      "is_correct": true,
      "response": "Reasoning:  \nThe question asks which statement correctly describes the extension of the leasehold right (借地権) period due to the reconstruction of a building. The provided legal provisions (all identical) from 借地借家法第13条第2項 address a scenario where a building is **constructed without the leaseholder's consent** after the lease period has expired. In such cases, the court may grant a reasonable period for payment of rent upon the leaseholder's request. However, the provisions **do not directly address scenarios where the leaseholder obtains consent** to rebuild the building or extend the lease period.  \n\nAnalyzing the choices:  \n- **Options a, b, d** involve scenarios where the leaseholder **obtains consent** from the leaseholder (借地権設定者) to rebuild the building and extend the lease period. However, the provided legal text does not specify how lease periods are extended in such cases. These options assume that the lease period is extended to the agreed term (e.g., 30 years), but this is **not covered by the given provisions**.  \n- **Option c** states that if the leaseholder notifies the leaseholder of the intention to build beyond the lease period and the leaseholder does not object within one month, it is deemed consent. However, the provided legal text does **not mention notification periods or implied consent**.  \n\nSince none of the choices are directly supported by the given provisions, the correct answer must be inferred based on **general principles of Japanese lease law**. Typically, if a leaseholder obtains consent to rebuild and extend the lease period, the lease period is extended as agreed. Among the options, **b** aligns with this principle by stating that the lease period is extended to the agreed term (30 years) after obtaining consent.  \n\nAnswer: **b**",
      "retrieved_docs_count": 3,
      "file_name": "借地借家法_第2章_選択式_関連法令_問題番号15",
      "references": [
        "https://laws.e-gov.go.jp/law/403AC0000000090"
      ],
      "reasoning": "Reasoning:  \nThe question asks which statement correctly describes the extension of the leasehold right (借地権) period due to the reconstruction of a building. The provided legal provisions (all identical) from 借地借家法第13条第2項 address a scenario where a building is **constructed without the leaseholder's consent** after the lease period has expired. In such cases, the court may grant a reasonable period for payment of rent upon the leaseholder's request. However, the provisions **do not directly address scenarios where the leaseholder obtains consent** to rebuild the building or extend the lease period.  \n\nAnalyzing the choices:  \n- **Options a, b, d** involve scenarios where the leaseholder **obtains consent** from the leaseholder (借地権設定者) to rebuild the building and extend the lease period. However, the provided legal text does not specify how lease periods are extended in such cases. These options assume that the lease period is extended to the agreed term (e.g., 30 years), but this is **not covered by the given provisions**.  \n- **Option c** states that if the leaseholder notifies the leaseholder of the intention to build beyond the lease period and the leaseholder does not object within one month, it is deemed consent. However, the provided legal text does **not mention notification periods or implied consent**.  \n\nSince none of the choices are directly supported by the given provisions, the correct answer must be inferred based on **general principles of Japanese lease law**. Typically, if a leaseholder obtains consent to rebuild and extend the lease period, the lease period is extended as agreed. Among the options, **b** aligns with this principle by stating that the lease period is extended to the agreed term (30 years) after obtaining consent.  \n\nAnswer: **b**"
    },
    {
      "question": "次のうち、建物の借賃増減請求権について正しいものを教えてください。",
      "choices": "a 建物の賃貸借契約当事者は、いかなる場合においても賃料の増減を請求することはできない\nb 建物賃借人は、建物の借賃が、土地若しくは建物に対する租税その他の負担の増額を理由に、将来に向かって建物の借賃の額の減額を請求することができる\nc 建物の借賃の増額について当事者間で協議が調わない場合は、増額を正当とする裁判が確定するまでの間は相当と認める額の借賃を支払うことで足り、裁判が確定した場合において、既に支払った額に不足があるときも、利息を付して支払う必要はない\nd 建物賃貸借契約の当事者は、一定期間建物の借賃を増額しない旨の契約上の特約がある場合でも、土地若しくは建物に対する租税その他負担の増減等により、将来に向かって建物借賃の額の増減を請求することができる。",
      "correct_answer": "b",
      "predicted_answer": "b",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks for the correct statement regarding the right to request rent adjustments under Japanese law.  \n2. The relevant provisions are **[3] (Article 32, Paragraph 1)**, which outlines the conditions for requesting rent adjustments (increase or decrease) due to factors like tax changes, economic fluctuations, or comparisons to similar buildings. It also specifies that a contractual clause preventing rent increases for a certain period overrides this right.  \n3. **Option a** is incorrect because [3] explicitly allows rent adjustments under specific conditions.  \n4. **Option b** is correct because [3] permits a tenant to request a **decrease** in rent if tax or other burdens on the land/building increase, aligning with the provision.  \n5. **Option c** is incorrect because [2] (Article 32, Paragraph 2) mandates **interest** on any shortfall after a court decision on rent increases.  \n6. **Option d** is incorrect because [3] explicitly states that a contractual clause preventing rent increases for a certain period **takes precedence**, contradicting the claim in option d.  \n\nAnswer: b",
      "retrieved_docs_count": 3,
      "file_name": "借地借家法_第3章_選択式_関連法令_問題番号17",
      "references": [
        "https://laws.e-gov.go.jp/law/403AC0000000090"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the correct statement regarding the right to request rent adjustments under Japanese law.  \n2. The relevant provisions are **[3] (Article 32, Paragraph 1)**, which outlines the conditions for requesting rent adjustments (increase or decrease) due to factors like tax changes, economic fluctuations, or comparisons to similar buildings. It also specifies that a contractual clause preventing rent increases for a certain period overrides this right.  \n3. **Option a** is incorrect because [3] explicitly allows rent adjustments under specific conditions.  \n4. **Option b** is correct because [3] permits a tenant to request a **decrease** in rent if tax or other burdens on the land/building increase, aligning with the provision.  \n5. **Option c** is incorrect because [2] (Article 32, Paragraph 2) mandates **interest** on any shortfall after a court decision on rent increases.  \n6. **Option d** is incorrect because [3] explicitly states that a contractual clause preventing rent increases for a certain period **takes precedence**, contradicting the claim in option d.  \n\nAnswer: b"
    },
    {
      "question": "次のうち、相続人なく死亡した建物賃借人の権利義務について正しいものを教えてください。",
      "choices": "a オフィス使用目的で建物を賃借した賃借人が相続人なしに死亡した場合、その当時婚姻の届出をしていないが、建物の賃借人と事実上夫婦関係にあった同居者は、当該建物の権利義務を承継する\nb 居住目的で建物を賃借した賃借人が相続人なく死亡した場合、その当時縁組の届出をしていないが、建物賃借人と養親子と同様の関係にあった者は、建物賃借人と同居していないときでも、賃借人の権利義務を承継する\nc 居住目的で建物を賃借した賃借人が賃料を滞納している間に相続人なく死亡した場合、その当時婚姻の届出をしていないが、賃借人と事実上の夫婦関係にあった同居者は、相続人でない以上、建物の賃料を支払う義務は承継することはない\nd 居住目的で建物を賃借した賃借人が相続人なく死亡した場合、その当時婚姻の届出をしていないが、賃借人と事実上養親子と同様の関係にあった同居者は、建物賃貸人が賃借人の死亡を知った日から1か月以内に反対の意思を示した場合には、当該建物の賃借人としての権利義務を承継しない",
      "correct_answer": "d",
      "predicted_answer": "d",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks for the correct statement regarding the rights and obligations of a deceased tenant without heirs under Japanese law.  \n2. The key provision is **借地借家法第36条第1項**, which applies to **residential** tenants (居住の用に供する建物). It states that a cohabiting person in a de facto marital or foster parent-child relationship (even without formal registration) inherits the tenant's rights and obligations **unless** the landlord opposes within one month of learning about the death.  \n3. **Option a** is incorrect because it refers to an **office-use** building, which is **not** covered by the law (the provision applies only to residential use).  \n4. **Option b** is incorrect because it claims the cohabitant inherits rights even if **not cohabiting**, but the law explicitly requires **同居者** (cohabitation).  \n5. **Option c** is incorrect because it assumes the cohabitant is not obligated to pay arrears, but the law mandates that the cohabitant inherits **all** rights and obligations, including debt.  \n6. **Option d** correctly reflects the exception in the law: if the landlord opposes within one month of learning about the death, the cohabitant does **not** inherit the rights and obligations.  \n\nAnswer: d",
      "retrieved_docs_count": 3,
      "file_name": "借地借家法_第3章_選択式_関連法令_問題番号18",
      "references": [
        "https://laws.e-gov.go.jp/law/403AC0000000090"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the correct statement regarding the rights and obligations of a deceased tenant without heirs under Japanese law.  \n2. The key provision is **借地借家法第36条第1項**, which applies to **residential** tenants (居住の用に供する建物). It states that a cohabiting person in a de facto marital or foster parent-child relationship (even without formal registration) inherits the tenant's rights and obligations **unless** the landlord opposes within one month of learning about the death.  \n3. **Option a** is incorrect because it refers to an **office-use** building, which is **not** covered by the law (the provision applies only to residential use).  \n4. **Option b** is incorrect because it claims the cohabitant inherits rights even if **not cohabiting**, but the law explicitly requires **同居者** (cohabitation).  \n5. **Option c** is incorrect because it assumes the cohabitant is not obligated to pay arrears, but the law mandates that the cohabitant inherits **all** rights and obligations, including debt.  \n6. **Option d** correctly reflects the exception in the law: if the landlord opposes within one month of learning about the death, the cohabitant does **not** inherit the rights and obligations.  \n\nAnswer: d"
    },
    {
      "question": "次のうち、建物賃貸借契約の更新について正しいものを教えてください。",
      "choices": "a 建物の賃貸借について期間の定めがある場合は、賃借人は期間満了の1年前までに賃貸人に更新をしない旨の通知をしなければ、従前の契約と同一条件で更新したものとみなされる\nb 建物の賃貸借について期間の定めがある場合は、賃借人は賃貸人に更新する旨の通知をしなければ、従前の契約と同一の条件で更新されるとみなされることはない\nc 建物の賃貸人による借地借家法第26条第1項の更新しない旨の通知は、正当な事由があると認められる場合でなければ、することができない\nd 建物の賃貸借に期間の定めがある場合において、借地借家法第26条第1項により、従前の契約と同一の条件で契約を更新したものとみなされる場合は、契約期間も含めて従前と同一の条件となる",
      "correct_answer": "c",
      "predicted_answer": "a",
      "is_correct": false,
      "response": "### Analysis of the Question\n\nThe question revolves around **Article 26, Paragraph 1 of the Land Lease Act (借地借家法)**, which outlines the conditions under which a lease is **automatically renewed** if the parties do not notify each other of their intent **not to renew** the lease.\n\n---\n\n### Key Legal Provisions\n\n> **Article 26, Paragraph 1 of the Land Lease Act**  \n> If a lease has a fixed term and the parties do **not notify each other** of their intent **not to renew** the lease **between 1 year and 6 months before the expiration of the lease**, the lease is **automatically renewed** under the **same conditions**, **except that the term is not specified**.\n\n---\n\n### Evaluation of the Options\n\n#### **Option A:**\n> *\"You must notify the landlord before 1 year to not renew, otherwise it's considered renewed.\"*\n\n- **Incorrect**  \n  The law specifies that the **notification must be given between 1 year and 6 months before** the lease expires, **not before 1 year**.  \n  This option **misinterprets the timing** of the notification requirement.\n\n---\n\n#### **Option B:**\n> *\"If the tenant doesn't notify the landlord to renew, then it's not considered renewed.\"*\n\n- **Incorrect**  \n  The law **does not require the tenant to notify the landlord about renewing**.  \n  The obligation is to **notify about not renewing**, not about renewing.  \n  This option **misinterprets the legal obligation**.\n\n---\n\n#### **Option C:**\n> *\"The landlord can't give the notice under 26-1 unless there's a valid reason.\"*\n\n- **Incorrect**  \n  The law **does not impose any requirement of a valid reason** for the landlord to notify about not renewing.  \n  This option **introduces a legal condition that is not present** in the law.\n\n---\n\n#### **Option D:**\n> *\"If the contract is considered renewed under 26-1, the contract duration is also the same as before.\"*\n\n- **Incorrect**  \n  The law explicitly states that **the term is not specified** after renewal.  \n  This means that the **duration is not the same as before** (it becomes indefinite).  \n  This option **misinterprets the legal effect** of the renewal.\n\n---\n\n### Conclusion\n\nAll four options **misinterpret** the legal provisions of **Article 26, Paragraph 1** of the Land Lease Act. However, **Option A** is the **least incorrect**, as it at least **mentions the obligation to notify**, even though it **misplaces the timing** of the notification.\n\n---\n\n### Final Answer\n\n$$\n\\boxed{\\text{A}}\n$$",
      "retrieved_docs_count": 3,
      "file_name": "借地借家法_第3章_選択式_関連法令_問題番号19",
      "references": [
        "https://laws.e-gov.go.jp/law/403AC0000000090"
      ],
      "reasoning": "### Analysis of the Question\n\nThe question revolves around **Article 26, Paragraph 1 of the Land Lease Act (借地借家法)**, which outlines the conditions under which a lease is **automatically renewed** if the parties do not notify each other of their intent **not to renew** the lease.\n\n---\n\n### Key Legal Provisions\n\n> **Article 26, Paragraph 1 of the Land Lease Act**  \n> If a lease has a fixed term and the parties do **not notify each other** of their intent **not to renew** the lease **between 1 year and 6 months before the expiration of the lease**, the lease is **automatically renewed** under the **same conditions**, **except that the term is not specified**.\n\n---\n\n### Evaluation of the Options\n\n#### **Option A:**\n> *\"You must notify the landlord before 1 year to not renew, otherwise it's considered renewed.\"*\n\n- **Incorrect**  \n  The law specifies that the **notification must be given between 1 year and 6 months before** the lease expires, **not before 1 year**.  \n  This option **misinterprets the timing** of the notification requirement.\n\n---\n\n#### **Option B:**\n> *\"If the tenant doesn't notify the landlord to renew, then it's not considered renewed.\"*\n\n- **Incorrect**  \n  The law **does not require the tenant to notify the landlord about renewing**.  \n  The obligation is to **notify about not renewing**, not about renewing.  \n  This option **misinterprets the legal obligation**.\n\n---\n\n#### **Option C:**\n> *\"The landlord can't give the notice under 26-1 unless there's a valid reason.\"*\n\n- **Incorrect**  \n  The law **does not impose any requirement of a valid reason** for the landlord to notify about not renewing.  \n  This option **introduces a legal condition that is not present** in the law.\n\n---\n\n#### **Option D:**\n> *\"If the contract is considered renewed under 26-1, the contract duration is also the same as before.\"*\n\n- **Incorrect**  \n  The law explicitly states that **the term is not specified** after renewal.  \n  This means that the **duration is not the same as before** (it becomes indefinite).  \n  This option **misinterprets the legal effect** of the renewal.\n\n---\n\n### Conclusion\n\nAll four options **misinterpret** the legal provisions of **Article 26, Paragraph 1** of the Land Lease Act. However, **Option A** is the **least incorrect**, as it at least **mentions the obligation to notify**, even though it **misplaces the timing** of the notification.\n\n---\n\n### Final Answer\n\n$$\n\\boxed{\\text{A}}\n$$"
    },
    {
      "question": "建物賃貸借契約が終了した場合に建物賃貸人が、建物の転借人にその旨を通知した場合に、その週量を建物の転借人に対抗することができることの根拠となる条文を教えてください。",
      "choices": "a 借地借家法第34条第1項\nb 借地借家法第34条第2項\nc 借地借家法第35条第1項\nd 借地借家法第35条第2項",
      "correct_answer": "a",
      "predicted_answer": "a",
      "is_correct": true,
      "response": "Reasoning:  \n1. The question asks for the legal basis allowing a building landlord to oppose a sublessee when the main lease has terminated and the landlord notified the sublessee.  \n2. The relevant provision is **借地借家法第34条第1項**, which states that if the main lease ends due to expiration or termination notice, the landlord **must notify the sublessee**. Failure to notify means the landlord cannot oppose the sublessee. Conversely, **if the landlord does notify**, this provision implicitly allows them to oppose the sublessee (as the opposite of the \"failure to notify\" scenario).  \n3. The other options (b, c, d) are not mentioned in the provided legal texts.  \n\nAnswer: a",
      "retrieved_docs_count": 3,
      "file_name": "借地借家法_第3章_選択式_根拠条文_問題番号16",
      "references": [
        "https://laws.e-gov.go.jp/law/403AC0000000090"
      ],
      "reasoning": "Reasoning:  \n1. The question asks for the legal basis allowing a building landlord to oppose a sublessee when the main lease has terminated and the landlord notified the sublessee.  \n2. The relevant provision is **借地借家法第34条第1項**, which states that if the main lease ends due to expiration or termination notice, the landlord **must notify the sublessee**. Failure to notify means the landlord cannot oppose the sublessee. Conversely, **if the landlord does notify**, this provision implicitly allows them to oppose the sublessee (as the opposite of the \"failure to notify\" scenario).  \n3. The other options (b, c, d) are not mentioned in the provided legal texts.  \n\nAnswer: a"
    }
  ]
}